Effects O
of O
hydrochlorothiazide B-intervention
on O
drainage B-condition
volume I-condition
and I-condition
seroma I-condition
formation I-condition
in O
deep O
inferior O
epigastric O
perforator O
flap O
breast O
reconstruction O
: O
Randomized O
controlled O
trial O
. O
Seroma O
is O
a O
recognized O
complication O
encountered O
at O
the O
reconstructed O
breast O
and O
donor O
site O
after O
abdominal O
- O
based O
breast O
reconstruction O
. O
Seroma O
is O
caused O
by O
lymphatic O
channel O
disruption O
and O
the O
formation O
of O
a O
large O
space O
between O
the O
deep O
fascia O
during O
flap O
elevation O
. O
Surgical O
techniques O
to O
preserve O
the O
lymphatics O
and O
secure O
the O
closure O
of O
the O
donor O
site O
can O
reduce O
seroma O
formation O
. O
This O
study O
investigated O
the O
safety O
and O
effectiveness O
of O
the O
diuretic O
hydrochlorothiazide O
at O
reducing O
interstitial O
fluid O
accumulation O
and O
seroma O
formation O
during O
deep O
inferior O
epigastric O
perforator O
( O
DIEP O
) O
flap O
breast O
reconstruction O
. O
Sixty B-total-participants
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
underwent I-eligibility
skin- I-eligibility
or I-eligibility
nipple I-eligibility
- I-eligibility
sparing I-eligibility
mastectomy I-eligibility
and I-eligibility
DIEP I-eligibility
flap I-eligibility
reconstruction I-eligibility
were O
enrolled O
between O
August O
2016 O
and O
June O
2017 O
. O
The O
patients O
were O
randomly O
assigned O
to O
receive O
either O
25 O
  O
mg O
per O
day O
of O
hydrochlorothiazide O
from O
the O
second O
to O
the O
twentieth O
day O
after O
surgery O
( O
treatment O
) O
or O
no B-control
diuretic I-control
( I-control
control I-control
) I-control
. O
The O
clinicopathological O
characteristics O
, O
drainage O
time O
, O
and O
drainage O
volume O
were O
statistically O
compared O
between O
the O
two O
groups O
. O
The O
average B-outcome
total I-outcome
drainage I-outcome
volume I-outcome
at I-outcome
the I-outcome
donor I-outcome
site I-outcome
was O
291 B-iv-cont-mean
  I-iv-cont-mean
mL I-iv-cont-mean
in O
the O
treatment O
group O
and O
434 B-cv-cont-mean
  I-cv-cont-mean
mL I-cv-cont-mean
in O
the O
control O
group O
( O
p O
  O
= O
  O
0.003 O
) O
. O
The O
differences O
in O
body B-outcome
mass I-outcome
index I-outcome
and O
flap B-outcome
weight I-outcome
between O
the O
two O
groups O
were O
not O
statistically O
significant O
( O
p O
  O
= O
  O
0.879 O
and O
p O
  O
= O
  O
0.963 O
, O
respectively O
) O
. O
No B-outcome
hypotension I-outcome
or I-outcome
electrolyte I-outcome
imbalance I-outcome
was O
noted O
during O
the O
follow O
- O
up O
. O
Intake O
of O
25 O
  O
mg O
per O
day O
of O
hydrochlorothiazide O
tablets O
effectively O
reduced O
the O
total O
abdominal O
drainage O
volume O
and O
removal O
time O
of O
indwelling O
drains O
. O
However O
, O
the O
adverse O
effects O
should O
be O
further O
investigated O
in O
a O
large O
population O
and O
multiracial O
cohort O
before O
using O
hydrochlorothiazide O
for O
seroma O
prevention O
. O

Prophylactic O
use O
of O
levonorgestrel B-intervention
- I-intervention
releasing I-intervention
intrauterine I-intervention
system I-intervention
in O
women O
with O
breast O
cancer O
treated O
with O
tamoxifen O
: O
a O
randomized O
controlled O
trial O
. O
To O
estimate O
the O
rate O
of O
endometrial O
pathology O
with O
the O
prophylactic O
use O
of O
levonorgestrel O
- O
releasing O
intrauterine O
system O
in O
women O
with O
breast O
cancer O
treated O
with O
tamoxifen O
. O
This O
was O
a O
randomized O
contro O
- O
lled O
trial O
of O
129 B-total-participants
Chinese B-ethinicity
women O
who O
attended O
a O
university O
hospital O
in O
Hong B-ethinicity
Kong I-ethinicity
and O
required B-eligibility
adjuvant I-eligibility
tamoxifen I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
after I-eligibility
the I-eligibility
completion I-eligibility
of I-eligibility
postoperative I-eligibility
radiotherapy I-eligibility
and I-eligibility
chemotherapy I-eligibility
. O
Women O
were O
randomized O
to O
treatment O
( O
prophylactic O
levonorgestrel O
- O
releasing O
intrauterine O
system O
insertion O
before O
the O
commencement O
of O
tamoxifen O
) O
or O
control B-control
group I-control
. O
The O
uterine O
cavity O
was O
examined O
by O
hysteroscopy O
and O
endometrial O
sampling O
before O
the O
commencement O
of O
tamoxifen O
and O
at O
12 O
, O
24 O
, O
45 O
, O
and O
60 O
months O
afterward O
. O
Any O
endometrial O
polyps O
or O
submucosal O
fibroids O
were O
resected O
through O
hysteroscopy O
at O
each O
assessment O
and O
specimens O
were O
sent O
for O
histologic O
confirmation O
. O
A O
total O
of O
94 B-total-participants
women O
completed O
5 O
-year O
follow O
- O
up O
. O
There O
was O
no O
significant O
difference O
in O
the O
occurrence B-outcome
of I-outcome
submucosal I-outcome
fibroids I-outcome
( O
1 B-iv-bin-abs
[ O
1.8 B-iv-bin-percent
% I-iv-bin-percent
] O
compared O
with O
2 B-cv-bin-abs
[ O
3.4 B-cv-bin-percent
% I-cv-bin-percent
] O
) O
and O
endometrial B-outcome
hyperplasia I-outcome
( O
both O
0 B-iv-bin-abs
) O
in O
the O
treatment O
and O
control O
groups O
, O
respectively O
. O
Levonorgestrel O
- O
releasing O
intrauterine O
system O
significantly O
reduced O
de B-outcome
novo I-outcome
endometrial I-outcome
polyps I-outcome
( O
hazard O
ratio O
0.19 O
, O
95 O
% O
confidence O
interval O
0.07 O
- O
0.48 O
) O
over O
the O
course O
of O
5 O
years O
on O
an O
intention O
- O
to O
- O
treat O
basis O
. O
There O
was O
no O
statistically O
significant O
increase O
in O
breast B-outcome
cancer I-outcome
recurrence I-outcome
rate I-outcome
( O
10 B-cv-bin-abs
[ O
17.2 B-cv-bin-percent
% I-cv-bin-percent
] O
compared O
with O
6 B-iv-bin-abs
[ O
10.0 B-iv-bin-percent
% I-iv-bin-percent
] O
) O
or O
cancer B-outcome
- I-outcome
related I-outcome
deaths I-outcome
( O
6 B-cv-bin-abs
[ O
10.3 B-cv-bin-percent
% I-cv-bin-percent
] O
compared O
with O
5 B-iv-bin-abs
[ O
8.3 B-iv-bin-percent
% I-iv-bin-percent
] O
) O
in O
the O
treatment O
group O
, O
but O
the O
study O
was O
underpowered O
in O
this O
regard O
. O
Prophylactic O
levonorgestrel O
- O
releasing O
intrauterine O
system O
prevents O
de O
novo O
endometrial O
polyps O
in O
women O
using O
tamoxifen O
. O
However O
, O
its O
role O
in O
the O
prevention O
of O
endometrial O
hyperplasia O
and O
adenocarcinoma O
as O
well O
as O
its O
effect O
on O
risk O
of O
breast O
cancer O
recurrence O
remain O
uncertain O
. O
Chinese O
Clinical O
Trial O
Registry O
, O
http://www.chictr.org/en/ O
, O
ChiCTR O
- O
TRC- O
09000625 O
. O
I O
. O

Preoperative B-intervention
MRI I-intervention
and O
surgical O
management O
in O
patients O
with O
nonpalpable O
breast O
cancer O
: O
the O
MONET O
- O
randomised O
controlled O
trial O
. O
We O
evaluated O
whether O
performing O
contrast O
- O
enhanced O
breast O
MRI O
in O
addition O
to O
mammography O
and/or O
ultrasound O
in O
patients B-eligibility
with I-eligibility
nonpalpable I-eligibility
suspicious I-eligibility
breast I-eligibility
lesions I-eligibility
improves O
breast O
cancer O
management O
. O
The O
MONET O
- O
study O
( O
MR O
mammography O
of O
nonpalpable O
breast O
tumours O
) O
is O
a O
randomised O
controlled O
trial O
in O
patients O
with O
a O
nonpalpable O
BIRADS O
3 O
- O
5 O
lesion O
. O
Patients O
were O
randomly O
assigned O
to O
receive O
routine B-control
medical I-control
care I-control
, O
including O
mammography O
, O
ultrasound O
and O
lesion O
sampling O
by O
large O
core O
needle O
biopsy O
or O
additional O
MRI O
preceding O
biopsy O
. O
Patients O
with O
cancer O
were O
referred O
for O
surgery O
. O
Primary O
end O
- O
point O
was O
the O
rate B-outcome-measure
of I-outcome-measure
additional I-outcome-measure
surgical I-outcome-measure
procedures I-outcome-measure
( I-outcome-measure
re I-outcome-measure
- I-outcome-measure
excisions I-outcome-measure
and I-outcome-measure
conversion I-outcome-measure
to I-outcome-measure
mastectomy I-outcome-measure
) I-outcome-measure
in O
patients O
with O
a O
nonpalpable O
breast O
cancer O
. O
Four B-total-participants
hundred I-total-participants
and I-total-participants
eighteen I-total-participants
patients O
were O
randomised O
, O
207 B-intervention-participants
patients O
were O
allocated O
to O
MRI O
, O
and O
211 B-control-participants
patients O
to O
the O
control O
group O
. O
In O
the O
MRI O
group O
74 B-iv-bin-abs
patients O
had O
83 O
malignant B-outcome
lesions I-outcome
, O
compared O
to O
75 B-cv-bin-abs
patients O
with O
80 O
malignant O
lesions O
in O
the O
control O
group O
. O
The O
primary B-outcome
breast I-outcome
conserving I-outcome
surgery I-outcome
( I-outcome
BCS I-outcome
) I-outcome
rate I-outcome
was O
similar O
in O
both O
groups O
; O
68 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
MRI O
group O
versus O
66 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
control O
group O
. O
The O
number B-outcome
of I-outcome
re I-outcome
- I-outcome
excisions I-outcome
performed O
because O
of O
positive O
resection O
margins O
after O
primary O
BCS O
was O
increased O
in O
the O
MRI O
group O
; O
18 B-iv-bin-abs
/ O
53 B-intervention-participants
( O
34 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
in O
the O
MRI O
group O
versus O
6 B-cv-bin-abs
/ O
50 B-control-participants
( O
12 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
control O
group O
( O
p= O
0.008 O
) O
. O
The O
number B-outcome
of I-outcome
conversions I-outcome
to I-outcome
mastectomy I-outcome
did O
not O
differ O
significantly O
between O
groups O
. O
Overall O
, O
the O
rate B-outcome
of I-outcome
an I-outcome
additional I-outcome
surgical I-outcome
intervention I-outcome
( O
BCS O
and O
mastectomy O
combined O
) O
after O
initial O
breast O
conserving O
surgery O
was O
24 B-iv-bin-abs
/ O
53 B-intervention-participants
( O
45 B-iv-bin-percent
% I-iv-bin-percent
) O
in O
the O
MRI O
group O
versus O
14 B-cv-bin-abs
/ O
50 B-control-participants
( O
28 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
control O
group O
( O
p= O
0.069 O
) O
. O
Addition O
of O
MRI O
to O
routine O
clinical O
care O
in O
patients O
with O
nonpalpable O
breast O
cancer O
was O
paradoxically O
associated O
with O
an O
increased O
re B-outcome
- I-outcome
excision I-outcome
rate I-outcome
. O
Breast O
MRI O
should O
not O
be O
used O
routinely O
for O
preoperative O
work O
- O
up O
of O
patients O
with O
nonpalpable O
breast O
cancer O
. O

Association O
of O
tamoxifen B-intervention
use O
and O
reduced O
cardiovascular O
events O
among O
asian B-ethinicity
females O
with O
breast O
cancer O
. O
Tamoxifen O
is O
used O
for O
breast O
cancer O
treatment O
and O
has O
been O
reported O
to O
be O
beneficial O
for O
the O
cardiovascular O
system O
, O
but O
it O
is O
unclear O
whether O
tamoxifen O
exhibits O
a O
favorable O
cardiovascular O
effect O
in O
Asian O
patients O
. O
From O
January O
, O
1998 O
to O
December O
, O
2006 O
, O
a O
breast O
cancer O
cohort O
study O
was O
conducted O
using O
the O
Taiwan B-location
National O
Health O
Insurance O
database O
. O
Patients O
were O
divided O
according O
to O
whether O
tamoxifen O
was O
used O
. O
Study O
endpoints O
were O
occurrence B-outcome-measure
of I-outcome-measure
acute I-outcome-measure
myocardial I-outcome-measure
infarction I-outcome-measure
( I-outcome-measure
AMI I-outcome-measure
) I-outcome-measure
, O
ischemic B-outcome-measure
or I-outcome-measure
hemorrhagic I-outcome-measure
stroke I-outcome-measure
and O
total B-outcome-measure
cardiovascular I-outcome-measure
events I-outcome-measure
. O
A O
total O
of O
3 B-total-participants
, I-total-participants
690 I-total-participants
female O
subjects O
were O
enrolled O
( O
mean O
age O
50.1 B-age
± I-age
11.3 I-age
) O
, O
2 B-intervention-participants
, I-intervention-participants
056 I-intervention-participants
of O
whom O
received O
tamoxifen O
and O
1 B-control-participants
, I-control-participants
634 I-control-participants
did B-control
not I-control
. O
During O
a O
mean O
follow O
- O
up O
of O
6.9 O
years O
, O
the O
tamoxifen O
group O
had O
a O
significantly O
lower O
incidence B-outcome
of I-outcome
AMI I-outcome
( O
0.15 B-iv-bin-percent
% I-iv-bin-percent
vs. O
0.67 B-cv-bin-percent
% I-cv-bin-percent
, O
P= O
0.008 O
) O
, O
ischemic B-outcome
stroke I-outcome
( O
1.99 B-iv-bin-percent
% I-iv-bin-percent
vs. O
3.30 B-cv-bin-percent
% I-cv-bin-percent
, O
P= O
0.008 O
) O
, O
hemorrhagic B-outcome
stroke I-outcome
( O
0.15 B-iv-bin-percent
% I-iv-bin-percent
vs. O
0.55 B-cv-bin-percent
% I-cv-bin-percent
, O
P= O
0.029 O
) O
, O
and O
total B-outcome
cardiovascular I-outcome
events I-outcome
( O
2.24 B-iv-bin-percent
% I-iv-bin-percent
vs. O
4.16 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
< O
0.001 O
) O
than O
the O
non O
- O
exposed O
group O
. O
After O
adjusting O
for O
comorbidities O
, O
tamoxifen O
was O
independently O
associated O
with O
a O
reduced O
risk B-outcome
of I-outcome
myocardial I-outcome
infarction I-outcome
( O
hazard O
ratio O
[ O
HR O
] O
0.22 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
0.07 O
- O
0.70 O
, O
ischemic B-outcome
stroke I-outcome
( O
HR O
0.52 O
; O
95 O
% O
CI O
0.35 O
- O
0.78 O
) O
, O
hemorrhagic B-outcome
stroke I-outcome
( O
HR O
0.25 O
; O
95 O
% O
CI O
0.07 O
- O
0.92 O
) O
, O
and O
total B-outcome
cardiovascular I-outcome
events I-outcome
( O
HR O
0.54 O
; O
95 O
% O
CI O
0.37 O
- O
0.78 O
) O
. O
In O
Asian O
female O
breast O
cancer O
patients O
, O
tamoxifen O
use O
was O
associated O
with O
reduced O
risks O
of O
AMI O
, O
ischemic O
, O
hemorrhagic O
stroke O
and O
total O
cardiovascular O
events O
. O

Smartphone B-intervention
- I-intervention
Enabled I-intervention
Health I-intervention
Coaching I-intervention
Intervention O
( O
iMOVE O
) O
to O
Promote O
Long O
- O
Term O
Maintenance O
of O
Physical O
Activity O
in O
Breast O
Cancer O
Survivors O
: O
Protocol O
for O
a O
Feasibility O
Pilot O
Randomized O
Controlled O
Trial O
. O
Although O
physical O
activity O
has O
been O
shown O
to O
contribute O
to O
long O
- O
term O
disease O
control O
and O
health O
in O
breast O
cancer O
survivors O
, O
a O
majority O
of O
breast O
cancer O
survivors O
do O
not O
meet O
physical O
activity O
guidelines O
. O
Past O
research O
has O
focused O
on O
promoting O
physical O
activity O
components O
for O
short O
- O
term O
breast O
cancer O
survivor O
benefits O
, O
but O
insufficient O
attention O
has O
been O
devoted O
to O
long O
- O
term O
outcomes O
and O
sustained O
exercise O
adherence O
. O
We O
are O
assessing O
a O
health O
coach O
intervention O
( O
iMOVE O
) O
that O
uses O
mobile O
technology O
to O
increase O
and O
sustain O
physical O
activity O
maintenance O
in O
initially O
inactive O
breast O
cancer O
survivors O
. O
This O
pilot O
randomized O
controlled O
trial O
( O
RCT O
) O
is O
an O
initial O
step O
in O
evaluating O
the O
iMOVE O
intervention O
and O
will O
inform O
development O
of O
a O
full O
- O
scale O
pragmatic O
RCT O
. O
We O
will O
enroll O
107 B-total-participants
physically O
inactive O
breast O
cancer O
survivors O
and O
randomly O
assign O
them O
to O
intervention O
or O
control B-control
groups I-control
at O
the O
University O
Health O
Network O
, O
a O
tertiary O
cancer O
care O
center O
in O
Toronto B-location
, I-location
Canada I-location
. O
Participants O
will O
be O
women O
( O
age O
18 B-age
to I-age
74 I-age
years I-age
) O
stratified B-eligibility
by I-eligibility
age I-eligibility
( I-eligibility
55 I-eligibility
years I-eligibility
and I-eligibility
older I-eligibility
/ I-eligibility
younger I-eligibility
than I-eligibility
55 I-eligibility
years I-eligibility
) I-eligibility
and I-eligibility
adjuvant I-eligibility
hormone I-eligibility
therapy I-eligibility
( I-eligibility
AHT I-eligibility
) I-eligibility
exposure I-eligibility
( I-eligibility
AHT I-eligibility
vs I-eligibility
no I-eligibility
AHT I-eligibility
) I-eligibility
following I-eligibility
breast I-eligibility
cancer I-eligibility
treatment I-eligibility
with I-eligibility
no I-eligibility
metastases I-eligibility
or I-eligibility
recurrence I-eligibility
who I-eligibility
report I-eligibility
less I-eligibility
than I-eligibility
60 I-eligibility
minutes I-eligibility
of I-eligibility
preplanned I-eligibility
physical I-eligibility
activity I-eligibility
per I-eligibility
week I-eligibility
. O
Both O
intervention O
and O
control O
groups O
receive O
the O
12 O
-week O
physical O
activity O
program O
with O
weekly O
group O
sessions O
and O
an O
individualized O
, O
progressive O
, O
home O
- O
based O
exercise O
program O
. O
The O
intervention O
group O
will O
additionally O
receive O
( O
1 O
) O
10 O
telephone O
- O
based O
health O
coaching O
sessions O
, O
( O
2 O
) O
smartphone O
with O
data O
plan O
, O
if O
needed O
, O
( O
3 O
) O
supportive O
health O
tracking O
software O
( O
Connected O
Wellness O
, O
NexJ O
Health O
Inc O
) O
, O
and O
( O
4 O
) O
a O
wearable O
step O
- O
counting O
device O
linked O
to O
a O
smartphone O
program O
. O
We O
will O
be O
assessing O
recruitment O
rates O
; O
acceptability O
reflected O
in O
selective O
, O
semistructured O
interviews O
; O
and O
enrollment O
, O
retention O
, O
and O
adherence O
quantitative O
intervention O
markers O
as O
pilot O
outcome O
measures O
. O
The O
primary O
clinical O
outcome O
will O
be O
directly O
measured O
peak B-outcome-measure
oxygen I-outcome-measure
consumption I-outcome-measure
. O
Secondary O
clinical O
outcomes O
include O
health B-outcome-measure
- I-outcome-measure
related I-outcome-measure
quality I-outcome-measure
of I-outcome-measure
life I-outcome-measure
and O
anthropometric B-outcome-measure
measures I-outcome-measure
. O
All O
outcome O
measures O
are O
administered O
at O
baseline O
, O
after O
exercise O
program O
( O
month O
3 O
) O
, O
and O
6 O
months O
after O
program O
( O
month O
9 O
) O
. O
This O
pilot O
RCT O
will O
inform O
full O
- O
scale O
RCT O
planning O
. O
We O
will O
assess O
pilot O
procedures O
and O
interventions O
and O
collect O
preliminary O
effect O
estimates O
. O
ClinicalTrials.gov O
NCT O
02620735 O
; O
https://clinicaltrials.gov/ct2/show/NCT O
02620735 O
( O
Archived O
by O
WebCite O
at O
https://clinicaltrials.gov/ct2/show/NCT O
02620735 O
) O
. O

Long O
- O
term O
prevention O
of O
skeletal B-condition
complications I-condition
of O
metastatic O
breast O
cancer O
with O
pamidronate B-intervention
. O
Protocol O
19 O
Aredia O
Breast O
Cancer O
Study O
Group O
. O
Pamidronate O
, O
an O
aminobisphosphonate O
, O
has O
been O
shown O
to O
lower O
the O
risk O
of O
skeletal O
complications O
associated O
with O
lytic O
bone O
lesions O
for O
up O
to O
1 O
year O
in O
women O
with O
stage O
IV O
breast O
cancer O
who O
received O
chemotherapy O
. O
We O
studied O
the O
long O
- O
term O
effectiveness O
and O
safety O
of O
continued O
treatment O
with O
intravenous O
pamidronate O
infusions O
for O
up O
to O
2 O
years O
. O
Three B-total-participants
hundred I-total-participants
eighty I-total-participants
- I-total-participants
two I-total-participants
women O
with O
metastatic O
breast O
cancer O
and O
lytic O
bone O
lesions O
who O
received O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
either O
90 O
mg O
of O
pamidronate O
or O
placebo B-control
intravenously O
every O
3 O
to O
4 O
weeks O
in O
this O
double O
- O
blind O
, O
multicenter O
, O
parallel O
- O
group O
trial O
. O
Patients O
were O
evaluated O
monthly O
for O
2 O
years O
for O
skeletal O
complications O
, O
which O
included O
pathologic O
fractures O
, O
need O
for O
radiation O
or O
surgery O
to O
treat O
bone O
complications O
, O
spinal O
cord O
compression O
, O
and O
hypercalcemia O
. O
Bone O
pain O
, O
analgesic O
use O
, O
bone O
biochemical O
markers O
, O
performance O
status O
, O
quality O
of O
life O
, O
radiologic O
response O
in O
bone O
, O
and O
survival O
were O
also O
evaluated O
. O
As O
in O
the O
first O
year O
of O
treatment O
, O
the O
proportion B-outcome
of I-outcome
patients I-outcome
with I-outcome
any I-outcome
skeletal I-outcome
complication I-outcome
was O
significantly O
less O
for O
the O
pamidronate O
than O
the O
placebo O
group O
at O
15 O
, O
18 O
, O
21 O
, O
and O
24 O
months O
( O
P O
< O
. O
001 O
) O
. O
The O
proportions O
of O
patients B-outcome
with I-outcome
any I-outcome
pathologic I-outcome
fracture I-outcome
( O
i.e. O
, O
vertebral O
and O
nonvertebral O
fractures O
) O
, O
need B-outcome
for I-outcome
radiation I-outcome
or I-outcome
surgery I-outcome
to I-outcome
treat I-outcome
bone I-outcome
complications I-outcome
, I-outcome
and I-outcome
hypercalcemia I-outcome
were O
also O
statistically O
less O
for O
the O
pamidronate O
than O
the O
placebo O
group O
. O
The O
median B-outcome
time I-outcome
to I-outcome
the I-outcome
first I-outcome
skeletal I-outcome
complication I-outcome
was O
13.9 B-iv-cont-median
months I-iv-cont-median
in O
the O
pamidronate O
- O
treated O
women O
and O
7.0 B-cv-cont-median
months I-cv-cont-median
in O
the O
placebo O
group O
( O
P O
< O
. O
001 O
) O
. O
Long O
- O
term O
treatment O
did O
not O
result O
in O
any O
unexpected O
adverse B-outcome
events I-outcome
. O
Survival B-outcome
did O
not O
differ O
between O
the O
two O
groups O
. O
The O
risk O
for O
osteolytic O
bone O
lesion O
complications O
in O
metastatic O
breast O
cancer O
was O
significantly O
decreased O
with O
monthly O
infusions O
of O
90 O
mg O
of O
pamidronate O
, O
and O
this O
effect O
was O
maintained O
for O
at O
least O
2 O
years O
. O
Pamidronate O
is O
a O
useful O
adjunct O
to O
standard O
chemotherapy O
in O
the O
palliative O
treatment O
of O
metastatic O
breast O
cancer O
. O

OlympiAD O
final O
overall O
survival O
and O
tolerability O
results O
: O
Olaparib B-intervention
versus O
chemotherapy B-control
treatment I-control
of O
physician O
's O
choice O
in O
patients O
with O
a O
germline O
BRCA O
mutation O
and O
HER O
2 O
- O
negative O
metastatic O
breast O
cancer O
. O
In O
the O
OlympiAD O
study O
, O
olaparib O
was O
shown O
to O
improve O
progression O
- O
free O
survival O
compared O
with O
chemotherapy O
treatment O
of O
physician O
's O
choice O
( O
TPC O
) O
in O
patients O
with O
a O
germline O
BRCA O
1 O
and/or O
BRCA O
2 O
mutation O
( O
BRCAm O
) O
and O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER O
2 O
) O
-negative O
metastatic O
breast O
cancer O
( O
mBC O
) O
. O
We O
now O
report O
the O
planned O
final O
overall O
survival O
( O
OS O
) O
results O
, O
and O
describe O
the O
most O
common O
adverse O
events O
( O
AEs O
) O
to O
better O
understand O
olaparib O
tolerability O
in O
this O
population O
. O
OlympiAD O
, O
a O
Phase O
III O
, O
randomized O
, O
controlled O
, O
open O
- O
label O
study O
( O
NCT O
02000622 O
) O
, O
enrolled B-eligibility
patients I-eligibility
with I-eligibility
a I-eligibility
germline I-eligibility
BRCAm I-eligibility
and I-eligibility
HER I-eligibility
2 I-eligibility
- I-eligibility
negative I-eligibility
mBC I-eligibility
who I-eligibility
had I-eligibility
received I-eligibility
≤ I-eligibility
2 I-eligibility
lines I-eligibility
of I-eligibility
chemotherapy I-eligibility
for I-eligibility
mBC I-eligibility
. O
Patients O
were O
randomized O
to O
olaparib O
tablets O
( O
300 O
  O
mg O
bid O
) O
or O
predeclared O
TPC O
( O
capecitabine O
, O
vinorelbine O
, O
or O
eribulin O
) O
. O
OS B-outcome-measure
and O
safety B-outcome-measure
were O
secondary O
end O
points O
. O
A O
total O
of O
205 B-intervention-participants
patients O
were O
randomized O
to O
olaparib O
and O
97 B-control-participants
to O
TPC O
. O
At O
64 O
% O
data O
maturity O
, O
median B-outcome
OS I-outcome
was O
19.3 B-iv-cont-median
  I-iv-cont-median
months I-iv-cont-median
with O
olaparib O
versus O
17.1 B-cv-cont-median
  I-cv-cont-median
months I-cv-cont-median
with O
TPC O
( O
HR O
0.90 O
, O
95 O
% O
CI O
0.66 O
- O
1.23 O
; O
P O
  O
= O
  O
0.513 O
) O
; O
median O
follow O
- O
up O
was O
25.3 O
and O
26.3 O
  O
months O
, O
respectively O
. O
HR O
for O
OS O
with O
olaparib O
versus O
TPC O
in O
prespecified O
subgroups O
were O
: O
prior B-outcome
chemotherapy I-outcome
for I-outcome
mBC I-outcome
[ O
no O
( O
first O
- O
line O
setting O
) O
: O
0.51 O
, O
95 O
% O
CI O
0.29 O
- O
0.90 O
; O
yes O
( O
second O
/ O
third O
- O
line O
) O
: O
1.13 O
, O
0.79 O
- O
1.64 O
] O
; O
receptor B-outcome
status I-outcome
( O
triple O
negative O
: O
0.93 O
, O
0.62 O
- O
1.43 O
; O
hormone O
receptor O
positive O
: O
0.86 O
, O
0.55 O
- O
1.36 O
) O
; O
prior B-outcome
platinum I-outcome
( O
yes O
: O
0.83 O
, O
0.49 O
- O
1.45 O
; O
no O
: O
0.91 O
, O
0.64 O
- O
1.33 O
) O
. O
Adverse B-outcome
events I-outcome
during O
olaparib O
treatment O
were O
generally O
low O
grade O
and O
manageable O
by O
supportive O
treatment O
or O
dose O
modification O
. O
There O
was O
a O
low O
rate B-outcome
of I-outcome
treatment I-outcome
discontinuation I-outcome
( O
4.9 O
% O
) O
, O
and O
the O
risk O
of O
developing O
anemia B-outcome
did O
not O
increase O
with O
extended O
olaparib O
exposure O
. O
While O
there O
was O
no O
statistically O
significant O
improvement O
in O
OS O
with O
olaparib O
compared O
to O
TPC O
, O
there O
was O
the O
possibility O
of O
meaningful O
OS O
benefit O
among O
patients O
who O
had O
not O
received O
chemotherapy O
for O
metastatic O
disease O
. O
Olaparib O
was O
generally O
well O
- O
tolerated O
, O
with O
no O
evidence O
of O
cumulative O
toxicity O
during O
extended O
exposure O
. O
Please O
see O
the O
article O
online O
for O
additional O
video O
content O
. O

Yoga B-intervention
and O
self O
- O
reported O
cognitive O
problems O
in O
breast O
cancer O
survivors O
: O
a O
randomized O
controlled O
trial O
. O
Cancer O
survivors O
often O
report O
cognitive O
problems O
. O
Furthermore O
, O
decreases O
in O
physical O
activity O
typically O
occur O
over O
the O
course O
of O
cancer O
treatment O
. O
Although O
physical O
activity O
benefits O
cognitive O
function O
in O
noncancer O
populations O
, O
evidence O
linking O
physical O
activity O
to O
cognitive O
function O
in O
cancer O
survivors O
is O
limited O
. O
In O
our O
recent O
randomized O
controlled O
trial O
, O
breast O
cancer O
survivors O
who O
received O
a O
yoga O
intervention O
had O
lower O
fatigue O
and O
inflammation O
following O
the O
trial O
compared O
with O
a O
wait O
list O
control O
group O
. O
This O
secondary O
analysis O
of O
the O
parent O
trial O
addressed O
yoga O
's O
impact O
on O
cognitive O
complaints O
. O
Posttreatment B-eligibility
stage I-eligibility
0 I-eligibility
-IIIA I-eligibility
breast I-eligibility
cancer I-eligibility
survivors I-eligibility
( O
n O
  O
= O
  O
200 B-total-participants
) O
were O
randomized O
to O
a O
12 O
-week O
, O
twice O
- O
weekly O
Hatha O
yoga O
intervention O
or O
a O
wait B-control
list I-control
control I-control
group I-control
. O
Participants O
reported O
cognitive O
complaints O
using O
the O
Breast O
Cancer O
Prevention O
Trial O
Cognitive O
Problems O
Scale O
at O
baseline O
, O
immediately O
postintervention O
, O
and O
3 O
-month O
follow O
- O
up O
. O
Cognitive B-outcome
complaints I-outcome
did O
not O
differ O
significantly O
between O
groups O
immediately O
postintervention O
( O
p O
  O
= O
  O
0.250 O
) O
. O
However O
, O
at O
3 O
-month O
follow O
- O
up O
, O
yoga O
participants O
' O
Breast O
Cancer O
Prevention O
Trial O
Cognitive B-outcome
Problems I-outcome
Scale I-outcome
scores I-outcome
were O
an O
average O
of O
23 O
% O
lower O
than O
wait O
list O
participants O
' O
scores O
( O
p O
  O
= O
  O
0.003 O
) O
. O
These O
group O
differences O
in O
cognitive B-outcome
complaints I-outcome
remained O
after O
controlling O
for O
psychological O
distress O
, O
fatigue O
, O
and O
sleep O
quality O
. O
Consistent O
with O
the O
primary O
results O
, O
those O
who O
practiced O
yoga O
more O
frequently O
reported O
significantly O
fewer O
cognitive B-outcome
problems I-outcome
at I-outcome
3 I-outcome
-month I-outcome
follow I-outcome
- I-outcome
up I-outcome
than O
those O
who O
practiced O
less O
frequently O
( O
p O
  O
< O
  O
0.001 O
) O
. O
These O
findings O
suggest O
that O
yoga O
can O
effectively O
reduce O
breast O
cancer O
survivors O
' O
cognitive O
complaints O
and O
prompt O
further O
research O
on O
mind O
- O
body O
and O
physical O
activity O
interventions O
for O
improving O
cancer O
- O
related O
cognitive O
problems O
. O

Risk B-intervention
Model I-intervention
- I-intervention
Guided I-intervention
Antiemetic I-intervention
Prophylaxis I-intervention
vs O
Physician B-control
's I-control
Choice I-control
in O
Patients O
Receiving O
Chemotherapy O
for O
Early O
- O
Stage O
Breast O
Cancer O
: O
A O
Randomized O
Clinical O
Trial O
. O
Despite O
multiple O
patient O
- O
centered O
factors O
being O
associated O
with O
the O
risk O
of O
chemotherapy O
- O
induced O
nausea O
and O
vomiting O
( O
CINV O
) O
, O
these O
factors O
are O
rarely O
considered O
when O
making O
antiemetic O
recommendations O
. O
To O
compare O
risk O
model O
- O
guided O
( O
RMG O
) O
antiemetic O
prophylaxis O
with O
physician O
's O
choice O
( O
PC O
) O
in O
patients O
receiving O
chemotherapy O
for O
early O
- O
stage O
breast O
cancer O
. O
A O
randomized O
clinical O
trial O
of O
324 B-total-participants
patients B-eligibility
with I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
undergoing I-eligibility
chemotherapy I-eligibility
( I-eligibility
cyclophosphamide I-eligibility
and I-eligibility
an I-eligibility
anthracycline I-eligibility
) I-eligibility
for I-eligibility
the I-eligibility
first I-eligibility
time I-eligibility
at O
2 O
specialty O
cancer O
care O
centers O
in O
Ottawa B-location
from O
April O
10 O
, O
2012 O
, O
to O
September O
2 O
, O
2014 O
. O
Patients O
were O
randomized O
to O
either O
the O
RMG O
arm O
( O
n O
= O
154 B-intervention-participants
) O
or O
the O
PC O
control O
arm O
( O
n O
= O
170 B-control-participants
) O
. O
Prior O
to O
each O
cycle O
of O
chemotherapy O
patients O
in O
the O
RMG O
group O
were O
categorized O
as O
low O
or O
high O
risk O
for O
CINV O
, O
and O
their O
antiemetic O
treatments O
were O
adjusted O
accordingly O
. O
Patients O
considered O
to O
be O
at O
low O
risk O
received O
standard O
dexamethasone O
and O
a O
5 O
-HT O
3 O
antagonist O
, O
while O
those O
at O
high O
risk O
also O
received O
aprepitant O
with O
or O
without O
olanzapine O
, O
based O
on O
their O
risk O
level O
. O
The O
PC O
control O
group O
received O
antiemetic O
agents O
according O
to O
the O
treating O
physician O
's O
discretion O
. O
The O
primary O
end O
points O
were O
control B-outcome-measure
of I-outcome-measure
both I-outcome-measure
nausea I-outcome-measure
and I-outcome-measure
vomiting I-outcome-measure
in O
the O
acute O
posttreatment O
period O
( O
first O
24 O
hours O
after O
therapy O
) O
and O
in O
the O
delayed O
posttreatment O
period O
( O
days O
2 O
- O
5 O
after O
therapy O
) O
. O
The O
total O
numbers O
of O
chemotherapy O
cycles O
delivered O
in O
the O
RMG O
and O
PC O
control O
groups O
were O
497 O
and O
551 O
respectively O
. O
In B-outcome
the I-outcome
acute I-outcome
period I-outcome
, O
significantly O
more O
patients O
in O
the O
RMG O
group O
reported O
no B-outcome
nausea I-outcome
( O
53.7 B-iv-bin-percent
% I-iv-bin-percent
[ O
95 O
% O
CI O
, O
49.2 O
% O
- O
58.1 O
% O
] O
vs O
41.6 B-cv-bin-percent
% I-cv-bin-percent
[ O
95 O
% O
CI O
, O
37.4 O
% O
- O
45.3 O
% O
] O
; O
P O
< O
  O
. O
001 O
) O
and O
no B-outcome
vomiting I-outcome
( O
91.8 B-iv-bin-percent
% I-iv-bin-percent
[ O
95 O
% O
CI O
, O
89.0 O
% O
- O
94.0 O
% O
] O
vs O
82.2 B-cv-bin-percent
% I-cv-bin-percent
[ O
95 O
% O
CI O
, O
78.8 O
% O
- O
85.3 O
% O
] O
; O
P O
< O
  O
. O
001 O
) O
compared O
with O
the O
PC O
control O
group O
. O
Similarly O
, O
significantly O
more O
patients O
in O
the O
RMG O
group O
reported O
no B-outcome
nausea I-outcome
( O
39.6 B-iv-bin-percent
% I-iv-bin-percent
[ O
95 O
% O
CI O
, O
35.3 O
% O
- O
44.1 O
% O
] O
vs O
30.7 B-cv-bin-percent
% I-cv-bin-percent
[ O
95 O
% O
CI O
, O
26.8 O
% O
- O
34.7 O
% O
] O
; O
P O
= O
  O
. O
01 O
) O
and O
no B-outcome
vomiting I-outcome
( O
87.1 B-iv-bin-percent
% I-iv-bin-percent
[ O
95 O
% O
CI O
, O
83.8 O
% O
- O
90.0 O
% O
) O
vs O
78.0 B-cv-bin-percent
% I-cv-bin-percent
[ O
95 O
% O
CI O
, O
74.3 O
% O
- O
81.4 O
% O
] O
; O
P O
< O
  O
. O
001 O
) O
in B-outcome
the I-outcome
delayed I-outcome
period I-outcome
respectively O
. O
In O
this O
trial O
, O
the O
RMG O
antiemetic O
prophylaxis O
led O
to O
improved O
control O
of O
acute O
and O
delayed O
CINV O
compared O
with O
physician O
's O
choice O
of O
therapy O
. O
clinicaltrials.gov O
Identifier O
: O
NCT O
01913990 O
. O

No O
Evidence O
for O
Effect O
of O
Exercise B-intervention
on O
Transcriptome O
of O
NK O
Cells O
in O
Breast O
Cancer O
Patients O
Undergoing O
Adjuvant O
Therapy O
: O
Results O
From O
a O
Pilot O
Study O
. O
Mobilization O
and O
activation O
of O
natural O
killer O
cells O
( O
NK O
cells O
) O
have O
been O
hypothesized O
to O
contribute O
to O
observed O
protective O
effects O
of O
exercise O
on O
cancer O
development O
and O
progression O
. O
Some O
evidence O
exists O
for O
acute O
effects O
of O
aerobic O
exercise O
on O
NK O
cell O
mobilization O
and O
function O
, O
i.e. O
, O
alteration O
of O
the O
gene O
expression O
profile O
of O
NK O
cells O
. O
Yet O
, O
the O
chronic O
effects O
of O
exercise O
training O
, O
and O
effects O
of O
other O
modalities O
than O
endurance O
exercise O
are O
still O
understudied O
. O
Here O
, O
we O
investigated O
the O
chronic O
effects O
of O
a O
12 O
-week O
resistance O
exercise O
program O
on O
NK O
cell O
gene O
expression O
in O
breast O
cancer O
patients O
undergoing O
adjuvant O
chemo- O
or O
radiotherapy O
. O
Breast B-eligibility
cancer I-eligibility
patients I-eligibility
were O
randomly O
assigned O
to O
either O
a O
12 O
-week O
resistance O
exercise O
program O
or O
a O
relaxation B-control
control I-control
group I-control
concomitant O
to O
adjuvant O
therapy O
. O
In O
a O
subsample O
of O
19 B-total-participants
participants O
, O
RNA O
was O
extracted O
from O
magnet O
bead O
isolated O
NK O
cells O
and O
subsequently O
analyzed O
for O
differential O
gene O
expression O
using O
microarray O
Illumina O
HumanHT- O
12 O
v O
4 O
before O
and O
after O
the O
intervention O
. O
After O
chronic O
exercise O
intervention O
several O
genes O
showed O
higher B-outcome
differential I-outcome
expression I-outcome
compared O
to O
the O
control O
group O
. O
However O
, O
after O
correction O
for O
multiple O
testing O
, O
baseline O
- O
adjusted O
analyses O
of O
covariance O
indicated O
no O
significant O
differences O
between O
the O
intervention O
and O
the O
control O
group O
with O
regard O
to O
the O
gene B-outcome
expression I-outcome
profile I-outcome
. O
Our O
findings O
suggest O
that O
12 O
-week O
resistance O
- O
exercise O
did O
not O
alter O
the O
gene O
expression O
profile O
of O
NK O
cells O
in O
breast O
cancer O
patients O
undergoing O
adjuvant O
therapy O
on O
the O
long O
term O
. O
Further O
studies O
with O
larger O
sample O
sizes O
and O
specifically O
designed O
to O
investigate O
whether O
exercise O
- O
induced O
changes O
in O
NK O
cell O
function O
are O
attributed O
to O
acute O
effects O
are O
warranted O
. O

Explicit B-intervention
prognostic I-intervention
disclosure I-intervention
to O
Asian B-ethinicity
women O
with O
breast O
cancer O
: O
A O
randomized O
, O
scripted O
video O
- O
vignette O
study O
( O
J O
- O
SUPPORT O
1601 O
) O
. O
Nondisclosure O
of O
a O
poor O
prognosis O
to O
patients O
with O
advanced O
cancer O
remains O
a O
typical O
practice O
in O
Asia O
. O
Although O
the O
importance O
of O
prognostic O
communication O
has O
increasingly O
been O
recognized O
worldwide O
, O
little O
is O
known O
about O
whether O
explicit O
prognostic O
disclosure O
positively O
affects O
Asian O
patients O
with O
advanced O
cancer O
. O
The O
objective O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
explicit O
prognostic O
communication O
on O
patients O
with O
cancer O
recurrence O
. O
In O
this O
randomized O
, O
video O
- O
vignette O
study O
, O
Japanese B-ethinicity
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
had I-eligibility
undergone I-eligibility
curative I-eligibility
surgery I-eligibility
viewed O
videos O
of O
prognostic O
communication O
between O
a O
patient O
with O
recurrent O
, O
incurable O
breast O
cancer O
and O
her O
oncologist O
. O
The O
videos O
differed O
only O
in O
the O
presence O
or O
absence O
of O
explicit O
prognostic O
disclosure O
. O
The O
primary O
outcome O
was O
participants B-outcome-measure
' I-outcome-measure
uncertainty I-outcome-measure
( O
rated O
from O
0 O
to O
10 O
) O
, O
and O
the O
secondary O
outcomes O
included O
anxiety B-outcome-measure
( O
measured O
on O
the O
State O
- O
Trait O
Anxiety O
Inventory O
- O
State O
: O
range O
, O
20 O
- O
80 O
) O
, O
satisfaction B-outcome-measure
( O
Patient O
Satisfaction O
Questionnaire O
; O
range O
0 O
- O
10 O
) O
, O
self B-outcome-measure
- I-outcome-measure
efficacy I-outcome-measure
( O
range O
, O
0 O
- O
10 O
) O
, O
and O
willingness B-outcome-measure
to I-outcome-measure
discuss I-outcome-measure
advance I-outcome-measure
care I-outcome-measure
planning I-outcome-measure
( O
range O
, O
1 O
- O
4 O
) O
. O
In O
total O
, O
105 B-total-participants
women O
participated O
( O
mean O
  O
± O
  O
SD O
age O
, O
53.8 B-age
  I-age
± I-age
  I-age
8.2 I-age
  I-age
years I-age
) O
. O
After O
viewing O
the O
video O
with O
more O
versus O
less O
explicit O
disclosure O
, O
participants O
showed O
significantly O
lower O
uncertainty B-outcome
( O
mean O
  O
± O
  O
SE O
scores O
, O
5.3 B-iv-cont-mean
± O
0.2 B-iv-cont-sd
vs O
5.7 B-cv-cont-mean
  O
± O
  O
0.2 B-cv-cont-sd
, O
respectively O
; O
P O
  O
= O
  O
. O
032 O
) O
and O
higher O
satisfaction B-outcome
( O
5.6 B-iv-cont-mean
  O
± O
  O
0.2 B-iv-cont-sd
vs O
5.2 B-cv-cont-mean
  O
± O
  O
0.2 B-cv-cont-sd
, O
respectively O
; O
P O
  O
= O
  O
. O
010 O
) O
without O
increasing O
anxiety B-outcome
( O
changes O
in O
scores O
on O
the O
State O
- O
Trait O
Anxiety O
Inventory O
- O
State O
: O
0.06 B-iv-cont-mean
  O
± O
  O
0.5 B-iv-cont-sd
vs O
0.6 B-cv-cont-mean
  O
± O
  O
0.5 B-cv-cont-sd
, O
respectively O
; O
P O
  O
= O
  O
. O
198 O
) O
. O
No O
significant O
differences O
were O
observed O
in O
self B-outcome
- I-outcome
efficacy I-outcome
( O
5.2 B-iv-cont-mean
  O
± O
  O
0.2 B-iv-cont-sd
vs O
5.0 B-cv-cont-mean
  O
± O
  O
0.2 B-cv-cont-sd
, O
respectively O
; O
P O
  O
= O
  O
. O
277 O
) O
or O
willingness B-outcome
to I-outcome
discuss I-outcome
advance I-outcome
care I-outcome
planning I-outcome
( O
2.7 B-iv-cont-mean
  O
± O
  O
0.1 B-iv-cont-sd
vs O
2.7 B-cv-cont-mean
  O
± O
  O
0.1 B-cv-cont-sd
, O
respectively O
; O
P O
  O
= O
  O
. O
240 O
) O
. O
Explicit O
prognostic O
disclosure O
prompted O
better O
outcomes O
than O
nondisclosure B-control
in O
Japanese O
women O
with O
breast O
cancer O
. O
When O
asked O
about O
the O
prognosis O
by O
Asian O
patients O
with O
cancer O
, O
clinicians O
may O
be O
encouraged O
to O
respect O
their O
wishes O
and O
explicitly O
discuss O
the O
prognosis O
if O
deemed O
appropriate O
. O

Incidence O
of O
invasive O
breast O
cancer O
in O
postmenopausal O
women O
after O
discontinuation O
of O
long O
- O
term O
raloxifene B-intervention
administration O
. O
Postmenopausal B-eligibility
women I-eligibility
with I-eligibility
osteoporosis I-eligibility
had O
a O
66 O
% O
relative O
risk O
reduction O
for O
invasive O
breast O
cancer O
over O
8 O
years O
of O
raloxifene O
therapy O
in O
the O
randomized O
, O
placebo O
- O
controlled O
4 O
-year O
MORE O
( O
Multiple O
Outcomes O
of O
Raloxifene O
Evaluation O
) O
trial O
and O
the O
CORE O
( O
Continuing O
Outcomes O
Relevant O
to O
Evista O
) O
trial O
, O
a O
4 O
-year O
follow O
- O
up O
to O
MORE O
. O
The O
first O
post O
hoc O
analysis O
examined O
the O
effects O
of O
raloxifene O
on O
the O
cumulative O
incidence O
of O
invasive O
breast O
cancer O
on O
a O
yearly O
basis O
. O
Another O
analysis O
compared O
the O
incidence O
of O
invasive O
breast O
cancer O
in O
3967 B-total-participants
patients O
who O
continued O
raloxifene O
for O
8 O
years O
( O
RLX O
- O
C O
, O
n O
= O
2280 B-intervention-participants
) O
, O
discontinued O
raloxifene O
after O
4 O
years O
in O
MORE O
( O
RLX O
- O
D O
, O
n O
= O
401 B-intervention-participants
) O
, O
or O
took O
placebo B-control
( O
n O
= O
1286 B-control-participants
) O
for O
a O
mean O
2.9 O
years O
' O
treatment O
duration O
( O
57 O
, O
338 O
patient O
- O
years O
) O
. O
The O
unadjusted O
breast B-outcome
cancer I-outcome
incidence I-outcome
rate I-outcome
was O
5.39 B-cv-bin-abs
per O
1000 B-control-participants
patient O
- O
years O
in O
the O
placebo O
group O
compared O
with O
2.26 B-iv-bin-abs
in O
the O
RLX O
- O
C O
group O
( O
hazard O
ratio O
[ O
HR O
] O
, O
0.41 O
[ O
95 O
% O
CI O
0.21 O
- O
0.81 O
] O
) O
and O
3.59 B-iv-bin-abs
in O
the O
RLX O
- O
D O
group O
( O
HR O
, O
0.69 O
[ O
95 O
% O
CI O
0.23 O
- O
2.01 O
] O
) O
. O
Because O
the O
choice O
of O
taking O
the O
study O
drug O
was O
not O
randomized O
in O
CORE O
, O
propensity O
scores O
were O
used O
to O
adjust O
for O
potential O
imbalances O
in O
baseline O
characteristics O
before O
CORE O
. O
Results O
after O
adjustment O
by O
the O
propensity O
score O
method O
were O
similar O
to O
the O
unadjusted O
results O
. O
This O
analysis O
suggests O
a O
persistent O
effect O
for O
breast O
cancer O
risk O
reduction O
in O
patients O
who O
discontinued O
raloxifene O
, O
although O
this O
conclusion O
is O
limited O
by O
the O
small O
sample O
size O
. O

Impact O
of O
a O
higher B-intervention
radiation I-intervention
dose I-intervention
on O
local O
control O
and O
survival O
in O
breast O
- O
conserving O
therapy O
of O
early O
breast O
cancer O
: O
10 O
-year O
results O
of O
the O
randomized O
boost O
versus O
no O
boost O
EORTC O
22881 O
- O
10882 O
trial O
. O
To O
investigate O
the O
long O
- O
term O
impact O
of O
a O
boost O
radiation O
dose O
of O
16 O
Gy O
on O
local O
control O
, O
fibrosis O
, O
and O
overall O
survival O
for O
patients O
with O
stage O
I O
and O
II O
breast O
cancer O
who O
underwent O
breast O
- O
conserving O
therapy O
. O
A O
total O
of O
5 B-total-participants
, I-total-participants
318 I-total-participants
patients B-eligibility
with I-eligibility
microscopically I-eligibility
complete I-eligibility
excision I-eligibility
followed I-eligibility
by I-eligibility
whole I-eligibility
- I-eligibility
breast I-eligibility
irradiation I-eligibility
of I-eligibility
50 I-eligibility
Gy I-eligibility
were O
randomly O
assigned O
to O
receive O
either O
a O
boost O
dose O
of O
16 O
Gy O
( O
2 B-intervention-participants
, I-intervention-participants
661 I-intervention-participants
patients O
) O
or O
no B-control
boost I-control
dose I-control
( O
2 B-control-participants
, I-control-participants
657 I-control-participants
patients O
) O
, O
with O
a O
median O
follow O
- O
up O
of O
10.8 O
years O
. O
The O
median O
age O
was O
55 B-age
years I-age
. O
Local B-outcome
recurrence I-outcome
was O
reported O
as O
the O
first O
treatment O
failure O
in O
278 B-cv-bin-abs
patients O
with O
no O
boost O
versus O
165 B-iv-bin-abs
patients O
with O
boost O
; O
at O
10 B-outcome
years I-outcome
, O
the O
cumulative B-outcome
incidence I-outcome
of I-outcome
local I-outcome
recurrence I-outcome
was O
10.2 B-cv-bin-percent
% I-cv-bin-percent
versus O
6.2 B-iv-bin-percent
% I-iv-bin-percent
for O
the O
no O
boost O
and O
the O
boost O
group O
, O
respectively O
( O
P O
< O
. O
0001 O
) O
. O
The O
hazard O
ratio O
of O
local B-outcome
recurrence I-outcome
was O
0.59 O
( O
0.46 O
to O
0.76 O
) O
in O
favor O
of O
the O
boost O
, O
with O
no O
statistically O
significant O
interaction O
per O
age O
group O
. O
The O
absolute B-outcome
risk I-outcome
reduction I-outcome
at I-outcome
10 I-outcome
years I-outcome
per O
age O
group O
was O
the O
largest O
in O
patients O
< O
or= O
40 O
years O
of O
age O
: O
23.9 O
% O
to O
13.5 O
% O
( O
P O
= O
. O
0014 O
) O
. O
As O
a O
result O
, O
the O
number B-outcome
of I-outcome
salvage I-outcome
mastectomies I-outcome
has O
been O
reduced O
by O
41 O
% O
. O
Severe B-outcome
fibrosis I-outcome
was O
statistically O
significantly O
increased O
( O
P O
< O
. O
0001 O
) O
in O
the O
boost O
group O
, O
with O
a O
10 B-outcome
-year I-outcome
rate I-outcome
of O
4.4 B-iv-bin-percent
% I-iv-bin-percent
versus O
1.6 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
no O
boost O
group O
( O
P O
< O
. O
0001 O
) O
. O
Survival B-outcome
at I-outcome
10 I-outcome
years I-outcome
was O
82 B-iv-bin-percent
% I-iv-bin-percent
in O
both O
arms O
. O
After O
a O
median O
follow O
- O
up O
period O
of O
10.8 O
years O
, O
a O
boost O
dose O
of O
16 O
Gy O
led O
to O
improved O
local O
control O
in O
all O
age O
groups O
, O
but O
no O
difference O
in O
survival O
. O

A O
phase O
III O
adjuvant O
randomised O
trial O
of O
6 B-intervention
cycles I-intervention
of I-intervention
5 I-intervention
-fluorouracil I-intervention
- I-intervention
epirubicine I-intervention
- I-intervention
cyclophosphamide I-intervention
( I-intervention
FEC I-intervention
100 I-intervention
) I-intervention
versus O
4 B-control
FEC I-control
100 I-control
followed I-control
by I-control
4 I-control
Taxol I-control
( I-control
FEC I-control
- I-control
T I-control
) I-control
in O
node B-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
( O
Trial O
B O
2000 O
) O
. O
Standard O
adjuvant O
chemotherapy O
regimens O
for O
patients O
with O
node O
positive O
( O
N+ O
) O
breast O
cancer O
consisted O
of O
anthracycline O
followed O
by O
taxane O
. O
The O
European O
Association O
for O
Research O
in O
Oncology O
embarked O
in O
2000 O
on O
a O
phase O
III O
trial O
comparing O
6 O
cycles O
of O
FEC O
100 O
versus O
4 O
FEC O
100 O
followed O
by O
4 O
Taxol O
. O
Primary O
end O
- O
point O
was O
disease B-outcome-measure
free I-outcome-measure
survival I-outcome-measure
. O
Secondary O
end O
- O
points O
were O
overall B-outcome-measure
survival I-outcome-measure
, O
local B-outcome-measure
recurrence I-outcome-measure
free I-outcome-measure
interval I-outcome-measure
, O
metastases B-outcome-measure
free I-outcome-measure
interval I-outcome-measure
and O
safety B-outcome-measure
. O
Between O
March O
2000 O
and O
December O
2002 O
, O
837 B-total-participants
patients O
were O
randomised O
between O
6 O
FEC O
100 O
for O
6 O
cycles O
( O
417 B-intervention-participants
patients O
) O
or O
FEC O
100 O
for O
4 O
cycles O
then O
Taxol O
175 O
mg O
/ O
m O
( O
2 O
) O
/ O
3 O
weeks O
for O
4 O
cycles O
( O
4 O
FEC O
100 O
- O
4 O
T O
) O
( O
420 B-control-participants
patients O
) O
. O
One B-total-participants
thousand I-total-participants
patients O
had O
been O
planned O
initially O
but O
the O
trial O
was O
closed O
earlier O
due O
to O
slow O
accrual O
. O
Hazard O
ratios O
( O
HRs O
) O
were O
0.99 O
for O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
DFS I-outcome
) I-outcome
( O
95 O
% O
CI O
: O
0.77 O
- O
1.26 O
; O
p= O
0.91 O
) O
, O
and O
0.85 O
for O
overall B-outcome
survival I-outcome
( I-outcome
OS I-outcome
) I-outcome
( O
95 O
% O
CI O
: O
0.62 O
- O
1.15 O
; O
p= O
0.29 O
) O
. O
Nine B-outcome
- I-outcome
year I-outcome
DFS I-outcome
were O
62.9 B-iv-bin-percent
% I-iv-bin-percent
versus O
62.5 B-cv-bin-percent
% I-cv-bin-percent
for O
6 O
FEC O
100 O
and O
4 O
FEC O
100 O
- O
4 O
T O
, O
respectively O
. O
Nine B-outcome
- I-outcome
year I-outcome
OS I-outcome
were O
73.9 B-iv-bin-percent
% I-iv-bin-percent
versus O
77 B-cv-bin-percent
% I-cv-bin-percent
for O
6 O
FEC O
100 O
and O
4 O
FEC O
100 O
- O
4 O
T O
, O
respectively O
. O
Toxicity O
analyses O
based O
on O
803 O
evaluable O
patients O
showed O
that O
overall O
grade B-outcome
3 I-outcome
- I-outcome
4 I-outcome
toxicities I-outcome
were O
similar O
in O
both O
arms O
( O
63 B-iv-bin-percent
% I-iv-bin-percent
versus O
58 B-cv-bin-percent
% I-cv-bin-percent
for O
6 O
FEC O
100 O
arm O
and O
4 O
FEC O
100 O
- O
4 O
T O
arm O
, O
respectively O
; O
p= O
0.16 O
) O
. O
In O
this O
trial O
replacing O
the O
last O
2 O
FEC O
100 O
cycles O
of O
6 O
FEC O
100 O
regimen O
by O
4 O
Taxol O
does O
not O
lead O
to O
a O
discernable O
DFS O
or O
OS O
advantage O
. O
The O
lack O
of O
a O
significant O
difference O
between O
the O
randomised O
treatment O
arms O
may O
however O
be O
due O
to O
a O
lack O
of O
power O
of O
this O
trial O
to O
detect O
small O
, O
yet O
clinically O
worthwhile O
, O
treatment O
benefits O
. O

Lifestyle O
and O
breast O
cancer O
recurrences O
: O
the O
DIANA- O
5 O
trial O
. O
The O
DIANA O
( O
Diet O
and O
Androgens O
) O
- O
5 O
study O
is O
a O
multi O
- O
institutional O
randomized O
controlled O
trial O
of O
the O
effectiveness O
of O
a O
diet O
based O
on O
Mediterranean O
and O
macrobiotic O
recipes O
and O
principles O
, O
associated O
with O
moderate O
physical O
activity O
, O
in O
reducing O
additional O
breast O
cancer O
events O
in O
women B-eligibility
with I-eligibility
early I-eligibility
stage I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
at I-eligibility
high I-eligibility
risk I-eligibility
of I-eligibility
recurrence I-eligibility
because I-eligibility
of I-eligibility
metabolic I-eligibility
or I-eligibility
endocrine I-eligibility
milieu I-eligibility
. O
The O
intervention O
is O
expected O
to O
reduce O
serum O
insulin O
and O
sex O
hormones O
, O
which O
were O
associated O
with O
breast O
prognosis O
in O
previous O
studies O
. O
Between O
2008 O
and O
2010 O
, O
the O
study O
randomly O
assigned O
1208 B-total-participants
patients O
to O
an O
intensive B-intervention
diet I-intervention
and I-intervention
exercise I-intervention
intervention O
or O
to O
a O
comparison B-control
group I-control
, O
to O
be O
followed O
- O
up O
through O
2015 O
. O
General O
lifestyle O
recommendations O
for O
the O
prevention O
of O
cancer O
are O
given O
to O
both O
groups O
, O
and O
the O
intervention O
group O
is O
being O
offered O
a O
comprehensive O
lifestyle O
intervention O
, O
including O
cooking O
classes O
, O
conferences O
, O
common O
meals O
and O
exercise O
sessions O
. O
Adherence O
assessments O
occurred O
at O
baseline O
and O
at O
12 O
months O
and O
are O
planned O
at O
36 O
and O
60 O
months O
. O
They O
include O
food O
frequency O
diaries O
, O
anthropometric O
measures O
, O
body O
fat O
distribution O
assessed O
with O
impedance O
scale O
, O
one O
week O
registration O
of O
physical O
activity O
with O
a O
multisensor O
arm O
- O
band O
monitor O
, O
metabolic O
and O
endocrine O
blood O
parameters O
. O
Outcome O
breast O
cancer O
events O
are O
assessed O
through O
self O
report O
at O
semi O
annual O
meetings O
or O
telephone O
interview O
and O
are O
validated O
through O
medical O
record O
verification O
. O
The O
randomized O
groups O
were O
comparable O
for O
age O
( O
51.8 B-age
years I-age
) O
, O
proportion O
of O
ER O
- O
negative O
tumors O
( O
22 O
% O
) O
, O
axillary O
node O
metastasis O
( O
42 O
% O
) O
, O
reproductive O
variables O
, O
tobacco O
smoking O
, O
blood O
pressure O
, O
anthropometric O
measurements O
and O
hormonal O
and O
metabolic O
parameters O
. O
DIANA- O
5 O
has O
the O
potential O
to O
establish O
whether O
a O
Mediterranean O
- O
macrobiotic O
lifestyle O
may O
reduce B-outcome
breast I-outcome
cancer I-outcome
recurrences I-outcome
. O
We O
will O
assess O
evidence O
of O
effectiveness O
, O
first O
by O
comparing O
the O
incidence O
of O
additional O
breast O
cancer O
events O
( O
local O
or O
distant O
recurrence O
, O
second O
ipsilateral O
or O
contralateral O
cancer O
) O
in O
the O
intervention O
and O
in O
the O
control O
group O
, O
by O
an O
intention O
- O
to O
- O
treat O
analysis O
, O
and O
second O
by O
analyzing O
the O
incidence O
of O
breast O
cancer O
events O
in O
the O
total O
study O
population O
by O
compliance O
assessment O
score O
. O

Group B-intervention
medical I-intervention
consultations I-intervention
( I-intervention
GMCs I-intervention
) I-intervention
and I-intervention
tablet I-intervention
- I-intervention
based I-intervention
online I-intervention
support I-intervention
group I-intervention
sessions I-intervention
in O
the O
follow O
- O
up O
of O
breast O
cancer O
: O
A O
multicenter O
randomized O
controlled O
trial O
. O
Group O
medical O
consultations O
( O
GMCs O
) O
provide O
individual O
medical O
visits O
in O
the O
presence O
of O
≤ O
7 O
peer O
- O
patients O
. O
In O
the O
follow O
- O
up O
of O
breast O
cancer O
, O
we O
evaluated O
the O
efficacy O
of O
a O
new O
type O
of O
blended O
care O
My O
- O
GMC O
, O
a O
GMC O
combined O
with O
a O
tablet O
- O
based O
online O
app O
, O
consisting O
of O
three O
online O
support O
group O
sessions O
( O
SGS O
) O
and O
additional O
information O
. O
This O
randomized O
controlled O
trial O
compared O
the O
effect O
of O
My O
- O
GMC O
( O
n O
  O
= O
  O
59 B-intervention-participants
) O
with O
one O
individual O
medical O
visit O
( O
n O
  O
= O
  O
50 B-control-participants
) O
( O
care B-control
as I-control
usual I-control
) O
. O
Between O
- O
group O
differences O
on O
the O
outcomes O
distress O
and O
empowerment O
were O
analyzed O
1 O
week O
, O
3 O
and O
6 O
months O
after O
the O
visit O
. O
No O
between O
- O
group O
differences O
were O
found O
for O
the O
primary O
outcomes O
distress B-outcome-measure
and I-outcome-measure
empowerment I-outcome-measure
. O
More O
themes O
were O
discussed O
in O
GMCs O
compared O
to O
individual O
visits O
. O
Significantly O
more O
patients O
experienced B-outcome
peer I-outcome
- I-outcome
support I-outcome
in O
GMCs O
( O
78 B-iv-bin-percent
% I-iv-bin-percent
) O
than O
via O
the O
online O
app O
( O
29 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
Satisfaction B-outcome
with O
the O
online O
app O
was O
low O
. O
My O
- O
GMC O
did O
not O
result O
in O
improvements O
in O
distress B-outcome
or I-outcome
empowerment I-outcome
, O
which O
might O
partly O
be O
explained O
by O
low O
baseline O
distress O
levels O
. O
This O
paper O
provides O
valuable O
information O
concerning O
factors O
on O
organizational O
level O
as O
well O
as O
individual O
level O
influencing O
the O
evaluation O
of O
a O
blended O
care O
intervention O
. O
My O
- O
GMC O
provided O
an O
innovative O
alternative O
, O
combining O
professional O
and O
peer O
- O
support O
in O
face O
- O
to O
- O
face O
and O
online O
SGS O
, O
resulting O
in O
additional O
information O
provision O
and O
peer O
- O
support O
. O
Further O
improvement O
of O
the O
apps O
is O
needed O
to O
improve O
user O
satisfaction O
. O
NTR O
3771 O
. O

Survival O
outcomes O
of O
neoadjuvant B-intervention
chemotherapy I-intervention
with I-intervention
zoledronic I-intervention
acid I-intervention
for O
HER O
2 O
- O
negative O
breast O
cancer O
. O
A O
randomized O
phase O
2 O
trial O
in O
women O
with O
HER O
2 O
- O
negative O
breast O
cancer O
has O
shown O
that O
adding O
zoledronic O
acid O
( O
ZOL O
) O
to O
neoadjuvant O
chemotherapy O
( O
CT O
) O
has O
potential O
anticancer O
benefits O
in O
postmenopausal O
and O
triple O
- O
negative O
( O
TN O
) O
breast O
cancer O
patients O
. O
We O
report O
the O
data O
for O
the O
secondary O
end O
point O
of O
disease O
- O
free O
survival O
( O
DFS O
) O
. O
Patients O
were O
randomly O
assigned O
to O
receive O
CT O
or O
CT O
  O
+ O
  O
ZOL O
( O
CT O
- O
Z O
) O
. O
All O
patients O
received O
four O
cycles O
of O
FEC O
100 O
followed O
by O
12 O
cycles O
of O
paclitaxel O
weekly O
. O
ZOL O
( O
4 O
  O
mg O
) O
was O
administered O
3 O
- O
4 O
times O
weekly O
for O
7 O
  O
wk O
to O
the O
CT O
- O
Z O
group O
patients O
. O
The O
primary O
end O
point O
was O
pathologic B-outcome-measure
complete I-outcome-measure
response I-outcome-measure
( I-outcome-measure
pCR I-outcome-measure
) I-outcome-measure
. O
The O
secondary O
end O
points O
were O
the O
clinical B-outcome-measure
response I-outcome-measure
rates I-outcome-measure
, O
rate B-outcome-measure
of I-outcome-measure
breast I-outcome-measure
- I-outcome-measure
conserving I-outcome-measure
surgery I-outcome-measure
, O
safety B-outcome-measure
, O
and O
DFS B-outcome-measure
. O
Of O
the O
188 B-total-participants
patients O
enrolled O
, O
95 B-control-participants
were O
assigned O
to O
the O
CT O
group O
and O
93 B-intervention-participants
to O
the O
CT O
- O
Z O
group O
. O
DFS B-outcome
and O
overall B-outcome
survival I-outcome
were O
analyzed O
in O
92 B-control-participants
and O
88 B-intervention-participants
patients O
with O
the O
mean O
times O
of O
5.15 B-cv-cont-mean
  I-cv-cont-mean
y I-cv-cont-mean
and O
5.38 B-iv-cont-mean
  I-iv-cont-mean
y I-iv-cont-mean
, O
respectively O
. O
The O
3 B-outcome
-y I-outcome
DFS I-outcome
rate I-outcome
was O
84.6 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
CT O
group O
and O
90.8 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
CT O
- O
Z O
group O
( O
P O
  O
= O
  O
0.188 O
) O
. O
The O
particular O
benefit O
from O
ZOL O
for O
the O
neoadjuvant O
CT O
seen O
as O
  O
improvement O
of O
the O
pCR B-outcome
rate I-outcome
was O
indicated O
in O
the O
3 O
-y O
DFS O
period O
for O
TN O
cancer O
cases O
( O
CT O
  O
versus O
CT O
- O
Z O
: O
70.6 B-cv-bin-percent
% I-cv-bin-percent
versus O
94.1 B-iv-bin-percent
% I-iv-bin-percent
) O
but O
not O
for O
postmenopausal O
cases O
. O
ZOL O
did O
not O
improve O
DFS B-outcome
when O
combined O
with O
CT O
. O
However O
, O
the O
improvement O
of O
the O
pCR O
rate O
translated O
to O
survival O
outcomes O
in O
TN O
breast O
cancer O
. O
The O
short O
- O
term O
application O
of O
ZOL O
may O
not O
be O
sufficient O
to O
improve O
the O
outcome O
in O
postmenopausal O
patients O
. O

Ten O
- O
year O
follow O
- O
up O
of O
a O
randomized O
controlled O
trial O
of O
adjuvant B-intervention
clodronate I-intervention
treatment O
in O
node O
- O
positive O
breast O
cancer O
patients O
. O
Ten O
- O
year O
follow O
- O
up O
results O
are O
presented O
of O
an O
adjuvant O
clodronate O
trial O
in O
patients O
with O
primary O
breast O
cancer O
. O
Between O
1990 O
and O
1993 O
, O
299 B-total-participants
women B-eligibility
with I-eligibility
primary I-eligibility
node I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
to O
oral O
clodronate O
1600 O
mg O
daily O
( O
149 B-intervention-participants
) O
or O
controls B-control
( O
150 B-control-participants
) O
for O
3 O
years O
. O
All O
patients O
received O
adjuvant O
chemo- O
or O
endocrine O
therapy O
. O
Within O
10 O
years O
bone B-outcome
metastases I-outcome
were O
detected O
at O
the O
same O
frequency O
in O
the O
clodronate O
and O
control O
groups O
: O
44 B-iv-bin-abs
( O
32 B-iv-bin-percent
% I-iv-bin-percent
) O
vs. O
42 B-cv-bin-abs
( O
29 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
respectively O
, O
( O
p= O
0.35 O
) O
. O
The O
frequency B-outcome
of I-outcome
non I-outcome
- I-outcome
skeletal I-outcome
recurrences I-outcome
( O
visceral O
and O
local O
) O
was O
significantly O
higher O
in O
the O
clodronate O
group O
69 B-iv-bin-abs
( O
50 B-iv-bin-percent
% I-iv-bin-percent
) O
as O
compared O
with O
the O
controls O
51 B-cv-bin-abs
( O
36 B-cv-bin-percent
% I-cv-bin-percent
) O
( O
p= O
0.005 O
) O
. O
Ten B-outcome
- I-outcome
year I-outcome
disease I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
DFS I-outcome
) I-outcome
remained O
significantly O
lower O
in O
the O
clodronate O
group O
( O
45 B-iv-bin-percent
% I-iv-bin-percent
vs. O
58 B-cv-bin-percent
% I-cv-bin-percent
, O
p= O
0.01 O
, O
respectively O
) O
. O
This O
was O
especially O
seen O
in O
oestrogen B-outcome
receptor I-outcome
negative I-outcome
patients I-outcome
( O
25 B-iv-bin-percent
% I-iv-bin-percent
vs. O
58 B-cv-bin-percent
% I-cv-bin-percent
, O
p= O
0.004 O
, O
respectively O
) O
. O
No O
significant O
overall B-outcome
survival I-outcome
difference O
was O
found O
between O
the O
groups O
. O
As O
previously O
reported O
3 O
-year O
adjuvant O
clodronate O
treatment O
did O
not O
prevent O
the O
development O
of O
bone O
metastases O
in O
node O
- O
positive O
breast O
cancer O
patients O
. O
A O
negative O
effect O
of O
clodronate O
on O
DFS O
by O
increasing O
the O
development O
of O
visceral O
metastases O
was O
still O
seen O
at O
10 O
years O
, O
but O
this O
did O
not O
significantly O
compromise O
overall O
survival O
. O

Intake O
of O
vitamin B-intervention
D I-intervention
and I-intervention
calcium I-intervention
, I-intervention
sun I-intervention
exposure I-intervention
, O
and O
risk O
of O
breast O
cancer O
subtypes O
among O
black O
women O
. O
The O
randomized O
placebo O
- O
controlled O
Vitamin O
D O
and O
Omega- O
3 O
Trial O
suggested O
a O
possible O
benefit O
of O
vitamin O
D O
on O
cancer O
incidence O
among O
black B-ethinicity
individuals O
. O
However O
, O
data O
are O
limited O
regarding O
the O
impact O
of O
vitamin O
D O
on O
breast O
cancer O
subtypes O
among O
African B-ethinicity
- I-ethinicity
American I-ethinicity
/ I-ethinicity
black I-ethinicity
women O
, O
who O
tend O
to O
develop O
more O
aggressive O
forms O
of O
breast O
cancer O
. O
We O
hypothesize O
that O
more O
vitamin O
D O
exposure O
( O
through O
diet O
, O
supplements O
, O
and O
sunlight O
) O
and O
higher O
intake O
of O
calcium O
are O
associated O
with O
decreased O
risk O
of O
estrogen O
receptor O
( O
ER O
) O
+ O
and O
ER- O
breast O
cancer O
, O
and O
of O
triple O
- O
negative O
breast O
cancer O
( O
TNBC O
) O
among O
black O
women O
. O
This O
study O
was O
conducted O
among O
1724 B-intervention-participants
black O
cases O
and O
1233 B-control-participants
controls B-control
in O
the O
Women O
's O
Circle O
of O
Health O
Study O
( O
WCHS O
) O
and O
WCHS O
2 O
. O
Polytomous O
logistic O
regressions O
were O
used O
to O
estimate O
ORs O
and O
95 O
% O
CIs O
of O
ER+ O
and O
ER- O
breast O
cancer O
; O
logistic O
regressions O
were O
used O
for O
TNBC O
. O
The O
ORs O
from O
each O
study O
were O
pooled O
using O
an O
inverse O
- O
variance O
- O
weighted O
random O
- O
effects O
model O
. O
Dietary B-outcome
vitamin I-outcome
D I-outcome
and I-outcome
calcium I-outcome
intake I-outcome
were O
not O
associated O
with O
risk O
of O
breast O
cancer O
subtypes O
in O
the O
pooled O
analysis O
. O
For O
supplemental O
vitamin O
D O
, O
we O
observed O
possible O
inverse O
associations O
between O
intake O
of O
≤ O
800 O
IU O
/ O
d O
( O
compared O
with O
nonuse O
) O
and O
risk B-outcome
of I-outcome
several I-outcome
subtypes I-outcome
, O
with O
effects O
that O
appeared O
strongest O
for O
TNBC O
( O
OR O
: O
0.58 O
; O
95 O
% O
CI O
: O
0.35 O
, O
0.94 O
) O
; O
no O
association O
was O
found O
for O
> O
800 O
IU O
/ O
d. O
More O
daylight O
hours O
spent O
outdoors O
in O
a O
year O
was O
associated O
with O
lower O
risk B-outcome
of I-outcome
ER+ I-outcome
, I-outcome
ER- I-outcome
, I-outcome
and I-outcome
TNBC I-outcome
( O
e.g. O
, O
highest O
compared O
with O
lowest O
quartile O
: O
TNBC O
OR O
: O
0.53 O
; O
95 O
% O
CI O
: O
0.31 O
, O
0.91 O
; O
P O
- O
trend O
  O
= O
  O
0.02 O
) O
. O
Moderate O
supplemental O
vitamin O
D O
intake O
was O
associated O
with O
decreased O
risk O
of O
TNBC O
, O
and O
increased O
sun O
exposure O
was O
associated O
with O
reduced O
risk O
of O
ER+ O
, O
ER- O
, O
and O
TNBC O
among O
black O
women O
. O

A O
Randomized O
Controlled O
Trial O
of O
Green B-intervention
Tea I-intervention
Extract I-intervention
Supplementation O
and O
Mammographic O
Density O
in O
Postmenopausal O
Women O
at O
Increased O
Risk O
of O
Breast O
Cancer O
. O
Epidemiologic O
and O
animal O
studies O
suggest O
a O
protective O
role O
of O
green O
tea O
against O
breast O
cancer O
. O
However O
, O
the O
underlying O
mechanism O
is O
not O
understood O
. O
We O
conducted O
a O
randomized O
, O
double O
- O
blinded O
, O
placebo O
- O
controlled O
phase O
II O
clinical O
trial O
to O
investigate O
whether O
supplementation O
with O
green O
tea O
extract O
( O
GTE O
) O
modifies O
mammographic O
density O
( O
MD O
) O
, O
as O
a O
potential O
mechanism O
, O
involving O
1 B-total-participants
, I-total-participants
075 I-total-participants
healthy B-eligibility
postmenopausal I-eligibility
women I-eligibility
. O
Women O
assigned O
to O
the O
treatment O
arm O
consumed O
daily O
4 O
decaffeinated O
GTE O
capsules O
containing O
1 O
, O
315 O
mg O
total O
catechins O
, O
including O
843 O
mg O
epigallocatechin- O
3 O
- O
gallate O
( O
EGCG O
) O
for O
12 O
months O
. O
A O
computer O
- O
assisted O
method O
( O
Madena O
) O
was O
used O
to O
assess O
MD O
in O
digital O
mammograms O
at O
baseline O
and O
month O
12 O
time O
points O
in O
932 B-total-participants
completers O
( O
462 B-intervention-participants
in O
GTE O
and O
470 B-control-participants
in O
placebo B-control
) O
. O
GTE O
supplementation O
for O
12 O
months O
did O
not O
significantly O
change O
percent O
MD O
( O
PMD O
) O
or O
absolute O
MD O
in O
all O
women O
. O
In O
younger O
women O
( O
50 O
- O
55 O
years O
) O
, O
GTE O
supplementation O
significantly O
reduced O
PMD B-outcome
by O
4.40 B-iv-bin-percent
% I-iv-bin-percent
as O
compared O
with O
the O
placebo O
with O
a O
1.02 B-cv-bin-percent
% I-cv-bin-percent
PMD O
increase O
from O
pre- O
to O
postintervention O
( O
P O
= O
0.05 O
) O
, O
but O
had O
no O
effect O
in O
older O
women O
( O
Pinteraction O
= O
0.07 O
) O
. O
GTE O
supplementation O
did O
not O
induce O
MD B-outcome
change I-outcome
in O
other O
subgroups O
of O
women O
stratified O
by O
catechol O
- O
O O
- O
methyltransferase O
genotype O
or O
level O
of O
body O
mass O
index O
. O
In O
conclusion O
, O
1 O
-year O
supplementation O
with O
a O
high O
dose O
of O
EGCG O
did O
not O
have O
a O
significant O
effect O
on O
MD O
measures O
in O
all O
women O
, O
but O
reduced B-outcome
PMD I-outcome
in O
younger O
women O
, O
an O
age O
- O
dependent O
effect O
similar O
to O
those O
of O
tamoxifen O
. O
Further O
investigation O
of O
the O
potential O
chemopreventive O
effect O
of O
green O
tea O
intake O
on O
breast O
cancer O
risk O
in O
younger O
women O
is O
warranted O
. O
Cancer O
Prev O
Res O
; O
10 O
( O
12 O
) O
; O
710 O
- O
8 O
. O
© O
2017 O
AACR O
. O

Effectiveness O
of O
Tailored B-intervention
Rehabilitation I-intervention
Education I-intervention
in O
Improving O
the O
Health O
Literacy O
and O
Health O
Status O
of O
Postoperative B-eligibility
Patients I-eligibility
With I-eligibility
Breast I-eligibility
Cancer I-eligibility
: O
A O
Randomized O
Controlled O
Trial O
. O
The O
improvement O
of O
breast O
cancer O
treatment O
and O
the O
extension O
of O
survivorship O
have O
led O
to O
the O
development O
of O
postoperative O
complications O
among O
cancer O
survivors O
. O
Health O
literacy O
( O
HL O
) O
, O
defined O
as O
patients O
' O
capability O
of O
using O
health O
information O
to O
maintain O
their O
health O
status O
, O
can O
enable O
breast O
cancer O
patients O
to O
manage O
postoperative O
complications O
. O
The O
aims O
of O
this O
study O
were O
to O
develop O
a O
tailored O
rehabilitation O
education O
( O
TRE O
) O
program O
and O
examine O
the O
effectiveness O
of O
this O
program O
in O
improving O
the O
HL O
and O
health O
status O
with O
breast O
cancer O
. O
This O
randomized O
controlled O
trial O
recruited O
99 B-total-participants
breast O
cancer O
patients O
( O
49 B-intervention-participants
and O
50 B-control-participants
in O
the O
intervention O
and O
control B-control
groups O
, O
respectively O
) O
within O
1 O
week O
after O
surgery O
. O
Four O
- O
week O
individualized O
TRE O
programs O
were O
implemented O
to O
improve O
their O
HL O
and O
health O
status O
. O
Our O
results O
showed O
that O
the O
TRE O
program O
produced O
significant O
improvements O
in O
HL B-outcome
and I-outcome
health I-outcome
status I-outcome
in I-outcome
the I-outcome
components I-outcome
of I-outcome
the I-outcome
International I-outcome
Classification I-outcome
of I-outcome
Functioning I-outcome
, I-outcome
Disability I-outcome
and I-outcome
Health I-outcome
. O
However O
, O
no O
significant O
difference O
was O
observed O
in O
the O
activity B-outcome
scores I-outcome
obtained I-outcome
using I-outcome
the I-outcome
Barthel I-outcome
Index I-outcome
between O
the O
2 O
groups O
. O
Our O
finding O
supports O
the O
effectiveness O
of O
1 O
-month O
TRE O
in O
improving O
HL O
and O
all O
components O
of O
the O
International O
Classification O
of O
Functioning O
, O
Disability O
and O
Health O
status O
, O
except O
the O
activity O
component O
among O
breast O
cancer O
in O
Taiwan B-location
. O
Clinicians O
could O
incorporate O
the O
TRE O
techniques O
in O
the O
rehabilitation O
sessions O
according O
to O
the O
healthcare O
, O
disease O
prevention O
, O
and O
health O
promotion O
domains O
to O
improve O
the O
clinical O
outcomes O
as O
well O
as O
change O
their O
health O
behaviors O
and O
attitudes O
of O
patients O
with O
breast O
cancer O
. O

High B-intervention
- I-intervention
dose I-intervention
chemotherapy I-intervention
with O
haematopoietic O
stem O
cell O
transplantation O
for O
metastatic O
breast O
cancer O
patients O
: O
final O
results O
of O
the O
French B-location
multicentric O
randomised O
CMA O
/ O
PEGASE O
04 O
protocol O
. O
The O
aim O
of O
our O
study O
was O
to O
evaluate O
the O
impact O
on O
time O
to O
progression O
( O
TTP O
) O
and O
overall O
survival O
( O
OS O
) O
of O
high O
- O
dose O
chemotherapy O
( O
HD O
- O
CT O
) O
over O
conventional B-control
CT I-control
in O
metastatic B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
. O
Between O
09 O
/ O
92 O
and O
12 O
/ O
96 O
, O
61 B-total-participants
patients B-eligibility
with I-eligibility
chemosensitive I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomised O
between O
HD O
- O
CT O
using O
the O
CMA O
regimen O
( O
Mitoxantrone O
, O
Cyclophosphamide O
, O
Melphalan O
) O
applied O
as O
consolidation O
( O
32 B-intervention-participants
patients O
) O
or O
maintenance O
CT O
( O
29 B-control-participants
patients O
) O
. O
At O
randomisation O
, O
13 O
patients O
were O
in O
complete B-outcome
response I-outcome
, O
47 O
in O
partial B-outcome
response I-outcome
and O
one O
had O
stable B-outcome
disease I-outcome
. O
The O
median B-outcome
TTPs I-outcome
from O
randomisation O
were O
6 B-iv-cont-median
and O
12 B-cv-cont-median
months I-cv-cont-median
in O
the O
standard O
and O
intensive O
groups O
, O
respectively O
( O
P O
< O
0.0056 O
) O
, O
with O
a O
relapse B-outcome
rate I-outcome
of O
86.2 B-iv-bin-percent
% I-iv-bin-percent
vs. O
62.5 B-cv-bin-percent
% I-cv-bin-percent
at B-outcome
2 I-outcome
years I-outcome
, O
and O
100 B-iv-bin-percent
% I-iv-bin-percent
vs. O
81.3 B-cv-bin-percent
% I-cv-bin-percent
at B-outcome
5 I-outcome
years I-outcome
. O
The O
median B-outcome
OS I-outcome
times I-outcome
were O
19.3 B-iv-cont-median
and O
44.1 B-cv-cont-median
months I-cv-cont-median
, O
with O
an O
OS B-outcome
rate I-outcome
of O
13.8 B-iv-bin-percent
% I-iv-bin-percent
vs. O
36.8 B-cv-bin-percent
% I-cv-bin-percent
at B-outcome
5 I-outcome
years I-outcome
( O
P O
< O
0.0294 O
) O
. O
The O
CMA O
regimen O
could O
prolong O
the O
TTP O
of O
patients O
with O
chemosensitive O
metastatic O
breast O
cancer O
. O
Further O
studies O
are O
needed O
to O
determine O
if O
this O
translates O
into O
an O
effect O
on O
OS O
. O

High B-intervention
- I-intervention
dose I-intervention
chemotherapy I-intervention
with O
hematopoietic O
stem O
- O
cell O
rescue O
for O
high O
- O
risk O
breast O
cancer O
. O
The O
use O
of O
high O
- O
dose O
adjuvant O
chemotherapy O
for O
high O
- O
risk O
primary O
breast O
cancer O
is O
controversial O
. O
We O
studied O
its O
efficacy O
in O
patients O
with O
4 O
to O
9 O
or O
10 O
or O
more O
tumor O
- O
positive O
axillary O
lymph O
nodes O
. O
Patients O
younger B-age
than I-age
56 I-age
years I-age
of O
age O
who B-eligibility
had I-eligibility
undergone I-eligibility
surgery I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
who I-eligibility
had I-eligibility
no I-eligibility
distant I-eligibility
metastases I-eligibility
were O
eligible O
if O
they O
had O
at O
least O
four O
tumor O
- O
positive O
axillary O
lymph O
nodes O
. O
Patients O
in O
the O
conventional O
- O
dose O
group O
received O
fluorouracil O
, O
epirubicin O
, O
and O
cyclophosphamide O
( O
FEC O
) O
every O
three O
weeks O
for O
five O
courses O
, O
followed O
by O
radiotherapy O
and O
tamoxifen O
. O
The O
high O
- O
dose O
treatment O
was O
identical O
, O
except O
that O
high O
- O
dose O
chemotherapy O
( O
6 O
g O
of O
cyclophosphamide O
per O
square O
meter O
of O
body O
- O
surface O
area O
, O
480 O
mg O
of O
thiotepa O
per O
square O
meter O
, O
and O
1600 O
mg O
of O
carboplatin O
per O
square O
meter O
) O
with O
autologous O
peripheral O
- O
blood O
hematopoietic O
progenitor O
- O
cell O
transplantation O
replaced O
the O
fifth O
course O
of O
FEC O
. O
Of O
the O
885 B-total-participants
patients O
, O
442 B-intervention-participants
were O
assigned O
to O
the O
high O
- O
dose O
group O
and O
443 B-control-participants
to O
the O
conventional B-control
- I-control
dose I-control
group I-control
. O
After O
a O
median O
follow O
- O
up O
of O
57 O
months O
, O
the O
actuarial O
5 B-outcome
-year I-outcome
relapse I-outcome
- I-outcome
free I-outcome
survival I-outcome
rates I-outcome
were O
59 B-cv-bin-percent
percent I-cv-bin-percent
in O
the O
conventional O
- O
dose O
group O
and O
65 B-iv-bin-percent
percent I-iv-bin-percent
in O
the O
high O
- O
dose O
group O
( O
hazard O
ratio O
for O
relapse O
in O
the O
high O
- O
dose O
group O
, O
0.83 O
; O
95 O
percent O
confidence O
interval O
, O
0.66 O
to O
1.03 O
; O
P= O
0.09 O
) O
. O
In O
the O
group O
with O
10 O
or O
more O
positive O
nodes O
, O
the O
relapse B-outcome
- I-outcome
free I-outcome
survival I-outcome
rates I-outcome
were O
51 B-cv-bin-percent
percent I-cv-bin-percent
in O
the O
conventional O
- O
dose O
group O
and O
61 B-iv-bin-percent
percent I-iv-bin-percent
in O
the O
high O
- O
dose O
group O
( O
P= O
0.05 O
by O
the O
log O
- O
rank O
test O
; O
hazard O
ratio O
for O
relapse O
, O
0.71 O
; O
95 O
percent O
confidence O
interval O
, O
0.50 O
to O
1.00 O
) O
. O
High O
- O
dose O
alkylating O
therapy O
improves O
relapse B-outcome
- I-outcome
free I-outcome
survival I-outcome
among O
patients O
with O
stage O
II O
or O
III O
breast O
cancer O
and O
10 O
or O
more O
positive O
axillary O
lymph O
nodes O
. O
This O
benefit O
may O
be O
confined O
to O
patients O
with O
HER- O
2 O
/ O
neu O
- O
negative O
tumors O
. O

Race O
and O
hormone O
receptor O
- O
positive O
breast O
cancer O
outcomes O
in O
a O
randomized O
chemotherapy B-intervention
trial O
. O
The O
association O
between O
black O
race O
and O
worse O
outcomes O
in O
operable O
breast O
cancer O
reported O
in O
previous O
studies O
has O
been O
attributed O
to O
a O
higher O
incidence O
of O
more O
aggressive O
triple O
- O
negative O
disease O
, O
disparities O
in O
care O
, O
and O
comorbidities O
. O
We O
evaluated O
associations O
between O
black B-ethinicity
race I-ethinicity
and O
outcomes O
, O
by O
tumor O
hormone O
receptor O
and O
HER O
2 O
expression O
, O
in O
patients B-eligibility
who I-eligibility
were I-eligibility
treated I-eligibility
with I-eligibility
contemporary I-eligibility
adjuvant I-eligibility
therapy I-eligibility
. O
The O
effect O
of O
black O
race O
on O
disease O
- O
free O
and O
overall O
survival O
was O
evaluated O
using O
Cox O
proportional O
hazards O
models O
adjusted O
for O
multiple O
covariates O
in O
a O
clinical O
trial O
population O
that O
was O
treated O
with O
anthracycline- O
and O
taxane O
- O
containing O
chemotherapy O
. O
Categorical O
variables O
were O
compared O
using O
the O
Fisher O
exact O
test O
. O
All O
P O
values O
are O
two O
- O
sided O
. O
Of O
4817 B-total-participants
eligible O
patients O
, O
405 B-intervention-participants
( O
8.4 O
% O
) O
were O
black B-ethinicity
. O
Compared O
with O
nonblack B-control
patients O
, O
black B-intervention
patients O
had O
a O
higher O
rate B-outcome
of I-outcome
triple I-outcome
- I-outcome
negative I-outcome
disease I-outcome
( O
31.9 B-iv-bin-percent
% I-iv-bin-percent
vs O
17.2 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
< O
. O
001 O
) O
and O
a O
higher O
body O
mass O
index O
( O
median O
: O
31.7 O
vs O
27.4 O
kg O
/ O
m O
( O
2 O
) O
; O
P O
< O
. O
001 O
) O
. O
Black O
race O
was O
statistically O
significantly O
associated O
with O
worse O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
5 O
-year O
disease O
- O
free O
survival O
, O
black O
vs O
nonblack O
: O
76.7 B-iv-bin-percent
% I-iv-bin-percent
vs O
84.5 B-cv-bin-percent
% I-cv-bin-percent
; O
hazard O
ratio O
of O
recurrence O
or O
death O
= O
1.58 O
, O
95 O
% O
confidence O
interval O
= O
1.19 O
to O
2.10 O
, O
P O
= O
. O
0015 O
) O
and O
overall B-outcome
survival I-outcome
( O
5 B-outcome
-year I-outcome
overall I-outcome
survival I-outcome
, O
black O
vs O
nonblack O
: O
87.6 B-iv-bin-percent
% I-iv-bin-percent
vs O
91.9 B-cv-bin-percent
% I-cv-bin-percent
; O
hazard O
ratio O
of O
death O
= O
1.49 O
, O
95 O
% O
confidence O
interval O
= O
1.05 O
to O
2.12 O
, O
P O
= O
. O
025 O
) O
in O
patients O
with O
hormone O
receptor O
- O
positive O
HER O
2 O
- O
negative O
disease O
but O
not O
in O
patients O
with O
triple O
- O
negative O
or O
HER O
2 O
- O
positive O
disease O
. O
In O
a O
model O
that O
included O
black O
race O
, O
hormone O
receptor O
- O
positive O
HER O
2 O
- O
negative O
disease O
vs O
other O
subtypes O
, O
and O
their O
interaction O
, O
the O
interaction O
term O
was O
statistically O
significant O
for O
disease O
- O
free O
survival O
( O
P O
= O
. O
027 O
) O
but O
not O
for O
overall O
survival O
( O
P O
= O
. O
086 O
) O
. O
Factors O
other O
than O
disparities O
in O
care O
or O
aggressive O
disease O
contribute O
to O
increased O
recurrence O
in O
black O
women O
with O
hormone O
receptor O
- O
positive O
breast O
cancer O
. O

Exemestane B-intervention
for O
breast O
cancer O
prevention O
: O
a O
critical O
shift O
? O
The O
Mammary O
Prevention O
3 O
( O
MAP O
. O
3 O
) O
placebo O
- O
controlled O
randomized O
trial O
in O
4 B-total-participants
, I-total-participants
560 I-total-participants
high B-eligibility
- I-eligibility
risk I-eligibility
postmenopausal I-eligibility
women I-eligibility
showed O
a O
65 B-iv-bin-percent
% I-iv-bin-percent
reduction B-outcome
in I-outcome
invasive I-outcome
breast I-outcome
cancer I-outcome
with O
the O
use O
of O
exemestane O
at O
35 O
months O
median O
follow O
- O
up O
. O
Few O
differences O
in O
adverse B-outcome
events I-outcome
were O
observed O
between O
the O
arms O
, O
suggesting O
a O
promising O
risk O
: O
benefit O
balance O
with O
exemestane O
for O
use O
in O
chemoprevention O
. O
Yet O
, O
the O
MAP O
. O
3 O
design O
and O
implementation O
raise O
concerns O
regarding O
limited O
data O
maturity O
and O
not O
prospectively O
including O
key O
bone O
- O
related O
and O
other O
toxicities O
as O
study O
end O
points O
. O
Exemestane O
for O
prevention O
is O
juxtaposed O
against O
selective O
estrogen O
receptor O
modulators O
and O
the O
other O
aromatase O
inhibitors O
. O
Additional O
issues O
for O
prevention O
, O
including O
the O
influence O
of O
obesity O
, O
alternative O
dosing O
, O
and O
biomarker O
use O
in O
phase O
III O
trials O
, O
are O
addressed O
. O
The O
recently O
completed O
MAP O
. O
3 O
trial O
of O
exemestane O
for O
breast O
cancer O
prevention O
offers O
a O
potential O
new O
standard O
for O
pharmaceutical O
risk O
reduction O
in O
high O
- O
risk O
postmenopausal O
women O
. O
In O
addition O
to O
describing O
key O
findings O
from O
the O
publication O
of O
MAP O
. O
3 O
and O
related O
trials O
, O
our O
review O
undertakes O
a O
detailed O
analysis O
of O
the O
strengths O
and O
weaknesses O
of O
MAP O
. O
3 O
as O
well O
as O
the O
implications O
for O
future O
prevention O
research O
. O

The O
Patient O
's O
Anastrozole O
Compliance O
to O
Therapy O
( O
PACT O
) O
Program O
: O
a O
randomized O
, O
in O
- O
practice O
study O
on O
the O
impact O
of O
a O
standardized B-intervention
information I-intervention
program I-intervention
on O
persistence O
and O
compliance O
to O
adjuvant O
endocrine O
therapy O
in O
postmenopausal O
women O
with O
early O
breast O
cancer O
. O
Compliance O
and O
persistence O
are O
often O
overlooked O
in O
adjuvant O
breast O
cancer O
treatment O
. O
PACT O
was O
a O
prospective O
, O
multicenter O
, O
randomized O
, O
open O
, O
parallel O
- O
group O
study O
assessing O
whether O
educational O
materials O
( O
EMs O
) O
enhanced O
compliance O
with O
aromatase O
inhibitor O
( O
AI O
) O
therapy O
in O
postmenopausal O
women O
with O
early O
, O
hormone O
- O
receptor O
- O
positive O
( O
HR+ O
) O
breast O
cancer O
. O
The O
primary O
end O
points O
were O
compliance B-outcome-measure
( O
proportion O
taking O
≥ O
80 O
% O
anastrozole O
) O
at O
12 O
months O
and O
persistence B-outcome-measure
( O
proportion O
reporting O
anastrozole O
intake O
during O
the O
study O
period O
) O
. O
Four B-total-participants
thousand I-total-participants
eight I-total-participants
hundred I-total-participants
and I-total-participants
forty I-total-participants
- I-total-participants
four I-total-participants
patients O
were O
randomly O
assigned O
1 O
:1 O
to O
receive O
standard B-control
therapy I-control
or O
standard O
therapy O
with O
EMs O
. O
There O
was O
no O
difference O
between O
arms O
in O
compliance B-outcome
( O
N O
= O
2740 O
; O
88.5 B-cv-bin-percent
% I-cv-bin-percent
/ O
88.8 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
, O
P O
= O
0.81 O
) O
or O
persistence B-outcome
rates I-outcome
( O
N O
= O
2740 O
; O
40.5 B-cv-bin-percent
% I-cv-bin-percent
/ O
43.0 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
, O
P O
= O
0.18 O
) O
. O
Modified O
end O
point O
analyses O
found O
no O
differences O
in O
compliance B-outcome
between O
arms O
based O
on O
the O
classification O
of O
: O
( O
i O
) O
patients B-outcome
with I-outcome
missing I-outcome
documentation I-outcome
or I-outcome
follow I-outcome
- I-outcome
up I-outcome
visit I-outcome
< O
9 O
months O
as O
non O
- O
compliant O
( O
N O
= O
4397 O
, O
P O
= O
0.15 O
) O
; O
( O
ii O
) O
patients B-outcome
with I-outcome
early I-outcome
( I-outcome
≤ I-outcome
292 I-outcome
days I-outcome
) I-outcome
12 I-outcome
-month I-outcome
follow I-outcome
- I-outcome
up I-outcome
documentation I-outcome
excluded I-outcome
( O
N O
= O
4091 O
, O
P O
= O
0.19 O
) O
; O
( O
iii O
) O
patients B-outcome
reaching I-outcome
≥ I-outcome
80 I-outcome
% I-outcome
compliance I-outcome
during O
individual O
follow O
- O
up O
as O
compliant O
( O
N O
= O
4397 O
, O
P O
= O
0.26 O
) O
. O
Modified O
persistence O
analyses O
found O
no O
difference O
between O
arms O
( O
N O
= O
4397 O
, O
P O
= O
0.37 O
) O
. O
Addition O
of O
EMs O
to O
standard O
therapy O
did O
not O
significantly O
affect O
compliance O
and O
persistence O
with O
adjuvant O
anastrozole O
. O
CLINICALTRIALS O
ID O
: O
NCT O
00555867 O
. O

Phase O
III O
trial O
comparing O
doxorubicin B-intervention
plus I-intervention
cyclophosphamide I-intervention
with O
docetaxel B-control
plus I-control
cyclophosphamide I-control
as O
adjuvant O
therapy O
for O
operable O
breast O
cancer O
. O
The O
combination O
of O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
is O
a O
standard O
adjuvant O
chemotherapy O
regimen O
. O
Studies O
of O
docetaxel O
and O
cyclophosphamide O
( O
TC O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
showed O
promise O
in O
MBC O
. O
In O
1997 O
, O
we O
initiated O
a O
randomized O
adjuvant O
trial O
of O
TC O
compared O
with O
standard O
- O
dose O
AC O
with O
a O
primary O
end O
point O
of O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
DFS I-outcome-measure
) I-outcome-measure
. O
Patients O
were O
eligible O
if O
they O
had O
stage B-eligibility
I I-eligibility
to I-eligibility
III I-eligibility
operable I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
with I-eligibility
complete I-eligibility
surgical I-eligibility
excision I-eligibility
of I-eligibility
the I-eligibility
primary I-eligibility
tumor I-eligibility
. O
Between O
June O
1997 O
and O
December O
1999 O
, O
1 B-total-participants
, I-total-participants
016 I-total-participants
patients O
were O
randomly O
assigned O
to O
four O
cycles O
of O
either O
standard O
- O
dose O
AC O
( O
60 O
and O
600 O
mg O
/ O
m O
2 O
, O
respectively O
; O
n O
= O
510 B-intervention-participants
) O
or O
TC O
( O
75 O
and O
600 O
mg O
/ O
m O
2 O
, O
respectively O
; O
n O
= O
506 B-control-participants
) O
, O
administered O
intravenously O
every O
3 O
weeks O
as O
adjuvant O
chemotherapy O
. O
Radiation O
therapy O
( O
as O
indicated O
) O
and O
tamoxifen O
, O
for O
patients O
with O
hormone O
receptor O
- O
positive O
disease O
, O
were O
administered O
after O
completion O
of O
chemotherapy O
. O
Both O
treatment O
groups O
( O
TC O
and O
AC O
) O
were O
well O
balanced O
with O
respect O
to O
major O
prognostic O
factors O
. O
Patients O
were O
observed O
through O
2005 O
for O
a O
median O
of O
5.5 O
years O
. O
At O
5 O
years O
, O
DFS B-outcome
rate I-outcome
was O
significantly O
superior O
for O
TC O
compared O
with O
AC O
( O
86 B-iv-bin-percent
% I-iv-bin-percent
v O
80 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
hazard O
ratio O
[ O
HR O
] O
= O
0.67 O
; O
95 O
% O
CI O
, O
0.50 O
to O
0.94 O
; O
P O
= O
. O
015 O
) O
. O
Overall B-outcome
survival I-outcome
rates I-outcome
for O
TC O
and O
AC O
were O
90 B-iv-bin-percent
% I-iv-bin-percent
and O
87 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
( O
HR O
= O
0.76 O
; O
95 O
% O
CI O
, O
0.52 O
to O
1.1 O
; O
P O
= O
. O
13 O
) O
. O
More O
myalgia B-outcome
, I-outcome
arthralgia I-outcome
, I-outcome
edema I-outcome
, I-outcome
and I-outcome
febrile I-outcome
neutropenia I-outcome
occurred O
on O
the O
TC O
arm O
; O
more O
nausea B-outcome
and I-outcome
vomiting I-outcome
occurred O
on O
the O
AC O
arm O
as O
well O
as O
one O
incident O
of O
congestive B-outcome
heart I-outcome
failure I-outcome
. O
At O
5 O
years O
, O
TC O
was O
associated O
with O
a O
superior O
DFS O
and O
a O
different O
toxicity O
profile O
compared O
with O
AC O
. O

Randomized O
, O
controlled O
trial O
of O
yoga B-intervention
in O
women O
with O
breast O
cancer O
undergoing O
radiotherapy O
. O
Previous O
research O
incorporating O
yoga O
( O
YG O
) O
into O
radiotherapy O
( O
XRT O
) O
for O
women O
with O
breast O
cancer O
finds O
improved O
quality O
of O
life O
( O
QOL O
) O
. O
However O
, O
shortcomings O
in O
this O
research O
limit O
the O
findings O
. O
Patients B-eligibility
with I-eligibility
stages I-eligibility
0 I-eligibility
to I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
were O
recruited O
before O
starting O
XRT O
and O
were O
randomly O
assigned O
to O
YG O
( O
n O
= O
53 B-intervention-participants
) O
or O
stretching B-control
( O
ST O
; O
n O
= O
56 B-control-participants
) O
three O
times O
a O
week O
for O
6 O
weeks O
during O
XRT O
or O
waitlist B-control
( O
WL O
; O
n O
= O
54 B-control-participants
) O
control O
. O
Self O
- O
report O
measures O
of O
QOL B-outcome-measure
( O
Medical O
Outcomes O
Study O
36 O
-item O
short O
- O
form O
survey O
; O
primary O
outcomes O
) O
, O
fatigue B-outcome-measure
, O
depression B-outcome-measure
, O
and O
sleep B-outcome-measure
quality I-outcome-measure
, O
and O
five O
saliva O
samples O
per O
day O
for O
3 O
consecutive O
days O
were O
collected O
at O
baseline O
, O
end O
of O
treatment O
, O
and O
1 O
, O
3 O
, O
and O
6 O
months O
later O
. O
The O
YG O
group O
had O
significantly O
greater O
increases O
in O
physical B-outcome
component I-outcome
scale I-outcome
scores I-outcome
compared O
with O
the O
WL O
group O
at O
1 O
and O
3 O
months O
after O
XRT O
( O
P O
= O
. O
01 O
and O
P O
= O
. O
01 O
) O
. O
At O
1 O
, O
3 O
, O
and O
6 O
months O
, O
the O
YG O
group O
had O
greater O
increases O
in O
physical B-outcome
functioning I-outcome
compared O
with O
both O
ST O
and O
WL O
groups O
( O
P O
< O
. O
05 O
) O
, O
with O
ST O
and O
WL O
differences O
at O
only O
3 O
months O
( O
P O
< O
. O
02 O
) O
. O
The O
group O
differences O
were O
similar O
for O
general O
health O
reports O
. O
By O
the O
end O
of O
XRT O
, O
the O
YG O
and O
ST O
groups O
also O
had O
a O
reduction O
in O
fatigue B-outcome
( O
P O
< O
. O
05 O
) O
. O
There O
were O
no O
group O
differences O
for O
mental B-outcome
health I-outcome
and I-outcome
sleep I-outcome
quality I-outcome
. O
Cortisol B-outcome
slope I-outcome
was O
steepest O
for O
the O
YG O
group O
compared O
with O
the O
ST O
and O
WL O
groups O
at O
the O
end O
( O
P O
= O
. O
023 O
and O
P O
= O
. O
008 O
) O
and O
1 O
month O
after O
XRT O
( O
P O
= O
. O
05 O
and O
P O
= O
. O
04 O
) O
. O
YG O
improved O
QOL O
and O
physiological O
changes O
associated O
with O
XRT O
beyond O
the O
benefits O
of O
simple O
ST O
exercises O
, O
and O
these O
benefits O
appear O
to O
have O
long O
- O
term O
durability O
. O

Sensitivity O
and O
specificity O
of O
mammography B-intervention
and I-intervention
adjunctive I-intervention
ultrasonography I-intervention
to O
screen O
for O
breast O
cancer O
in O
the O
Japan B-location
Strategic O
Anti O
- O
cancer O
Randomized O
Trial O
( O
J O
- O
START O
) O
: O
a O
randomised O
controlled O
trial O
. O
Mammography O
is O
the O
only O
proven O
method O
for O
breast O
cancer O
screening O
that O
reduces O
mortality O
, O
although O
it O
is O
inaccurate O
in O
young O
women O
or O
women O
with O
dense O
breasts O
. O
We O
investigated O
the O
efficacy O
of O
adjunctive O
ultrasonography O
. O
Between O
July O
, O
2007 O
, O
and O
March O
, O
2011 O
, O
we O
enrolled O
asymptomatic O
women O
aged O
40 B-age
- I-age
49 I-age
years I-age
at O
42 O
study O
sites O
in O
23 O
prefectures O
into O
the O
Japan O
Strategic O
Anti O
- O
cancer O
Randomized O
Trial O
( O
J O
- O
START O
) O
. O
Eligible O
women O
had O
no B-eligibility
history I-eligibility
of I-eligibility
any I-eligibility
cancer I-eligibility
in I-eligibility
the I-eligibility
previous I-eligibility
5 I-eligibility
years I-eligibility
and I-eligibility
were I-eligibility
expected I-eligibility
to I-eligibility
live I-eligibility
for I-eligibility
more I-eligibility
than I-eligibility
5 I-eligibility
years I-eligibility
. O
Randomisation O
was O
done O
centrally O
by O
the O
Japan O
Clinical O
Research O
Support O
Unit O
. O
Participants O
were O
randomly O
assigned O
in O
1 O
:1 O
ratio O
to O
undergo O
mammography O
and O
ultrasonography O
( O
intervention O
group O
) O
or O
mammography B-control
alone I-control
( I-control
control I-control
group I-control
) I-control
twice O
in O
2 O
years O
. O
The O
primary O
outcome O
was O
sensitivity B-outcome-measure
, O
specificity B-outcome-measure
, O
cancer B-outcome-measure
detection I-outcome-measure
rate I-outcome-measure
, O
and O
stage B-outcome-measure
distribution I-outcome-measure
at O
the O
first O
round O
of O
screening O
. O
Analysis O
was O
by O
intention O
to O
treat O
. O
This O
study O
is O
registered O
, O
number O
UMIN O
000000757 O
. O
Of O
72 B-total-participants
, I-total-participants
998 I-total-participants
women O
enrolled O
, O
36 B-intervention-participants
, I-intervention-participants
859 I-intervention-participants
were O
assigned O
to O
the O
intervention O
group O
and O
36 B-control-participants
, I-control-participants
139 I-control-participants
to O
the O
control O
group O
. O
Sensitivity B-outcome
was O
significantly O
higher O
in O
the O
intervention O
group O
than O
in O
the O
control O
group O
( O
91 B-iv-bin-percent
· I-iv-bin-percent
1 I-iv-bin-percent
% I-iv-bin-percent
, O
95 O
% O
CI O
87 O
· O
2 O
- O
95 O
· O
0 O
vs O
77 B-cv-bin-percent
· I-cv-bin-percent
0 I-cv-bin-percent
% I-cv-bin-percent
, O
70 O
· O
3 O
- O
83 O
· O
7 O
; O
p= O
0 O
· O
0004 O
) O
, O
whereas O
specificity B-outcome
was O
significantly O
lower O
( O
87 B-iv-bin-percent
· I-iv-bin-percent
7 I-iv-bin-percent
% I-iv-bin-percent
, O
87 O
· O
3 O
- O
88 O
· O
0 O
vs O
91 B-cv-bin-percent
· I-cv-bin-percent
4 I-cv-bin-percent
% I-cv-bin-percent
, O
91 O
· O
1 O
- O
91 O
· O
7 O
; O
p O
< O
0 O
· O
0001 O
) O
. O
More O
cancers B-outcome
were O
detected O
in O
the O
intervention O
group O
than O
in O
the O
control O
group O
( O
184 B-iv-bin-abs
[ O
0 B-iv-bin-percent
· I-iv-bin-percent
50 I-iv-bin-percent
% I-iv-bin-percent
] I-iv-bin-percent
vs O
117 B-cv-bin-abs
[ O
0 B-cv-bin-percent
· I-cv-bin-percent
32 I-cv-bin-percent
% I-cv-bin-percent
] O
, O
p= O
0 O
· O
0003 O
) O
and O
were O
more O
frequently O
stage B-outcome
0 I-outcome
and I-outcome
I I-outcome
( O
144 B-iv-bin-abs
[ O
71 B-iv-bin-percent
· I-iv-bin-percent
3 I-iv-bin-percent
% I-iv-bin-percent
] O
vs O
79 B-cv-bin-abs
[ O
52 B-cv-bin-percent
· I-cv-bin-percent
0 I-cv-bin-percent
% I-cv-bin-percent
] O
, O
p= O
0 O
· O
0194 O
) O
. O
18 B-iv-bin-abs
( O
0 B-iv-bin-percent
· I-iv-bin-percent
05 I-iv-bin-percent
% I-iv-bin-percent
) O
interval B-outcome
cancers I-outcome
were O
detected O
in O
the O
intervention O
group O
compared O
with O
35 B-cv-bin-abs
( O
0 B-cv-bin-percent
· I-cv-bin-percent
10 I-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
control O
group O
( O
p= O
0 O
· O
034 O
) O
. O
Adjunctive O
ultrasonography O
increases O
sensitivity O
and O
detection O
rate O
of O
early O
cancers O
. O
Ministry O
of O
Health O
, O
Labour O
and O
Welfare O
of O
Japan O
. O

[ O
Treatment O
of O
advanced O
metastatic O
breast O
cancer O
with O
exemestane B-intervention
, O
a O
multicenter O
randomized O
controlled O
study O
of O
195 O
cases O
] O
. O
To O
observe O
the O
efficacy O
of O
exemestane O
for O
postmenopausal O
advanced O
metastatic O
breast O
cancer O
, O
and O
to O
assess O
its O
side O
effects O
. O
A O
randomized O
, O
double O
- O
blind O
, O
and O
parallel O
controlled O
study O
was O
conducted O
among O
195 B-total-participants
patients B-eligibility
with I-eligibility
postmenopausal I-eligibility
advanced I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
from O
December O
2001 O
to O
June O
2002 O
. O
Except O
for O
the O
4 O
cases O
who O
were O
lost O
to O
follow O
- O
up O
, O
the O
remaining O
191 B-total-participants
patients O
were O
divided O
into O
two O
groups O
: O
study O
group O
( O
n O
= O
96 B-intervention-participants
, O
treated O
with O
exemestane O
capsule O
25 O
mg O
and O
one O
model O
tablet O
of O
letrozole O
orally O
q. O
d. O
for O
8 O
weeks O
) O
, O
and O
control B-control
group I-control
( O
n O
= O
95 B-control-participants
, O
treated O
with O
letrozole O
2.5 O
mg O
and O
one O
model O
capsule O
of O
exemestane O
orally O
q. O
d. O
for O
8 O
weeks O
) O
. O
Physical O
examination O
, O
roentgenography O
and O
CT O
were O
conducted O
to O
observe O
the O
outcome O
of O
the O
tumor O
and O
the O
level O
of O
estrogen O
was O
tested O
2 O
weeks O
before O
and O
4 O
and O
8 O
weeks O
after O
the O
beginning O
of O
treatment O
. O
The O
effective B-outcome
rate I-outcome
was O
44.8 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
study O
group O
and O
45.3 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
control O
group O
( O
P O
= O
0.971 O
) O
. O
The O
level B-outcome
of I-outcome
estradiol I-outcome
was O
5.17 B-iv-cont-mean
+ O
/- O
6.68 B-iv-cont-sd
x I-iv-cont-sd
10 I-iv-cont-sd
( I-iv-cont-sd
4 I-iv-cont-sd
) I-iv-cont-sd
pg I-iv-cont-sd
/ I-iv-cont-sd
L I-iv-cont-sd
and O
4.19 B-cv-cont-mean
+ O
/- O
3.06 B-cv-cont-sd
x I-cv-cont-sd
10 I-cv-cont-sd
( I-cv-cont-sd
4 I-cv-cont-sd
) I-cv-cont-sd
pg I-cv-cont-sd
/ I-cv-cont-sd
L I-cv-cont-sd
in O
the O
study O
group O
and O
control O
group O
respectively O
; O
and O
was O
3.08 B-iv-cont-mean
+ O
/- O
2.80 B-iv-cont-sd
x I-iv-cont-sd
10 I-iv-cont-sd
( I-iv-cont-sd
4 I-iv-cont-sd
) I-iv-cont-sd
pg I-iv-cont-sd
/ I-iv-cont-sd
L I-iv-cont-sd
and O
2.76 B-cv-cont-mean
+ O
/- O
1.98 B-cv-cont-sd
x I-cv-cont-sd
10 I-cv-cont-sd
( I-cv-cont-sd
4 I-cv-cont-sd
) I-cv-cont-sd
pg I-cv-cont-sd
/ I-cv-cont-sd
L I-cv-cont-sd
in O
the O
study O
group O
and O
control O
group O
respectively O
8 O
weeks O
after O
the O
beginning O
of O
treatment O
, O
both O
decreased O
by O
43.7 O
% O
in O
comparison O
with O
those O
before O
treatment O
( O
both O
P O
< O
0.001 O
) O
, O
however O
, O
there O
was O
no O
significant O
difference O
between O
the O
study O
group O
and O
control O
group O
( O
P O
= O
0.141 O
) O
. O
The O
side O
effects O
of O
exemestane O
included O
thirst B-outcome
, O
giddiness B-outcome
, O
and O
nausea B-outcome
. O
An O
effective O
hormonal O
medicine O
, O
exemestane O
has O
good O
therapeutic O
efficacy O
in O
postmenopausal O
advanced O
metastatic O
breast O
cancer O
with O
only O
mild O
side O
effects O
. O

Mindfulness B-intervention
based I-intervention
stress I-intervention
reduction I-intervention
( I-intervention
MBSR I-intervention
( I-intervention
BC I-intervention
) I-intervention
) I-intervention
in O
breast O
cancer O
: O
evaluating O
fear O
of O
recurrence O
( O
FOR O
) O
as O
a O
mediator O
of O
psychological O
and O
physical O
symptoms O
in O
a O
randomized O
control O
trial O
( O
RCT O
) O
. O
To O
investigate O
the O
mechanism O
( O
s O
) O
of O
action O
of O
mindfulness O
based O
stress O
reduction O
( O
MBSR O
( O
BC O
) O
) O
including O
reductions O
in O
fear O
of O
recurrence O
and O
other O
potential O
mediators O
. O
Eighty B-total-participants
- I-total-participants
two I-total-participants
post B-eligibility
- I-eligibility
treatment I-eligibility
breast I-eligibility
cancer I-eligibility
survivors I-eligibility
( I-eligibility
stages I-eligibility
0 I-eligibility
-III I-eligibility
) I-eligibility
were O
randomly O
assigned O
to O
a O
6 O
-week O
MBSR O
( O
BC O
) O
program O
( O
n O
  O
= O
  O
40 B-intervention-participants
) O
or O
to O
usual B-control
care I-control
group I-control
( I-control
UC I-control
) I-control
( O
n O
  O
= O
  O
42 B-control-participants
) O
. O
Psychological O
and O
physical O
variables O
were O
assessed O
as O
potential O
mediators O
at O
baseline O
and O
at O
6 O
  O
weeks O
. O
MBSR O
( O
BC O
) O
compared O
to O
UC O
experienced O
favorable O
changes O
for O
five O
potential O
mediators O
: O
( O
1 O
) O
change B-outcome
in I-outcome
fear I-outcome
of I-outcome
recurrence I-outcome
problems I-outcome
mediated O
the O
effect O
of O
MBSR O
( O
BC O
) O
on O
6 O
-week O
change O
in O
perceived B-outcome
stress I-outcome
( O
z O
  O
= O
  O
2.12 O
, O
p O
  O
= O
  O
0.03 O
) O
and O
state B-outcome
anxiety I-outcome
( O
z O
  O
= O
  O
2.03 O
, O
p O
  O
= O
  O
0.04 O
) O
; O
and O
( O
2 O
) O
change B-outcome
in I-outcome
physical I-outcome
functioning I-outcome
mediated O
the O
effect O
of O
MBSR O
( O
BC O
) O
on O
6 O
-week O
change O
in O
perceived B-outcome
stress I-outcome
( O
z O
  O
= O
  O
2.27 O
, O
p O
  O
= O
  O
0.02 O
) O
and O
trait B-outcome
anxiety I-outcome
( O
z O
  O
= O
  O
1.98 O
, O
p O
  O
= O
  O
0.05 O
) O
. O
MBSR O
( O
BC O
) O
reduces O
fear B-outcome
of I-outcome
recurrence I-outcome
and O
improves O
physical B-outcome
functioning I-outcome
which O
reduces O
perceived B-outcome
stress I-outcome
and I-outcome
anxiety I-outcome
. O
Findings O
support O
the O
beneficial O
effects O
of O
MBSR O
( O
BC O
) O
and O
provide O
insight O
into O
the O
possible O
cognitive O
mechanism O
of O
action O
. O

Randomized O
placebo O
- O
controlled O
study O
of O
recombinant B-intervention
human I-intervention
interleukin- I-intervention
11 I-intervention
to O
prevent O
chemotherapy B-condition
- I-condition
induced I-condition
thrombocytopenia I-condition
in O
patients O
with O
breast O
cancer O
receiving O
dose O
- O
intensive O
cyclophosphamide O
and O
doxorubicin O
. O
Thrombocytopenia O
may O
compromise O
cancer O
treatment O
, O
causing O
chemotherapy O
dose O
reductions O
, O
schedule O
alterations O
, O
or O
the O
need O
for O
platelet O
transfusions O
. O
We O
evaluated O
the O
efficacy O
and O
safety O
of O
recombinant O
human O
interleukin- O
11 O
( O
rhIL- O
11 O
; O
Neumega O
, O
Genetics O
Institute O
, O
Inc O
, O
Cambridge O
, O
MA O
) O
, O
a O
novel O
thrombopoietic O
growth O
factor O
, O
in O
reducing O
the O
need O
for O
platelet O
transfusions O
in O
patients O
who O
undergo O
dose O
- O
intensive O
chemotherapy O
. O
Women B-eligibility
with I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
received O
cyclophosphamide O
( O
3 O
, O
200 O
mg O
/ O
m O
2 O
) O
and O
doxorubicin O
( O
75 O
mg O
/ O
m O
2 O
) O
plus O
granulocyte O
colony O
- O
stimulating O
factor O
( O
G O
- O
CSF O
; O
5 O
microg O
/ O
kg O
/ O
d O
) O
. O
Patients O
were O
randomized O
to O
blinded O
treatment O
with O
placebo B-control
or O
50 O
microg O
/ O
kg O
/ O
d O
rhIL- O
11 O
subcutaneously O
for O
10 O
or O
17 O
days O
after O
the O
first O
two O
chemotherapy O
cycles O
. O
Seventy B-total-participants
- I-total-participants
seven I-total-participants
patients O
were O
randomized O
and O
constitute O
the O
intent O
- O
to O
- O
treat O
( O
ITT O
) O
population O
. O
Sixty B-total-participants
- I-total-participants
seven I-total-participants
patients O
( O
the O
assessable O
subgroup O
) O
either O
completed O
both O
cycles O
without O
a O
major O
protocol O
violation O
( O
n O
= O
62 O
) O
or O
received O
a O
platelet O
transfusion O
before O
treatment O
was O
discontinued O
after O
the O
first O
cycle O
. O
In O
the O
ITT O
population O
, O
rhIL- O
11 O
significantly O
decreased O
the O
requirement O
for O
platelet B-outcome
transfusions I-outcome
; O
27 B-iv-bin-abs
of O
40 B-intervention-participants
( O
68 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
who O
received O
rhIL- O
11 O
did O
not O
require O
transfusions O
, O
compared O
with O
15 B-cv-bin-abs
of O
37 B-control-participants
( O
41 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
placebo O
group O
( O
P O
= O
. O
04 O
) O
. O
Treatment O
with O
rhIL- O
11 O
significantly O
reduced O
the O
total B-outcome
number I-outcome
of I-outcome
platelet I-outcome
transfusions I-outcome
required I-outcome
in O
the O
assessable O
subgroup O
( O
P O
= O
. O
03 O
) O
and O
the O
time B-outcome
to I-outcome
platelet I-outcome
recovery I-outcome
to O
more O
than O
50 O
, O
000 O
/microL O
in O
the O
second O
cycle O
( O
P O
= O
. O
01 O
) O
. O
Most O
adverse B-outcome
events I-outcome
associated O
with O
rhIL- O
11 O
were O
reversible O
, O
mild O
to O
moderate O
in O
severity O
, O
and O
likely O
related O
to O
fluid O
retention O
. O
rhIL- O
11 O
is O
safe O
and O
effective O
in O
reducing O
treatment O
- O
associated O
thrombocytopenia O
and O
the O
need O
for O
platelet O
transfusions O
in O
patients O
who O
undergo O
dose O
- O
intensive O
chemotherapy O
, O
and O
thus O
may O
permit O
chemotherapy O
to O
be O
administered O
as O
planned O
at O
intended O
doses O
and O
thereby O
maximize O
the O
potential O
for O
a O
successful O
outcome O
. O

Effect O
of O
a O
Scalp B-intervention
Cooling I-intervention
Device I-intervention
on O
Alopecia B-condition
in O
Women B-eligibility
Undergoing I-eligibility
Chemotherapy I-eligibility
for I-eligibility
Breast I-eligibility
Cancer I-eligibility
: O
The O
SCALP O
Randomized O
Clinical O
Trial O
. O
Chemotherapy O
may O
induce O
alopecia O
. O
Although O
scalp O
cooling O
devices O
have O
been O
used O
to O
prevent O
this O
alopecia O
, O
efficacy O
has O
not O
been O
assessed O
in O
a O
randomized O
clinical O
trial O
. O
To O
assess O
whether O
a O
scalp O
cooling O
device O
is O
effective O
at O
reducing O
chemotherapy O
- O
induced O
alopecia O
and O
to O
assess O
adverse O
treatment O
effects O
. O
Multicenter O
randomized O
clinical O
trial O
of O
women O
with O
breast O
cancer O
undergoing O
chemotherapy O
. O
Patients O
were O
enrolled O
from O
December O
9 O
, O
2013 O
, O
to O
September O
30 O
, O
2016 O
. O
One O
interim O
analysis O
was O
planned O
to O
allow O
the O
study O
to O
stop O
early O
for O
efficacy O
. O
Data O
reported O
are O
from O
the O
interim O
analysis O
. O
This O
study O
was O
conducted O
at O
7 O
sites O
in O
the O
United B-location
States I-location
, O
and O
182 B-total-participants
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
requiring I-eligibility
chemotherapy I-eligibility
were O
enrolled O
and O
randomized O
. O
Participants O
were O
randomized O
to O
scalp O
cooling O
( O
n O
  O
= O
  O
119 B-intervention-participants
) O
or O
control B-control
( O
n O
  O
= O
  O
63 B-control-participants
) O
. O
Scalp O
cooling O
was O
done O
using O
a O
scalp O
cooling O
device O
. O
The O
primary O
efficacy O
end O
points O
were O
successful B-outcome-measure
hair I-outcome-measure
preservation I-outcome-measure
assessed O
using O
the O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
version O
4.0 O
scale O
( O
grade O
0 O
[ O
no O
hair O
loss O
] O
or O
grade O
1 O
[ O
< O
50 O
% O
hair O
loss O
not O
requiring O
a O
wig O
] O
were O
considered O
to O
have O
hair O
preservation O
) O
at O
the O
end O
of O
4 O
cycles O
of O
chemotherapy O
by O
a O
clinician O
unaware O
of O
treatment O
assignment O
, O
and O
device O
safety O
. O
Secondary O
end O
points O
included O
wig B-outcome-measure
use I-outcome-measure
and O
scores O
on O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality B-outcome-measure
of I-outcome-measure
Life I-outcome-measure
Questionnaire O
- O
Core O
30 O
, O
Hospital B-outcome-measure
Anxiety I-outcome-measure
and I-outcome-measure
Depression I-outcome-measure
Scale I-outcome-measure
, O
and O
a O
summary B-outcome-measure
scale I-outcome-measure
of I-outcome-measure
the I-outcome-measure
Body I-outcome-measure
Image I-outcome-measure
Scale I-outcome-measure
. O
At O
the O
time O
of O
the O
interim O
analysis O
, O
142 B-total-participants
participants O
were O
evaluable O
. O
The O
mean O
( O
SD O
) O
age O
of O
the O
patients O
was O
52.6 B-age
( I-age
10.1 I-age
) I-age
years I-age
; O
36 O
% O
( O
n O
  O
= O
  O
51 O
) O
received O
anthracycline O
- O
based O
chemotherapy O
and O
64 O
% O
( O
n O
  O
= O
  O
91 O
) O
received O
taxane O
- O
based O
chemotherapy O
. O
Successful B-outcome
hair I-outcome
preservation I-outcome
was O
found O
in O
48 B-iv-bin-abs
of O
95 B-intervention-participants
women O
with O
cooling O
( O
50.5 B-iv-bin-percent
% I-iv-bin-percent
; O
95 O
% O
CI O
, O
40.7 O
% O
- O
60.4 O
% O
) O
compared O
with O
0 B-cv-bin-abs
of O
47 B-control-participants
women O
in O
the O
control O
group O
( O
0 B-cv-bin-percent
% I-cv-bin-percent
; O
95 O
% O
CI O
, O
0 O
% O
- O
7.6 O
% O
) O
( O
success O
rate O
difference O
, O
50.5 O
% O
; O
95 O
% O
CI O
, O
40.5 O
% O
- O
60.6 O
% O
) O
. O
Because O
the O
1 O
-tailed O
P O
value O
from O
the O
Fisher O
exact O
test O
was O
< O
. O
001 O
, O
which O
crossed O
the O
superiority O
boundary O
( O
P O
  O
= O
  O
. O
0061 O
) O
, O
the O
data O
and O
safety O
monitoring O
board O
recommended O
study O
termination O
on O
September O
26 O
, O
2016 O
. O
There O
were O
no O
statistically O
significant O
differences O
in O
changes B-outcome
in I-outcome
any I-outcome
of I-outcome
the I-outcome
scales I-outcome
of I-outcome
quality I-outcome
of I-outcome
life I-outcome
from O
baseline O
to O
chemotherapy O
cycle O
4 O
among O
the O
scalp O
cooling O
and O
control O
groups O
. O
Only O
adverse B-outcome
events I-outcome
related O
to O
device O
use O
were O
collected O
; O
54 B-cv-bin-abs
adverse O
events O
were O
reported O
in O
the O
cooling O
group O
, O
all O
grades O
1 O
and O
2 O
. O
There O
were O
no O
serious O
adverse B-outcome
device I-outcome
events I-outcome
. O
Among O
women O
with O
stage O
I O
to O
II O
breast O
cancer O
receiving O
chemotherapy O
with O
a O
taxane O
, O
anthracycline O
, O
or O
both O
, O
those O
who O
underwent O
scalp O
cooling O
were O
significantly O
more O
likely O
to O
have O
less O
than O
50 O
% O
hair O
loss O
after O
the O
fourth O
chemotherapy O
cycle O
compared O
with O
those O
who O
received O
no O
scalp O
cooling O
. O
Further O
research O
is O
needed O
to O
assess O
longer O
- O
term O
efficacy O
and O
adverse O
effects O
. O
clinicaltrials.gov O
Identifier O
: O
NCT O
01986140 O
. O

Acute O
and O
Short O
- O
term O
Toxic O
Effects O
of O
Conventionally B-control
Fractionated I-control
vs O
Hypofractionated B-intervention
Whole I-intervention
- I-intervention
Breast I-intervention
Irradiation I-intervention
: O
A O
Randomized O
Clinical O
Trial O
. O
The O
most O
appropriate O
dose O
fractionation O
for O
whole O
- O
breast O
irradiation O
( O
WBI O
) O
remains O
uncertain O
. O
To O
assess O
acute O
and O
6 O
-month O
toxic O
effects O
and O
quality O
of O
life O
( O
QOL O
) O
with O
conventionally O
fractionated O
WBI O
( O
CF O
- O
WBI O
) O
vs O
hypofractionated O
WBI O
( O
HF O
- O
WBI O
) O
. O
Unblinded O
randomized O
trial O
of O
CF O
- O
WBI O
( O
n O
  O
= O
  O
149 B-control-participants
; O
50.00 O
Gy O
/ O
25 O
fractions O
  O
+ O
  O
boost O
[ O
10.00 O
- O
14.00 O
Gy O
/ O
5 O
- O
7 O
fractions O
] O
) O
vs O
HF O
- O
WBI O
( O
n O
  O
= O
  O
138 B-intervention-participants
; O
42.56 O
Gy O
/ O
16 O
fractions O
  O
+ O
  O
boost O
[ O
10.00 O
- O
12.50 O
Gy O
/ O
4 O
- O
5 O
fractions O
] O
) O
following O
breast O
- O
conserving O
surgery O
administered O
in O
community O
- O
based O
and O
academic O
cancer O
centers O
to O
287 O
women O
40 B-age
years I-age
or I-age
older I-age
with B-eligibility
stage I-eligibility
0 I-eligibility
to I-eligibility
II I-eligibility
breast I-eligibility
cancer I-eligibility
for I-eligibility
whom I-eligibility
WBI I-eligibility
without I-eligibility
addition I-eligibility
of I-eligibility
a I-eligibility
third I-eligibility
field I-eligibility
was I-eligibility
recommended I-eligibility
; O
76 O
% O
of O
study O
participants O
( O
n O
  O
= O
  O
217 O
) O
were O
overweight O
or O
obese O
. O
Patients O
were O
enrolled O
from O
February O
2011 O
through O
February O
2014 O
and O
observed O
for O
a O
minimum O
of O
6 O
months O
. O
Administration O
of O
CF O
- O
WBI O
or O
HF O
- O
WBI O
. O
Physician O
- O
reported O
acute O
and O
6 O
-month O
toxic O
effects O
using O
National O
Cancer O
Institute O
Common O
Toxicity O
Criteria O
, O
and O
patient O
- O
reported O
QOL O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
for O
Patients O
with O
Breast O
Cancer O
( O
FACT O
- O
B O
) O
. O
All O
analyses O
were O
intention O
to O
treat O
, O
with O
outcomes O
compared O
using O
the O
χ O
2 O
test O
, O
Cochran O
- O
Armitage O
test O
, O
and O
ordinal O
logistic O
regression O
. O
Of O
287 B-total-participants
participants O
, O
149 B-control-participants
were O
randomized O
to O
CF O
- O
WBI O
and O
138 B-intervention-participants
to O
HF O
- O
WBI O
. O
Treatment O
arms O
were O
well O
matched O
for O
baseline O
characteristics O
, O
including O
FACT O
- O
B O
total O
score O
( O
HF O
- O
WBI O
, O
120.1 O
vs O
CF O
- O
WBI O
, O
118.8 O
; O
P O
  O
= O
  O
. O
46 O
) O
and O
individual O
QOL O
items O
such O
as O
somewhat O
or O
more O
lack O
of O
energy O
( O
HF O
- O
WBI O
, O
38 O
% O
vs O
CF O
- O
WBI O
, O
39 O
% O
; O
P O
  O
= O
  O
. O
86 O
) O
and O
somewhat O
or O
more O
trouble O
meeting O
family O
needs O
( O
HF O
- O
WBI O
, O
10 O
% O
vs O
CF O
- O
WBI O
, O
14 O
% O
; O
P O
  O
= O
  O
. O
54 O
) O
. O
Maximum O
physician B-outcome
- I-outcome
reported I-outcome
acute I-outcome
dermatitis I-outcome
( O
36 B-iv-bin-percent
% I-iv-bin-percent
vs O
69 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
  O
< O
  O
. O
001 O
) O
, O
pruritus B-outcome
( O
54 B-iv-bin-percent
% I-iv-bin-percent
vs O
81 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
  O
< O
  O
. O
001 O
) O
, O
breast B-outcome
pain I-outcome
( O
55 B-iv-bin-percent
% I-iv-bin-percent
vs O
74 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
  O
= O
  O
. O
001 O
) O
, O
hyperpigmentation B-outcome
( O
9 B-iv-bin-percent
% I-iv-bin-percent
vs O
20 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
  O
= O
  O
. O
002 O
) O
, O
and O
fatigue B-outcome
( O
9 B-iv-bin-percent
% I-iv-bin-percent
vs O
17 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
  O
= O
  O
. O
02 O
) O
during O
irradiation O
were O
lower O
in O
patients O
randomized O
to O
HF O
- O
WBI O
. O
The O
rate O
of O
overall O
grade B-outcome
2 I-outcome
or I-outcome
higher I-outcome
acute I-outcome
toxic I-outcome
effects I-outcome
was O
less O
with O
HF O
- O
WBI O
than O
with O
CF O
- O
WBI O
( O
47 B-iv-bin-percent
% I-iv-bin-percent
vs O
78 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
  O
< O
  O
. O
001 O
) O
. O
Six O
months O
after O
irradiation O
, O
physicians O
reported O
less O
fatigue B-outcome
in O
patients O
randomized O
to O
HF O
- O
WBI O
( O
0 B-iv-bin-percent
% I-iv-bin-percent
vs O
6 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
  O
= O
  O
. O
01 O
) O
, O
and O
patients O
randomized O
to O
HF O
- O
WBI O
reported O
less O
lack B-outcome
of I-outcome
energy I-outcome
( O
23 B-iv-bin-percent
% I-iv-bin-percent
vs O
39 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
  O
< O
  O
. O
001 O
) O
and O
less O
trouble B-outcome
meeting I-outcome
family I-outcome
needs I-outcome
( O
3 B-iv-bin-percent
% I-iv-bin-percent
vs O
9 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
  O
= O
  O
. O
01 O
) O
. O
Multivariable O
regression O
confirmed O
the O
superiority O
of O
HF O
- O
WBI O
in O
terms O
of O
patient O
- O
reported O
lack O
of O
energy O
( O
odds O
ratio O
[ O
OR O
] O
, O
0.39 O
; O
95 O
% O
CI O
, O
0.24 O
- O
0.63 O
) O
and O
trouble O
meeting O
family O
needs O
( O
OR O
, O
0.34 O
; O
95 O
% O
CI O
, O
0.16 O
- O
0.75 O
) O
. O
Treatment O
with O
HF O
- O
WBI O
appears O
to O
yield O
lower O
rates O
of O
acute O
toxic O
effects O
than O
CF O
- O
WBI O
as O
well O
as O
less O
fatigue O
and O
less O
trouble O
meeting O
family O
needs O
6 O
months O
after O
completing O
radiation O
therapy O
. O
These O
findings O
should O
be O
communicated O
to O
patients O
as O
part O
of O
shared O
decision O
making O
. O
clinicaltrials.gov O
Identifier O
: O
NCT O
01266642 O
. O

A O
cancer O
research O
( O
UK O
) O
randomized O
phase O
II O
study O
of O
idoxifene B-intervention
in O
patients O
with O
locally O
advanced O
/ O
metastatic O
breast O
cancer O
resistant O
to O
tamoxifen O
. O
Idoxifene O
is O
a O
novel O
selective O
oestrogen O
receptor O
modulator O
( O
SERM O
) O
which O
had O
greater O
binding O
affinity O
for O
the O
oestrogen O
receptor O
( O
ER O
) O
and O
reduced O
agonist O
activity O
compared O
with O
tamoxifen O
in O
preclinical O
studies O
. O
In O
a O
randomized O
phase O
II O
trial O
in O
56 B-total-participants
postmenopausal B-eligibility
patients I-eligibility
with I-eligibility
progressive I-eligibility
locally I-eligibility
advanced I-eligibility
/ I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
we O
assessed O
whether O
idoxifene O
showed O
evidence O
of O
activity O
compared O
with O
an O
increased O
40 O
mg O
/ O
day O
dose O
of O
tamoxifen B-control
in O
patients O
who O
had O
previously O
demonstrated O
resistance O
to O
the O
standard O
20 O
mg O
/ O
day O
dose O
of O
tamoxifen O
. O
Of O
47 B-total-participants
patients O
eligible O
for O
response O
( O
25 B-intervention-participants
idoxifene O
, O
22 B-control-participants
tamoxifen O
) O
, O
two B-iv-bin-abs
partial B-outcome
responses I-outcome
and O
two B-iv-bin-abs
disease B-outcome
stabilizations I-outcome
( I-outcome
SD I-outcome
) I-outcome
for O
> O
6 O
months O
were O
seen O
with O
idoxifene O
( O
overall B-outcome
clinical I-outcome
benefit I-outcome
rate I-outcome
16 B-iv-bin-percent
% I-iv-bin-percent
, O
95 O
% O
CI O
4.5 O
- O
36.1 O
% O
) O
. O
The O
median B-outcome
duration I-outcome
of I-outcome
clinical I-outcome
benefit I-outcome
was O
9.8 B-iv-cont-median
months I-iv-cont-median
. O
In O
contrast O
, O
no B-cv-bin-abs
objective B-outcome
responses I-outcome
were O
seen O
with O
the O
increased O
40 O
mg O
/ O
day O
dose O
of O
tamoxifen O
, O
although O
two B-cv-bin-abs
patients O
had O
SD B-outcome
for O
7 O
and O
14 O
months O
( O
clinical B-outcome
benefit I-outcome
rate I-outcome
9 B-cv-bin-percent
% I-cv-bin-percent
, O
95 O
% O
CI O
1.1 O
- O
29.2 O
% O
) O
. O
Idoxifene O
was O
well O
tolerated O
and O
the O
reported O
possible O
drug B-outcome
- I-outcome
related I-outcome
toxicities I-outcome
were O
similar O
in O
frequency O
to O
those O
with O
tamoxifen O
( O
hot B-outcome
flushes I-outcome
13 B-iv-bin-percent
% I-iv-bin-percent
vs O
15 B-cv-bin-percent
% I-cv-bin-percent
, O
mild B-outcome
nausea I-outcome
20 B-iv-bin-percent
% I-iv-bin-percent
vs O
15 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Endocrine O
and O
lipid O
analysis O
in O
both O
groups O
showed O
a O
similar O
significant O
fall O
in O
serum B-outcome
follicle I-outcome
- I-outcome
stimulating I-outcome
hormone I-outcome
and I-outcome
luteinizing I-outcome
hormone I-outcome
after O
4 O
weeks O
, O
together O
with O
a O
significant O
rise O
in O
sex O
hormone O
binding O
globulin O
levels O
and O
11 O
% O
reduction O
in O
serum B-outcome
cholesterol I-outcome
levels I-outcome
. O
In O
conclusion O
, O
while O
idoxifene O
was O
associated O
with O
only O
modest O
evidence O
of O
clinical O
activity O
in O
patients O
with O
tamoxifen O
- O
resistant O
breast O
cancer O
, O
its O
toxicity O
profile O
and O
effects O
on O
endocrine O
/ O
lipid O
parameters O
were O
similar O
to O
those O
of O
tamoxifen O
. O

Tamoxifen B-intervention
for O
the O
prevention O
of O
breast O
cancer O
: O
current O
status O
of O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
P- O
1 O
study O
. O
Initial O
findings O
from O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
Breast O
Cancer O
Prevention O
Trial O
( O
P- O
1 O
) O
demonstrated O
that O
tamoxifen O
reduced O
the O
risk O
of O
estrogen O
receptor O
- O
positive O
tumors O
and O
osteoporotic O
fractures O
in O
women B-eligibility
at I-eligibility
increased I-eligibility
risk I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Side O
effects O
of O
varying O
clinical O
significance O
were O
observed O
. O
The O
trial O
was O
unblinded O
because O
of O
the O
positive O
results O
, O
and O
follow O
- O
up O
continued O
. O
This O
report O
updates O
our O
initial O
findings O
. O
Women O
( O
n O
= O
13 B-total-participants
, I-total-participants
388 I-total-participants
) O
were O
randomly O
assigned O
to O
receive O
placebo B-control
or O
tamoxifen O
for O
5 O
years O
. O
Rates O
of O
breast O
cancer O
and O
other O
events O
were O
compared O
by O
the O
use O
of O
risk O
ratios O
( O
RRs O
) O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
. O
Estimates O
of O
the O
net O
benefit O
from O
5 O
years O
of O
tamoxifen O
therapy O
were O
compared O
by O
age O
, O
race O
, O
and O
categories O
of O
predicted O
breast O
cancer O
risk O
. O
Statistical O
tests O
were O
two O
- O
sided O
. O
After O
7 O
years O
of O
follow O
- O
up O
, O
the O
cumulative B-outcome
rate I-outcome
of I-outcome
invasive I-outcome
breast I-outcome
cancer I-outcome
was O
reduced O
from O
42.5 B-cv-bin-abs
per O
1000 B-control-participants
women O
in O
the O
placebo O
group O
to O
24.8 B-iv-bin-abs
per O
1000 B-intervention-participants
women O
in O
the O
tamoxifen O
group O
( O
RR O
= O
0.57 O
, O
95 O
% O
CI O
= O
0.46 O
to O
0.70 O
) O
and O
the O
cumulative B-outcome
rate I-outcome
of I-outcome
noninvasive I-outcome
breast I-outcome
cancer I-outcome
was O
reduced O
from O
15.8 B-cv-bin-abs
per O
1000 B-control-participants
women O
in O
the O
placebo O
group O
to O
10.2 B-iv-bin-abs
per O
1000 B-intervention-participants
women O
in O
the O
tamoxifen O
group O
( O
RR O
= O
0.63 O
, O
95 O
% O
CI O
= O
0.45 O
to O
0.89 O
) O
. O
These O
reductions O
were O
similar O
to O
those O
seen O
in O
the O
initial O
report O
. O
Tamoxifen O
led O
to O
a O
32 B-iv-bin-percent
% I-iv-bin-percent
reduction B-outcome
in I-outcome
osteoporotic I-outcome
fractures I-outcome
( O
RR O
= O
0.68 O
, O
95 O
% O
CI O
= O
0.51 O
to O
0.92 O
) O
. O
Relative O
risks O
of O
stroke B-outcome
, O
deep B-outcome
- I-outcome
vein I-outcome
thrombosis I-outcome
, O
and O
cataracts B-outcome
( O
which O
increased O
with O
tamoxifen O
) O
and O
of O
ischemic B-outcome
heart I-outcome
disease I-outcome
and O
death B-outcome
( O
which O
were O
not O
changed O
with O
tamoxifen O
) O
were O
also O
similar O
to O
those O
initially O
reported O
. O
Risks B-outcome
of I-outcome
pulmonary I-outcome
embolism I-outcome
were O
approximately O
11 O
% O
lower O
than O
in O
the O
original O
report O
, O
and O
risks O
of O
endometrial O
cancer O
were O
about O
29 O
% O
higher O
, O
but O
these O
differences O
were O
not O
statistically O
significant O
. O
The O
net O
benefit O
achieved O
with O
tamoxifen O
varied O
according O
to O
age O
, O
race O
, O
and O
level O
of O
breast O
cancer O
risk O
. O
Despite O
the O
potential O
bias O
caused O
by O
the O
unblinding O
of O
the O
P- O
1 O
trial O
, O
the O
magnitudes O
of O
all O
beneficial O
and O
undesirable O
treatment O
effects O
of O
tamoxifen O
were O
similar O
to O
those O
initially O
reported O
, O
with O
notable O
reductions O
in O
breast O
cancer O
and O
increased O
risks O
of O
thromboembolic O
events O
and O
endometrial O
cancer O
. O
Readily O
identifiable O
subsets O
of O
individuals O
comprising O
2.5 O
million O
women O
could O
derive O
a O
net O
benefit O
from O
the O
drug O
. O

Comparison O
of O
fulvestrant B-intervention
versus O
tamoxifen B-control
for O
the O
treatment O
of O
advanced O
breast O
cancer O
in O
postmenopausal O
women O
previously O
untreated O
with O
endocrine O
therapy O
: O
a O
multinational O
, O
double O
- O
blind O
, O
randomized O
trial O
. O
To O
evaluate O
the O
efficacy O
and O
tolerability O
of O
fulvestrant O
( O
Faslodex O
; O
AstraZeneca O
Pharmaceuticals O
LP O
, O
Wilmington O
, O
DE O
) O
, O
a O
new O
estrogen O
receptor O
( O
ER O
) O
antagonist O
that O
downregulates O
ER O
and O
has O
no O
agonist O
effects O
, O
versus O
tamoxifen O
, O
an O
antiestrogen O
with O
agonist O
and O
antagonist O
effects O
, O
for O
the O
treatment O
of O
advanced O
breast O
cancer O
in O
postmenopausal O
women O
. O
In O
this O
multicenter O
, O
double O
- O
blind O
, O
randomized O
trial O
, O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
/ I-eligibility
locally I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
previously I-eligibility
untreated I-eligibility
for I-eligibility
advanced I-eligibility
disease I-eligibility
were O
randomly O
assigned O
to O
receive O
either O
fulvestrant O
( O
250 O
mg O
, O
via O
intramuscular O
injection O
, O
once O
monthly O
; O
n O
= O
313 B-intervention-participants
) O
or O
tamoxifen O
( O
20 O
mg O
, O
orally O
, O
once O
daily O
; O
n O
= O
274 B-control-participants
) O
. O
Patients O
' O
tumors O
were O
positive O
for O
ER O
( O
ER+ O
) O
and/or O
progesterone O
receptor O
( O
PgR+ O
) O
, O
or O
had O
an O
unknown O
receptor O
status O
. O
At O
a O
median O
follow O
- O
up O
of O
14.5 O
months O
, O
there O
was O
no O
significant O
difference O
between O
fulvestrant O
and O
tamoxifen O
for O
the O
primary O
end O
point O
of O
time B-outcome
to I-outcome
progression I-outcome
( O
TTP O
; O
median O
TTP O
, O
6.8 B-iv-cont-median
months I-iv-cont-median
and O
8.3 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
hazard O
ratio O
, O
1.18 O
; O
95 O
% O
CI O
, O
0.98 O
to O
1.44 O
; O
P O
= O
. O
088 O
) O
. O
In O
a O
prospectively O
planned O
subset O
analysis O
of O
patients O
with O
known O
ER+ O
and/or O
PgR+ O
tumors O
( O
approximately O
78 O
% O
) O
, O
median B-outcome
TTP I-outcome
was O
8.2 B-iv-cont-median
months I-iv-cont-median
for O
fulvestrant O
and O
8.3 B-cv-cont-median
months I-cv-cont-median
for O
tamoxifen O
( O
hazard O
ratio O
, O
1.10 O
; O
95 O
% O
CI O
, O
0.89 O
to O
1.36 O
; O
P O
= O
. O
39 O
) O
. O
The O
objective B-outcome
response I-outcome
rate I-outcome
for O
the O
overall O
population O
was O
31.6 B-iv-bin-percent
% I-iv-bin-percent
with O
fulvestrant O
and O
33.9 B-cv-bin-percent
% I-cv-bin-percent
with O
tamoxifen O
, O
and O
33.2 B-iv-bin-percent
% I-iv-bin-percent
and O
31.1 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
, O
in O
the O
known O
hormone O
receptor O
- O
positive O
subgroup O
. O
Both O
treatments O
were O
well B-outcome
tolerated I-outcome
. O
In O
the O
overall O
population O
, O
between O
- O
group O
differences O
in O
efficacy O
end O
points O
favored O
tamoxifen O
, O
and O
statistical O
noninferiority O
of O
fulvestrant O
could O
not O
be O
demonstrated O
. O
However O
, O
in O
patients O
with O
hormone O
receptor O
- O
positive O
tumors O
, O
fulvestrant O
had O
similar O
efficacy O
to O
tamoxifen O
and O
was O
well O
tolerated O
. O

Long O
- O
term O
survival O
analysis O
of O
addition O
of O
carboplatin B-intervention
to O
neoadjuvant O
chemotherapy O
in O
HER O
2 O
- O
negative O
breast O
cancer O
. O
Addition O
of O
carboplatin O
( O
CBDCA O
) O
to O
neoadjuvant O
chemotherapy O
( O
NAC O
) O
in O
triple O
- O
negative O
breast O
cancer O
( O
TNBC O
) O
has O
improved O
pathological O
complete O
response O
( O
pCR O
) O
rates O
in O
previous O
studies O
. O
We O
present O
long O
- O
term O
survival O
outcomes O
( O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
[ I-outcome-measure
DFS I-outcome-measure
] I-outcome-measure
, O
pre O
- O
planned O
secondary O
endpoint O
; O
overall B-outcome-measure
survival I-outcome-measure
[ I-outcome-measure
OS I-outcome-measure
] I-outcome-measure
, I-outcome-measure
post O
hoc O
exploratory O
endpoint O
) O
of O
our O
randomized O
study O
of O
the O
addition O
of O
CBDCA O
to O
NAC O
for O
HER O
2 O
- O
negative O
breast O
cancer O
. O
Patients B-eligibility
with I-eligibility
stage I-eligibility
II I-eligibility
/ I-eligibility
III I-eligibility
, I-eligibility
HER I-eligibility
2 I-eligibility
- I-eligibility
negative I-eligibility
breast I-eligibility
cancer I-eligibility
( O
N O
  O
= O
  O
179 B-total-participants
) O
were O
randomly O
assigned O
to O
receive O
CP O
- O
CEF O
( O
four O
3 O
-week O
cycles O
of O
CBDCA O
[ O
area O
under O
the O
curve O
, O
5 O
  O
mg O
/ O
mL O
/ O
min O
, O
day O
1 O
] O
and O
weekly O
paclitaxel O
[ O
wPTX O
, O
80 O
  O
mg O
/ O
m O
2 O
, O
day O
1 O
, O
8 O
, O
15 O
] O
followed O
by O
four O
3 O
-week O
cycles O
of O
cyclophosphamide O
, O
epirubicin O
, O
and O
5 O
-fluorouracil O
[ O
CEF O
, O
500 O
/ O
100 O
/ O
500 O
  O
mg O
/ O
m O
2 O
] O
) O
or O
P O
- O
CEF O
( O
four O
cycles O
of O
wPTX O
followed O
by O
four O
cycles O
of O
CEF O
) O
as O
NAC O
. O
DFS O
and O
OS O
were O
analyzed O
at O
each O
population O
of O
pCR O
status O
and O
assigned O
treatment O
arm O
. O
Of O
179 B-total-participants
patients O
, O
154 B-total-participants
were O
available O
for O
long O
- O
term O
follow O
- O
up O
. O
At O
a O
median O
follow O
- O
up O
of O
6.6 O
  O
years O
( O
range O
, O
0.7 O
- O
8.0 O
  O
years O
) O
, O
patients B-outcome
who I-outcome
achieved I-outcome
pCR I-outcome
[ O
n O
  O
= O
  O
42 O
, O
23.5 O
% O
( O
CP O
- O
CEF O
: O
n O
  O
= O
  O
28 O
, O
P O
- O
CEF O
: O
n O
  O
= O
  O
16 O
) O
] O
had O
longer O
DFS B-outcome
and I-outcome
OS I-outcome
than O
non O
- O
pCR O
patients O
[ O
DFS B-outcome
; O
HR O
0.15 O
( O
0.04 O
- O
0.61 O
) O
, O
P O
  O
= O
  O
0.008 O
, O
OS O
; O
log O
- O
rank O
P O
  O
= O
  O
0.003 O
] O
. O
Addition O
of O
carboplatin O
to O
NAC O
significantly O
improved O
DFS B-outcome
and I-outcome
OS I-outcome
in I-outcome
the I-outcome
subset I-outcome
of I-outcome
patients I-outcome
with I-outcome
TNBC I-outcome
[ O
DFS B-outcome
: O
HR O
, O
0.22 O
( O
0.06 O
- O
0.82 O
) O
, O
P O
  O
= O
  O
0.015 O
; O
OS B-outcome
: O
HR O
, O
0.12 O
( O
0.01 O
- O
0.96 O
) O
, O
P O
  O
= O
  O
0.046 O
] O
, O
but O
not O
in O
the O
subset B-outcome
of I-outcome
patients I-outcome
with I-outcome
hormone I-outcome
receptor I-outcome
- I-outcome
positive I-outcome
disease I-outcome
or I-outcome
among I-outcome
all I-outcome
patients I-outcome
. O
Addition O
of O
carboplatin O
to O
neoadjuvant O
chemotherapy O
significantly O
improved O
DFS O
and O
OS O
in O
patients O
with O
TNBC O
but O
not O
in O
those O
with O
hormone O
receptor O
- O
positive O
, O
HER O
2 O
- O
negative O
breast O
cancer O
. O

The O
effect O
of O
body O
mass O
index O
on O
overall O
and O
disease O
- O
free O
survival O
  O
in O
node B-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
treated I-eligibility
with I-eligibility
docetaxel I-eligibility
  I-eligibility
and I-eligibility
doxorubicin I-eligibility
- I-eligibility
containing I-eligibility
adjuvant I-eligibility
chemotherapy I-eligibility
: O
  O
the O
experience O
of O
the O
BIG O
02 O
- O
98 O
trial O
. O
Obesity O
has O
been O
shown O
to O
be O
an O
indicator O
of O
poor O
prognosis O
for O
patients O
with O
primary O
breast O
cancer O
( O
BC O
) O
regardless O
of O
the O
use O
of O
adjuvant O
systemic O
therapy O
. O
This O
is O
a O
retrospective O
analysis O
of O
2 B-total-participants
, I-total-participants
887 I-total-participants
node O
- O
positive O
BC O
patients O
enrolled O
in O
the O
BIG O
02 O
- O
98 O
adjuvant O
study O
, O
a O
randomised O
phase O
III O
trial O
whose O
primary O
objective O
was O
to O
evaluate O
disease O
- O
free O
survival O
( O
DFS O
) O
by O
adding O
docetaxel O
to O
doxorubicin O
- O
based O
chemotherapy O
. O
In O
the O
current O
analysis O
, O
the O
effect O
of O
body O
mass O
index O
( O
BMI O
) O
on O
DFS O
and O
overall O
survival O
( O
OS O
) O
was O
assessed O
. O
BMI O
was O
obtained O
before O
the O
first O
cycle O
of O
chemotherapy O
. O
Obesity O
was O
defined O
as O
a O
BMI O
> O
or= O
30 O
kg O
/ O
m O
2 O
. O
In O
total O
, O
547 B-intervention-participants
( O
19 O
% O
) O
patients O
were O
obese B-intervention
at O
baseline O
, O
while O
2 B-control-participants
, I-control-participants
340 I-control-participants
( O
81 O
% O
) O
patients O
were O
non B-control
- I-control
obese I-control
. O
Estimated O
5 B-outcome
-year I-outcome
OS I-outcome
was O
87.5 B-cv-bin-percent
% I-cv-bin-percent
for O
non O
- O
obese O
and O
82.9 B-iv-bin-percent
% I-iv-bin-percent
for O
obese O
patients O
( O
HR O
1.34 O
; O
P O
= O
0.013 O
) O
. O
Estimated O
5 B-outcome
-years I-outcome
DFS I-outcome
was O
75.9 B-cv-bin-percent
% I-cv-bin-percent
for O
nonobese O
and O
70.0 B-iv-bin-percent
% I-iv-bin-percent
for O
obese O
patients O
( O
HR O
1.20 O
; O
P O
= O
0.041 O
) O
. O
Ina O
multivariate O
model O
, O
obesity O
remained O
an O
independent O
prognostic O
factor O
for O
OS O
and O
DFS O
. O
In O
this O
study O
, O
obesity O
was O
associated O
with O
poorer O
outcome O
in O
node O
- O
positive O
BC O
patients O
. O
Given O
the O
increasing O
prevalence O
of O
obesity O
worldwide O
, O
more O
research O
on O
improving O
the O
treatment O
of O
obese O
BC O
patients O
is O
needed O
. O

Role O
of O
axillary O
clearance O
after O
a O
tumor O
- O
positive O
sentinel O
node O
in O
the O
administration O
of O
adjuvant O
therapy O
in O
early O
breast O
cancer O
. O
PURPOSE O
The O
After O
Mapping O
of O
the O
Axilla O
: O
Radiotherapy O
or O
Surgery O
? O
( O
AMAROS O
) O
phase O
III O
study O
compares O
axillary B-intervention
lymph I-intervention
node I-intervention
dissection I-intervention
( I-intervention
ALND I-intervention
) I-intervention
and O
axillary B-control
radiation I-control
therapy I-control
( I-control
ART I-control
) I-control
in O
early B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
with I-eligibility
tumor I-eligibility
- I-eligibility
positive I-eligibility
sentinel I-eligibility
nodes I-eligibility
. O
In O
the O
ART O
arm O
, O
the O
extent O
of O
nodal O
involvement O
remains O
unknown O
, O
which O
could O
have O
implications O
on O
the O
administration O
of O
adjuvant O
therapy O
. O
In O
this O
preliminary O
analysis O
, O
we O
studied O
the O
influence O
of O
random O
assignment O
to O
ALND O
or O
ART O
on O
the O
choice O
for O
adjuvant O
treatment O
. O
PATIENTS O
AND O
METHODS O
In O
the O
first O
2 B-total-participants
, I-total-participants
000 I-total-participants
patients O
enrolled O
in O
the O
AMAROS O
trial O
, O
we O
analyzed O
the O
administration O
of O
adjuvant O
systemic O
therapy O
. O
Multivariate O
analysis O
was O
used O
to O
assess O
variables O
affecting O
the O
administration O
of O
adjuvant O
chemotherapy O
. O
Adjuvant O
therapy O
was O
applied O
according O
to O
institutional O
guidelines O
. O
Results O
Of O
2 B-total-participants
, I-total-participants
000 I-total-participants
patients O
, O
566 O
patients O
had O
a O
positive O
sentinel O
node O
and O
were O
treated O
per O
random O
assignment O
. O
There O
was O
no O
significant O
difference O
in O
the O
administration O
of O
adjuvant O
systemic O
therapy O
. O
In O
the O
ALND O
and O
ART O
arms O
, O
58 B-iv-bin-percent
% I-iv-bin-percent
( O
175 B-iv-bin-abs
of O
300 B-intervention-participants
) O
and O
61 B-cv-bin-percent
% I-cv-bin-percent
( O
162 B-cv-bin-abs
of O
266 B-control-participants
) O
of O
the O
patients O
, O
respectively O
, O
received B-outcome
chemotherapy I-outcome
. O
Endocrine B-outcome
therapy I-outcome
was O
administered O
in O
78 B-iv-bin-percent
% I-iv-bin-percent
( O
235 B-iv-bin-abs
of O
300 B-intervention-participants
) O
of O
the O
patients O
in O
the O
ALND O
arm O
and O
in O
76 B-cv-bin-percent
% I-cv-bin-percent
( O
203 B-cv-bin-abs
of O
266 B-control-participants
) O
of O
the O
patients O
in O
the O
ART O
arm O
. O
Treatment O
arm O
was O
not O
a O
significant O
factor O
in O
the O
decision O
, O
and O
no O
interactions O
between O
treatment O
arm O
and O
other O
factors O
were O
observed O
. O
Multivariate O
analysis O
showed O
that O
age O
, O
tumor O
grade O
, O
multifocality O
, O
and O
size O
of O
the O
sentinel O
node O
metastasis O
significantly O
affected O
the O
administration O
of O
chemotherapy O
. O
Within O
the O
ALND O
arm O
, O
the O
extent O
of O
nodal O
involvement O
remained O
not O
significant O
in O
a O
sensitivity O
multivariate O
analysis O
. O
CONCLUSION O
Absence O
of O
knowledge O
regarding O
the O
extent O
of O
nodal O
involvement O
in O
the O
ART O
arm O
appears O
to O
have O
no O
major O
impact O
on O
the O
administration O
of O
adjuvant O
therapy O
. O

[ O
Survival O
of O
breast O
cancer O
patients O
treated O
with O
inhibitors B-intervention
of I-intervention
the I-intervention
aromatase I-intervention
vs O
tamoxifen B-control
] O
. O
In O
Mexico B-location
the O
breast O
cancer O
occupies O
the O
second O
place O
as O
cause O
of O
death O
by O
oncological O
illness O
and O
the O
etiology O
is O
considered O
multifactorial O
. O
The O
systemic O
treatment O
of O
this O
cancer O
is O
necessarily O
after O
the O
surgery O
and O
simultaneously O
when O
radiotherapy O
is O
used O
; O
therefore O
the O
recent O
introduction O
of O
newly O
non O
toxics O
and O
efficient O
antiestrogens O
which O
block O
the O
effect O
of O
estrogens O
from O
circulation O
have O
become O
drugs O
of O
first O
line O
in O
the O
metastasis O
illness O
. O
To O
compare O
the O
clinical O
evolution O
and O
the O
survival O
of O
patients O
with O
locally O
advanced O
breast O
cancer O
and O
metastasis O
with O
the O
use O
of O
two O
therapeutic O
modalities O
. O
Under O
informed O
consent O
20 B-total-participants
patients B-eligibility
with I-eligibility
diagnosis I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
out I-eligibility
of I-eligibility
oncological I-eligibility
therapeutic I-eligibility
processing I-eligibility
were O
included O
. O
Randomly O
an O
inhibitor O
of O
the O
aromatase O
( O
anastrozole O
, O
1 O
mg O
for O
day O
) O
was O
used O
in O
10 B-intervention-participants
patients O
and O
in O
the O
other O
10 B-control-participants
patients O
tamoxifen O
( O
20 O
mg O
for O
day O
) O
both O
for O
2 O
years O
, O
subject O
to O
verification O
of O
positive O
estrogens O
- O
progesterone O
receptors O
. O
Half O
of O
the O
patients O
of O
each O
group O
had O
a O
clinical O
stage O
III O
. O
The O
most O
frequent O
histological O
diagnosis O
was O
the O
ductal B-outcome
carcinoma I-outcome
in O
70 B-cv-bin-percent
% I-cv-bin-percent
of O
the O
group O
with O
tamoxifen O
use O
, O
while O
in O
anastrozole O
group O
was O
90 B-iv-bin-percent
% I-iv-bin-percent
; O
the O
mastectomy B-outcome
prior I-outcome
to I-outcome
the I-outcome
tamoxifen I-outcome
was O
carried O
out O
in O
60 B-iv-bin-percent
% I-iv-bin-percent
of O
the O
patients O
and O
in O
50 B-cv-bin-percent
% I-cv-bin-percent
of O
the O
group O
with O
anastrozole O
. O
The O
acceptable O
response O
to O
the O
processing O
in O
the O
patients O
with O
tamoxifen O
was O
complete B-outcome
in O
the O
60 B-cv-bin-percent
% I-cv-bin-percent
of O
the O
cases O
, O
but O
with O
the O
use O
of O
anastrozole O
was O
80 B-iv-bin-percent
% I-iv-bin-percent
; O
survival B-outcome
in O
the O
group O
with O
anastrozole O
was O
of O
100 B-iv-bin-percent
% I-iv-bin-percent
in O
two O
years O
of O
follow O
up O
, O
while O
in O
women O
that O
received O
tamoxifen O
the O
survival O
was O
90 B-cv-bin-percent
% I-cv-bin-percent
( O
p O
< O
0.001 O
) O
. O
The O
use O
of O
anastrozole O
improved O
the O
survival B-outcome
as O
well O
as O
the O
quality B-outcome
of I-outcome
life I-outcome
, O
showing O
no O
side O
effects O
in O
this O
group O
of O
patients O
. O

Effects O
of O
adjuvant O
exemestane B-intervention
versus O
anastrozole B-control
on O
bone O
mineral O
density O
for O
women B-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
MA. I-eligibility
27 I-eligibility
B I-eligibility
) I-eligibility
: O
a O
companion O
analysis O
of O
a O
randomised O
controlled O
trial O
. O
Treatment O
of O
breast O
cancer O
with O
aromatase O
inhibitors O
is O
associated O
with O
damage O
to O
bones O
. O
NCIC O
CTG O
MA O
. O
27 O
was O
an O
open O
- O
label O
, O
phase O
3 O
, O
randomised O
controlled O
trial O
in O
which O
women O
with O
breast O
cancer O
were O
assigned O
to O
one O
of O
two O
adjuvant O
oral O
aromatase O
inhibitors O
- O
exemestane O
or O
anastrozole O
. O
We O
postulated O
that O
exemestane O
- O
a O
mildly O
androgenic O
steroid O
- O
might O
have O
a O
less O
detrimental O
effect O
on O
bone O
than O
non O
- O
steroidal O
anastrozole O
. O
In O
this O
companion O
study O
to O
MA O
. O
27 O
, O
we O
compared O
changes O
in O
bone O
mineral O
density O
( O
BMD O
) O
in O
the O
lumbar O
spine O
and O
total O
hip O
between O
patients O
treated O
with O
exemestane O
and O
patients O
treated O
with O
anastrozole O
. O
In O
MA O
. O
27 O
, O
postmenopausal O
women O
with O
early O
stage O
hormone O
( O
oestrogen O
) O
receptor O
- O
positive O
invasive O
breast O
cancer O
were O
randomly O
assigned O
to O
exemestane O
25 O
mg O
versus O
anastrozole O
1 O
mg O
, O
daily O
. O
MA. O
27 O
B O
recruited O
two O
groups O
of O
women O
from O
MA O
. O
27 O
: O
those O
with O
BMD O
T O
- O
scores O
of O
- O
2 O
· O
0 O
or O
more O
( O
up O
to O
2 O
SDs O
below O
sex O
- O
matched O
, O
young O
adult O
mean O
) O
and O
those O
with O
at O
least O
one O
T O
- O
score O
( O
hip O
or O
spine O
) O
less O
than O
- O
2 O
· O
0 O
. O
Both O
groups O
received O
vitamin O
D O
and O
calcium O
; O
those O
with O
baseline O
T O
- O
scores O
of O
less O
than O
- O
2 O
· O
0 O
also O
received O
bisphosphonates O
. O
The O
primary O
endpoints O
were O
percent B-outcome-measure
change I-outcome-measure
of I-outcome-measure
BMD I-outcome-measure
at I-outcome-measure
2 I-outcome-measure
years I-outcome-measure
in I-outcome-measure
lumbar I-outcome-measure
spine I-outcome-measure
and I-outcome-measure
total I-outcome-measure
hip I-outcome-measure
for O
both O
groups O
. O
We O
analysed O
patients O
according O
to O
which O
aromatase O
inhibitor O
and O
T O
- O
score O
groups O
they O
were O
allocated O
to O
but O
BMD O
assessments O
ceased O
if O
patients O
deviated O
from O
protocol O
. O
This O
study O
is O
registered O
with O
ClinicalTrials.gov O
, O
NCT O
00354302 O
. O
Between O
April O
24 O
, O
2006 O
, O
and O
May O
30 O
, O
2008 O
, O
300 B-total-participants
patients O
with O
baseline O
T O
- O
scores O
of O
- O
2 O
· O
0 O
or O
more O
were O
accrued O
( O
147 B-intervention-participants
allocated O
exemestane O
, O
153 B-control-participants
anastrozole O
) O
; O
and O
197 B-total-participants
patients O
with O
baseline O
T O
- O
scores O
of O
less O
than O
- O
2 O
· O
0 O
( O
101 B-intervention-participants
exemestane O
, O
96 B-control-participants
anastrozole O
) O
. O
For O
patients O
with O
T O
- O
scores O
greater O
than O
- O
2 O
· O
0 O
at O
baseline O
, O
mean B-outcome
change I-outcome
of I-outcome
bone I-outcome
mineral I-outcome
density I-outcome
in I-outcome
the I-outcome
spine I-outcome
at I-outcome
2 I-outcome
years I-outcome
did O
not O
differ O
significantly O
between O
patients O
taking O
exemestane O
and O
patients O
taking O
anastrozole O
( O
- B-iv-cont-mean
0 I-iv-cont-mean
· I-iv-cont-mean
92 I-iv-cont-mean
% I-iv-cont-mean
, O
95 O
% O
CI O
- O
2 O
· O
35 O
to O
0 O
· O
50 O
vs O
- B-cv-cont-mean
2 I-cv-cont-mean
· I-cv-cont-mean
39 I-cv-cont-mean
% I-cv-cont-mean
, O
95 O
% O
CI O
- O
3 O
· O
77 O
to O
- O
1 O
· O
01 O
; O
p= O
0 O
· O
08 O
) O
. O
Respective O
mean B-outcome
loss I-outcome
in I-outcome
the I-outcome
hip I-outcome
was O
- B-iv-cont-mean
1 I-iv-cont-mean
· I-iv-cont-mean
93 I-iv-cont-mean
% I-iv-cont-mean
( O
95 O
% O
CI O
- O
2 O
· O
93 O
to O
- O
0 O
· O
93 O
) O
versus O
- B-cv-cont-mean
2 I-cv-cont-mean
· I-cv-cont-mean
71 I-cv-cont-mean
% I-cv-cont-mean
( O
95 O
% O
CI O
- O
4 O
· O
32 O
to O
- O
1 O
· O
11 O
; O
p= O
0 O
· O
10 O
) O
. O
Likewise O
for O
those O
who O
started O
with O
T O
- O
scores O
of O
less O
than O
- O
2 O
· O
0 O
, O
mean B-outcome
change I-outcome
of I-outcome
spine I-outcome
bone I-outcome
mineral I-outcome
density I-outcome
at I-outcome
2 I-outcome
years I-outcome
did O
not O
differ O
significantly O
between O
the O
exemestane O
and O
anastrozole O
treatment O
groups O
( O
2 B-iv-cont-mean
· I-iv-cont-mean
11 I-iv-cont-mean
% I-iv-cont-mean
, O
95 O
% O
CI O
- O
0 O
· O
84 O
to O
5 O
· O
06 O
vs O
3 B-cv-cont-mean
· I-cv-cont-mean
72 I-cv-cont-mean
% I-cv-cont-mean
, O
95 O
% O
CI O
1 O
· O
54 O
to O
5 O
· O
89 O
; O
p= O
0 O
· O
26 O
) O
, O
nor O
did O
hip B-outcome
bone I-outcome
mineral I-outcome
density I-outcome
( O
2 B-iv-cont-mean
· I-iv-cont-mean
09 I-iv-cont-mean
% I-iv-cont-mean
, O
95 O
% O
CI O
- O
1 O
· O
45 O
to O
5 O
· O
63 O
vs O
0 B-cv-cont-mean
· I-cv-cont-mean
0 I-cv-cont-mean
% I-cv-cont-mean
, O
95 O
% O
CI O
- O
3 O
· O
67 O
to O
3 O
· O
66 O
; O
p= O
0 O
· O
28 O
) O
. O
Patients O
with O
baseline O
T O
- O
score O
of O
- O
2 O
· O
0 O
or O
more O
taking O
exemestane O
had O
two B-iv-bin-abs
fragility B-outcome
fractures I-outcome
and O
two B-iv-bin-abs
other B-outcome
fractures I-outcome
, O
those O
taking O
anastrozole O
had O
three B-cv-bin-abs
fragility B-outcome
fractures I-outcome
and O
five B-cv-bin-abs
other B-outcome
fractures I-outcome
. O
For O
patients O
who O
had O
baseline O
T O
- O
scores O
of O
less O
than O
- O
2 O
· O
0 O
taking O
exemestane O
, O
one B-iv-bin-abs
had O
a O
fragility B-outcome
fracture I-outcome
and O
four B-iv-bin-abs
had O
other B-outcome
fractures I-outcome
, O
whereas O
those O
taking O
anastrozole O
had O
five B-cv-bin-abs
fragility B-outcome
fractures I-outcome
and O
one B-cv-bin-abs
other B-outcome
fracture I-outcome
. O
Our O
results O
demonstrate O
that O
adjuvant O
treatment O
with O
aromatase O
inhibitors O
can O
be O
considered O
for O
breast O
cancer O
patients O
who O
have O
T O
- O
scores O
less O
than O
- O
2 O
· O
0 O
. O
Canadian O
Cancer O
Society O
Research O
Institute O
, O
Pfizer O
, O
Canadian O
Institutes O
of O
Health O
Research O
. O

Effectiveness O
of O
early O
physiotherapy B-intervention
to O
prevent O
lymphoedema B-condition
after O
surgery O
for O
breast O
cancer O
: O
randomised O
, O
single O
blinded O
, O
clinical O
trial O
. O
To O
determine O
the O
effectiveness O
of O
early O
physiotherapy O
in O
reducing O
the O
risk O
of O
secondary O
lymphoedema O
after O
surgery O
for O
breast O
cancer O
. O
Randomised O
, O
single O
blinded O
, O
clinical O
trial O
. O
University O
hospital O
in O
Alcalá O
de O
Henares O
, O
Madrid B-location
, I-location
Spain I-location
. O
120 B-total-participants
women B-eligibility
who I-eligibility
had I-eligibility
breast I-eligibility
surgery I-eligibility
involving I-eligibility
dissection I-eligibility
of I-eligibility
axillary I-eligibility
lymph I-eligibility
nodes O
between O
May O
2005 O
and O
June O
2007 O
. O
The O
early O
physiotherapy O
group O
was O
treated O
by O
a O
physiotherapist O
with O
a O
physiotherapy O
programme O
including O
manual O
lymph O
drainage O
, O
massage O
of O
scar O
tissue O
, O
and O
progressive O
active O
and O
action O
assisted O
shoulder O
exercises O
. O
This O
group O
also O
received O
an O
educational O
strategy O
. O
The O
control B-control
group I-control
received O
the O
educational O
strategy O
only O
. O
Incidence O
of O
clinically O
significant O
secondary O
lymphoedema O
( O
> O
2 O
cm O
increase O
in O
arm O
circumference O
measured O
at O
two O
adjacent O
points O
compared O
with O
the O
non O
- O
affected O
arm O
) O
. O
116 B-total-participants
women O
completed O
the O
one O
year O
follow O
- O
up O
. O
Of O
these O
, O
18 O
developed O
secondary B-outcome
lymphoedema I-outcome
( O
16 O
% O
) O
: O
14 B-cv-bin-abs
in O
the O
control O
group O
( O
25 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
four B-iv-bin-abs
in O
the O
intervention O
group O
( O
7 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
The O
difference B-outcome
was O
significant O
( O
P= O
0.01 O
) O
; O
risk O
ratio O
0.28 O
( O
95 O
% O
confidence O
interval O
0.10 O
to O
0.79 O
) O
. O
A O
survival O
analysis O
showed O
a O
significant O
difference O
, O
with O
secondary B-outcome
lymphoedema I-outcome
being I-outcome
diagnosed I-outcome
four I-outcome
times I-outcome
earlier I-outcome
in O
the O
control O
group O
than O
in O
the O
intervention O
group O
( O
intervention O
/ O
control O
, O
hazard O
ratio O
0.26 O
, O
95 O
% O
confidence O
interval O
0.09 O
to O
0.79 O
) O
. O
Early O
physiotherapy O
could O
be O
an O
effective O
intervention O
in O
the O
prevention O
of O
secondary O
lymphoedema O
in O
women O
for O
at O
least O
one O
year O
after O
surgery O
for O
breast O
cancer O
involving O
dissection O
of O
axillary O
lymph O
nodes O
. O
Current O
controlled O
trials O
ISRCTN O
95870846 O
. O

Effectiveness O
of O
OK- B-intervention
432 I-intervention
( I-intervention
Sapylin I-intervention
) I-intervention
to O
reduce O
seroma B-condition
formation I-condition
after O
axillary O
lymphadenectomy O
for O
breast O
cancer O
. O
The O
occurrence O
of O
seroma O
formation O
after O
axillary O
lymphadenectomy O
for O
breast O
cancer O
can O
not O
be O
ignored O
. O
Various O
approaches O
have O
been O
used O
in O
an O
effort O
to O
reduce O
it O
, O
but O
these O
results O
are O
still O
controversial O
. O
We O
aimed O
to O
describe O
a O
new O
method O
of O
application O
of O
OK- O
432 O
( O
Sapylin O
, O
heat O
- O
treated O
Su O
strain O
of O
Streptococcus O
) O
to O
reduce O
seroma O
formation O
after O
axillary O
lymphadenectomy O
for O
breast O
cancer O
and O
to O
verify O
the O
safety O
and O
efficacy O
of O
it O
as O
a O
beneficial O
supplement O
for O
conventional O
surgery O
. O
A O
prospective O
, O
randomized O
analysis O
of O
consecutive O
quadrantectomy O
or O
mastectomy O
plus O
axillary O
lymphadenectomy O
using O
or O
not O
using O
OK- O
432 O
was O
designed O
. O
From O
July O
2010 O
to O
November O
2011 O
, O
a O
total O
of O
111 B-total-participants
patients O
were O
enrolled O
in O
this O
prospective O
, O
randomized O
study O
and O
completed O
the O
follow O
- O
up O
. O
OK- O
432 O
applied O
to O
the O
axillary O
fossa O
plus O
placement O
of O
closed O
suction O
drainage O
was O
used O
in O
54 B-intervention-participants
patients O
( O
the O
experimental O
group O
) O
; O
placement O
of O
closed O
suction O
drainage O
was O
used O
in O
57 B-control-participants
patients O
( O
the O
control B-control
group I-control
) O
. O
There O
were O
no O
statistical O
significance O
between O
the O
two O
groups O
in O
terms O
of O
age O
, O
body O
mass O
index O
, O
treatment O
received O
, O
tumor O
size O
, O
number O
of O
removed O
lymph O
nodes O
, O
and O
lymph O
node O
status O
. O
Postoperative B-outcome
drainage I-outcome
magnitude I-outcome
and I-outcome
duration I-outcome
were O
significantly O
reduced O
in O
the O
experimental O
group O
( O
P O
= O
0.008 O
and O
0.003 O
, O
respectively O
) O
. O
One O
week O
after O
hospital O
discharge O
, O
fewer O
patients O
developed O
a O
palpable B-outcome
seroma I-outcome
in O
the O
experimental O
group O
: O
10 B-iv-bin-abs
in O
the O
experimental O
group O
versus O
28 B-cv-bin-abs
in O
the O
control O
group O
( O
P O
= O
0.001 O
) O
. O
Fewer O
seromas B-outcome
needed I-outcome
aspiration I-outcome
( O
mean O
1 B-iv-cont-mean
[ O
range O
0 O
- O
3 O
] O
in O
the O
experimental O
group O
vs. O
mean O
4 B-cv-cont-mean
[ O
range O
1 O
- O
5 O
] O
in O
the O
control O
group O
; O
P O
< O
0.001 O
) O
. O
There O
were O
no O
significant O
differences O
in O
terms O
of O
the O
incidence B-outcome
of I-outcome
complications I-outcome
associated I-outcome
with I-outcome
axillary I-outcome
lymphadenectomy I-outcome
( O
P O
= O
0.941 O
) O
. O
OK- O
432 O
is O
a O
feasible O
and O
safe O
option O
for O
axillary O
lymphadenectomy O
for O
breast O
cancer O
. O
The O
use O
of O
it O
does O
not O
always O
prevent O
seroma O
formation O
, O
but O
it O
can O
reduce O
drainage O
magnitude O
and O
duration O
, O
as O
well O
as O
decrease O
the O
incidence O
of O
seroma O
after O
the O
removal O
of O
drainage O
. O
It O
may O
be O
increasingly O
conducted O
in O
day O
surgery O
clinics O
. O

A O
text B-intervention
message I-intervention
intervention I-intervention
to O
support O
women O
's O
physical B-condition
and I-condition
mental I-condition
health I-condition
after O
breast O
cancer O
treatments O
( O
EMPOWER O
- O
SMS O
) O
: O
a O
randomised O
controlled O
trial O
protocol O
. O
Breast O
cancer O
is O
the O
most O
common O
cancer O
diagnosed O
in O
women O
worldwide O
. O
In O
developed O
countries O
, O
80 O
- O
90 O
% O
of O
women O
will O
survive O
five O
years O
after O
diagnosis O
but O
the O
transition O
from O
hospital O
- O
based O
care O
to O
health O
self O
- O
management O
and O
self O
- O
efficacy O
can O
be O
difficult O
. O
Text O
messaging O
programs O
offer O
a O
simple O
and O
proven O
way O
to O
provide O
support O
to O
people O
with O
chronic O
diseases O
. O
This O
study O
aims O
to O
test O
the O
effectiveness O
of O
a O
text O
message O
support O
program O
at O
improving O
women O
's O
health O
self O
- O
efficacy O
, O
and O
physical O
and O
mental O
health O
outcomes O
after O
breast O
cancer O
treatments O
compared O
to O
usual B-control
care I-control
at O
6 O
-months O
and O
to O
understand O
the O
barriers O
and O
enablers O
to O
widespread O
implementation O
. O
Single O
- O
blind O
randomised O
control O
trial O
( O
RCT O
; O
N O
  O
= O
  O
160 B-total-participants
) O
comparing O
a O
text O
message O
support O
intervention O
to O
usual O
care O
in O
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
( O
recruited O
from O
a O
large O
tertiary O
referral O
hospital O
in O
Sydney B-location
, I-location
Australia I-location
) O
. O
The O
intervention O
group O
will O
receive O
a O
six O
- O
month O
text O
message O
support O
program O
, O
which O
consists O
of O
semi O
- O
personalised O
, O
supportive O
, O
lifestyle O
- O
focused O
text O
messages O
( O
4 O
messages O
/ O
week O
) O
in O
addition O
to O
usual O
care O
. O
The O
control O
group O
will O
receive O
usual B-control
care I-control
without O
the O
text O
message O
program O
. O
Outcomes O
will O
be O
assessed O
at O
6 O
-months O
. O
The O
primary O
outcome O
is O
change B-outcome-measure
in I-outcome-measure
self I-outcome-measure
- I-outcome-measure
efficacy I-outcome-measure
for I-outcome-measure
managing I-outcome-measure
chronic I-outcome-measure
disease I-outcome-measure
. O
Secondary O
outcomes O
include O
change B-outcome-measure
in I-outcome-measure
clinical I-outcome-measure
outcomes I-outcome-measure
( I-outcome-measure
body I-outcome-measure
mass I-outcome-measure
index I-outcome-measure
) I-outcome-measure
, O
lifestyle B-outcome-measure
outcomes I-outcome-measure
( I-outcome-measure
physical I-outcome-measure
activity I-outcome-measure
levels I-outcome-measure
, I-outcome-measure
dietary I-outcome-measure
behaviours I-outcome-measure
) I-outcome-measure
, O
mood B-outcome-measure
( I-outcome-measure
depression I-outcome-measure
and I-outcome-measure
anxiety I-outcome-measure
scales I-outcome-measure
) I-outcome-measure
, O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
, O
satisfaction B-outcome-measure
with I-outcome-measure
, O
and O
usefulness B-outcome-measure
of I-outcome-measure
the I-outcome-measure
intervention I-outcome-measure
. O
Analyses O
will O
be O
performed O
on O
the O
principle O
of O
intention O
- O
to O
- O
treat O
to O
examine O
differences O
between O
intervention O
and O
control O
groups O
. O
This O
study O
will O
test O
if O
a O
scalable O
and O
cost O
- O
effective O
text O
- O
messaging O
intervention O
is O
effective O
at O
improving O
women O
's O
health O
self O
- O
efficacy O
, O
as O
well O
as O
physical O
and O
mental O
health O
outcomes O
. O
Moreover O
, O
this O
study O
will O
provide O
essential O
preliminary O
data O
to O
bolster O
a O
large O
multicentre O
RCT O
to O
helpsupport O
breast O
cancer O
survivors O
throughout O
recovery O
and O
beyond O
. O
Australia O
New O
Zealand O
Clinical O
Trials O
Registry O
( O
ANZCTR O
) O
number O
ACTRN O
12618002020268 O
, O
17 O
December O
2018 O
. O

Serum B-intervention
lipids I-intervention
, O
lipoproteins O
, O
and O
risk O
of O
breast O
cancer O
: O
a O
nested O
case O
- O
control O
study O
using O
multiple O
time O
points O
. O
There O
is O
strong O
evidence O
that O
breast O
cancer O
risk O
is O
influenced O
by O
environmental O
factors O
. O
Blood O
lipid O
and O
lipoprotein O
levels O
are O
also O
influenced O
by O
environmental O
factors O
and O
are O
associated O
with O
some O
breast O
cancer O
risk O
factors O
. O
We O
examined O
whether O
serial O
measures O
of O
serum O
lipids O
and O
lipoproteins O
were O
associated O
with O
breast O
cancer O
risk O
. O
We O
carried O
out O
a O
nested O
case O
- O
control O
study O
within O
a O
randomized O
long O
- O
term O
dietary O
intervention O
trial O
with O
4690 B-total-participants
women B-eligibility
with I-eligibility
extensive I-eligibility
mammographic I-eligibility
density I-eligibility
followed I-eligibility
for I-eligibility
an I-eligibility
average I-eligibility
of I-eligibility
10 I-eligibility
years I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
incidence I-eligibility
. O
We O
measured O
lipids O
in O
an O
average O
of O
4.2 O
blood O
samples O
for O
279 B-intervention-participants
invasive O
breast O
cancer O
case O
subjects O
and O
558 B-control-participants
matched O
control B-control
subjects I-control
. O
We O
calculated O
subaverages O
of O
lipids O
for O
each O
subject O
based O
on O
menopausal O
status O
and O
use O
of O
hormone O
replacement O
therapy O
( O
HRT O
) O
at O
blood O
collection O
and O
analyzed O
their O
association O
with O
breast O
cancer O
using O
generalized O
estimating O
equations O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
. O
High B-outcome
- I-outcome
density I-outcome
lipoprotein I-outcome
- I-outcome
cholesterol I-outcome
( O
HDL O
- O
C O
) O
( O
P O
= O
. O
05 O
) O
and O
apoA B-outcome
1 I-outcome
( O
P O
= O
. O
02 O
) O
levels O
were O
positively O
associated O
with O
breast B-outcome
cancer I-outcome
risk I-outcome
( O
75 O
( O
th O
) O
vs O
25 O
( O
th O
) O
percentile O
: O
HDL O
- O
C O
, O
23 O
% O
higher O
; O
apoA O
1 O
, O
28 O
% O
higher O
) O
and O
non B-outcome
- I-outcome
HDL I-outcome
- I-outcome
C I-outcome
( O
P O
= O
. O
03 O
) O
and O
apoB O
( O
P O
= O
. O
01 O
) O
levels O
were O
negatively O
associated O
( O
75 O
( O
th O
) O
vs O
25 O
( O
th O
) O
percentile O
: O
non O
- O
HDL O
- O
C O
, O
19 O
% O
lower O
; O
apoB O
, O
22 O
% O
lower O
) O
. O
These O
associations O
were O
observed O
only O
when O
lipids O
were O
measured O
when O
HRT O
was O
not O
used O
. O
Total B-outcome
cholesterol I-outcome
and I-outcome
triglyceride I-outcome
levels I-outcome
were O
not O
statistically O
significantly O
associated O
with O
breast O
cancer O
risk O
. O
These O
results O
demonstrate O
that O
serum O
lipids O
are O
associated O
with O
breast O
cancer O
risk O
in O
women O
with O
extensive O
mammographic O
density O
. O
The O
possibility O
that O
interventions O
for O
heart O
disease O
prevention O
, O
which O
aim O
to O
reduce O
non O
- O
HDL O
- O
C O
or O
raise O
HDL O
- O
C O
, O
may O
have O
effects O
on O
breast O
cancer O
risk O
merits O
examination O
. O

Letrozole B-intervention
and I-intervention
palbociclib I-intervention
versus O
chemotherapy B-control
as O
neoadjuvant O
therapy O
of O
high O
- O
risk O
luminal O
breast O
cancer O
. O
Palbociclib O
is O
a O
CDK O
4 O
/ O
6 O
inhibitor O
with O
demonstrated O
efficacy O
and O
safety O
in O
combination O
with O
endocrine O
therapy O
in O
advanced O
luminal O
breast O
cancer O
( O
LBC O
) O
. O
We O
evaluated O
the O
respective O
efficacy O
and O
safety O
of O
chemotherapy O
and O
letrozole O
- O
palbociclib O
( O
LETPAL O
) O
combination O
as O
neoadjuvant O
treatment O
in O
patients O
with O
high O
- O
risk O
LBC O
. O
NeoPAL O
( O
UCBG O
10 O
/ O
4 O
, O
NCT O
02400567 O
) O
is O
a O
randomised O
, O
parallel O
, O
non O
- O
comparative O
phase O
II O
study O
. O
Patients B-eligibility
with I-eligibility
ER I-eligibility
- I-eligibility
positive I-eligibility
, I-eligibility
HER I-eligibility
2 I-eligibility
- I-eligibility
negative I-eligibility
, I-eligibility
Prosigna I-eligibility
® I-eligibility
-defined I-eligibility
luminal I-eligibility
B I-eligibility
, I-eligibility
or I-eligibility
luminal I-eligibility
A I-eligibility
and I-eligibility
node I-eligibility
- I-eligibility
positive I-eligibility
, I-eligibility
stage I-eligibility
II I-eligibility
- I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
, I-eligibility
not I-eligibility
candidate I-eligibility
for I-eligibility
breast I-eligibility
- I-eligibility
conserving I-eligibility
surgery I-eligibility
, O
were O
randomly O
assigned O
to O
either O
letrozole O
( O
2.5 O
  O
mg O
daily O
) O
and O
palbociclib O
( O
125 O
  O
mg O
daily O
, O
3 O
  O
weeks O
/ O
4 O
) O
during O
19 O
  O
weeks O
, O
or O
to O
FEC O
100 O
( O
5 O
FU O
500 O
  O
mg O
/ O
m O
2 O
, O
epirubicin O
100 O
  O
mg O
/ O
m O
2 O
, O
cyclophosphamide O
500 O
  O
mg O
/ O
m O
2 O
) O
× O
3 O
21 O
-day O
courses O
followed O
by O
docetaxel O
100 O
  O
mg O
/ O
m O
2 O
× O
3 O
21 O
-day O
courses O
. O
Primary O
end O
point O
was O
residual B-outcome-measure
cancer I-outcome-measure
burden I-outcome-measure
( I-outcome-measure
RCB I-outcome-measure
0 I-outcome-measure
-I I-outcome-measure
rate I-outcome-measure
) I-outcome-measure
. O
Secondary O
end O
points O
included O
clinical B-outcome-measure
response I-outcome-measure
, O
proliferation B-outcome-measure
- I-outcome-measure
based I-outcome-measure
markers I-outcome-measure
, O
and O
safety B-outcome-measure
. O
Overall O
, O
106 B-total-participants
patients O
were O
randomised O
[ O
median O
Prosigna O
® O
ROR O
Score O
71 O
( O
22 O
- O
93 O
) O
] O
. O
RCB B-outcome
0 I-outcome
-I I-outcome
was O
observed O
in O
four B-iv-bin-abs
and O
eight B-cv-bin-abs
patients O
in O
LETPAL O
[ O
7.7 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
0.4 O
- O
14.9 O
) O
] O
and O
chemotherapy O
[ O
15.7 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
5.7 O
- O
25.7 O
) O
] O
arms O
, O
respectively O
. O
Pathological B-outcome
complete I-outcome
response I-outcome
rates I-outcome
were O
3.8 B-iv-bin-percent
% I-iv-bin-percent
and O
5.9 B-cv-bin-percent
% I-cv-bin-percent
. O
Clinical B-outcome
response I-outcome
( O
75 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
breast B-outcome
- I-outcome
conserving I-outcome
surgery I-outcome
rates I-outcome
( O
69 B-cv-bin-percent
% I-cv-bin-percent
) O
were O
similar O
in O
both O
arms O
. O
Preoperative O
Endocrine O
Prognostic O
Index O
0 O
scores O
( O
breast B-outcome
cancer I-outcome
- I-outcome
specific I-outcome
survival I-outcome
) O
were O
observed O
in O
17.6 B-iv-bin-percent
% I-iv-bin-percent
and O
8.0 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
in O
LETPAL O
and O
chemotherapy O
arms O
, O
respectively O
. O
Safety O
profile O
was O
as O
expected O
, O
with O
2 B-iv-bin-abs
versus O
17 B-cv-bin-abs
serious B-outcome
adverse I-outcome
events I-outcome
( O
including O
11 B-cv-bin-abs
grade B-outcome
4 I-outcome
serious I-outcome
AEs I-outcome
in O
the O
chemotherapy O
arm O
) O
. O
LETPAL O
combination O
was O
associated O
with O
poor O
pathological B-outcome
response I-outcome
but O
encouraging O
clinical B-outcome
and I-outcome
biomarker I-outcome
responses I-outcome
in O
Prosigna O
® O
-defined O
high O
- O
risk O
LBC O
. O
Contemporary O
chemotherapy O
regimen O
was O
associated O
with O
poor O
pathological O
and O
biomarker O
responses O
, O
with O
a O
much O
less O
favourable O
safety O
profile O
. O
LETPAL O
combination O
might O
represent O
an O
alternative O
to O
chemotherapy O
in O
early O
high O
- O
risk O
LBC O
. O
NCT O
02400567 O
. O

Effect O
of O
different O
doses O
of O
metformin B-intervention
on O
serum B-condition
testosterone I-condition
and I-condition
insulin I-condition
in O
non O
- O
diabetic O
women O
with O
breast O
cancer O
: O
a O
randomized O
study O
. O
This O
is O
a O
randomized O
controlled O
trial O
to O
test O
the O
effect O
of O
different O
doses O
of O
metformin O
in O
patients O
with O
breast O
cancer O
and O
without O
diabetes O
, O
with O
the O
aim O
of O
modifying O
the O
hormonal O
and O
metabolic O
parameters O
linked O
to O
breast O
cancer O
prognosis O
. O
Analysis O
of O
the O
results O
suggest O
that O
the O
dose O
of O
1500 O
mg O
/ O
d O
of O
metformin O
causes O
a O
significant O
reduction O
of O
insulin O
and O
testosterone O
serum O
levels O
. O
Serum O
levels O
of O
insulin O
and O
testosterone O
may O
affect O
both O
breast O
cancer O
( O
BC O
) O
incidence O
and O
prognosis O
. O
Metformin O
reduces O
hyperglycemia O
and O
insulin O
levels O
in O
patients O
with O
diabetes O
. O
In O
women O
without O
diabetes O
and O
with O
polycystic O
ovary O
syndrome O
, O
metformin O
lowers O
both O
insulin O
and O
testosterone O
levels O
. O
Patients O
with O
diabetes O
who O
are O
treated O
with O
metformin O
showed O
a O
lower O
risk O
of O
cancer O
; O
a O
protective O
effect O
of O
metformin O
also O
was O
observed O
for O
BC O
. O
Recently O
, O
studies O
on O
metformin O
use O
for O
prevention O
or O
treatment O
of O
BC O
have O
been O
proposed O
in O
patients O
who O
are O
not O
diabetic O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
test O
the O
effect O
of O
different O
doses O
of O
metformin O
on O
serum O
levels O
of O
insulin O
and O
testosterone O
in O
those O
postmenopausal B-eligibility
patients I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
without I-eligibility
diabetes I-eligibility
who I-eligibility
have I-eligibility
basal I-eligibility
testosterone I-eligibility
levels I-eligibility
≥ I-eligibility
0.28 I-eligibility
ng I-eligibility
/ I-eligibility
mL I-eligibility
( O
median O
value O
) O
. O
A O
total O
of O
125 B-total-participants
eligible O
women O
were O
initially O
invited O
to O
take O
metformin O
500 O
mg O
/ O
d O
for O
3 O
months O
. O
The O
108 B-total-participants
women O
who O
completed O
the O
first O
3 O
months O
were O
invited O
to O
continue O
the O
study O
with O
metformin O
1000 O
mg O
/ O
d O
( O
500 O
mg O
twice O
a O
day O
[ O
b.i.d O
. O
] O
) O
for O
1 O
month O
. O
The O
women O
were O
then O
randomized O
into O
2 O
groups O
, O
and O
, O
for O
the O
subsequent O
5 O
months O
, O
1 O
group O
increased O
the O
dose O
by O
taking O
metformin O
1500 O
mg O
/ O
d O
( O
500 O
mg O
3 O
times O
a O
day O
[ O
t.i.d O
. O
] O
) O
, O
and O
the O
other O
group O
continued O
with O
metformin B-control
1000 I-control
mg I-control
/d I-control
( O
500 O
[ O
b.i.d O
. O
] O
) O
. O
A O
total O
of O
96 B-total-participants
women O
completed O
the O
study O
: O
43 B-intervention-participants
women O
received O
1500 O
mg O
/ O
d O
, O
and O
53 B-control-participants
women O
received O
1000 O
mg O
/ O
d. O
The O
women O
who O
took O
1500 O
mg O
/ O
d O
showed O
a O
significant O
reduction O
of O
insulin B-outcome
level I-outcome
, O
HOMA B-outcome
- I-outcome
IR I-outcome
index I-outcome
( O
homeostasis O
model O
assessment O
- O
insulin O
resistance O
index O
) O
, O
testosterone B-outcome
level I-outcome
, O
and O
free B-outcome
androgen I-outcome
index I-outcome
compared O
with O
women O
treated O
with O
1000 O
mg O
/ O
d. O
After O
treatment O
with O
1500 O
mg O
/ O
d O
, O
the O
insulin B-outcome
level I-outcome
decreased O
by O
25 O
% O
and O
the O
testosterone B-outcome
level I-outcome
decreased O
by O
23 O
% O
. O
Both O
these O
changes O
might O
have O
a O
prognostic O
importance O
. O

Breast O
cancer O
incidence O
in O
the O
randomized O
PEARL O
trial O
of O
lasofoxifene B-intervention
in O
postmenopausal B-eligibility
osteoporotic I-eligibility
women I-eligibility
. O
Currently O
available O
selective O
estrogen O
receptor O
modulators O
reduce O
the O
risk O
of O
breast O
cancer O
, O
but O
they O
are O
not O
widely O
used O
. O
In O
the O
Postmenopausal O
Evaluation O
and O
Risk O
- O
Reduction O
with O
Lasofoxifene O
( O
PEARL O
) O
trial O
, O
lasofoxifene O
was O
shown O
to O
reduce O
the O
risk O
of O
estrogen O
receptor O
- O
positive O
( O
ER+ O
) O
breast O
cancer O
, O
nonvertebral O
and O
vertebral O
fractures O
, O
coronary O
artery O
disease O
, O
and O
stroke O
, O
but O
the O
effects O
on O
total O
breast O
cancer O
( O
invasive O
and O
ductal O
carcinoma O
in O
situ O
, O
ER+ O
and O
estrogen O
receptor O
- O
negative O
[ O
ER- O
] O
) O
and O
ER+ O
invasive O
breast O
cancer O
are O
unknown O
. O
Postmenopausal O
women O
( O
n O
= O
8556 B-total-participants
) O
aged O
59 B-age
- I-age
80 I-age
years I-age
with B-eligibility
low I-eligibility
bone I-eligibility
density I-eligibility
and I-eligibility
normal I-eligibility
mammograms I-eligibility
were O
randomly O
assigned O
to O
two O
doses O
of O
lasofoxifene O
( O
0.25 O
and O
0.5 O
mg O
) O
or O
placebo B-control
. O
The O
primary O
endpoints O
of O
the O
PEARL O
trial O
were O
incidence B-outcome-measure
of I-outcome-measure
ER+ I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
and I-outcome-measure
nonvertebral I-outcome-measure
fractures I-outcome-measure
at O
5 O
years O
. O
A O
nested O
case O
- O
control O
study O
of O
49 O
incident O
breast O
cancer O
case O
patients O
and O
156 O
unaffected O
control O
subjects O
from O
the O
PEARL O
trial O
was O
performed O
to O
evaluate O
treatment O
effects O
on O
risk O
of O
total O
and O
ER+ O
invasive O
breast O
cancer O
by O
baseline O
serum O
estradiol O
and O
sex O
hormone O
- O
binding O
globulin O
levels O
using O
logistic O
regression O
models O
. O
Cox O
proportional O
hazards O
models O
were O
used O
to O
evaluate O
risk O
of O
total O
breast O
cancer O
and O
ER+ O
invasive O
breast O
cancer O
using O
intention O
- O
to O
- O
treat O
analysis O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
. O
Breast B-outcome
cancer I-outcome
was O
confirmed O
in O
49 O
women O
. O
Compared O
with O
placebo O
, O
0.5 O
mg O
of O
lasofoxifene O
statistically O
significantly O
reduced O
the O
risk B-outcome
of I-outcome
total I-outcome
breast I-outcome
cancer I-outcome
by O
79 B-iv-bin-percent
% I-iv-bin-percent
( O
hazard O
ratio O
= O
0.21 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.08 O
to O
0.55 O
) O
and O
ER+ B-outcome
invasive I-outcome
breast I-outcome
cancer I-outcome
by O
83 B-iv-bin-percent
% I-iv-bin-percent
( O
hazard O
ratio O
= O
0.17 O
; O
95 O
% O
CI O
= O
0.05 O
to O
0.57 O
) O
. O
The O
effects O
of O
0.5 O
mg O
of O
lasofoxifene O
on O
total B-outcome
breast I-outcome
cancer I-outcome
were O
similar O
regardless O
of O
Gail O
score O
, O
whereas O
the O
effects O
were O
markedly O
stronger O
for O
women O
with O
baseline O
estradiol O
levels O
greater O
than O
the O
median O
( O
odds O
ratio O
= O
0.11 O
; O
95 O
% O
CI O
= O
0.02 O
to O
0.51 O
) O
vs O
those O
with O
levels O
less O
than O
the O
median O
( O
odds O
ratio O
= O
0.78 O
; O
95 O
% O
CI O
= O
0.16 O
to O
3.79 O
; O
P O
( O
interaction O
) O
= O
. O
04 O
) O
. O
A O
0.5 O
-mg O
dose O
of O
lasofoxifene O
appears O
to O
reduce O
the O
risks O
of O
both O
total O
and O
ER+ O
invasive O
breast O
cancer O
in O
postmenopausal O
women O
with O
osteoporosis O
. O

Focused B-intervention
microwave I-intervention
thermotherapy I-intervention
for O
preoperative O
treatment O
of O
invasive O
breast O
cancer O
: O
a O
review O
of O
clinical O
studies O
. O
Preoperative O
focused O
microwave O
thermotherapy O
( O
FMT O
) O
is O
a O
promising O
method O
for O
targeted O
treatment O
of O
breast O
cancer O
cells O
. O
Results O
of O
four O
multi O
- O
institutional O
clinical O
studies O
of O
preoperative O
FMT O
for O
treating O
invasive O
carcinomas O
in O
the O
intact O
breast O
are O
reviewed O
. O
Externally O
applied O
wide O
- O
field O
adaptive O
phased O
- O
array O
FMT O
has O
been O
investigated O
both O
as O
a O
preoperative O
heat O
- O
alone O
ablation O
treatment O
and O
as O
a O
combination O
treatment O
with O
preoperative O
anthracycline O
- O
based O
chemotherapy O
for O
breast O
tumors O
ranging O
in O
ultrasound O
- O
measured O
size O
from O
0.8 O
to O
7.8 O
cm O
. O
In O
phase O
I O
, O
eight B-iv-bin-abs
of O
ten B-intervention-participants
( O
80 O
% O
) O
patients O
receiving O
a O
single O
low O
dose O
of O
FMT O
prior O
to O
receiving O
mastectomy O
had O
a O
partial B-outcome
tumor I-outcome
response I-outcome
quantified O
by O
either O
ultrasound O
measurements O
of O
tumor O
volume O
reduction O
or O
by O
pathologic O
cell O
kill O
. O
In O
phase O
II O
, O
the O
FMT O
thermal O
dose O
was O
increased O
to O
establish O
a O
threshold O
dose O
to O
induce O
100 O
% O
pathologic O
tumor O
cell O
kill O
for O
invasive O
carcinomas O
prior O
to O
breast B-control
- I-control
conserving I-control
surgery I-control
( I-control
BCS I-control
) I-control
. O
In O
a O
randomized O
study O
for O
patients B-eligibility
with I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
, O
of O
those O
patients O
receiving O
preoperative O
FMT O
at O
ablative O
temperatures O
, O
0 B-iv-bin-abs
of O
34 B-intervention-participants
( O
0 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
had O
positive B-outcome
tumor I-outcome
margins I-outcome
, O
whereas O
positive B-outcome
margins I-outcome
occurred O
in O
4 B-cv-bin-abs
of O
41 B-control-participants
( O
9.8 B-cv-bin-percent
% I-cv-bin-percent
) O
of O
patients O
receiving O
BCS O
alone O
( O
P O
= O
0.13 O
) O
. O
In O
a O
randomized O
study O
for O
patients O
with O
large O
tumors O
, O
based O
on O
ultrasound O
measurements O
the O
median B-outcome
tumor I-outcome
volume I-outcome
reduction I-outcome
was O
88.4 B-iv-bin-percent
% I-iv-bin-percent
( O
n O
= O
14 B-iv-bin-percent
) O
for O
patients O
receiving O
FMT O
and O
neoadjuvant O
chemotherapy O
, O
compared O
with O
58.8 B-cv-bin-percent
% I-cv-bin-percent
( O
n O
= O
10 B-cv-bin-abs
) O
reduction O
in O
the O
neoadjuvant O
chemotherapy O
- O
alone O
arm O
( O
P O
= O
0.048 O
) O
. O
Wide O
- O
field O
adaptive O
phased O
- O
array O
FMT O
can O
be O
safely O
administered O
in O
a O
preoperative O
setting O
, O
and O
data O
from O
randomized O
studies O
suggest O
both O
a O
reduction O
in O
positive O
tumor O
margins O
as O
a O
heat O
- O
alone O
treatment O
for O
early O
- O
stage O
breast O
cancer O
and O
a O
reduction O
in O
tumor O
volume O
when O
used O
in O
combination O
with O
anthracycline O
- O
based O
chemotherapy O
for O
patients O
with O
large O
breast O
cancer O
tumors O
. O
Larger O
randomized O
studies O
are O
required O
to O
verify O
these O
conclusions O
. O

Preventive O
effect O
of O
oral B-intervention
magnesium I-intervention
in O
postmastectomy B-condition
pain I-condition
: O
protocol O
for O
a O
randomised O
, O
double O
- O
blind O
, O
controlled O
clinical O
trial O
. O
Breast O
cancer O
affects O
1 O
in O
10 O
women O
worldwide O
, O
and O
mastectomy O
is O
a O
cause O
of O
chronic O
pain O
with O
neuropathic O
characteristics O
. O
N O
- O
methyl O
- O
D O
- O
aspartate O
receptor O
( O
NMDAR O
) O
antagonists O
such O
as O
ketamine O
, O
memantine O
, O
dextromethorphan O
or O
magnesium O
are O
used O
to O
treat O
refractory O
pain O
by O
blocking O
NMDAR O
. O
Oral O
memantine O
has O
been O
shown O
to O
prevent O
postmastectomy O
pain O
and O
cognitive O
impact O
and O
to O
maintain O
quality O
of O
life O
. O
Likewise O
, O
the O
present O
study O
is O
intended O
to O
assess O
the O
preventive O
effect O
of O
oral O
magnesium O
, O
administered O
ahead O
of O
mastectomy O
, O
on O
the O
development O
of O
neuropathic O
pain O
. O
As O
a O
physiological O
blocker O
of O
NMDAR O
, O
magnesium O
could O
be O
an O
interesting O
candidate O
to O
prevent O
postoperative O
pain O
and O
associated O
comorbidities O
, O
including O
cognitive O
and O
emotional O
disorders O
, O
multiple O
analgesic O
consumption O
and O
impaired O
quality O
of O
life O
. O
A O
randomised O
double O
- O
blind O
controlled O
clinical O
trial O
( O
NCT O
03063931 O
) O
will O
include O
100 B-total-participants
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
undergoing I-eligibility
mastectomy I-eligibility
at O
the O
Oncology O
Hospital O
, O
Clermont O
- O
Ferrand O
, O
France B-location
. O
Magnesium O
( O
100 O
  O
mg O
/ O
day O
; O
n= O
50 B-intervention-participants
) O
or O
placebo B-control
( O
n= O
50 B-control-participants
) O
will O
be O
administered O
for O
6 O
weeks O
, O
starting O
2 O
weeks O
before O
surgery O
. O
Intensity O
of O
pain O
, O
cognitive O
and O
emotional O
function O
and O
quality O
of O
life O
will O
be O
assessed O
by O
questionnaires O
. O
The O
primary O
endpoint O
is O
pain B-outcome-measure
intensity I-outcome-measure
on I-outcome-measure
a I-outcome-measure
0 I-outcome-measure
- I-outcome-measure
10 I-outcome-measure
numerical I-outcome-measure
rating I-outcome-measure
scale I-outcome-measure
at I-outcome-measure
1 I-outcome-measure
  I-outcome-measure
month I-outcome-measure
postmastectomy I-outcome-measure
. I-outcome-measure
Data O
analysis O
will O
use O
mixed O
models O
; O
all O
tests O
will O
be O
two O
- O
tailed O
, O
with O
type O
- O
I O
error O
set O
at O
α= O
0.05 O
. O
The O
study O
protocol O
and O
informed O
consent O
form O
were O
approved O
in O
December O
2016 O
by O
the O
French O
Research O
Ethics O
Committee O
( O
South O
East O
VI O
Committee O
) O
. O
Results O
will O
be O
communicated O
in O
various O
congresses O
and O
published O
in O
international O
publications O
. O
NCT O
03063931 O
. O

No O
effect O
of O
exercise B-intervention
on O
insulin O
- O
like O
growth O
factor O
- O
I O
, O
insulin O
, O
and O
glucose O
in O
young O
women O
participating O
in O
a O
16 O
-week O
randomized O
controlled O
trial O
. O
Insulin O
- O
like O
growth O
factor O
I O
( O
IGF O
- O
I O
) O
and O
IGF O
binding O
protein O
3 O
( O
IGFBP- O
3 O
) O
have O
been O
associated O
with O
increased O
risk O
of O
breast O
cancer O
. O
We O
report O
our O
findings O
on O
the O
effects O
of O
16 O
weeks O
of O
aerobic O
exercise O
on O
IGF O
axis O
proteins O
, O
insulin O
, O
glucose O
, O
and O
insulin O
resistance O
of O
319 B-total-participants
young B-eligibility
sedentary I-eligibility
women I-eligibility
. O
Demographics O
, O
health O
surveys O
, O
body O
composition O
, O
dietary O
intake O
, O
and O
blood O
samples O
were O
collected O
at O
baseline O
and O
16 O
weeks O
. O
IGF O
- O
I O
and O
IGFBP- O
1 O
, O
IGFBP- O
2 O
, O
and O
IGFBP- O
3 O
were O
measured O
by O
ELISA O
. O
Exercise B-outcome
adherence I-outcome
was O
88 O
% O
. O
The O
dropout B-outcome
rates I-outcome
for O
the O
exercise O
and O
control B-control
groups I-control
were O
21.7 B-iv-bin-percent
% I-iv-bin-percent
and O
14.5 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
. O
There O
was O
a O
small O
significant O
change B-outcome
from I-outcome
baseline I-outcome
in I-outcome
IGFBP- I-outcome
3 I-outcome
concentrations I-outcome
. O
IGFBP- B-outcome
3 I-outcome
levels I-outcome
decreased O
in O
controls O
and O
increased O
in O
exercisers O
. O
The O
between O
- O
group O
difference O
was O
significant O
. O
No O
other O
changes O
were O
noted O
. O
Sixteen O
weeks O
of O
exercise O
had O
minimum O
or O
no O
effect B-outcome
on I-outcome
IGF I-outcome
proteins I-outcome
of O
young O
women O
. O
Our O
study O
supports O
findings O
from O
previous O
studies O
conducted O
in O
older O
populations O
and O
raises O
the O
question O
of O
what O
type O
of O
intervention O
is O
needed O
to O
change O
circulating O
levels O
of O
IGF O
proteins O
in O
humans O
. O

Histopathological O
assessment O
of O
anastrozole B-intervention
and O
tamoxifen B-control
as O
preoperative O
( O
neoadjuvant O
) O
treatment O
in O
postmenopausal O
Japanese B-ethinicity
women O
with O
hormone O
receptor O
- O
positive O
breast O
cancer O
in O
the O
PROACT O
trial O
. O
The O
PReOperative O
' O
Arimidex O
' O
Compared O
with O
Tamoxifen O
( O
PROACT O
) O
trial O
compared O
neoadjuvant O
anastrozole O
and O
tamoxifen O
in O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
large I-eligibility
, I-eligibility
operable I-eligibility
or I-eligibility
potentially I-eligibility
operable I-eligibility
, I-eligibility
locally I-eligibility
advanced I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Here O
, O
we O
compare O
objective O
clinical O
responses O
with O
histopathological O
tumor O
responses O
to O
therapy O
in O
a O
cohort O
of O
97 B-total-participants
Japanese O
patients O
, O
in O
order O
to O
investigate O
the O
consistency O
of O
assessment O
methods O
and O
the O
change O
in O
estrogen O
- O
receptor O
( O
ER O
) O
and O
progesterone O
- O
receptor O
( O
PgR O
) O
status O
. O
Histopathological O
response O
and O
the O
change O
in O
ER O
and O
PgR O
status O
were O
assessed O
by O
comparing O
pathological O
specimens O
collected O
at O
baseline O
( O
via O
needle O
biopsy O
) O
with O
those O
collected O
at O
3 O
months O
( O
from O
excised O
tumors O
) O
. O
The O
response O
was O
evaluated O
using O
Pathological O
Response O
Criteria O
for O
Breast O
Cancer O
as O
defined O
by O
the O
Japanese O
Breast O
Cancer O
Society O
. O
The O
patients O
were O
randomized O
to O
receive O
anastrozole O
( O
n O
= O
48 B-intervention-participants
) O
or O
tamoxifen O
( O
n O
= O
49 B-control-participants
) O
. O
A O
numerically O
greater O
histopathological B-outcome
response I-outcome
rate I-outcome
was O
observed O
when O
neoadjuvant O
anastrozole O
compared O
with O
neoadjuvant O
tamoxifen O
( O
35.4 B-iv-bin-percent
and O
12.2 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
) O
. O
The O
histopathological B-outcome
and I-outcome
clinical I-outcome
objective I-outcome
response I-outcome
rates I-outcome
agreed O
in O
63 O
/ O
97 O
patients O
. O
The O
ER B-outcome
status I-outcome
of O
5 B-iv-bin-abs
/ O
40 B-intervention-participants
patients O
changed B-outcome
from I-outcome
positive I-outcome
at I-outcome
baseline I-outcome
to I-outcome
negative I-outcome
at I-outcome
3 I-outcome
months I-outcome
in O
the O
anastrozole O
group O
compared O
with O
20 B-cv-bin-abs
/ O
37 B-control-participants
patients O
in O
the O
tamoxifen O
group O
. O
The O
PgR B-outcome
status I-outcome
of O
16 B-iv-bin-abs
/ O
17 B-intervention-participants
patients O
in O
the O
anastrozole O
group O
and O
of O
1 B-cv-bin-abs
/ O
11 B-control-participants
patients O
in O
the O
tamoxifen O
group O
changed B-outcome
from I-outcome
positive I-outcome
to I-outcome
negative I-outcome
. O
These O
data O
support O
the O
findings O
of O
the O
main O
PROACT O
trial O
, O
which O
confirmed O
that O
anastrozole O
, O
as O
compared O
with O
tamoxifen O
, O
is O
an O
effective O
neoadjuvant O
endocrine O
treatment O
in O
objective O
response O
rates O
for O
postmenopausal O
women O
with O
large O
operable O
hormone O
- O
receptor O
positive O
breast O
cancer O
. O
Further O
follow O
- O
up O
is O
required O
to O
confirm O
whether O
histopathological O
responses O
to O
therapy O
correlate O
with O
an O
overall O
improvement O
in O
survival O
. O

Axillary B-intervention
node I-intervention
sampling I-intervention
in I-intervention
conjunction I-intervention
with I-intervention
sentinel I-intervention
node I-intervention
biopsy I-intervention
in O
patients O
with O
breast O
cancer O
. O
A O
prospective O
preliminary O
study O
. O
In O
patients O
with O
breast O
cancer O
( O
BC O
) O
, O
axillary O
lymph O
node O
sampling O
( O
ALNS O
) O
is O
a O
reliable O
procedure O
with O
low O
morbidity O
, O
alternative O
or O
complementary O
to O
sentinel O
lymph O
node O
biopsy O
( O
SLNB O
) O
, O
which O
may O
improve O
the O
detection O
rate O
of O
axillary O
node O
metastases O
as O
compared O
to O
SLNB O
alone O
in O
staging O
the O
axilla O
. O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
usefulness O
of O
ALNS O
in O
conjunction O
with O
SLNB O
in O
improving O
the O
sensitivity O
of O
SLNB O
alone O
at O
frozen O
section O
examination O
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
twelve I-total-participants
women O
( O
median O
age O
56 B-age
years I-age
, O
range O
29 O
- O
71 O
years O
) O
with B-eligibility
BC I-eligibility
underwent I-eligibility
SLNB I-eligibility
using I-eligibility
a I-eligibility
combined I-eligibility
radioisotope I-eligibility
and I-eligibility
isosulfan I-eligibility
blue I-eligibility
dye I-eligibility
technique I-eligibility
. O
Two O
groups O
of O
age- O
and O
tumor O
size O
- O
matched O
patients O
were O
prospectively O
randomized O
: O
Group O
A O
( O
SLNB B-control
alone I-control
, O
55 B-control-participants
women O
) O
and O
group O
B O
( O
SLNB O
plus O
ALNS O
, O
57 B-intervention-participants
women O
) O
. O
Intraoperative O
examination O
showed O
SN B-outcome
involvement I-outcome
in O
32 O
( O
28.6 O
% O
) O
patients O
: O
group O
A O
= O
14 B-cv-bin-abs
( O
25.5 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
group O
B O
= O
18 B-iv-bin-abs
( O
31.6 B-iv-bin-percent
% I-iv-bin-percent
) O
, O
whilst O
the O
final O
pathology O
showed O
axillary B-outcome
node I-outcome
involvement I-outcome
in O
7 O
further O
cases O
( O
group O
A O
= O
5 B-cv-bin-abs
, O
group O
B O
= O
2 B-iv-bin-abs
) O
. O
The O
sensitivity B-outcome
and O
accuracy B-outcome
were O
73.7 B-cv-bin-percent
% I-cv-bin-percent
vs. O
90.0 B-iv-bin-percent
% I-iv-bin-percent
( O
p O
= O
0.23 O
) O
and O
90.9 B-cv-bin-percent
% I-cv-bin-percent
vs. O
94.7 B-iv-bin-percent
% I-iv-bin-percent
( O
p O
= O
0.49 O
) O
, O
group O
A O
vs. O
B O
, O
respectively O
. O
Multivariate O
analysis O
showed O
that O
age O
> O
65 O
years O
and O
body O
mass O
index O
independently O
correlated O
with O
the O
amount B-outcome
of I-outcome
axillary I-outcome
drainage I-outcome
in O
both O
groups O
, O
which O
was O
47.5 B-cv-cont-mean
± O
11.3 B-cv-cont-sd
and O
49.6 B-iv-cont-mean
± O
12.2 B-iv-cont-sd
ml I-iv-cont-sd
( O
A O
vs. O
B O
, O
p O
= O
NS O
) O
, O
respectively O
. O
In O
conclusion O
, O
in O
our O
preliminary O
study O
, O
ALNS O
in O
conjunction O
with O
SLNB O
is O
a O
low O
- O
risk O
procedure O
, O
useful O
to O
reduce O
the O
false O
- O
negative O
rate O
of O
SLNB O
and O
to O
improve O
the O
accuracy O
of O
intraoperative O
evaluation O
of O
the O
axillary O
nodes O
in O
patients O
with O
BC O
. O

Preoperative B-intervention
MRI I-intervention
of O
the O
breast O
( O
POMB O
) O
influences O
primary O
treatment O
in O
breast O
cancer O
: O
a O
prospective O
, O
randomized O
, O
multicenter O
study O
. O
Breast O
magnetic O
resonance O
imaging O
( O
MRI O
) O
has O
shown O
high O
sensitivity O
in O
determining O
tumor O
extent O
, O
multifocality O
, O
and O
occult O
contralateral O
breast O
cancer O
. O
Low O
specificity O
, O
unnecessary O
mastectomies O
, O
and O
costs O
are O
arguments O
against O
MRI O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
whether O
preoperative O
breast O
MRI O
would O
affect O
primary O
surgical O
management O
, O
reduce O
reexcision O
/ O
reoperation O
procedures O
, O
and O
influence O
the O
choice O
of O
neoadjuvant O
treatment O
in O
patients O
with O
newly O
diagnosed O
breast O
cancer O
. O
This O
prospective O
, O
randomized O
, O
multicenter O
study O
included O
440 B-total-participants
breast O
cancer O
patients O
younger O
than O
aged O
56 B-age
years I-age
from O
three O
, O
Swedish B-location
, O
large O
- O
volume O
breast O
units O
. O
Patients O
were O
randomly O
allocated O
on O
a O
1 O
:1 O
basis O
to O
either O
preoperative O
staging O
with O
breast O
MRI O
( O
n O
= O
220 B-intervention-participants
) O
or O
no B-control
breast I-control
MRI I-control
( O
n O
= O
220 B-control-participants
) O
( O
control O
group O
) O
. O
Treatment O
planning O
of O
all O
patients O
was O
discussed O
at O
multidisciplinary O
team O
conferences O
. O
In O
patients O
randomized O
to O
the O
MRI O
group O
, O
who O
had O
an O
observed O
higher O
percentage O
of O
planned O
breast O
- O
conserving O
surgery O
( O
BCS O
) O
compared O
with O
the O
control O
group O
, O
a O
change B-outcome
from I-outcome
suggested I-outcome
breast I-outcome
conservation I-outcome
to I-outcome
mastectomy I-outcome
occurred O
in O
23 B-iv-bin-abs
of O
153 B-intervention-participants
( O
15 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
. O
Breast O
MRI O
provided O
additional O
information O
in O
83 O
of O
220 O
( O
38 O
% O
) O
patients O
, O
which O
caused O
a O
change B-outcome
in I-outcome
treatment I-outcome
plan I-outcome
in O
40 B-iv-bin-abs
( O
18 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
The O
breast B-outcome
reoperation I-outcome
rate I-outcome
was O
significantly O
lower O
in O
the O
MRI O
group O
: O
11 B-iv-bin-abs
of O
220 B-intervention-participants
( O
5 B-iv-bin-percent
% I-iv-bin-percent
) O
versus O
33 B-cv-bin-abs
of O
220 B-control-participants
( O
15 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
control O
group O
( O
p O
< O
0.001 O
) O
. O
The O
number B-outcome
of I-outcome
mastectomies I-outcome
, O
axillary B-outcome
reoperations I-outcome
, O
and O
the O
number B-outcome
of I-outcome
patients I-outcome
receiving I-outcome
neoadjuvant I-outcome
chemotherapy I-outcome
after O
definitive O
treatment O
did O
not O
differ O
significantly O
between O
the O
groups O
. O
Preoperative O
staging O
with O
breast O
MRI O
in O
women O
younger O
than O
age O
56 O
years O
altered B-outcome
the I-outcome
treatment I-outcome
plan I-outcome
in O
18 O
% O
of O
the O
patients O
. O
Although O
a O
higher O
MRI O
- O
related O
conversion O
rate O
from O
breast O
conservation O
to O
mastectomy O
was O
found O
, O
the O
final O
numbers O
of O
mastectomies O
did O
not O
differ O
between O
the O
two O
groups O
. O
The O
breast O
reoperation O
rate O
in O
the O
MRI O
group O
was O
significantly O
reduced O
. O

Palbociclib B-intervention
: O
A O
Novel O
Cyclin O
- O
Dependent O
Kinase O
Inhibitor O
for O
Hormone O
Receptor O
- O
Positive O
Advanced O
Breast O
Cancer O
. O
To O
review O
palbociclib O
, O
a O
novel O
small O
- O
molecule O
inhibitor O
of O
cyclin O
- O
dependent O
kinases O
4 O
and O
6 O
, O
and O
its O
current O
place O
in O
therapy O
for O
the O
treatment O
of O
hormone O
receptor O
( O
HMR O
) O
-positive O
, O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
Her O
2 O
) O
-negative O
advanced O
breast O
cancer O
. O
Four O
phase O
I O
trials O
, O
2 O
phase O
II O
trials O
, O
and O
1 O
phase O
III O
trial O
were O
identified O
from O
May O
2004 O
to O
May O
2015 O
using O
PubMed O
, O
American O
Society O
of O
Clinical O
Oncology O
( O
ASCO O
) O
abstracts O
, O
and O
European O
Society O
of O
Medical O
Oncology O
( O
ESMO O
) O
abstracts O
. O
In O
the O
first O
- O
line O
setting O
, O
the O
phase O
II O
PALbociclib O
: O
Ongoing O
trials O
in O
the O
Management O
of O
breast O
cAncer O
( O
PALOMA O
) O
- O
1 O
trial O
randomized O
patients O
to O
receive O
letrozole B-control
alone I-control
or O
letrozole O
plus O
palbociclib O
125 O
mg O
daily O
for O
3 O
weeks O
, O
followed O
by O
1 O
week O
off O
, O
as O
initial O
therapy O
for O
advanced O
breast O
cancer O
. O
The O
investigator O
- O
assessed O
median B-outcome
progression I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
PFS I-outcome
) I-outcome
was O
20.2 B-iv-cont-median
months I-iv-cont-median
for O
the O
combination O
versus O
10.2 B-cv-cont-median
months I-cv-cont-median
for O
letrozole O
alone O
( O
hazard O
ratio O
[ O
HR O
] O
= O
0.488 O
; O
95 O
% O
CI O
= O
0.319 O
- O
0.748 O
; O
1 O
-sided O
P O
= O
0.0004 O
) O
. O
The O
ensuing O
Food O
and O
Drug O
Administration O
approval O
of O
palbociclib O
was O
given O
a O
" O
breakthrough O
therapy O
" O
designation O
, O
where O
preliminary O
evidence O
suggests O
substantial O
improvement O
over O
existing O
therapies O
for O
a O
serious O
or O
life O
- O
threatening O
disease O
. O
A O
confirmatory O
phase O
III O
trial O
, O
PALOMA- O
2 O
, O
is O
under O
way O
. O
In O
patients O
who O
were O
previously O
treated O
with O
endocrine O
therapy O
for O
advanced O
breast O
cancer O
, O
the O
phase O
III O
PALOMA- O
3 O
trial O
randomized O
patients O
to O
fulvestrant O
plus O
palbociclib O
versus O
fulvestrant B-control
plus I-control
placebo I-control
. O
The O
investigator O
- O
assessed O
median B-outcome
PFS I-outcome
at I-outcome
the I-outcome
time I-outcome
of I-outcome
a I-outcome
preplanned I-outcome
analysis I-outcome
was O
9.2 B-iv-cont-median
months I-iv-cont-median
with O
palbociclib O
- O
fulvestrant O
compared O
with O
3.8 B-cv-cont-median
months I-cv-cont-median
with O
placebo O
- O
fulvestrant O
( O
HR O
= O
0.42 O
; O
95 O
% O
CI O
= O
0.32 O
- O
0.56 O
; O
P O
< O
0.001 O
) O
. O
Palbociclib O
, O
the O
first O
- O
in O
- O
class O
CDK O
4 O
/ O
6 O
inhibitor O
, O
significantly O
extended O
PFS O
in O
combination O
with O
endocrine O
therapy O
in O
the O
first O
and O
subsequent O
lines O
of O
treatment O
for O
HMR O
- O
positive O
, O
Her O
2 O
- O
negative O
advanced O
breast O
cancer O
. O

Vasomotor O
symptoms O
, O
adoption O
of O
a O
low B-intervention
- I-intervention
fat I-intervention
dietary I-intervention
pattern I-intervention
, O
and O
risk O
of O
invasive O
breast O
cancer O
: O
a O
secondary O
analysis O
of O
the O
Women O
's O
Health O
Initiative O
randomized O
controlled O
dietary O
modification O
trial O
. O
To O
assess O
whether O
the O
effect O
of O
a O
low O
- O
fat O
dietary O
pattern O
on O
breast O
cancer O
incidence O
varied O
by O
report O
of O
baseline O
vasomotor O
symptoms O
. O
Postmenopausal O
women O
age O
50 B-age
to I-age
79 I-age
years I-age
enrolled O
onto O
the O
Women O
's O
Health O
Initiative O
( O
WHI O
) O
Dietary O
Modification O
trial O
from O
1993 O
to O
1998 O
were O
randomly O
assigned O
to O
a O
low O
- O
fat O
dietary O
intervention O
( O
n O
= O
19 B-intervention-participants
, I-intervention-participants
541 I-intervention-participants
) O
or O
comparison B-control
( O
n O
= O
29 B-control-participants
, I-control-participants
294 I-control-participants
) O
. O
Presence O
of O
vasomotor O
symptoms O
at O
baseline O
was O
ascertained O
from O
a O
34 O
-item O
self O
- O
report O
symptom O
inventory O
. O
Women O
were O
queried O
semi O
- O
annually O
for O
a O
new O
diagnosis O
of O
breast O
cancer O
. O
Each O
case O
report O
was O
verified O
by O
medical O
record O
and O
pathology O
report O
review O
by O
centrally O
trained O
WHI O
physician O
adjudicators O
. O
Among O
participants O
who O
reported O
hot O
flashes O
( O
HFs O
) O
at O
baseline O
( O
n O
= O
3 O
, O
375 O
) O
, O
those O
assigned O
to O
the O
low O
- O
fat O
diet O
had O
a O
breast B-outcome
cancer I-outcome
rate I-outcome
of O
0.27 B-iv-bin-percent
compared O
with O
their O
counterparts O
in O
the O
control O
group O
who O
had O
a O
rate O
of O
0.41 B-cv-bin-percent
( O
hazard O
ratio O
[ O
HR O
] O
= O
0.65 O
; O
95 O
% O
CI O
, O
0.42 O
to O
1.01 O
) O
. O
Among O
women O
reporting O
no O
HFs O
( O
n O
= O
45 O
, O
160 O
) O
, O
the O
breast B-outcome
cancer I-outcome
rate I-outcome
was O
0.42 B-iv-bin-percent
in O
those O
assigned O
to O
the O
low O
- O
fat O
diet O
compared O
with O
0.46 B-cv-bin-percent
in O
the O
control O
group O
( O
HR O
= O
0.93 O
; O
95 O
% O
CI O
, O
0.84 O
to O
1.03 O
; O
P O
for O
interaction O
= O
. O
12 O
by O
HF O
status O
) O
. O
Furthermore O
, O
the O
dietary O
benefits O
observed O
seemed O
to O
be O
specific O
to O
estrogen O
receptor O
( O
ER O
) O
-positive O
/ O
progesterone O
receptor O
( O
PR O
) O
-positive O
tumors O
( O
ER O
positive O
/ O
PR O
positive O
v O
other O
, O
P O
for O
risk O
= O
. O
03 O
) O
. O
Although O
women O
with O
and O
without O
HFs O
differed O
with O
regard O
to O
breast O
cancer O
risk O
factors O
, O
the O
effect O
of O
the O
diet O
intervention O
on O
breast B-outcome
cancer I-outcome
incidence I-outcome
by O
HF O
status O
was O
consistent O
across O
risk O
factor O
strata O
. O
The O
results O
of O
this O
trial O
, O
which O
are O
hypothesis O
generating O
, O
suggest O
that O
HFs O
may O
identify O
a O
subgroup O
of O
postmenopausal O
women O
whose O
risk O
of O
invasive O
breast O
cancer O
might O
be O
reduced O
with O
the O
adoption O
of O
a O
low O
- O
fat O
eating O
pattern O
. O

Five O
- O
year O
outcome O
for O
women O
randomised O
in O
a O
phase O
III O
trial O
comparing O
doxorubicin B-intervention
and I-intervention
cyclophosphamide I-intervention
with O
doxorubicin B-control
and I-control
docetaxel I-control
as O
primary O
medical O
therapy O
in O
early O
breast O
cancer O
: O
an O
Anglo O
- O
Celtic O
Cooperative O
Oncology O
Group O
study O
. O
To O
compare O
the O
long O
- O
term O
outcome O
of O
women O
with O
primary O
or O
locally O
advanced O
breast O
cancer O
randomised O
to O
receive O
either O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
or O
doxorubicin O
and O
docetaxel O
( O
AD O
) O
as O
primary O
chemotherapy O
. O
Eligible O
patients B-eligibility
with I-eligibility
histologic I-eligibility
- I-eligibility
proven I-eligibility
breast I-eligibility
cancer I-eligibility
with I-eligibility
primary I-eligibility
tumours I-eligibility
> I-eligibility
or I-eligibility
= I-eligibility
3 I-eligibility
cm I-eligibility
, I-eligibility
inflammatory I-eligibility
or I-eligibility
locally I-eligibility
advanced I-eligibility
disease I-eligibility
, I-eligibility
and I-eligibility
no I-eligibility
evidence I-eligibility
of I-eligibility
distant I-eligibility
metastases I-eligibility
, O
were O
randomised O
to O
receive O
a O
maximum O
of O
6 O
cycles O
of O
either O
doxorubicin O
( O
60 O
mg O
/ O
m O
( O
2 O
) O
) O
plus O
cyclophosphamide O
( O
600 O
mg O
/ O
m O
( O
2 O
) O
) O
i O
/ O
v O
or O
doxorubicin O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
) O
plus O
docetaxel O
( O
75 O
mg O
/ O
m O
( O
2 O
) O
) O
i O
/ O
v O
every O
3 O
weeks O
, O
followed O
by O
surgery O
on O
completion O
of O
chemotherapy O
. O
Clinical O
and O
pathologic O
responses O
have O
previously O
been O
reported O
. O
Time O
to O
relapse O
, O
site O
of O
relapse O
, O
and O
all O
- O
cause O
mortality O
were O
recorded O
. O
This O
updated O
analysis O
compares O
long O
- O
term O
disease O
- O
free O
( O
DFS O
) O
and O
overall O
survival O
( O
OS O
) O
using O
stratified O
log O
rank O
methods O
. O
A O
total O
of O
363 B-total-participants
patients O
were O
randomised O
to O
AC O
( O
n O
= O
181 B-intervention-participants
) O
or O
AD O
( O
n O
= O
182 B-control-participants
) O
. O
A O
complete B-outcome
pathologic I-outcome
response I-outcome
was O
observed O
in O
16 B-iv-bin-percent
% I-iv-bin-percent
for O
AC O
and O
12 B-cv-bin-percent
% I-cv-bin-percent
for O
AD O
( O
P O
= O
0.43 O
) O
. O
The O
number B-outcome
of I-outcome
patients I-outcome
with I-outcome
positive I-outcome
axillary I-outcome
nodes I-outcome
at I-outcome
surgery I-outcome
with O
AC O
was O
61 B-iv-bin-percent
% I-iv-bin-percent
and O
AD O
66 B-cv-bin-percent
% I-cv-bin-percent
( O
P O
= O
0.36 O
) O
. O
At O
a O
median O
follow O
- O
up O
of O
99 O
months O
there O
is O
no O
significant O
difference O
between O
the O
two O
groups O
for O
DFS B-outcome
( O
P O
= O
0.20 O
) O
and O
OS B-outcome
( O
P O
= O
0.24 O
) O
. O
Deaths B-outcome
were O
due O
to O
metastatic O
breast O
cancer O
in O
96 O
% O
of O
patients O
. O
Our O
data O
do O
not O
support O
a O
clinical B-outcome
benefit I-outcome
for O
simultaneous O
administration O
of O
AD O
compared O
with O
AC O
. O
However O
, O
the O
data O
do O
not O
exclude O
a O
smaller O
benefit O
than O
the O
study O
was O
powered O
to O
detect O
and O
are O
consistent O
with O
an O
increase O
in O
both O
disease O
- O
free O
and O
overall O
survival O
of O
about O
5 O
% O
for O
AD O
compared O
with O
AC O
. O
Outcome O
is O
consistent O
with O
the O
pathologic O
complete O
response O
following O
surgery O
. O

Phase O
III O
placebo O
- O
controlled O
, O
double O
- O
blind O
, O
randomized O
trial O
of O
pegfilgrastim B-intervention
to O
reduce O
the O
risk O
of O
febrile B-condition
neutropenia I-condition
in O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
receiving I-eligibility
docetaxel I-eligibility
/ I-eligibility
cyclophosphamide I-eligibility
chemotherapy I-eligibility
. O
Pegfilgrastim O
is O
a O
pegylated O
form O
of O
filgrastim O
, O
a O
recombinant O
protein O
of O
granulocyte O
colony O
- O
stimulating O
factor O
, O
that O
is O
used O
to O
reduce O
the O
risk O
of O
febrile O
neutropenia O
( O
FN O
) O
. O
Here O
, O
we O
report O
the O
results O
of O
a O
phase O
III O
trial O
of O
pegfilgrastim O
in O
breast O
cancer O
patients O
receiving O
docetaxel O
and O
cyclophosphamide O
( O
TC O
) O
chemotherapy O
. O
We O
conducted O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
randomized O
trial O
to O
determine O
the O
efficacy O
of O
pegfilgrastim O
in O
reducing O
the O
risk O
of O
FN O
in O
early O
- O
stage O
breast O
cancer O
patients O
. O
A O
total O
of O
351 B-total-participants
women O
( O
177 B-intervention-participants
in O
the O
pegfilgrastim O
group O
and O
174 B-control-participants
in O
the O
placebo B-control
group O
) O
between B-age
20 I-age
and I-age
69 I-age
years I-age
of O
age O
with O
stage O
I O
- O
III O
invasive O
breast O
carcinoma O
who O
were O
to O
receive O
TC O
chemotherapy O
( O
docetaxel O
75 O
mg O
/ O
m O
( O
2 O
) O
and O
cyclophosphamide O
600 O
mg O
/ O
m O
( O
2 O
) O
every O
3 O
weeks O
) O
as O
either O
neoadjuvant O
or O
adjuvant O
therapy O
were O
enrolled O
; O
346 B-total-participants
of O
these O
patients O
were O
treated O
with O
either O
pegfilgrastim O
( O
n O
  O
= O
  O
173 B-intervention-participants
) O
or O
placebo O
( O
n O
  O
= O
  O
173 B-control-participants
) O
. O
The O
incidence B-outcome
of I-outcome
FN I-outcome
was O
significantly O
lower O
in O
the O
pegfilgrastim O
group O
than O
in O
the O
placebo O
group O
( O
1.2 B-iv-bin-percent
vs. O
68.8 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
  O
< O
  O
0.001 O
) O
. O
In O
addition O
, O
patients O
in O
the O
pegfilgrastim O
group O
required O
less O
hospitalization B-outcome
and I-outcome
antibiotics I-outcome
for I-outcome
FN I-outcome
. O
Most O
adverse B-outcome
events I-outcome
were O
consistent O
with O
those O
expected O
for O
breast O
cancer O
subjects O
receiving O
TC O
chemotherapy O
. O
Pegfilgrastim O
is O
safe O
and O
significantly O
reduces O
the O
incidence O
of O
FN O
in O
breast O
cancer O
patients O
. O

Phase O
II O
study O
of O
gemcitabine B-intervention
in I-intervention
combination I-intervention
with I-intervention
vinorelbine I-intervention
versus O
gemcitabine B-control
followed I-control
by I-control
vinorelbine I-control
for O
metastatic B-eligibility
breast I-eligibility
cancer I-eligibility
. O
No O
clear O
data O
are O
available O
concerning O
the O
superiority O
of O
combination O
chemotherapy O
to O
sequential O
therapy O
using O
agents O
beyond O
1 O
st O
or O
2 O
nd O
line O
chemotherapy O
for O
treating O
patients O
with O
metastatic O
breast O
cancer O
. O
Patients O
were O
randomized O
to O
receive O
a O
combination O
of O
gemcitabine O
and O
vinorelbine O
or O
gemcitabine O
until O
disease O
progression O
followed O
by O
vinorelbine O
monotherapy O
. O
Quality O
of O
life O
was O
assessed O
using O
EORTC O
QLQ O
- O
C O
30 O
questionnaires O
. O
Forty B-intervention-participants
- I-intervention-participants
two I-intervention-participants
patients O
were O
randomized O
to O
the O
combination O
arm O
and O
40 B-control-participants
were O
randomized O
to O
the O
sequential O
arm O
. O
Baseline O
characteristics O
were O
well O
balanced O
between O
the O
arms O
. O
The O
median B-outcome
number I-outcome
of I-outcome
chemotherapy I-outcome
cycles I-outcome
was O
4 B-iv-cont-median
( O
range O
, O
1 O
- O
23 O
) O
for O
the O
combination O
arm O
and O
6 B-cv-cont-median
( O
range O
, O
1 O
- O
25 O
) O
for O
the O
sequential O
arm O
. O
Patients O
receiving O
combination O
therapy O
had O
a O
higher O
composite B-outcome
response I-outcome
rate I-outcome
( O
26.8 B-iv-bin-percent
% I-iv-bin-percent
vs. O
12.5 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.106 O
) O
but O
a O
shorter O
median B-outcome
time I-outcome
to I-outcome
treatment I-outcome
failure I-outcome
( O
3.6 B-iv-cont-median
vs. O
4.4 B-cv-cont-median
months I-cv-cont-median
, O
P O
= O
0.252 O
) O
as O
compared O
to O
patients O
receiving O
sequential O
monotherapy O
. O
Median B-outcome
overall I-outcome
survival I-outcome
for O
the O
combination O
and O
sequential O
arms O
was O
10.6 B-iv-cont-median
months I-iv-cont-median
and O
8.9 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
( O
P O
= O
0.436 O
) O
. O
Toxicities B-outcome
were O
manageable O
and O
similar O
in O
both O
arms O
. O
Quality B-outcome
of I-outcome
life I-outcome
measurements O
in O
global O
health O
, O
role O
, O
and O
social O
function O
were O
superior O
in O
the O
combination O
arm O
( O
P O
< O
0.05 O
) O
. O
Combined O
gemcitabine O
and O
vinorelbine O
therapy O
appears O
comparable O
to O
sequential O
monotherapy O
for O
heavily O
pretreated O
patients O
with O
metastatic O
breast O
cancer O
as O
demonstrated O
by O
improved O
quality O
of O
life O
outcomes O
with O
similar O
therapeutic O
efficacies O
and O
incidences O
of O
adverse O
events O
. O

Randomized O
controlled O
trial O
of O
mindfulness B-intervention
- I-intervention
based I-intervention
stress I-intervention
reduction I-intervention
( O
MBSR O
) O
for O
survivors O
of O
breast O
cancer O
. O
Considerable O
morbidity O
persists O
among O
survivors O
of O
breast O
cancer O
( O
BC O
) O
including O
high O
levels O
of O
psychological O
stress O
, O
anxiety O
, O
depression O
, O
fear O
of O
recurrence O
, O
and O
physical O
symptoms O
including O
pain O
, O
fatigue O
, O
and O
sleep O
disturbances O
, O
and O
impaired O
quality O
of O
life O
. O
Effective O
interventions O
are O
needed O
during O
this O
difficult O
transitional O
period O
. O
We O
conducted O
a O
randomized O
controlled O
trial O
of O
84 B-total-participants
female B-eligibility
BC I-eligibility
survivors I-eligibility
( I-eligibility
Stages I-eligibility
0 I-eligibility
-III I-eligibility
) I-eligibility
recruited O
from O
the O
H O
. O
Lee O
Moffitt O
Cancer O
and O
Research O
Institute O
. O
All O
subjects O
were O
within O
18 O
months O
of O
treatment O
completion O
with O
surgery O
and O
adjuvant O
radiation O
and/or O
chemotherapy O
. O
Subjects O
were O
randomly O
assigned O
to O
a O
6 O
-week O
Mindfulness O
- O
Based O
Stress O
Reduction O
( O
MBSR O
) O
program O
designed O
to O
self O
- O
regulate O
arousal O
to O
stressful O
circumstances O
or O
symptoms O
( O
n= O
41 B-intervention-participants
) O
or O
to O
usual B-control
care I-control
( O
n= O
43 B-control-participants
) O
. O
Outcome O
measures O
compared O
at O
6 O
weeks O
by O
random O
assignment O
included O
validated B-outcome-measure
measures I-outcome-measure
of I-outcome-measure
psychological I-outcome-measure
status I-outcome-measure
( I-outcome-measure
depression I-outcome-measure
, I-outcome-measure
anxiety I-outcome-measure
, I-outcome-measure
perceived I-outcome-measure
stress I-outcome-measure
, I-outcome-measure
fear I-outcome-measure
of I-outcome-measure
recurrence I-outcome-measure
, I-outcome-measure
optimism I-outcome-measure
, I-outcome-measure
social I-outcome-measure
support I-outcome-measure
) I-outcome-measure
and O
psychological B-outcome-measure
and I-outcome-measure
physical I-outcome-measure
subscales I-outcome-measure
of I-outcome-measure
quality I-outcome-measure
of I-outcome-measure
life I-outcome-measure
( O
SF- O
36 O
) O
. O
Compared O
with O
usual O
care O
, O
subjects O
assigned O
to O
MBSR O
( O
BC O
) O
had O
significantly O
lower O
( O
two O
- O
sided O
p O
< O
0.05 O
) O
adjusted O
mean B-outcome
levels I-outcome
of I-outcome
depression I-outcome
( O
6.3 B-iv-cont-mean
vs O
9.6 B-cv-cont-mean
) O
, O
anxiety B-outcome
( O
28.3 B-iv-cont-mean
vs O
33.0 B-cv-cont-mean
) O
, O
and O
fear B-outcome
of I-outcome
recurrence I-outcome
( O
9.3 B-iv-cont-mean
vs O
11.6 B-cv-cont-mean
) O
at O
6 O
weeks O
, O
along O
with O
higher B-outcome
energy I-outcome
( O
53.5 B-iv-cont-mean
vs O
49.2 B-cv-cont-mean
) O
, O
physical B-outcome
functioning I-outcome
( O
50.1 B-iv-cont-mean
vs O
47.0 B-cv-cont-mean
) O
, O
and O
physical B-outcome
role I-outcome
functioning I-outcome
( O
49.1 B-iv-cont-mean
vs O
42.8 B-cv-cont-mean
) O
. O
In O
stratified O
analyses O
, O
subjects O
more O
compliant O
with O
MBSR O
tended O
to O
experience O
greater O
improvements O
in O
measures O
of O
energy B-outcome
and I-outcome
physical I-outcome
functioning I-outcome
. O
Among O
BC O
survivors O
within O
18 O
months O
of O
treatment O
completion O
, O
a O
6 O
-week O
MBSR O
( O
BC O
) O
program O
resulted O
in O
significant O
improvements O
in O
psychological O
status O
and O
quality O
of O
life O
compared O
with O
usual O
care O
. O

Multidisciplinary B-intervention
rehabilitation I-intervention
in O
women O
following O
breast O
cancer O
treatment O
: O
a O
randomized O
controlled O
trial O
. O
To O
assess O
the O
effectiveness O
of O
a O
multidisciplinary O
ambulatory O
rehabilitation O
programme O
for O
women O
following O
definitive O
breast O
cancer O
treatment O
in O
an O
Australian B-ethinicity
community O
cohort O
. O
Eighty B-total-participants
- I-total-participants
five I-total-participants
women O
in O
the O
community O
randomized O
to O
a O
treatment O
group O
( O
n O
= O
43 B-intervention-participants
) O
for O
individualized O
high O
- O
intensity O
programme O
, O
or O
a O
control O
group O
( O
n O
= O
42 B-control-participants
) O
comprising O
usual B-control
activity I-control
. O
The O
primary O
outcome O
Depression B-outcome-measure
Anxiety I-outcome-measure
Stress I-outcome-measure
Scale I-outcome-measure
( I-outcome-measure
DASS I-outcome-measure
) I-outcome-measure
scale I-outcome-measure
measured O
restriction O
in O
participation O
. O
Secondary O
measures O
included O
Perceived B-outcome-measure
Impact I-outcome-measure
Problem I-outcome-measure
Profile I-outcome-measure
( I-outcome-measure
PIPP I-outcome-measure
) I-outcome-measure
and O
Cancer B-outcome-measure
Rehabilitation I-outcome-measure
Evaluation I-outcome-measure
System I-outcome-measure
Short I-outcome-measure
- I-outcome-measure
Form I-outcome-measure
( I-outcome-measure
CARES I-outcome-measure
- I-outcome-measure
SF I-outcome-measure
) I-outcome-measure
; O
and O
Functional B-outcome-measure
Independence I-outcome-measure
Measure I-outcome-measure
( I-outcome-measure
FIM I-outcome-measure
) I-outcome-measure
motor I-outcome-measure
subscale I-outcome-measure
for O
activity O
limitation O
. O
Assessments O
were O
at O
baseline O
and O
4 O
months O
. O
Intention O
- O
to O
- O
treat O
analysis O
of O
data O
showed O
a O
significant O
difference O
between O
both O
groups O
in O
DASS B-outcome
Depression I-outcome
scores I-outcome
( O
p O
= O
0.006 O
) O
( O
moderate O
effect O
size O
, O
r O
> O
0.3 O
) O
, O
PIPP B-outcome
Mobility I-outcome
( O
p O
= O
0.05 O
) O
and O
Participation B-outcome
( O
p O
= O
0.04 O
) O
scales O
, O
and O
CARES B-outcome
- I-outcome
SF I-outcome
Global I-outcome
score I-outcome
( O
p O
= O
0.02 O
) O
( O
small O
effect O
size O
, O
r O
< O
0.3 O
) O
. O
The O
treatment O
group O
, O
compared O
with O
control O
group O
, O
showed O
significant O
improvement B-outcome
in I-outcome
the I-outcome
DASS I-outcome
Depression I-outcome
scores I-outcome
: O
22 B-iv-bin-abs
/ O
42 B-intervention-participants
( O
52.4 B-iv-bin-percent
% I-iv-bin-percent
) O
vs O
12 B-cv-bin-abs
/ O
37 B-control-participants
( O
32.4 B-cv-bin-percent
% I-cv-bin-percent
) O
( O
p O
= O
0.02 O
) O
. O
No O
difference O
between O
groups O
was O
noted O
in O
the O
FIM B-outcome
scale I-outcome
. O
Rehabilitation O
can O
benefit O
participation O
in O
breast O
cancer O
survivors O
. O
Evidence O
for O
specific O
rehabilitation O
interventions O
is O
needed O
. O
Integrated O
cancer O
programmes O
allow O
opportunities O
to O
evaluate O
patients O
in O
various O
settings O
, O
but O
require O
outcome O
research O
to O
develop O
service O
models O
for O
survivorship O
issues O
. O

Protocol O
for O
the O
" O
Chemobrain O
in O
Motion O
- O
study O
" O
( O
CIM O
- O
study O
) O
: O
a O
randomized O
placebo O
- O
controlled O
trial O
of O
the O
impact O
of O
a O
high B-intervention
- I-intervention
intensity I-intervention
interval I-intervention
endurance I-intervention
training I-intervention
on O
cancer O
related O
cognitive O
impairments O
in O
women O
with O
breast O
cancer O
receiving O
first O
- O
line O
chemotherapy O
. O
Up O
to O
80 O
% O
of O
breast O
cancer O
patients O
suffer O
from O
Cancer O
Related O
Cognitive O
Impairments O
( O
CRCI O
) O
. O
Exercise O
is O
suggested O
as O
a O
potential O
supportive O
care O
option O
to O
reduce O
cognitive O
decline O
in O
cancer O
patients O
. O
This O
study O
will O
investigate O
the O
effects O
of O
a O
high O
- O
intensity O
interval O
endurance O
training O
( O
HIIT O
) O
on O
CRCI O
in O
breast O
cancer O
patients O
. O
Potentially O
underlying O
immunological O
and O
neurobiological O
mechanisms O
, O
as O
well O
as O
effects O
on O
patients O
' O
self O
- O
perceived O
cognitive O
functioning O
and O
common O
cancer O
related O
side O
- O
effects O
, O
will O
be O
explored O
. O
A O
single O
- O
blinded O
randomized O
controlled O
trial O
will O
be O
carried O
out O
. O
The O
impact O
of O
HIIT O
on O
CRCI O
will O
be O
compared O
to O
that O
of O
a O
placebo B-control
- I-control
intervention I-control
( I-control
supervised I-control
myofascial I-control
release I-control
training I-control
) I-control
. O
Both O
interventions O
will O
be O
conducted O
simultaneously O
with O
the O
patients O
' O
first O
- O
line O
chemotherapy O
treatment O
typically O
lasting O
12 O
- O
18 O
  O
weeks O
. O
Fifty B-total-participants
- I-total-participants
nine I-total-participants
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
will O
be O
included O
in O
each O
of O
the O
two O
groups O
. O
The O
study O
is O
powered O
to O
detect O
( O
α O
  O
= O
  O
. O
05 O
, O
β O
  O
= O
  O
. O
2 O
) O
a O
medium O
effect O
size O
difference O
between O
the O
two O
groups O
( O
d O
  O
= O
  O
. O
5 O
) O
in O
terms O
of O
patients O
' O
change O
in O
cognitive O
testing O
performances O
, O
from O
baseline O
until O
the O
end O
of O
the O
exercise O
- O
intervention O
. O
The O
cognitive B-outcome-measure
test I-outcome-measure
battery I-outcome-measure
, O
recommended O
by O
the O
International O
Cancer O
and O
Cognition O
Task O
Force O
to O
assess O
CRCI O
, O
will O
be O
used O
as O
primary O
measure O
. O
This O
includes O
the O
Hopkins O
Verbal O
Learning O
Test O
( O
learning O
/ O
verbal O
memory O
) O
, O
the O
Controlled O
Oral O
Word O
Association O
Test O
( O
verbal O
fluency O
) O
and O
the O
Trail O
- O
Making O
- O
Test O
A O
/ O
B O
( O
attention O
/ O
set O
- O
switching O
) O
. O
The O
following O
endpoints O
will O
be O
assessed O
as O
secondary O
measures O
: O
Go- O
/ O
No O
- O
Go O
test O
performance O
( O
response O
inhibition O
) O
, O
self O
- O
perceived O
cognitive O
functioning O
, O
serum O
levels O
of O
pro- O
and O
antiinflammatory O
markers O
( O
tumor O
necrosis O
factor O
alpha O
, O
Interleukin- O
6 O
, O
Interleukin- O
1 O
alpha O
, O
Interleukin- O
1 O
beta O
, O
C O
- O
reactive O
protein O
, O
Interleukin- O
1 O
receptor O
antagonist O
and O
Interleukin- O
10 O
) O
, O
serum O
levels O
of O
neurotrophic O
and O
growth O
factors O
( O
brain O
- O
derived O
neurotrophic O
factor O
, O
insulin O
- O
like O
growth O
factor O
1 O
and O
vascular O
endothelial O
growth O
factor O
) O
, O
as O
well O
as O
common O
cancer O
- O
related O
side O
effects O
( O
decrease O
in O
physical O
capacity O
, O
fatigue O
, O
anxiety O
and O
depression O
, O
sleep O
disturbances O
, O
quality O
of O
life O
and O
chemotherapy O
compliance O
) O
. O
This O
study O
will O
provide O
data O
on O
the O
question O
whether O
HIIT O
is O
an O
effective O
supportive O
therapy O
that O
alleviates O
CRCI O
in O
breast O
cancer O
patients O
. O
Moreover O
, O
the O
present O
study O
will O
help O
shed O
light O
on O
the O
underlying O
mechanisms O
of O
potential O
CRCI O
improving O
effects O
of O
exercise O
in O
breast O
cancer O
patients O
. O
DRKS.de O
, O
German O
Clinical O
Trials O
Register O
( O
DRKS O
) O
, O
ID O
: O
DRKS O
00011390 O
, O
Registered O
on O
17 O
January O
2018 O
. O

A O
randomized O
control O
study O
of O
treating O
secondary O
stage O
II O
breast O
cancer O
- O
related O
lymphoedema O
with O
free B-intervention
lymph I-intervention
node I-intervention
transfer I-intervention
. O
Microsurgical O
techniques O
are O
increasingly O
used O
for O
treating O
severe O
lymphoedema O
cases O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effectiveness O
of O
free O
vascularized O
lymph O
node O
transfer O
( O
LNT O
) O
in O
stage B-eligibility
II I-eligibility
breast I-eligibility
cancer I-eligibility
- I-eligibility
related I-eligibility
lymphoedema I-eligibility
patients I-eligibility
in O
comparison O
with O
non O
- O
surgical O
management O
. O
During O
the O
last O
3 O
years O
, O
83 O
female O
patients O
were O
examined O
at O
our O
lymphoedema O
clinic O
. O
Finally O
, O
36 B-total-participants
cases O
were O
included O
in O
this O
study O
and O
randomly O
divided O
in O
two O
groups O
: O
group O
A O
patients O
( O
n O
= O
18 B-intervention-participants
, O
mean O
age O
47 B-age
years I-age
) O
underwent O
microsurgical B-intervention
LNT I-intervention
; I-intervention
followed I-intervention
by I-intervention
6 I-intervention
months I-intervention
of I-intervention
physiotherapy I-intervention
and I-intervention
compression I-intervention
, O
while O
group O
B O
patients O
( O
n O
= O
18 B-control-participants
, O
mean O
age O
49 B-age
years I-age
) O
were O
managed O
by O
physiotherapy B-control
and I-control
compression I-control
alone I-control
for O
6 O
months O
. O
Patients O
of O
both O
groups O
removed O
their O
elastic O
garments O
after O
6 O
months O
and O
were O
re O
- O
examined O
1 O
year O
later O
. O
All O
the O
36 B-total-participants
patients O
had O
detailed O
evaluation O
of O
the O
affected O
extremity O
including O
limb O
volume O
measurement O
, O
infection O
episodes O
and O
scale O
scoring O
of O
pain O
, O
feeling O
of O
heaviness O
and O
functional O
status O
both O
at O
baseline O
and O
18 O
month O
. O
Limb B-outcome
volume I-outcome
reduction I-outcome
was O
observed O
in O
both O
groups O
; O
mean O
reduction O
was O
greater O
in O
group O
A O
( O
57 B-iv-bin-percent
% I-iv-bin-percent
) O
than O
in O
group O
B O
( O
18 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Infection B-outcome
episodes I-outcome
in O
group O
A O
were O
significantly O
reduced O
compared O
to O
those O
in O
group O
B O
patients O
. O
All O
group O
A O
patients O
reported O
painless O
and O
feeling O
of O
heaviness O
- O
free O
extremities O
with O
overall O
functional O
improvement O
, O
while O
the O
corresponding O
changes O
in O
group O
B O
patients O
were O
no O
more O
than O
marginal O
. O
Moreover O
, O
the O
LNT O
procedure O
was O
estimated O
as O
cost O
effective O
compared O
to O
conservative O
treatment O
alone O
. O
LNT O
represents O
an O
effective O
therapeutic O
approach O
for O
stage O
II O
lymphoedema O
patients O
; O
it O
significantly O
reduces O
limb O
volume O
, O
decreases O
recurrent O
infections O
and O
improves O
the O
overall O
function O
. O

Progressive B-intervention
resistance I-intervention
versus O
relaxation B-control
training I-control
for O
breast O
cancer O
patients O
during O
adjuvant O
chemotherapy O
: O
design O
and O
rationale O
of O
a O
randomized O
controlled O
trial O
( O
BEATE O
study O
) O
. O
Cancer O
- O
related O
fatigue O
is O
a O
common O
severe O
symptom O
in O
breast O
cancer O
patients O
, O
especially O
during O
chemotherapy O
. O
Exercise O
appears O
to O
be O
promising O
in O
prevention O
or O
treatment O
of O
fatigue O
. O
Resistance O
training O
as O
an O
accompanying O
treatment O
to O
chemotherapy O
has O
been O
minimally O
investigated O
, O
yet O
might O
counteract O
muscle O
degradation O
and O
inflammation O
caused O
by O
many O
chemotherapeutics O
, O
and O
thus O
forestall O
or O
reduce O
fatigue O
. O
Previous O
exercise O
trials O
mostly O
compared O
the O
intervention O
with O
' O
usual O
care O
' O
. O
Therefore O
, O
it O
is O
unclear O
to O
what O
extent O
the O
observed O
effects O
on O
fatigue O
are O
based O
on O
physical O
adaptations O
by O
exercise O
itself O
, O
or O
rather O
on O
psycho O
- O
social O
factors O
linked O
to O
the O
group O
support O
or O
attention O
by O
the O
trainer O
. O
The O
BEATE O
study O
is O
a O
randomized O
, O
controlled O
intervention O
trial O
comparing O
a O
12 O
-week O
supervised O
progressive O
resistance O
training O
program O
with O
a O
supervised O
group O
- O
based O
progressive O
muscle O
relaxation O
training O
in O
100 B-total-participants
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
under I-eligibility
adjuvant I-eligibility
chemotherapy I-eligibility
. O
The O
primary O
endpoint O
is O
cancer B-outcome-measure
- I-outcome-measure
related I-outcome-measure
fatigue I-outcome-measure
; O
secondary O
endpoints O
include O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
, O
depression B-outcome-measure
, O
and O
cognitive B-outcome-measure
capacity I-outcome-measure
. O
In O
addition O
, O
isokinetic B-outcome-measure
and I-outcome-measure
isometric I-outcome-measure
muscle I-outcome-measure
strength I-outcome-measure
, O
cardiorespiratory B-outcome-measure
fitness I-outcome-measure
, O
and O
body B-outcome-measure
composition I-outcome-measure
are O
measured O
, O
and O
biomarkers B-outcome-measure
, O
such O
as O
inflammatory O
parameters O
, O
cortisol O
, O
and O
oxidative O
stress O
are O
analyzed O
in O
blood O
, O
saliva O
and O
urine O
. O
Safety B-outcome-measure
of O
the O
resistance O
training O
during O
chemotherapy O
is O
monitored O
. O
Strengths O
of O
the O
BEATE O
study O
include O
the O
investigation O
of O
progressive O
resistance O
training O
parallel O
with O
chemotherapy O
, O
the O
choice O
of O
a O
control O
group O
that O
enables O
an O
evaluation O
of O
the O
physiological O
effects O
of O
exercise O
beyond O
potential O
psycho O
- O
social O
effects O
, O
and O
the O
comprehensive O
and O
high O
- O
quality O
assessment O
of O
physiological O
factors O
and O
biomarkers O
potentially O
related O
to O
fatigue O
. O

Dose O
- O
dependent O
effect O
of O
aerobic B-intervention
exercise I-intervention
on O
inflammatory O
biomarkers O
in O
a O
randomized O
controlled O
trial O
of O
women O
at O
high O
risk O
of O
breast O
cancer O
. O
Increased O
levels O
of O
inflammation O
are O
associated O
with O
many O
diseases O
, O
including O
cancer O
. O
Physical O
activity O
can O
lower O
breast O
cancer O
risk O
as O
well O
as O
levels O
of O
inflammation O
. O
The O
Women O
In O
Steady O
Exercise O
Research O
( O
WISER O
) O
Sister O
trial O
was O
a O
randomized O
controlled O
trial O
that O
investigated O
the O
effects O
of O
a O
dosed O
, O
moderate O
to O
vigorous O
, O
aerobic O
exercise O
intervention O
on O
levels O
of O
inflammation O
in O
premenopausal B-eligibility
women I-eligibility
who I-eligibility
were I-eligibility
at I-eligibility
high I-eligibility
risk I-eligibility
of I-eligibility
developing I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Participants O
were O
randomized O
to O
control B-control
( O
< O
75 O
  O
minutes O
per O
week O
; O
41 B-control-participants
patients O
) O
, O
low O
- O
dose O
exercise O
( O
150 O
  O
minutes O
per O
week O
; O
38 B-intervention-participants
patients O
) O
, O
or O
high O
- O
dose O
exercise O
( O
300 O
  O
minutes O
per O
week O
; O
37 B-intervention-participants
patients O
) O
groups O
. O
The O
5 O
-menstrual O
cycles O
- O
long O
, O
home O
- O
based O
treadmill O
exercise O
intervention O
gradually O
increased O
in O
minutes O
per O
week O
and O
intensity O
up O
to O
a O
maximum O
of O
80 O
% O
of O
the O
age O
- O
predicted O
maximum O
heart O
rate O
. O
Blood O
was O
collected O
at O
baseline O
and O
at O
follow O
- O
up O
and O
assayed O
for O
chemokine O
( O
C O
- O
C O
motif O
) O
ligand O
2 O
( O
CCL O
2 O
) O
, O
interleukin O
10 O
( O
IL- O
10 O
) O
, O
interleukin O
12 O
( O
IL- O
12 O
) O
, O
and O
tumor O
necrosis O
factor O
α O
( O
TNF O
- O
α O
) O
. O
A O
linear O
dose O
- O
response O
relationship O
was O
observed O
for O
the O
proinflammatory B-outcome
biomarkers I-outcome
CCL I-outcome
2 I-outcome
( O
% O
Δ O
of O
- O
5.44 O
% O
in O
the O
control O
group O
, O
- O
0.03 O
% O
in O
the O
low O
- O
dose O
exercise O
group O
, O
and O
1.54 O
% O
in O
the O
high O
- O
dose O
exercise O
group O
) O
, O
IL- B-outcome
12 I-outcome
( O
% O
Δ O
of O
- O
21.5 O
% O
in O
the O
control O
group O
, O
38.2 O
% O
in O
the O
low O
- O
dose O
exercise O
group O
, O
and O
25.8 O
% O
in O
the O
high O
- O
dose O
exercise O
group O
, O
) O
and O
TNF B-outcome
- I-outcome
α I-outcome
( O
% O
Δ O
of O
- O
4.69 O
% O
in O
the O
control O
group O
, O
9.51 O
% O
in O
the O
low O
- O
dose O
exercise O
group O
, O
and O
15.7 O
% O
in O
the O
high O
- O
dose O
exercise O
group O
) O
but O
not O
for O
the O
anti B-outcome
- I-outcome
inflammatory I-outcome
biomarker I-outcome
IL- O
10 O
( O
% O
Δ O
of O
5.05 O
% O
in O
the O
control O
group O
, O
6.05 O
% O
in O
the O
low O
- O
dose O
exercise O
group O
, O
and O
10.6 O
% O
in O
the O
high O
- O
dose O
exercise O
group O
) O
. O
For O
IL- B-outcome
12 I-outcome
and I-outcome
TNF I-outcome
- I-outcome
α I-outcome
, I-outcome
the I-outcome
percentage I-outcome
change I-outcome
was O
significantly O
higher O
in O
the O
low B-outcome
- I-outcome
dose I-outcome
( I-outcome
IL- I-outcome
12 I-outcome
: O
P O
  O
< O
  O
. O
001 O
; O
and O
TNF O
- O
α O
: O
P O
  O
= O
  O
. O
01 O
) O
and O
high B-outcome
- I-outcome
dose I-outcome
( I-outcome
IL- I-outcome
12 I-outcome
: O
P O
  O
< O
  O
. O
001 O
; O
and O
TNF O
- O
α O
: O
P O
  O
< O
  O
. O
001 O
) O
exercise O
groups O
compared O
with O
the O
control O
group O
. O
Moderate O
to O
vigorous O
aerobic O
exercise O
appeared O
to O
increase O
levels O
of O
proinflammatory O
biomarkers O
in O
a O
dose O
- O
dependent O
manner O
in O
a O
population O
of O
healthy O
women O
at O
high O
risk O
of O
developing O
breast O
cancer O
. O
The O
results O
of O
the O
current O
study O
suggest O
that O
for O
healthy O
premenopausal O
women O
, O
the O
mechanism O
of O
reduced O
breast O
cancer O
risk O
observed O
in O
physically O
active O
individuals O
may O
not O
be O
a O
result O
of O
reduced O
levels O
of O
inflammation O
. O

Ultrasound B-intervention
- I-intervention
guided I-intervention
serratus I-intervention
plane I-intervention
block I-intervention
enhances O
pain B-condition
relief I-condition
and I-condition
quality I-condition
of I-condition
recovery I-condition
after O
breast O
cancer O
surgery O
: O
A O
randomised O
controlled O
trial O
. O
Multimodal O
analgesia O
can O
improve O
postoperative O
pain O
and O
possibly O
accelerate O
functional O
recovery O
after O
surgery O
. O
Serratus O
plane O
block O
( O
SPB O
) O
is O
a O
novel O
, O
ultrasound O
- O
guided O
regional O
anaesthetic O
technique O
for O
complete O
analgesia O
of O
the O
anterolateral O
chest O
wall O
. O
But O
, O
the O
effect O
of O
SPB O
on O
the O
quality O
of O
recovery O
after O
breast O
cancer O
surgery O
has O
not O
been O
established O
. O
To O
test O
the O
hypothesis O
that O
pre O
- O
operative O
SPB O
would O
enhance O
the O
quality O
of O
recovery O
following O
breast O
cancer O
surgery O
. O
A O
randomised O
, O
double O
- O
blind O
, O
parallel O
- O
group O
, O
placebo O
- O
controlled O
trial O
. O
Single O
university O
teaching O
hospital O
, O
from O
March O
2016 O
to O
June O
2017 O
. O
Seventy B-total-participants
- I-total-participants
two I-total-participants
women B-eligibility
scheduled I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
surgery I-eligibility
. O
Participants O
were O
randomised O
in O
a O
1 O
  O
: O
  O
1 O
ratio O
to O
receive O
SPB O
with O
25 O
  O
ml O
of O
ropivacaine O
0.5 O
% O
or O
physiological B-control
saline I-control
. O
The O
primary O
endpoint O
was O
the O
40 B-outcome-measure
-item I-outcome-measure
Quality I-outcome-measure
of I-outcome-measure
Recovery I-outcome-measure
questionnaire I-outcome-measure
score I-outcome-measure
24 I-outcome-measure
hours I-outcome-measure
postoperatively I-outcome-measure
hours I-outcome-measure
. O
Secondary O
endpoints O
were O
postoperative B-outcome-measure
pain I-outcome-measure
intensity I-outcome-measure
, O
cumulative B-outcome-measure
opioid I-outcome-measure
consumption I-outcome-measure
, O
postoperative B-outcome-measure
nausea I-outcome-measure
and I-outcome-measure
vomiting I-outcome-measure
, O
dizziness B-outcome-measure
, O
post B-outcome-measure
anaesthesia I-outcome-measure
care I-outcome-measure
unit I-outcome-measure
discharge I-outcome-measure
time I-outcome-measure
and O
patient B-outcome-measure
satisfaction I-outcome-measure
. O
The O
global O
median O
[ O
IQR O
] O
40 B-outcome
-item I-outcome
Quality I-outcome
of I-outcome
Recovery I-outcome
questionnaire I-outcome
score I-outcome
at O
24 O
postoperative O
hours O
was O
significantly O
higher O
in O
the O
SPB O
group O
( O
158 B-iv-cont-median
[ O
153.8 O
to O
159.3 O
] O
) O
than O
the O
control O
group O
( O
141 B-cv-cont-median
[ O
139 O
to O
145.3 O
] O
) O
with O
a O
median O
difference O
of O
15 O
( O
95 O
% O
confidence O
interval O
: O
13 O
to O
17 O
, O
P O
  O
< O
  O
0.001 O
) O
. O
Compared O
with O
the O
control O
group O
, O
postoperative B-outcome
pain I-outcome
scores I-outcome
at O
rest O
were O
significantly O
lower O
up O
to O
24 O
  O
h O
in O
the O
SPB O
group O
. O
Pre O
- O
operative O
SPB O
reduced O
postoperative B-outcome
cumulative I-outcome
opioid I-outcome
consumption I-outcome
, O
the O
incidence B-outcome
of I-outcome
postoperative I-outcome
nausea I-outcome
and I-outcome
vomiting I-outcome
and O
the O
post B-outcome
anaesthesia I-outcome
care I-outcome
unit I-outcome
discharge I-outcome
time I-outcome
. O
In O
addition O
, O
patient B-outcome
satisfaction I-outcome
scores I-outcome
were O
higher O
in O
the O
SPB O
group O
. O
Pre O
- O
operative O
administration O
of O
SPB O
with O
ropivacaine O
improved O
the O
quality O
of O
recovery O
, O
postoperative O
analgesia O
and O
patient O
satisfaction O
following O
breast O
cancer O
surgery O
. O
ClinicalTrials.gov O
( O
identifier O
: O
NCT O
02691195 O
) O
. O

A O
Randomized O
, O
Single O
- O
Blind O
Study O
Evaluating O
the O
Effect O
of O
a O
Bone B-intervention
Pain I-intervention
Education I-intervention
Video I-intervention
on O
Reported O
Bone B-condition
Pain I-condition
in O
Patients O
with O
Breast O
Cancer O
Receiving O
Chemotherapy O
and O
Pegfilgrastim O
. O
Mild O
- O
to O
- O
moderate O
bone O
pain O
is O
the O
most O
commonly O
reported O
adverse O
event O
associated O
with O
pegfilgrastim O
. O
To O
investigate O
the O
effect O
of O
bone O
pain O
education O
on O
pegfilgrastim O
- O
related O
bone O
pain O
in O
patients O
with O
breast O
cancer O
receiving O
chemotherapy O
and O
pegfilgrastim O
. O
Randomized O
, O
single O
- O
blind O
study O
. O
Forty O
- O
eight O
community O
oncology O
clinics O
throughout O
the O
United B-location
States I-location
. O
Three B-total-participants
hundred I-total-participants
women O
≥ B-age
18 I-age
years I-age
of O
age O
with B-eligibility
newly I-eligibility
diagnosed I-eligibility
stage I-eligibility
I I-eligibility
-III I-eligibility
breast I-eligibility
cancer I-eligibility
, I-eligibility
who I-eligibility
were I-eligibility
planning I-eligibility
≥ I-eligibility
4 I-eligibility
cycles I-eligibility
of I-eligibility
neoadjuvant I-eligibility
or I-eligibility
adjuvant I-eligibility
chemotherapy I-eligibility
with I-eligibility
pegfilgrastim I-eligibility
support I-eligibility
starting I-eligibility
in I-eligibility
cycle I-eligibility
1 I-eligibility
. O
Patients O
were O
randomized O
1 O
:1 O
to O
view O
a O
general B-control
education I-control
DVD I-control
on O
chemotherapy O
side O
effects O
( O
GE O
- O
DVD O
) O
or O
a O
DVD O
on O
bone O
pain O
following O
chemotherapy O
and O
pegfilgrastim O
( O
BP O
- O
DVD O
) O
. O
Patients O
recorded O
severity O
of O
bone O
pain O
on O
a O
scale O
of O
0 O
- O
10 O
, O
location O
of O
pain O
, O
and O
use O
of O
bone O
pain O
medications O
( O
i.e. O
, O
analgesics O
, O
antihistamines O
, O
and O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
) O
for O
5 O
days O
, O
beginning O
on O
the O
day O
of O
pegfilgrastim O
administration O
, O
in O
each O
of O
the O
first O
four O
chemotherapy O
cycles O
. O
Patient B-outcome
- I-outcome
reported I-outcome
maximum I-outcome
bone I-outcome
pain I-outcome
was O
similar O
in O
the O
two O
groups O
( O
GE O
- O
DVD O
vs O
BP O
- O
DVD O
: O
cycle O
1 O
, O
3.2 B-cv-cont-mean
vs. O
3.5 B-iv-cont-mean
, O
p O
= O
. O
3479 O
; O
across O
all O
cycles O
, O
4.1 O
vs. O
4.6 O
, O
p O
= O
. O
2196 O
) O
. O
Other O
measures B-outcome
of I-outcome
bone I-outcome
pain I-outcome
were O
also O
similar O
between O
the O
groups O
. O
Bone B-outcome
pain I-outcome
was O
highest O
in O
cycle O
1 O
but O
decreased O
and O
then O
remained O
stable O
in O
subsequent O
cycles O
. O
Bone B-outcome
pain I-outcome
medication I-outcome
use I-outcome
was O
similar O
in O
both O
groups O
and O
was O
highest O
in O
cycle O
1 O
. O
The O
bone O
pain O
- O
specific O
education O
evaluated O
here O
did O
not O
improve O
perceptions O
of O
bone O
pain O
reported O
in O
this O
patient O
population O
. O

Randomized O
trial O
of O
proactive B-intervention
rapid I-intervention
genetic I-intervention
counseling I-intervention
versus O
usual B-control
care I-control
for O
newly O
diagnosed O
breast O
cancer O
patients O
. O
Breast O
cancer O
patients O
who O
carry O
BRCA O
1 O
/ O
BRCA O
2 O
gene O
mutations O
may O
consider O
bilateral O
mastectomy O
. O
Having O
bilateral O
mastectomy O
at O
the O
time O
of O
diagnosis O
not O
only O
reduces O
risk O
of O
a O
contralateral O
breast O
cancer O
, O
but O
can O
eliminate O
the O
need O
for O
radiation O
therapy O
and O
yield O
improved O
reconstruction O
options O
. O
However O
, O
most O
patients O
do O
not O
receive O
genetic O
counseling O
or O
testing O
at O
the O
time O
of O
their O
diagnosis O
. O
In O
this O
trial O
, O
we O
tested O
proactive O
rapid O
genetic O
counseling O
and O
testing O
( O
RGCT O
) O
in O
newly B-eligibility
diagnosed I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
in O
order O
to O
facilitate O
pre O
- O
surgical O
genetic O
counseling O
and O
testing O
. O
We O
recruited O
  O
newly O
diagnosed O
breast O
cancer O
patients O
at O
increased O
risk O
for O
carrying O
a O
BRCA O
1 O
/ O
2 O
mutation O
. O
Of O
379 B-total-participants
eligible O
patients O
who O
completed O
a O
baseline O
survey O
, O
330 B-total-participants
agreed O
to O
randomization O
in O
a O
2 O
:1 O
ratio O
to O
RGCT O
( O
n O
  O
= O
  O
220 B-intervention-participants
) O
versus O
UC O
( O
n O
  O
= O
  O
108 B-control-participants
) O
. O
Primary O
outcomes O
were O
genetic B-outcome-measure
counseling I-outcome-measure
and I-outcome-measure
testing I-outcome-measure
uptake I-outcome-measure
and O
breast B-outcome-measure
cancer I-outcome-measure
surgical I-outcome-measure
decisions I-outcome-measure
. O
RGCT O
led O
to O
higher O
overall B-outcome
( O
83.8 B-iv-bin-percent
% I-iv-bin-percent
vs. O
54.6 B-cv-bin-percent
% I-cv-bin-percent
; O
p O
  O
< O
  O
0.0001 O
) O
and O
pre B-outcome
- I-outcome
surgical I-outcome
( O
57.8 B-iv-bin-percent
% I-iv-bin-percent
vs. O
38.7 B-cv-bin-percent
% I-cv-bin-percent
; O
p O
  O
= O
  O
0.001 O
) O
genetic B-outcome
counseling I-outcome
uptake I-outcome
compared O
to O
UC O
. O
Despite O
higher O
rates O
of O
genetic O
counseling O
, O
RGCT O
did O
not O
differ O
from O
UC O
in O
overall B-outcome
( O
54.1 B-iv-bin-percent
% I-iv-bin-percent
vs. O
49.1 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
  O
> O
  O
0.10 O
) O
or O
pre B-outcome
- I-outcome
surgical I-outcome
( O
30.6 B-iv-bin-percent
% I-iv-bin-percent
vs. O
27.4 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
  O
> O
  O
0.10 O
) O
receipt B-outcome
of I-outcome
genetic I-outcome
test I-outcome
results I-outcome
nor O
did O
they O
differ O
in O
uptake B-outcome
of I-outcome
bilateral I-outcome
mastectomy I-outcome
( O
26.6 B-iv-bin-percent
% I-iv-bin-percent
vs. O
21.8 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
  O
> O
  O
0.10 O
) O
. O
Although O
RGCT O
yielded O
increased O
genetic O
counseling O
participation O
, O
this O
did O
not O
result O
in O
increased O
rates O
of O
pre O
- O
surgical O
genetic O
testing O
or O
impact O
surgical O
decisions O
. O
These O
data O
suggest O
that O
those O
patients O
most O
likely O
to O
opt O
for O
genetic O
testing O
at O
the O
time O
of O
diagnosis O
are O
being O
effectively O
identified O
by O
their O
surgeons O
. O

Measuring O
the O
impact O
of O
guideline B-intervention
- I-intervention
based I-intervention
antiemetic I-intervention
therapy I-intervention
on O
nausea B-condition
and I-condition
vomiting I-condition
control I-condition
in O
breast O
cancer O
patients O
with O
multiple O
risk O
factors O
. O
The O
objective O
of O
this O
exploratory O
analysis O
was O
to O
determine O
if O
individual O
patient O
risk O
factors O
could O
be O
used O
to O
optimize O
chemotherapy O
- O
induced O
nausea O
and O
vomiting O
( O
CINV O
) O
. O
Through O
validated O
risk O
prediction O
models O
which O
quantify O
patient O
risk O
factors O
, O
152 B-total-participants
patients B-eligibility
with I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
scheduled I-eligibility
to I-eligibility
received I-eligibility
adjuvant I-eligibility
anthracycline I-eligibility
- I-eligibility
based I-eligibility
chemotherapy I-eligibility
were O
categorized O
as O
being O
at O
low O
( O
level O
0 O
) O
or O
high O
- O
risk O
( O
level O
1 O
) O
for O
CINV O
. O
Prior O
to O
the O
first O
cycle O
of O
chemotherapy O
, O
low O
- O
risk O
patients O
received O
ondansetron O
and O
dexamethasone O
, O
while O
high O
- O
risk O
level O
1 O
patients O
also O
received O
aprepitant O
. O
For O
subsequent O
cycles O
, O
patients O
who O
experienced O
CINV O
had O
their O
antiemetics O
changed O
in O
a O
stepwise O
manner O
to O
level O
2 O
( O
extended O
- O
duration O
dexamethasone O
) O
or O
level O
3 O
( O
extended O
- O
duration O
dexamethasone O
and O
low O
- O
dose O
olanzapine O
) O
. O
The O
study O
enrolled O
152 B-total-participants
patients O
who O
received O
484 O
cycles O
of O
chemotherapy O
. O
Forty O
patient O
cycles O
were O
classified O
as O
low O
risk O
( O
level O
0 O
) O
compared O
to O
201 O
, O
162 O
and O
81 O
that O
were O
classified O
as O
high O
- O
risk O
levels O
1 O
, O
2 O
and O
3 O
, O
respectively O
. O
Complete B-outcome
control I-outcome
of I-outcome
acute I-outcome
and I-outcome
delayed I-outcome
vomiting I-outcome
was O
comparable O
and O
was O
achieved O
in O
over O
85 O
% O
of O
patients O
across O
all O
risk O
levels O
( O
p O
= O
0.56 O
and O
p O
= O
0.99 O
) O
. O
In O
contrast O
, O
complete B-outcome
control I-outcome
of I-outcome
acute I-outcome
and I-outcome
delayed I-outcome
nausea I-outcome
was O
reduced O
in O
risk O
levels O
1 O
to O
3 O
compared O
to O
level O
0 O
( O
acute O
= O
51.2 O
, O
58.0 O
, O
45.7 O
vs. O
70.0 O
% O
; O
p O
= O
0.013 O
) O
- O
( O
delayed O
= O
32.8 O
, O
45.7 O
, O
34.6 O
vs. O
62.5 O
% O
; O
p O
< O
0.001 O
) O
. O
Despite O
the O
addition O
of O
aprepitant O
, O
extended O
- O
duration O
dexamethasone O
and O
olanzapine O
, O
patients O
at O
high O
risk O
for O
CINV O
due O
to O
personal O
risk O
factors O
failed O
to O
achieve O
good O
nausea O
control O
. O

Effect O
of O
Topical B-intervention
Anesthetic I-intervention
Cream I-intervention
on O
Pain B-condition
During O
Periareolar O
Injection O
of O
  O
Technetium O
Tc O
99 O
m O
Sulfur O
Colloid O
for O
Sentinel O
Lymph O
Node O
Biopsy O
in O
  O
Breast O
Cancer O
: O
A O
Randomized O
Control O
Trial O
. O
Injection O
of O
Tc O
99 O
m O
to O
localize O
nodes O
for O
sentinel O
lymph O
node O
biopsy O
is O
reported O
by O
patients O
as O
very O
painful O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
anesthetic O
cream O
reduces O
pain O
associated O
with O
periareolar O
injection O
of O
Tc O
99 O
m O
and O
to O
help O
elucidate O
conflicting O
literature O
regarding O
the O
efficacy O
of O
anesthetic O
cream O
for O
this O
procedure O
. O
A O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
methodology O
was O
used O
for O
adult B-eligibility
females I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
undergoing I-eligibility
periareolar I-eligibility
injection I-eligibility
of I-eligibility
Tc I-eligibility
99 I-eligibility
m I-eligibility
for I-eligibility
sentinel I-eligibility
lymph I-eligibility
node I-eligibility
biopsy I-eligibility
. O
Pain O
levels O
were O
compared O
using O
anesthetic O
cream O
( O
2.5 O
% O
lidocaine O
/ O
2.5 O
% O
prilocaine O
) O
vs. O
placebo B-control
. O
Patient O
exclusion O
criteria O
included O
use O
of O
  O
opioids O
or O
adjuvant O
pain O
medication O
or O
  O
injecting O
Tc O
99 O
m O
the O
day O
before O
surgery O
. O
The O
Numerical O
  O
Rating O
Scale O
was O
used O
to O
assess O
pain O
levels O
immediately O
after O
the O
  O
injections O
. O
Comparing O
23 B-intervention-participants
experimental O
and O
26 B-control-participants
control O
patients O
, O
there O
was O
no O
significant O
difference O
between O
the O
experimental O
( O
median O
  O
= O
  O
4 O
) O
and O
the O
control O
group O
( O
median O
  O
= O
  O
5 O
) O
on O
level O
of O
pain B-outcome
experienced I-outcome
U= O
0.492 O
, O
P O
  O
> O
. O
05 O
. O
The O
experimental O
group O
had O
a O
slightly O
lower O
median B-outcome
pain I-outcome
score I-outcome
; O
however O
, O
there O
was O
no O
statistically O
significant O
difference O
between O
those O
who O
used O
the O
cream O
compared O
with O
those O
who O
used O
a O
placebo O
, O
supporting O
the O
conclusion O
that O
anesthetic O
cream O
does O
not O
reduce O
pain O
during O
Tc O
99 O
m O
injections O
. O
This O
study O
adds O
to O
the O
current O
literature O
to O
provide O
a O
stronger O
position O
that O
there O
is O
no O
benefit O
to O
using O
anesthetic O
cream O
for O
this O
procedure O
. O

Mammographic O
density O
change O
with O
1 O
year O
of O
aerobic B-intervention
exercise I-intervention
among O
postmenopausal O
women O
: O
a O
randomized O
controlled O
trial O
. O
The O
Alberta O
Physical O
Activity O
and O
Breast O
Cancer O
Prevention O
( O
ALPHA O
) O
Trial O
examined O
the O
influence O
of O
aerobic O
exercise O
on O
biological O
factors O
that O
are O
associated O
with O
breast O
cancer O
risk O
. O
Mammographic O
density O
, O
a O
secondary O
outcome O
, O
is O
reported O
here O
. O
The O
ALPHA O
Trial O
was O
a O
parallel O
group O
randomized O
controlled O
trial O
conducted O
between O
May O
2003 O
and O
July O
2007 O
. O
Postmenopausal B-eligibility
, I-eligibility
sedentary I-eligibility
women I-eligibility
ages O
50 B-age
to I-age
74 I-age
years I-age
( O
n O
= O
320 B-total-participants
) O
were O
evenly O
randomized O
to O
aerobic O
exercise O
( O
45 O
minutes O
, O
5 O
days O
per O
week O
) O
or O
control B-control
( I-control
usual I-control
life I-control
- I-control
style I-control
) I-control
for O
1 O
year O
. O
Dense O
fibroglandular O
tissue O
and O
nondense O
fatty O
tissue O
were O
measured O
from O
mammograms O
at O
baseline O
and O
1 O
year O
using O
computer O
- O
assisted O
thresholding O
software O
for O
area O
measurements O
and O
a O
new O
technique O
that O
relies O
on O
the O
calibration O
of O
mammography O
units O
with O
a O
tissue O
- O
equivalent O
phantom O
for O
volumetric O
measurements O
. O
Nondense B-outcome
volume I-outcome
decreased O
in O
the O
exercise O
group O
relative O
to O
the O
control O
group O
( O
difference O
between O
groups O
= O
- O
38.5 O
cm O
( O
3 O
) O
; O
95 O
% O
confidence O
interval O
, O
- O
61.6 O
to O
15.4 O
; O
P O
= O
0.001 O
) O
. O
Changes B-outcome
in I-outcome
total I-outcome
body I-outcome
fat I-outcome
accounted O
for O
this O
decrease O
. O
Changes B-outcome
in I-outcome
dense I-outcome
area I-outcome
and I-outcome
dense I-outcome
volume I-outcome
, O
measures O
that O
have O
previously O
been O
associated O
with O
breast O
cancer O
risk O
, O
were O
not O
significantly O
different O
between O
the O
groups O
( O
P O
> O
or O
= O
0.26 O
) O
. O
Achieving O
changes O
in O
mammographic O
measures O
may O
require O
more O
exercise O
or O
a O
study O
population O
with O
higher O
baseline O
levels O
of O
sex O
hormones O
or O
a O
wider O
range O
of O
mammographic O
density O
. O
The O
data O
from O
this O
study O
, O
however O
, O
suggest O
that O
the O
protective O
effect O
of O
exercise O
on O
breast O
cancer O
risk O
may O
operate O
through O
a O
mechanism O
other O
than O
mammographic O
density O
. O

Perioperative B-intervention
intravenous I-intervention
lidocaine I-intervention
decreases O
the O
incidence B-condition
of I-condition
persistent I-condition
pain I-condition
after O
breast O
surgery O
. O
Breast O
cancer O
surgery O
is O
associated O
with O
a O
high O
incidence O
of O
persistent B-condition
postsurgical I-condition
pain I-condition
( I-condition
PPSP I-condition
) I-condition
. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
impact O
of O
intravenous O
( O
IV O
) O
lidocaine O
on O
acute O
and O
PPSP O
, O
analgesic O
requirements O
, O
and O
sensation O
abnormalities O
in O
patients O
undergoing O
surgery O
for O
breast O
cancer O
. O
Thirty B-total-participants
- I-total-participants
six I-total-participants
patients O
participated O
in O
this O
randomized O
, O
double O
- O
blinded O
study O
. O
Before O
induction O
of O
general O
anesthesia O
, O
patients O
received O
a O
bolus O
of O
intravenous O
lidocaine O
1.5 O
mg O
/ O
kg O
followed O
by O
a O
continuous O
infusion O
of O
lidocaine O
1.5 O
mg O
/ O
kgh O
( O
lidocaine O
group O
) O
or O
an O
equal O
volume O
of O
saline B-control
( I-control
control I-control
group I-control
) I-control
. O
The O
infusion O
was O
stopped O
1 O
hour O
after O
the O
skin O
closure O
. O
Pain O
scores O
and O
analgesic O
consumption O
were O
recorded O
at O
2 O
, O
4 O
, O
24 O
hours O
, O
and O
then O
daily O
for O
1 O
week O
postoperatively O
. O
Three O
months O
later O
, O
patients O
were O
assessed O
for O
PPSP O
and O
secondary O
hyperalgesia O
. O
Two B-iv-bin-abs
( O
11.8 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
in O
the O
lidocaine O
group O
and O
9 B-cv-bin-abs
( O
47.4 B-cv-bin-percent
% I-cv-bin-percent
) O
patients O
in O
the O
control O
group O
reported O
PPSP B-outcome
at I-outcome
3 I-outcome
months I-outcome
follow I-outcome
- I-outcome
up I-outcome
( O
P= O
0.031 O
) O
. O
McGill O
Pain O
Questionnaire O
revealed O
greater O
present O
pain B-outcome
intensity I-outcome
- I-outcome
visual I-outcome
analog I-outcome
scale I-outcome
in O
the O
control O
group O
( O
14.6 B-iv-cont-mean
± O
22.5 B-iv-cont-sd
vs. O
2.6 B-cv-cont-mean
± O
7.5 B-cv-cont-sd
; O
P= O
0.025 O
) O
. O
Secondary B-outcome
hyperalgesia I-outcome
( O
area B-outcome
of I-outcome
hyperalgesia I-outcome
/ I-outcome
length I-outcome
of I-outcome
surgical I-outcome
incision I-outcome
) O
was O
significantly O
less O
in O
the O
lidocaine O
group O
compared O
with O
control O
group O
( O
0.2 B-iv-cont-mean
± O
0.8 B-iv-cont-sd
vs. O
3.2 B-cv-cont-mean
± O
4.5 B-cv-cont-sd
cm I-cv-cont-sd
; O
P= O
0.002 O
) O
. O
The O
2 O
groups O
were O
similar O
in O
terms O
of O
analgesic B-outcome
consumption I-outcome
during O
the O
early O
postoperative O
period O
. O
Intravenous O
perioperative O
lidocaine O
decreases O
the O
incidence B-outcome
and I-outcome
severity I-outcome
of I-outcome
PPSP I-outcome
after O
breast O
cancer O
surgery O
. O
Prevention O
of O
the O
induction O
of O
central O
hyperalgesia O
is O
a O
potential O
mechanism O
. O

Impact O
of O
on B-intervention
- I-intervention
site I-intervention
initiation I-intervention
visits I-intervention
on O
patient O
recruitment O
and O
data O
quality O
in O
a O
randomized O
trial O
of O
adjuvant O
chemotherapy O
for O
breast O
cancer O
. O
To O
provide O
empirical O
evidence O
on O
the O
impact O
of O
on O
- O
site O
initiation O
visits O
on O
the O
following O
outcomes O
: O
patient O
recruitment O
, O
quantity O
and O
quality O
of O
data O
submitted O
to O
the O
trial O
coordinating O
office O
, O
and O
patients O
' O
follow O
- O
up O
time O
. O
This O
methodological O
study O
was O
performed O
as O
part O
of O
a O
randomized O
trial O
comparing O
two O
combination O
chemotherapies O
for O
adjuvant O
treatment O
of O
breast O
cancer O
. O
Centers O
participating O
to O
the O
trial O
were O
randomized O
to O
either O
receive O
systematic O
on O
- O
site O
visits O
( O
Visited O
group O
) O
, O
or O
not B-control
( I-control
Non I-control
- I-control
visited I-control
group I-control
) I-control
. O
The O
study O
was O
terminated O
after O
two O
years O
, O
while O
the O
main O
randomized O
trial O
continued O
. O
Of O
the O
135 B-total-participants
centers O
that O
had O
expressed O
an O
interest O
in O
the O
trial O
, O
only O
69 B-total-participants
randomized O
at O
least O
one O
patient O
( O
35 O
/ O
68 O
in O
the O
Visited O
group O
, O
34 O
/ O
67 O
in O
the O
Non O
- O
visited O
group O
) O
. O
Almost O
two O
- O
thirds O
of O
the O
patients O
were O
entered O
by O
17 B-total-participants
centers O
( O
10 B-intervention-participants
in O
the O
Visited O
group O
, O
seven B-control-participants
in O
the O
Non O
- O
visited O
group O
) O
that O
accrued O
more O
than O
10 O
patients O
each O
. O
None O
of O
the O
prespecified O
outcomes O
favored O
the O
group O
of O
centers O
submitted O
to O
on O
- O
site O
initiation O
visits O
( O
ie O
, O
mean O
number B-outcome
of I-outcome
queries I-outcome
par I-outcome
patient I-outcome
: O
6.1 B-iv-cont-mean
+ O
/- O
9.7 B-iv-cont-sd
versus O
5.4 B-cv-cont-mean
+ O
/- O
6.4 B-cv-cont-sd
, O
respectively O
for O
the O
Visited O
and O
Non O
- O
visited O
groups O
) O
. O
Spontaneous B-outcome
transmittal I-outcome
of I-outcome
case I-outcome
report I-outcome
forms I-outcome
, O
although O
required O
by O
protocol O
, O
was O
low O
in O
both O
randomized O
groups O
( O
mean O
number O
of O
pages O
per O
patient O
: O
1.5 B-iv-cont-mean
+ O
/- O
2.0 B-iv-cont-sd
versus O
2.1 B-cv-cont-mean
+ O
/- O
2.3 B-cv-cont-sd
, O
respectively O
) O
, O
with O
investigators O
submitting B-outcome
about I-outcome
one I-outcome
- I-outcome
third I-outcome
of I-outcome
the I-outcome
expected I-outcome
forms I-outcome
on I-outcome
time I-outcome
( O
29 B-iv-bin-percent
% I-iv-bin-percent
and O
39 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
) O
. O
This O
study O
could O
not O
evaluate O
the O
impact O
of O
repeated O
on O
- O
site O
visits O
on O
clinical O
outcomes O
. O
Systematic O
on O
- O
site O
initiation O
visits O
did O
not O
contribute O
significantly O
to O
this O
clinical O
trial O
. O

Reducing O
vasomotor O
symptoms O
with O
acupuncture B-intervention
in O
breast O
cancer O
patients O
treated O
with O
adjuvant O
tamoxifen O
: O
a O
randomized O
controlled O
trial O
. O
To O
evaluate O
true O
acupuncture O
to O
control B-control
acupuncture I-control
( O
CTRL O
) O
( O
non O
- O
insertive O
stimulation O
at O
non O
- O
acupuncture O
points O
) O
in O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
treated I-eligibility
with I-eligibility
adjuvant I-eligibility
tamoxifen I-eligibility
suffering I-eligibility
from I-eligibility
hot I-eligibility
flushes I-eligibility
and I-eligibility
sweatings I-eligibility
. O
Eighty B-total-participants
- I-total-participants
four I-total-participants
patients O
were O
randomized O
to O
receive O
either O
true O
acupuncture O
or O
CTRL O
twice O
a O
week O
for O
5 O
weeks O
. O
Seventy B-total-participants
- I-total-participants
four I-total-participants
patients O
were O
treated O
according O
to O
the O
protocol O
. O
In O
the O
true O
acupuncture O
group O
42 B-iv-bin-percent
% I-iv-bin-percent
( O
16 B-iv-bin-abs
/ O
38 B-intervention-participants
) O
reported O
improvements B-outcome
in I-outcome
hot I-outcome
flushes I-outcome
after I-outcome
6 I-outcome
weeks I-outcome
compared O
to O
47 B-cv-bin-percent
% I-cv-bin-percent
( O
17 B-cv-bin-abs
/ O
36 B-control-participants
) O
in O
the O
CTRL O
group O
( O
95 O
% O
CI O
, O
- O
28 O
to O
18 O
% O
) O
. O
Both O
groups O
reported O
improvement O
regarding O
severity B-outcome
and I-outcome
frequencies I-outcome
in I-outcome
hot I-outcome
flushes I-outcome
and I-outcome
sweatings I-outcome
but O
no O
statistical O
difference O
was O
found O
between O
the O
groups O
. O
In O
a O
subanalysis O
regarding O
the O
severity B-outcome
of I-outcome
sweatings I-outcome
at I-outcome
night I-outcome
a O
statistically O
significant O
difference O
P O
= O
0.03 O
was O
found O
in O
the O
true O
acupuncture O
group O
. O
Former O
experience O
of O
true O
acupuncture O
did O
not O
influence O
the O
perception O
of O
true O
acupuncture O
or O
CTRL O
. O
No O
significant O
differences O
in O
hormonal B-outcome
levels I-outcome
were O
found O
before O
and O
after O
treatment O
. O
In O
conclusion O
, O
convincing O
data O
that O
true O
acupuncture O
is O
more O
effective O
than O
CTRL O
in O
reducing O
vasomotor O
symptoms O
is O
still O
lacking O
. O
Our O
study O
shows O
that O
both O
true O
and O
CTRL O
reduce O
vasomotor O
symptoms O
in O
breast O
cancer O
patients O
treated O
with O
adjuvant O
tamoxifen O
. O

Efficacy O
and O
safety O
of O
lipegfilgrastim B-intervention
versus O
pegfilgrastim B-control
: O
a O
randomized O
, O
multicenter O
, O
active O
- O
control O
phase O
3 O
trial O
in O
patients O
with O
breast O
cancer O
receiving O
doxorubicin O
/ O
docetaxel O
chemotherapy O
. O
Lipegfilgrastim O
is O
a O
novel O
glyco O
- O
pegylated O
granulocyte O
- O
colony O
stimulating O
factor O
in O
development O
for O
neutropenia O
prophylaxis O
in O
cancer O
patients O
receiving O
chemotherapy O
. O
This O
phase O
III O
, O
double O
- O
blind O
, O
randomized O
, O
active O
- O
controlled O
, O
noninferiority O
trial O
compared O
the O
efficacy O
and O
safety O
of O
lipegfilgrastim O
versus O
pegfilgrastim O
in O
chemotherapy O
- O
naïve O
breast O
cancer O
patients O
receiving O
doxorubicin O
/ O
docetaxel O
chemotherapy O
. O
Patients B-eligibility
with I-eligibility
high I-eligibility
- I-eligibility
risk I-eligibility
stage I-eligibility
II I-eligibility
, I-eligibility
III I-eligibility
, I-eligibility
or I-eligibility
IV I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
an I-eligibility
absolute I-eligibility
neutrophil I-eligibility
count I-eligibility
≥ I-eligibility
1.5 I-eligibility
  I-eligibility
× I-eligibility
  I-eligibility
109 I-eligibility
cells I-eligibility
/ I-eligibility
L I-eligibility
were O
randomized O
to O
a O
single O
6 O
-mg O
subcutaneous O
injection O
of O
lipegfilgrastim O
( O
n O
  O
= O
  O
101 B-intervention-participants
) O
or O
pegfilgrastim O
( O
n O
  O
= O
  O
101 B-control-participants
) O
on O
day O
2 O
of O
each O
21 O
-day O
chemotherapy O
cycle O
( O
4 O
cycles O
maximum O
) O
. O
The O
primary O
efficacy O
endpoint O
was O
the O
duration B-outcome-measure
of I-outcome-measure
severe I-outcome-measure
neutropenia I-outcome-measure
during I-outcome-measure
cycle I-outcome-measure
1 I-outcome-measure
. O
Cycle O
1 O
: O
The O
mean B-outcome
duration I-outcome
of I-outcome
severe I-outcome
neutropenia I-outcome
for O
the O
lipegfilgrastim O
and O
pegfilgrastim O
groups O
was O
0.7 B-iv-cont-mean
and O
0.8 B-cv-cont-mean
days I-cv-cont-mean
, O
respectively O
( O
λ O
= O
- O
0.218 O
[ O
95 O
% O
confidence O
interval O
: O
- O
0.498 O
% O
, O
0.062 O
% O
] O
, O
p O
= O
0.126 O
) O
, O
and O
no B-outcome
severe I-outcome
neutropenia I-outcome
was O
observed O
in O
56 B-iv-bin-percent
% I-iv-bin-percent
and O
49 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
in O
the O
lipegfilgrastim O
and O
pegfilgrastim O
groups O
, O
respectively O
. O
All O
cycles O
: O
In O
the O
efficacy O
population O
, O
febrile B-outcome
neutropenia I-outcome
occurred O
in O
three B-cv-bin-abs
pegfilgrastim O
- O
treated O
patients O
( O
all O
in O
cycle O
1 O
) O
and O
zero B-iv-bin-abs
lipegfilgrastim O
- O
treated O
patients O
. O
Drug B-outcome
- I-outcome
related I-outcome
adverse I-outcome
events I-outcome
in O
the O
safety O
population O
were O
reported O
in O
28 B-iv-bin-percent
% I-iv-bin-percent
and O
26 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
in O
the O
lipegfilgrastim O
and O
pegfilgrastim O
groups O
, O
respectively O
. O
This O
study O
demonstrates O
that O
lipegfilgrastim O
6 O
mg O
is O
as O
effective O
as O
pegfilgrastim O
in O
reducing O
neutropenia O
in O
patients O
with O
breast O
cancer O
receiving O
myelosuppressive O
chemotherapy O
. O
Eudra O
EEACTA O
200901599910 O
. O

Genetically B-intervention
Predicted I-intervention
Body I-intervention
Mass I-intervention
Index I-intervention
and O
Breast O
Cancer O
Risk O
: O
Mendelian O
Randomization O
Analyses O
of O
Data O
from O
145 B-total-participants
, I-total-participants
000 I-total-participants
Women O
of O
European B-ethinicity
Descent O
. O
Observational O
epidemiological O
studies O
have O
shown O
that O
high O
body O
mass O
index O
( O
BMI O
) O
is O
associated O
with O
a O
reduced O
risk O
of O
breast O
cancer O
in O
premenopausal O
women O
but O
an O
increased O
risk O
in O
postmenopausal O
women O
. O
It O
is O
unclear O
whether O
this O
association O
is O
mediated O
through O
shared O
genetic O
or O
environmental O
factors O
. O
We O
applied O
Mendelian O
randomization O
to O
evaluate O
the O
association O
between O
BMI O
and O
risk O
of O
breast O
cancer O
occurrence O
using O
data O
from O
two O
large O
breast O
cancer O
consortia O
. O
We O
created O
a O
weighted O
BMI O
genetic O
score O
comprising O
84 O
BMI O
- O
associated O
genetic O
variants O
to O
predicted O
BMI O
. O
We O
evaluated O
genetically O
predicted O
BMI O
in O
association O
with O
breast O
cancer O
risk O
using O
individual O
- O
level O
data O
from O
the O
Breast O
Cancer O
Association O
Consortium O
( O
BCAC O
) O
( O
cases O
   O
= O
  B-intervention-participants
46 I-intervention-participants
, I-intervention-participants
325 I-intervention-participants
, O
controls B-control
   O
= O
  B-control-participants
42 I-control-participants
, I-control-participants
482 I-control-participants
) O
. O
We O
further O
evaluated O
the O
association O
between O
genetically O
predicted O
BMI O
and O
breast O
cancer O
risk O
using O
summary O
statistics O
from O
16 O
, O
003 O
cases O
and O
41 O
, O
335 O
controls O
from O
the O
Discovery O
, O
Biology O
, O
and O
Risk O
of O
Inherited O
Variants O
in O
Breast O
Cancer O
( O
DRIVE O
) O
Project O
. O
Because O
most O
studies O
measured O
BMI O
after O
cancer O
diagnosis O
, O
we O
could O
not O
conduct O
a O
parallel O
analysis O
to O
adequately O
evaluate O
the O
association O
of O
measured O
BMI O
with O
breast O
cancer O
risk O
prospectively O
. O
In O
the O
BCAC O
data O
, O
genetically O
predicted O
BMI O
was O
found O
to O
be O
inversely O
associated O
with O
breast B-outcome
cancer I-outcome
risk I-outcome
( O
odds O
ratio O
[ O
OR O
] O
   O
= O
  O
0.65 O
per O
5 O
kg O
/ O
m O
2 O
increase O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
: O
0.56 O
- O
0.75 O
, O
p O
= O
3.32 O
  O
× O
  O
10 O
- O
10 O
) O
. O
The O
associations O
were O
similar O
for O
both O
premenopausal B-outcome
( O
OR O
    O
= O
   O
0.44 O
, O
95 O
% O
CI: O
0.31 O
- O
0.62 O
, O
p O
   O
= O
  O
9.91 O
  O
× O
  O
10 O
- O
8 O
) O
and O
postmenopausal B-outcome
breast I-outcome
cancer I-outcome
( O
OR O
   O
= O
  O
0.57 O
, O
95 O
% O
  O
CI O
: O
0.46 O
- O
0.71 O
, O
p O
   O
= O
  O
1.88 O
  O
× O
  O
10 O
- O
8 O
) O
. O
This O
association O
was O
replicated O
in O
the O
data O
from O
the O
DRIVE O
consortium O
( O
OR O
   O
= O
  O
0.72 O
, O
95 O
% O
  O
CI O
: O
0.60 O
- O
0.84 O
, O
p O
    O
= O
   O
1.64 O
  O
× O
  O
10 O
- O
7 O
) O
. O
Single O
marker O
analyses O
identified O
17 O
of O
the O
84 O
BMI O
- O
associated O
single O
nucleotide O
polymorphisms O
( O
SNPs O
) O
in O
association O
with O
breast B-outcome
cancer I-outcome
risk I-outcome
at O
p O
  O
< O
  O
0.05 O
; O
for O
16 O
of O
them O
, O
the O
allele O
associated O
with O
elevated O
BMI O
was O
associated O
with O
reduced O
breast O
cancer O
risk O
. O
BMI O
predicted O
by O
genome O
- O
wide O
association O
studies O
( O
GWAS O
) O
-identified O
variants O
is O
inversely O
associated O
with O
the O
risk O
of O
both O
pre- O
and O
postmenopausal O
breast O
cancer O
. O
The O
reduced O
risk O
of O
postmenopausal O
breast O
cancer O
associated O
with O
genetically O
predicted O
BMI O
observed O
in O
this O
study O
differs O
from O
the O
positive O
association O
reported O
from O
studies O
using O
measured O
adult O
BMI O
. O
Understanding O
the O
reasons O
for O
this O
discrepancy O
may O
reveal O
insights O
into O
the O
complex O
relationship O
of O
genetic O
determinants O
of O
body O
weight O
in O
the O
etiology O
of O
breast O
cancer O
. O

Phase O
III O
study O
of O
letrozole B-intervention
versus O
tamoxifen B-control
as O
first O
- O
line O
therapy O
of O
advanced O
breast O
cancer O
in O
postmenopausal O
women O
: O
analysis O
of O
survival O
and O
update O
of O
efficacy O
from O
the O
International O
Letrozole O
Breast O
Cancer O
Group O
. O
To O
analyze O
overall O
survival O
( O
OS O
) O
and O
update O
efficacy O
data O
for O
letrozole O
versus O
tamoxifen O
as O
first O
- O
line O
therapy O
in O
postmenopausal O
women O
with O
locally O
advanced O
or O
metastatic O
breast O
cancer O
. O
This O
multicenter O
phase O
III O
trial O
randomly O
assigned O
916 B-total-participants
patients B-eligibility
with I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
or I-eligibility
unknown I-eligibility
tumors I-eligibility
letrozole O
2.5 O
mg O
( O
n O
= O
458 B-intervention-participants
) O
or O
tamoxifen O
20 O
mg O
( O
n O
= O
458 B-control-participants
) O
daily O
until O
disease O
progression O
. O
Optional O
cross O
- O
over O
was O
permitted O
at O
the O
treating O
physician O
's O
discretion O
. O
This O
report O
updates O
efficacy O
at O
a O
median O
follow O
- O
up O
of O
32 O
months O
. O
The O
superiority O
of O
letrozole O
to O
tamoxifen O
was O
confirmed O
for O
time B-outcome
to I-outcome
progression I-outcome
( O
median O
, O
9.4 B-iv-cont-median
v O
6.0 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
P O
< O
. O
0001 O
) O
, O
time B-outcome
to I-outcome
treatment I-outcome
failure I-outcome
( O
median O
, O
9 B-iv-cont-median
v O
5.7 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
P O
< O
. O
0001 O
) O
, O
overall B-outcome
objective I-outcome
response I-outcome
rate I-outcome
( O
32 B-iv-bin-percent
% I-iv-bin-percent
v O
21 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
= O
. O
0002 O
) O
, O
and O
overall B-outcome
clinical I-outcome
benefit I-outcome
. O
Median B-outcome
OS I-outcome
was O
slightly O
prolonged O
for O
the O
randomized O
letrozole O
arm O
( O
34 B-iv-cont-median
v O
30 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
) O
. O
Although O
this O
difference O
in O
OS O
is O
not O
significant O
, O
survival O
was O
improved O
in O
the O
randomized O
letrozole O
arm O
over O
the O
first O
2 O
years O
of O
the O
study O
. O
Approximately O
one O
half O
of O
the O
patients O
in O
each O
arm O
crossed O
over O
. O
Total O
duration O
of O
endocrine O
therapy O
( O
" B-outcome
time I-outcome
to I-outcome
chemotherapy I-outcome
" I-outcome
) O
was O
significantly O
longer O
( O
P O
= O
. O
005 O
) O
for O
patients O
initially O
on O
letrozole O
( O
median O
, O
16 B-iv-cont-median
months I-iv-cont-median
) O
than O
for O
patients O
initially O
on O
tamoxifen O
( O
median O
, O
9 B-cv-cont-median
months I-cv-cont-median
) O
. O
Time B-outcome
to I-outcome
worsening I-outcome
of O
Karnofsky O
performance O
score O
was O
significantly O
delayed O
with O
letrozole O
compared O
with O
tamoxifen O
( O
P O
= O
. O
001 O
) O
. O
This O
study O
documents O
the O
superiority O
of O
letrozole O
over O
tamoxifen O
in O
first O
- O
line O
endocrine O
therapy O
in O
postmenopausal O
women O
with O
advanced O
breast O
cancer O
. O

Treatment O
with O
Ruta B-intervention
graveolens I-intervention
5 I-intervention
CH I-intervention
and I-intervention
Rhus I-intervention
toxicodendron I-intervention
9 I-intervention
CH I-intervention
may O
reduce O
joint B-condition
pain I-condition
and I-condition
stiffness I-condition
linked O
to O
aromatase O
inhibitors O
in O
women B-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
: O
results O
of O
a O
pilot O
observational O
study O
. O
To O
determine O
the O
possible O
effect O
of O
two O
homeopathic O
medicines O
, O
Ruta O
graveolens O
5 O
CH O
and O
Rhus O
toxicodendron O
9 O
CH O
, O
in O
the O
prevention O
of O
aromatase O
inhibitor O
( O
AI O
) O
associated O
joint O
pain O
and/or O
stiffness O
in O
women B-eligibility
with I-eligibility
early I-eligibility
, I-eligibility
hormone I-eligibility
- I-eligibility
receptor I-eligibility
positive I-eligibility
, I-eligibility
breast I-eligibility
cancer I-eligibility
. O
This O
prospective O
, O
unrandomized O
observational O
study O
was O
carried O
out O
between O
April O
and O
October O
2014 O
. O
Women O
were O
recruited O
in O
two O
groups O
, O
according O
to O
which O
of O
the O
two O
study O
centres O
they O
attended O
: O
one O
receiving O
homeopathy O
in O
addition O
to O
standard O
treatment O
( O
group O
H O
) O
and O
a O
control O
group O
, O
receiving O
standard B-control
treatment I-control
( O
group O
C O
) O
. O
All O
women O
were O
treated O
with O
an O
AI O
. O
In O
addition O
, O
women O
in O
group O
H O
also O
took O
Ruta O
graveolens O
5 O
CH O
and O
Rhus O
toxicodendron O
9 O
CH O
( O
5 O
granules O
, O
twice O
a O
day O
) O
up O
to O
7 O
days O
before O
starting O
AI O
treatment O
. O
The O
homeopathic O
medicines O
were O
continued O
for O
3 O
months O
. O
Demographic O
and O
clinical O
data O
were O
recorded O
using O
a O
self O
- O
assessment O
questionnaire O
at O
inclusion O
( O
T O
0 O
) O
and O
3 O
months O
( O
T O
3 O
) O
. O
Primary O
evaluation O
criteria O
were O
the O
evolution B-outcome-measure
of I-outcome-measure
scores I-outcome-measure
for I-outcome-measure
joint I-outcome-measure
pain I-outcome-measure
and I-outcome-measure
stiffness I-outcome-measure
, O
the O
impact B-outcome-measure
of I-outcome-measure
pain I-outcome-measure
on I-outcome-measure
sleep I-outcome-measure
and I-outcome-measure
analgesic I-outcome-measure
consumption I-outcome-measure
in O
the O
two O
groups O
after O
3 O
months O
of O
treatment O
. O
Forty B-total-participants
patients O
( O
mean O
age O
64.9 B-age
± I-age
8.1 I-age
years I-age
) O
were O
recruited O
, O
20 B-intervention-participants
in O
each O
group O
. O
Two O
- O
thirds O
of O
the O
patients O
had O
joint O
pain O
before O
starting O
AI O
treatment O
. O
There O
was O
a O
significant O
difference O
in O
the O
evolution B-outcome
of I-outcome
mean I-outcome
composite I-outcome
pain I-outcome
score I-outcome
between O
T O
0 O
and O
T O
3 O
in O
the O
two O
groups O
( O
- B-iv-cont-mean
1.3 I-iv-cont-mean
in O
group O
H O
vs. O
+ B-cv-cont-mean
3.4 I-cv-cont-mean
in O
group O
C O
; O
p= O
0.0001 O
) O
. O
The O
individual B-outcome
components I-outcome
of I-outcome
the I-outcome
pain I-outcome
score I-outcome
( O
frequency O
, O
intensity O
and O
number O
of O
sites O
of O
pain O
) O
also O
decreased O
significantly O
in O
group O
H O
. O
Nine B-cv-bin-abs
patients O
in O
group O
C O
( O
45 B-cv-bin-percent
% I-cv-bin-percent
) O
vs. O
1 B-iv-bin-abs
( O
5 B-iv-bin-percent
% I-iv-bin-percent
) O
in O
group O
H O
increased O
their O
analgesic B-outcome
consumption I-outcome
between O
T O
0 O
and O
T O
3 O
( O
p= O
0.0076 O
) O
. O
After O
3 O
months O
of O
treatment O
, O
joint B-outcome
pain I-outcome
had I-outcome
a I-outcome
worse I-outcome
impact I-outcome
on I-outcome
sleep I-outcome
in O
patients O
in O
group O
C O
( O
35 B-cv-bin-percent
% I-cv-bin-percent
vs. O
0 B-iv-bin-percent
% I-iv-bin-percent
of O
patients O
; O
p= O
0.0083 O
) O
. O
The O
differences O
observed O
in O
the O
evolution B-outcome
of I-outcome
morning I-outcome
and I-outcome
daytime I-outcome
stiffness I-outcome
between O
the O
two O
groups O
were O
smaller O
( O
p= O
0.053 O
and O
p= O
0.33 O
, O
respectively O
) O
, O
with O
the O
exception O
of O
time O
necessary O
for O
the O
disappearance O
of O
morning O
stiffness O
which O
was O
greater O
in O
group O
C O
( O
37.7 B-iv-cont-mean
± O
23.0 B-iv-cont-sd
vs. O
17.9 B-cv-cont-mean
± O
20.1 B-cv-cont-sd
  I-cv-cont-sd
min I-cv-cont-sd
; O
p= O
0.0173 O
) O
. O
These O
preliminary O
results O
suggest O
that O
treatment O
with O
Ruta O
graveolens O
5 O
CH O
and O
Rhus O
toxicodendron O
9 O
CH O
may O
decrease O
joint O
pain O
/ O
stiffness O
in O
breast O
cancer O
patients O
treated O
with O
AIs O
. O
A O
larger O
- O
scale O
randomized O
study O
is O
required O
to O
confirm O
these O
results O
. O

Randomized O
trial O
of O
fenretinide B-intervention
to O
prevent O
second B-condition
breast I-condition
malignancy I-condition
in O
women O
with O
early O
breast O
cancer O
. O
Fenretinide O
, O
a O
vitamin O
A O
analogue O
, O
has O
been O
shown O
to O
inhibit O
breast O
carcinogenesis O
in O
preclinical O
studies O
. O
We O
determined O
the O
efficacy O
of O
fenretinide O
in O
preventing O
a O
second O
breast O
malignancy O
in O
women O
with O
breast O
cancer O
. O
We O
randomly O
assigned O
2972 B-total-participants
women O
, O
aged O
30 B-age
- I-age
70 I-age
years I-age
, O
with B-eligibility
surgically I-eligibility
removed I-eligibility
stage I-eligibility
I I-eligibility
breast I-eligibility
cancer I-eligibility
or I-eligibility
ductal I-eligibility
carcinoma I-eligibility
in I-eligibility
situ I-eligibility
to O
receive O
for O
5 O
years O
either O
fenretinide O
orally O
( O
200 O
mg O
/ O
day O
) O
or O
no B-control
treatment I-control
. O
The O
primary O
end O
point O
was O
the O
incidence B-outcome-measure
of I-outcome-measure
contralateral I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
or I-outcome-measure
ipsilateral I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
7 O
years O
after O
randomization O
. O
Other O
end O
points O
considered O
post O
hoc O
were O
the O
same O
outcomes O
stratified O
by O
menopausal B-outcome-measure
status I-outcome-measure
, O
incidence B-outcome-measure
of I-outcome-measure
distant I-outcome-measure
metastases I-outcome-measure
, O
overall B-outcome-measure
mortality I-outcome-measure
, O
and O
tumors B-outcome-measure
in I-outcome-measure
other I-outcome-measure
organs I-outcome-measure
. O
The O
hazards O
of O
breast O
cancer O
occurrence O
were O
determined O
by O
Cox O
proportional O
hazards O
regression O
analysis O
. O
Statistical O
tests O
were O
two O
- O
sided O
. O
At O
a O
median O
observation O
time O
of O
97 O
months O
, O
there O
were O
no O
statistically O
significant O
differences O
in O
the O
occurrence B-outcome
of I-outcome
contralateral I-outcome
breast I-outcome
cancer I-outcome
( O
P O
= O
. O
642 O
) O
or O
ipsilateral B-outcome
breast I-outcome
cancer I-outcome
( O
P O
= O
. O
177 O
) O
between O
the O
two O
arms O
. O
However O
, O
an O
interaction O
was O
detected O
between O
fenretinide O
treatment O
and O
menopausal O
status O
in O
both O
outcomes O
( O
P O
for O
interaction O
in O
both O
outcomes O
= O
. O
045 O
) O
, O
with O
a O
possible O
beneficial O
effect O
in O
premenopausal B-outcome
women I-outcome
( O
contralateral B-outcome
breast I-outcome
cancer I-outcome
: O
adjusted O
hazard O
ratio O
[ O
HR O
] O
= O
0.66 O
, O
and O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.41 O
- O
1.07 O
; O
ipsilateral B-outcome
breast I-outcome
cancer I-outcome
: O
adjusted O
HR O
= O
0.65 O
, O
and O
95 O
% O
CI O
= O
0.46 O
- O
0 O
. O
92 O
) O
and O
an O
opposite O
effect O
in O
postmenopausal B-outcome
women I-outcome
( O
contralateral B-outcome
breast I-outcome
cancer I-outcome
: O
adjusted O
HR O
= O
1.32 O
, O
and O
95 O
% O
CI O
= O
0.82 O
- O
2.15 O
; O
ipsilateral B-outcome
breast I-outcome
cancer I-outcome
: O
adjusted O
HR O
= O
1.19 O
, O
and O
95 O
% O
CI O
= O
0.75 O
- O
1 O
. O
89 O
) O
. O
There O
were O
no O
statistically O
significant O
differences O
between O
the O
two O
arms O
in O
tumors B-outcome
in I-outcome
other I-outcome
organs I-outcome
, O
incidence B-outcome
of I-outcome
distant I-outcome
metastasis I-outcome
, O
and O
all B-outcome
- I-outcome
cause I-outcome
mortality I-outcome
. O
Fenretinide O
treatment O
of O
women O
with O
breast O
cancer O
for O
5 O
years O
appears O
to O
have O
no O
statistically O
significant O
effect O
on O
the O
incidence O
of O
second O
breast O
malignancies O
overall O
, O
although O
a O
possible O
benefit O
was O
detected O
in O
premenopausal O
women O
. O
These O
studies O
, O
particularly O
the O
post O
hoc O
analyses O
, O
are O
considered O
exploratory O
and O
need O
to O
be O
confirmed O
. O

High B-control
- I-control
dose I-control
oral I-control
medroxyprogesterone I-control
acetate I-control
or O
tamoxifen B-intervention
as O
adjuvant O
hormone O
therapy O
for O
node O
- O
negative O
early O
- O
stage O
breast O
cancer O
: O
randomized O
trial O
with O
7 O
-year O
update O
. O
A O
randomized O
adjuvant O
trial O
compared O
tamoxifen O
20 O
mg O
daily O
for O
5 O
years O
with O
high O
- O
dose O
oral O
medroxyprogesterone O
acetate O
( O
MPA O
) O
1 O
g O
orally O
for O
9 O
months O
. O
One B-total-participants
hundred I-total-participants
ninety I-total-participants
- I-total-participants
four I-total-participants
patients B-eligibility
with I-eligibility
histologically I-eligibility
proven I-eligibility
primary I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
breast I-eligibility
carcinoma I-eligibility
were O
enrolled O
between O
December O
1990 O
and O
October O
1996 O
, O
with O
98 B-intervention-participants
patients O
randomized O
into O
the O
tamoxifen O
arm O
and O
96 B-control-participants
into O
the O
MPA O
arm O
. O
At O
a O
median O
follow O
- O
up O
of O
86 O
months O
, O
25 O
relapses B-outcome
and O
13 O
deaths B-outcome
were O
recorded O
. O
The O
relapse B-outcome
- I-outcome
free I-outcome
survival I-outcome
rate I-outcome
at I-outcome
7 I-outcome
years I-outcome
in O
the O
tamoxifen O
arm O
was O
93 B-iv-bin-percent
% I-iv-bin-percent
, O
versus O
81 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
MPA O
arm O
( O
P O
= O
0.02 O
) O
. O
The O
difference O
was O
observed O
in O
patients O
with O
stage B-outcome
T I-outcome
2 I-outcome
disease I-outcome
( O
100 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
tamoxifen O
group O
vs. O
64 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
MPA O
group O
; O
P O
= O
0.01 O
) O
, O
in O
younger B-outcome
and/or I-outcome
premenopausal I-outcome
patients I-outcome
( O
in O
patients O
< O
50 O
years O
of O
age O
, O
100 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
tamoxifen O
arm O
vs. O
81 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
MPA O
arm O
[ O
P O
= O
0.02 O
] O
, O
and O
in O
patients B-outcome
> I-outcome
or I-outcome
= I-outcome
50 I-outcome
years I-outcome
of I-outcome
age I-outcome
, O
90 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
tamoxifen O
arm O
vs. O
82 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
MPA O
arm O
[ O
P O
= O
0.16 O
] O
) O
. O
Also O
, O
the O
overall B-outcome
survival I-outcome
rate I-outcome
at I-outcome
7 I-outcome
years I-outcome
was O
lower O
in O
women O
< O
50 O
years O
of O
age O
( O
P O
= O
0.04 O
) O
. O

Randomized O
Controlled O
Trial O
of O
Zoledronic B-intervention
Acid I-intervention
plus I-intervention
Chemotherapy I-intervention
versus O
Chemotherapy B-control
Alone I-control
as O
Neoadjuvant O
Treatment O
of O
HER O
2 O
- O
Negative O
Primary O
Breast O
Cancer O
( O
JONIE O
Study O
) O
. O
Zoledronic O
acid O
( O
ZOL O
) O
is O
a O
nitrogen O
- O
containing O
bisphosphonate O
that O
induces O
osteoclast O
apoptosis O
and O
inhibits O
bone O
resorption O
by O
inhibiting O
the O
mevalonate O
pathway O
. O
Its O
benefit O
for O
the O
prevention O
of O
skeletal B-condition
complications I-condition
due O
to O
bone O
metastases O
has O
been O
established O
. O
However O
, O
the O
antitumor O
efficacy O
of O
ZOL O
, O
although O
suggested O
by O
multiple O
preclinical O
and O
clinical O
studies O
, O
has O
not O
yet O
been O
clinically O
proven O
. O
We O
performed O
the O
present O
randomized O
Phase O
2 O
trial O
to O
investigate O
the O
antitumor O
effect O
of O
ZOL O
with O
chemotherapy O
( O
CT O
) O
. O
Asian B-ethinicity
patients B-eligibility
with I-eligibility
HER I-eligibility
2 I-eligibility
- I-eligibility
negative I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
either O
the O
CT O
or O
CT+ZOL O
( O
CTZ O
) O
group O
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
eighty I-total-participants
- I-total-participants
eight I-total-participants
patients O
were O
randomized O
to O
either O
the O
CT O
group O
( O
n O
= O
95 B-control-participants
) O
or O
the O
CTZ O
group O
( O
n O
= O
93 B-intervention-participants
) O
from O
March O
2010 O
to O
April O
2012 O
, O
and O
180 B-total-participants
patients O
were O
assessed O
. O
All O
patients O
received O
four O
cycles O
of O
FEC O
100 O
( O
fluorouracil O
500 O
mg O
/ O
m O
2 O
, O
epirubicin O
100 O
mg O
/ O
m O
2 O
, O
and O
cyclophosphamide O
500 O
mg O
/ O
m O
2 O
) O
, O
followed O
by O
12 O
cycles O
of O
paclitaxel O
at O
80 O
mg O
/ O
m O
2 O
weekly O
. O
ZOL O
( O
4 O
mg O
) O
was O
administered O
three O
to O
four O
times O
weekly O
for O
7 O
weeks O
to O
the O
patients O
in O
the O
CTZ O
group O
. O
The O
primary O
endpoint O
was O
the O
pathological B-outcome-measure
complete I-outcome-measure
response I-outcome-measure
( I-outcome-measure
pCR I-outcome-measure
) I-outcome-measure
rate I-outcome-measure
, O
which O
was O
defined O
as O
no O
invasive O
cancer O
in O
the O
breast O
tissue O
specimen O
. O
Safety O
was O
assessed O
in O
all O
patients O
who O
received O
at O
least O
one O
dose O
of O
the O
study O
drug O
. O
This O
randomized O
controlled O
trial O
indicated O
that O
the O
rates B-outcome
of I-outcome
pCR I-outcome
in O
CTZ O
group O
( O
14.8 B-iv-bin-percent
% I-iv-bin-percent
) O
was O
doubled O
to O
CT O
group O
( O
7.7 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
respectively O
( O
one O
- O
sided O
chi O
- O
square O
test O
, O
p O
= O
0.068 O
) O
, O
though O
the O
additional O
efficacy O
of O
zoledronic O
acid O
was O
not O
demonstrated O
statistically O
. O
The O
pCR B-outcome
rate I-outcome
in B-outcome
postmenopausal I-outcome
patients I-outcome
was O
18.4 B-iv-bin-percent
% I-iv-bin-percent
and O
5.1 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
CTZ O
and O
CT O
groups O
, O
respectively O
( O
one O
- O
sided O
Fisher O
's O
exact O
test O
, O
p O
= O
0.071 O
) O
, O
and O
that O
in B-outcome
patients I-outcome
with I-outcome
triple I-outcome
- I-outcome
negative I-outcome
breast I-outcome
cancer I-outcome
was O
35.3 B-iv-bin-percent
% I-iv-bin-percent
and O
11.8 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
CTZ O
and O
CT O
groups O
, O
respectively O
( O
one O
- O
sided O
Fisher O
's O
exact O
test O
, O
p O
= O
0.112 O
) O
. O
Thus O
the O
addition O
of O
ZOL O
to O
neoadjuvant O
CT O
has O
potential O
anticancer O
benefits O
in O
postmenopausal O
patients O
and O
patients O
with O
triple O
- O
negative O
breast O
cancer O
. O
Further O
investigation O
is O
warranted O
. O
University O
Hospital O
Medical O
Information O
Network O
. O
UMIN O
000003261 O
. O

Weekly O
docetaxel B-intervention
versus O
CMF B-control
as O
adjuvant O
chemotherapy O
for O
elderly O
breast O
cancer O
patients O
: O
safety O
data O
from O
the O
multicentre O
phase O
3 O
randomised O
ELDA O
trial O
. O
Within O
an O
ongoing O
multicentre O
phase O
3 O
randomised O
trial O
( O
ELDA O
, O
cancertrials O
. O
gov O
ID O
: O
NCT O
00331097 O
) O
, O
early B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
, I-eligibility
65 I-eligibility
- I-eligibility
79 I-eligibility
years I-eligibility
old I-eligibility
, I-eligibility
with I-eligibility
average I-eligibility
to I-eligibility
high I-eligibility
risk I-eligibility
of I-eligibility
recurrence I-eligibility
, O
are O
randomly O
assigned O
to O
receive O
CMF O
( O
cyclophosphamide O
600 O
mg O
/ O
m O
2 O
, O
methotrexate O
40 O
mg O
/ O
m O
2 O
, O
fluorouracil O
600 O
mg O
/ O
m O
2 O
, O
days O
1 O
- O
8 O
) O
or O
docetaxel O
( O
35 O
mg O
/ O
m O
2 O
days O
1 O
- O
8 O
- O
15 O
) O
, O
every O
4 O
weeks O
. O
Here O
we O
report O
an O
unplanned O
safety O
analysis O
prompted O
by O
an O
amendment O
introducing O
creatinine O
clearance O
as O
a O
tool O
to O
adjust O
methotrexate O
dose O
. O
Before O
such O
change O
, O
101 B-total-participants
patients O
with O
a O
median O
age O
of O
70 B-age
were O
randomly O
assigned O
CMF O
( O
53 B-control-participants
patients O
) O
or O
docetaxel O
( O
48 B-intervention-participants
patients O
) O
. O
At O
least O
one O
grades B-outcome
3 I-outcome
- I-outcome
4 I-outcome
toxic I-outcome
event I-outcome
of I-outcome
any I-outcome
type I-outcome
was O
reported O
in O
40 B-cv-bin-abs
( O
75.5 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
19 B-iv-bin-abs
( O
39.6 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
with O
CMF O
and O
docetaxel O
, O
respectively O
( O
p= O
0.0002 O
) O
. O
Grades B-outcome
3 I-outcome
- I-outcome
4 I-outcome
hematological I-outcome
events I-outcome
were O
observed O
in O
37 B-cv-bin-abs
( O
69.8 B-cv-bin-percent
% I-cv-bin-percent
) O
vs. O
4 B-iv-bin-abs
( O
8.3 B-iv-bin-percent
% I-iv-bin-percent
) O
cases O
( O
p O
< O
0.0001 O
) O
and O
grades B-outcome
3 I-outcome
- I-outcome
4 I-outcome
non I-outcome
- I-outcome
hematological I-outcome
toxicity I-outcome
in O
12 B-cv-bin-abs
( O
22.6 B-cv-bin-percent
% I-cv-bin-percent
) O
vs. O
15 B-iv-bin-abs
( O
31.2 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
( O
p= O
0.11 O
) O
, O
with O
CMF O
and O
docetaxel O
, O
respectively O
. O
A O
higher O
incidence O
of O
anemia B-outcome
, O
neutropenia B-outcome
, O
thrombocytopenia B-outcome
and O
febrile B-outcome
neutropenia I-outcome
was O
reported O
with O
CMF O
. O
Constipation B-outcome
, O
mucositis B-outcome
, O
nausea B-outcome
and O
vomiting B-outcome
were O
more O
common O
with O
CMF O
; O
diarrhoea B-outcome
, O
abdominal B-outcome
pain I-outcome
, O
dysgeusia B-outcome
, O
neuropathy B-outcome
and O
liver B-outcome
toxicity I-outcome
were O
more O
frequent O
with O
docetaxel O
. O
No O
significant O
interaction O
was O
found O
between O
the O
occurrence O
of O
severe O
toxicity B-outcome
and O
baseline O
variables O
, O
including O
creatinine O
clearance O
and O
geriatric O
activity O
scales O
. O
In O
conclusion O
, O
weekly O
docetaxel O
appears O
to O
be O
less O
toxic O
than O
CMF O
in O
terms O
of O
hematological O
toxicity O
. O

Association O
of O
Transforming B-intervention
Growth I-intervention
Factor I-intervention
β I-intervention
Polymorphism I-intervention
C- I-intervention
509 I-intervention
T I-intervention
With O
Radiation B-condition
- I-condition
Induced I-condition
Fibrosis I-condition
Among O
Patients B-eligibility
With I-eligibility
Early I-eligibility
- I-eligibility
Stage I-eligibility
Breast I-eligibility
Cancer I-eligibility
: O
A O
Secondary O
Analysis O
of O
a O
Randomized O
Clinical O
Trial O
. O
Whether O
genetic O
factors O
can O
identify O
patients O
at O
risk O
for O
radiation O
- O
induced O
fibrosis O
remains O
unconfirmed O
. O
To O
assess O
the O
association O
between O
the O
C- O
509 O
T O
variant O
allele O
in O
the O
promoter O
region O
of O
TGFB O
1 O
and O
breast O
fibrosis O
3 O
years O
after O
radiotherapy O
. O
This O
is O
an O
a O
priori O
- O
specified O
, O
prospective O
, O
cohort O
study O
nested O
in O
an O
open O
- O
label O
, O
randomized O
clinical O
trial O
, O
which O
was O
conducted O
in O
community O
- O
based O
and O
academic O
cancer O
centers O
to O
compare O
hypofractionated O
whole O
- O
breast O
irradiation O
( O
WBI O
) O
( O
42.56 O
Gy O
in O
16 O
fractions O
) O
with O
conventionally B-control
fractionated I-control
WBI I-control
( O
50 O
Gy O
in O
25 O
fractions O
) O
after O
breast O
- O
conserving O
surgery O
. O
In O
total O
, O
287 B-total-participants
women O
40 B-age
years I-age
or I-age
older I-age
with B-eligibility
pathologically I-eligibility
confirmed I-eligibility
stage I-eligibility
0 I-eligibility
to I-eligibility
IIA I-eligibility
breast I-eligibility
cancer I-eligibility
treated I-eligibility
with I-eligibility
breast I-eligibility
- I-eligibility
conserving I-eligibility
surgery I-eligibility
were O
enrolled O
from O
February O
2011 O
to O
February O
2014 O
. O
Patients O
were O
observed O
for O
a O
minimum O
of O
3 O
years O
. O
Outcomes O
were O
compared O
using O
the O
1 O
-sided O
Fisher O
exact O
test O
and O
multivariable O
logistic O
regression O
. O
A O
C O
- O
to O
- O
T O
single O
- O
nucleotide O
polymorphism O
at O
position O
- O
509 O
relative O
to O
the O
first O
major O
transcription O
start O
site O
( O
C- O
509 O
T O
) O
of O
the O
TGFB O
1 O
gene O
. O
The O
primary O
outcome O
was O
grade B-outcome-measure
2 I-outcome-measure
or I-outcome-measure
higher I-outcome-measure
breast I-outcome-measure
fibrosis I-outcome-measure
as O
assessed O
using O
the O
Late O
Effects O
Normal O
Tissue O
/ O
Subjective O
, O
Objective O
, O
Medical O
Management O
, O
Analytic O
scale O
( O
range O
, O
0 O
to O
3 O
) O
three O
years O
after O
radiotherapy O
. O
Among O
287 B-total-participants
women O
enrolled O
in O
the O
trial O
, O
TGFB O
1 O
genotype O
and O
3 O
-year O
radiotherapy O
- O
induced O
toxicity O
data O
were O
available O
for O
174 B-total-participants
patients O
, O
of O
whom O
89 O
patients O
( O
51 O
% O
) O
with O
a O
mean O
( O
SD O
) O
age O
of O
60 O
( O
8 O
) O
years O
had O
at O
least O
1 O
copy O
of O
C- O
509 O
T O
. O
Grade B-outcome
2 I-outcome
or I-outcome
higher I-outcome
breast I-outcome
fibrosis I-outcome
was O
present O
in O
12 B-iv-bin-abs
of O
87 B-intervention-participants
patients O
with O
C- O
509 O
T O
( O
13.8 B-iv-bin-percent
% I-iv-bin-percent
) O
compared O
with O
3 B-cv-bin-abs
of O
80 B-control-participants
patients O
without O
the O
allele O
variant O
( O
3.8 B-cv-bin-percent
% I-cv-bin-percent
) O
( O
absolute O
difference O
, O
10.0 O
% O
; O
95 O
% O
CI O
, O
1.7 O
% O
- O
18.4 O
% O
; O
P O
  O
= O
  O
. O
02 O
) O
. O
The O
results O
of O
multivariable O
analyses O
indicated O
that O
only O
C- O
509 O
T O
( O
odds O
ratio O
, O
4.47 O
; O
95 O
% O
CI O
, O
1.25 O
- O
15.99 O
; O
P O
  O
= O
  O
. O
02 O
) O
and O
postoperative O
cosmetic O
outcome O
( O
odds O
ratio O
, O
7.09 O
; O
95 O
% O
CI O
, O
2.41 O
- O
20.90 O
; O
P O
  O
< O
  O
. O
001 O
) O
were O
significantly O
associated O
with O
breast B-outcome
fibrosis I-outcome
risk I-outcome
. O
To O
date O
, O
this O
study O
seems O
to O
be O
the O
first O
prospective O
validation O
of O
a O
genomic O
marker O
for O
radiation O
fibrosis O
. O
The O
C- O
509 O
T O
allele O
in O
TGFB O
1 O
is O
a O
key O
determinant O
of O
breast O
fibrosis O
risk O
. O
Assessing O
TGFB O
1 O
genotype O
may O
facilitate O
a O
more O
personalized O
approach O
to O
locoregional O
treatment O
decisions O
in O
breast O
cancer O
. O
ClinicalTrials.gov O
identifier O
: O
NCT O
01266642 O
. O

Effect O
of O
everolimus B-intervention
on O
bone O
marker O
levels O
and O
progressive O
disease O
in O
bone O
in O
BOLERO- O
2 O
. O
Breast O
Cancer O
Trials O
of O
Oral O
Everolimus O
2 O
( O
BOLERO- O
2 O
) O
, O
a O
phase O
III O
study O
in O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
estrogen I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
progressing I-eligibility
despite I-eligibility
nonsteroidal I-eligibility
aromatase I-eligibility
inhibitor I-eligibility
therapy I-eligibility
, O
showed O
statistically O
significant O
benefits O
with O
adding O
everolimus O
to O
exemestane O
. O
Moreover O
, O
in O
preclinical O
studies O
, O
mammalian O
target O
of O
rapamycin O
inhibition O
was O
associated O
with O
decreased O
osteoclast O
survival O
and O
activity O
. O
Exploratory O
analyses O
in O
BOLERO- O
2 O
evaluated O
the O
effect O
of O
everolimus O
on O
bone O
marker O
levels O
and O
progressive O
disease O
in O
bone O
. O
Patients O
were O
treated O
with O
exemestane O
( O
25 O
mg O
/ O
day O
) O
and O
randomized O
( O
2 O
:1 O
) O
to O
everolimus O
( O
10 O
mg O
/ O
day O
; O
combination O
) O
or O
placebo B-control
( I-control
exemestane I-control
only I-control
) I-control
. O
Exploratory O
endpoints O
included O
changes B-outcome-measure
in I-outcome-measure
bone I-outcome-measure
turnover I-outcome-measure
marker I-outcome-measure
levels I-outcome-measure
vs O
baseline B-outcome-measure
and I-outcome-measure
progressive I-outcome-measure
disease I-outcome-measure
in I-outcome-measure
bone I-outcome-measure
, O
defined O
as O
unequivocal O
progression O
of O
a O
preexisting O
bone O
lesion O
or O
the O
appearance O
of O
a O
new O
bone O
lesion O
. O
Baseline B-outcome
disease I-outcome
characteristics I-outcome
were O
well O
balanced O
between O
arms O
( O
N O
= O
724 B-total-participants
) O
; O
baseline O
bisphosphonate O
use O
was O
not O
( O
43.9 B-iv-bin-percent
% I-iv-bin-percent
combination O
vs O
54.0 B-cv-bin-percent
% I-cv-bin-percent
exemestane O
only O
) O
. O
At O
a O
median O
of O
18 O
months O
of O
follow O
- O
up O
, O
median O
progression B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
primary O
endpoint O
) O
was O
statistically O
significantly O
longer O
with O
the O
combination O
vs O
exemestane O
only O
( O
Cox O
proportional O
hazard O
ratio O
= O
0.45 O
, O
95 O
% O
confidence O
interval O
= O
0.38 O
to O
0.54 O
; O
log O
- O
rank O
, O
1 O
-sided O
P O
< O
. O
0001 O
) O
. O
Bone B-outcome
marker I-outcome
levels I-outcome
at B-outcome
6 I-outcome
and I-outcome
12 I-outcome
weeks I-outcome
increased O
with O
exemestane O
only O
, O
as O
expected O
, O
but O
decreased O
with O
the O
combination O
. O
The O
cumulative B-outcome
incidence I-outcome
rate I-outcome
of I-outcome
progressive I-outcome
disease I-outcome
in I-outcome
bone I-outcome
was O
lower O
in O
the O
combination O
arm O
. O
Bone B-outcome
- I-outcome
related I-outcome
adverse I-outcome
events I-outcome
occurred O
with O
similar O
frequency O
in O
both O
arms O
( O
3.3 B-iv-bin-percent
% I-iv-bin-percent
combination O
vs O
4.2 B-cv-bin-percent
% I-cv-bin-percent
exemestane O
only O
) O
. O
These O
exploratory O
analyses O
suggest O
that O
everolimus O
has O
beneficial O
effects O
on O
bone O
turnover O
and O
progressive O
disease O
in O
bone O
in O
patients O
receiving O
exemestane O
for O
hormone O
receptor O
- O
positive O
breast O
cancer O
progressing O
during O
/ O
after O
nonsteroidal O
aromatase O
inhibitor O
therapy O
. O

Use O
of O
axillary B-intervention
deodorant I-intervention
and O
effect O
on O
acute O
skin O
toxicity O
during O
radiotherapy O
for O
breast O
cancer O
: O
a O
prospective O
randomized O
noninferiority O
trial O
. O
To O
prospectively O
determine O
the O
effect O
of O
deodorant O
use O
on O
acute O
skin O
toxicity O
and O
quality O
of O
life O
during O
breast O
radiotherapy O
( O
RT O
) O
. O
Before O
breast O
RT O
, O
84 B-total-participants
patients O
were O
randomly O
assigned O
to O
the O
deodorant O
group O
( O
n O
= O
40 B-intervention-participants
) O
or O
the O
no B-control
- I-control
deodorant I-control
group O
( O
n O
= O
44 B-control-participants
) O
. O
The O
patients O
were O
stratified O
by O
axillary O
RT O
and O
previous O
chemotherapy O
. O
Toxicity O
evaluations O
were O
always O
performed O
by O
the O
principal O
investigator O
, O
who O
was O
unaware O
of O
the O
group O
assignment O
, O
at O
the O
end O
of O
RT O
and O
2 O
weeks O
after O
completion O
using O
the O
Radiation O
Therapy O
Oncology O
Group O
acute O
skin O
toxicity O
criteria O
. O
Symptoms O
of O
acute O
skin O
toxicity O
( O
i. O
e. O
, O
discomfort O
, O
pain O
, O
pruritus O
, O
sweating O
) O
and O
quality O
of O
life O
were O
self O
- O
evaluated O
. O
For O
each O
criterion O
, O
the O
point O
estimate O
of O
rate O
difference O
with O
the O
95 O
% O
one O
- O
sided O
upper O
confidence O
limit O
was O
computed O
. O
To O
claim O
noninferiority O
owing O
to O
deodorant O
use O
, O
the O
95 O
% O
one O
- O
sided O
upper O
confidence O
limit O
had O
to O
be O
lower O
than O
the O
noninferiority O
margin O
, O
fixed O
to O
12.8 O
% O
. O
In O
the O
deodorant O
vs. O
no O
- O
deodorant O
groups O
, O
Grade B-outcome
2 I-outcome
axillary I-outcome
radiodermatitis I-outcome
occurred O
in O
23 B-iv-bin-percent
% I-iv-bin-percent
vs. O
30 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
, O
satisfying O
the O
statistical O
criteria O
for O
noninferiority O
( O
p O
= O
. O
019 O
) O
. O
Grade B-outcome
2 I-outcome
breast I-outcome
radiodermatitis I-outcome
occurred O
in O
30 B-iv-bin-percent
% I-iv-bin-percent
vs. O
34 B-cv-bin-percent
% I-cv-bin-percent
of O
the O
deodorant O
vs. O
no O
- O
deodorant O
groups O
, O
respectively O
, O
also O
satisfying O
the O
statistical O
criteria O
for O
noninferiority O
( O
p O
= O
. O
049 O
) O
. O
Similar O
results O
were O
observed O
for O
the O
self O
- O
reported O
evaluations O
. O
The O
deodorant O
group O
reported O
less O
sweating B-outcome
( O
18 B-iv-bin-percent
% I-iv-bin-percent
vs. O
39 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
= O
. O
032 O
) O
. O
No O
Grade B-outcome
3 I-outcome
or I-outcome
4 I-outcome
radiodermatitis I-outcome
was O
observed O
. O
According O
to O
our O
noninferiority O
margin O
definition O
, O
the O
occurrence O
of O
skin O
toxicity O
and O
its O
related O
symptoms O
were O
statistically O
equivalent O
in O
both O
groups O
. O
No O
evidence O
was O
found O
to O
prohibit O
deodorant O
use O
( O
notwithstanding O
the O
use O
of O
an O
antiperspirant O
with O
aluminum O
) O
during O
RT O
for O
breast O
cancer O
. O

Topical B-intervention
silymarin I-intervention
administration O
for O
prevention O
of O
acute B-condition
radiodermatitis I-condition
in O
breast O
cancer O
patients O
: O
A O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
clinical O
trial O
. O
Radiation O
- O
induced O
dermatitis O
is O
one O
of O
the O
most O
common O
side O
effects O
of O
radiotherapy O
. O
Silymarin O
, O
a O
flavonoid O
extracted O
from O
the O
Silybum O
marianum O
, O
exhibits O
antioxidant O
and O
anti O
- O
inflammatory O
activities O
. O
The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
efficacy O
of O
silymarin O
gel O
in O
prevention O
of O
radiodermatitis O
in O
patients O
with O
breast O
cancer O
. O
During O
this O
randomized O
, O
double O
- O
blinded O
, O
placebo O
- O
controlled O
clinical O
trial O
, O
the O
preventive O
effect O
of O
silymarin O
1 O
% O
gel O
was O
assessed O
in O
comparison O
with O
placebo B-control
, O
on O
radiodermatitis O
occurrence O
. O
Forty B-total-participants
patients O
randomly O
received O
silymarin O
gel O
or O
placebo O
formulation O
on O
chest O
wall O
skin O
following O
modified O
radical O
mastectomy O
, O
once O
daily O
starting O
at O
the O
first O
day O
of O
radiotherapy O
for O
5 O
  O
weeks O
. O
Radiodermatitis O
severity O
was O
assessed O
weekly O
based O
on O
Radiation O
Therapy O
Oncology O
Group O
( O
RTOG O
) O
and O
National O
Cancer O
Institute O
Common O
Terminology O
for O
Adverse O
Events O
( O
NCI O
- O
CTCAE O
) O
criteria O
radiodermatits O
grading O
scale O
for O
5 O
  O
weeks O
. O
The O
median B-outcome
NCI I-outcome
- I-outcome
CTCAE I-outcome
and I-outcome
RTOG I-outcome
scores I-outcome
were O
significantly O
lower O
in O
silymarin O
group O
at O
the O
end O
of O
the O
third O
to O
fifth O
weeks O
( O
p O
value O
  O
< O
  O
0.05 O
) O
. O
The O
scores B-outcome
increased I-outcome
significantly I-outcome
in O
both O
placebo O
and O
silymarin O
groups O
during O
radiotherapy O
, O
but O
there O
was O
a O
delay O
in O
radiodermatitis O
development O
and O
progression O
in O
silymarin O
group O
. O
Prophylactic O
administration O
of O
silymarin O
gel O
could O
significantly O
reduce O
the O
severity O
of O
radiodermatitis O
and O
delay O
its O
occurrence O
after O
5 O
  O
weeks O
of O
application O
. O

Longitudinal O
social O
cognitive O
influences O
on O
physical B-intervention
activity I-intervention
and O
sedentary O
time O
in O
Hispanic B-ethinicity
breast O
cancer O
survivors O
. O
This O
study O
evaluated O
the O
effect O
of O
two O
home O
- O
based O
exercise O
interventions O
( O
one O
culturally O
adapted O
and O
one O
standard O
) O
on O
changes O
in O
social O
cognitive O
theory O
( O
SCT O
) O
variables O
, O
physical O
activity O
( O
PA O
) O
, O
and O
sedentary O
time O
( O
ST O
) O
, O
and O
determined O
the O
association O
between O
changes O
in O
SCT O
variables O
and O
changes O
in O
PA O
and O
ST O
in O
Hispanic B-eligibility
breast I-eligibility
cancer I-eligibility
survivors I-eligibility
. O
Project O
VIVA O
! O
was O
a O
16 O
-week O
randomized O
controlled O
pilot O
study O
to O
test O
the O
effectiveness O
and O
feasibility O
of O
a O
culturally O
adapted O
exercise O
intervention O
for O
Mexican B-age
American I-age
and O
Puerto B-ethinicity
Rican I-ethinicity
breast O
cancer O
survivors O
in O
Houston B-location
, O
Texas B-location
and O
San B-location
Juan I-location
, O
Puerto B-location
Rico I-location
, O
respectively O
. O
Women O
( O
N O
  O
= O
  O
89 B-total-participants
) O
completed O
questionnaires O
on O
SCT O
variables O
, O
PA O
, O
and O
ST O
and O
were O
then O
randomized O
to O
a O
16 O
-week O
culturally O
adapted O
exercise O
program O
, O
a O
non O
- O
culturally O
adapted O
standard O
exercise O
intervention O
or O
a O
wait B-control
- I-control
list I-control
control I-control
group I-control
. O
Multiple O
regression O
models O
were O
used O
to O
determine O
associations O
between O
changes O
in O
SCT O
variables O
and O
changes O
in O
PA O
and O
ST O
. O
Participants O
were O
in O
their O
late O
50 O
s O
( O
58.5 B-age
  I-age
± I-age
  I-age
9.2 I-age
  I-age
years I-age
) O
and O
obese O
( O
31.0 O
  O
± O
  O
6.5 O
  O
kg O
/ O
m O
2 O
) O
. O
Women O
reported O
doing O
roughly O
34.5 O
  O
min O
/ O
day O
of O
PA O
and O
spending O
over O
11 O
  O
h O
/ O
day O
in O
sedentary O
activities O
. O
Across O
groups O
, O
women O
reported O
significant O
increases O
in O
exercise B-outcome
self I-outcome
- I-outcome
efficacy I-outcome
and O
moderate B-outcome
- I-outcome
intensity I-outcome
, O
vigorous B-outcome
- I-outcome
intensity I-outcome
, O
and O
total B-outcome
PA I-outcome
from O
baseline O
to O
follow O
- O
up O
( O
p O
  O
< O
  O
0.05 O
) O
. O
Increased O
social O
support O
from O
family O
was O
associated O
with O
increases O
in O
vigorous B-outcome
- I-outcome
intensity I-outcome
PA I-outcome
. O
Increases O
in O
social O
modeling O
were O
associated O
with O
increases O
in O
moderate B-outcome
- I-outcome
intensity I-outcome
and O
total B-outcome
PA I-outcome
and O
with O
decreases O
in O
ST B-outcome
from O
baseline O
to O
follow O
- O
up O
( O
p O
  O
< O
  O
0.05 O
) O
. O
Hispanic O
cancer O
survivors O
benefit O
from O
PA O
interventions O
that O
focus O
on O
increasing O
social O
support O
from O
family O
and O
friends O
and O
social O
modeling O
. O
Copyright O
© O
2015 O
John O
Wiley O
& O
Sons O
, O
Ltd. O

Maintaining O
normal O
hemoglobin O
levels O
with O
epoetin B-intervention
alfa I-intervention
in O
mainly O
nonanemic B-eligibility
patients I-eligibility
with I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
receiving I-eligibility
first I-eligibility
- I-eligibility
line I-eligibility
chemotherapy I-eligibility
: O
a O
survival O
study O
. O
To O
evaluate O
the O
effect O
on O
survival O
and O
quality O
of O
life O
of O
maintaining O
hemoglobin O
( O
Hb O
) O
in O
the O
range O
of O
12 O
to O
14 O
g O
/ O
dL O
with O
epoetin O
alfa O
versus O
placebo O
in O
women O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
receiving O
first O
- O
line O
chemotherapy O
. O
Eligible O
patients O
were O
randomly O
assigned O
to O
receive O
epoetin O
alfa O
40 O
, O
000 O
U O
once O
weekly O
or O
placebo B-control
for O
12 O
months O
. O
Study O
drug O
was O
initiated O
if O
baseline O
Hb O
was O
< O
or O
= O
13 O
g O
/ O
dL O
or O
when O
Hb O
decreased O
to O
< O
or O
= O
13 O
g O
/ O
dL O
during O
the O
study O
. O
The O
primary O
end O
point O
was O
12 B-outcome-measure
-month I-outcome-measure
overall I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
. O
The O
study O
drug O
administration O
was O
stopped O
early O
in O
accordance O
with O
a O
recommendation O
from O
the O
Independent O
Data O
Monitoring O
Committee O
because O
of O
higher O
mortality O
in O
the O
group O
treated O
with O
epoetin O
alfa O
. O
Enrollment O
had O
been O
completed O
, O
with O
939 B-total-participants
patients O
enrolled O
( O
epoetin O
alfa O
, O
n O
= O
469 B-intervention-participants
; O
placebo O
, O
n O
= O
470 B-control-participants
) O
. O
Most O
patients O
had O
Hb O
more O
than O
12 O
g O
/ O
dL O
at O
baseline O
( O
median O
Hb O
, O
12.8 O
g O
/ O
dL O
) O
or O
during O
the O
study O
. O
From O
the O
final O
analysis O
, O
12 B-outcome
-month I-outcome
OS I-outcome
was O
70 B-iv-bin-percent
% I-iv-bin-percent
for O
epoetin O
alfa O
recipients O
and O
76 B-cv-bin-percent
% I-cv-bin-percent
for O
placebo O
recipients O
( O
P O
= O
. O
01 O
) O
. O
Optimal B-outcome
tumor I-outcome
response I-outcome
and O
time B-outcome
to I-outcome
disease I-outcome
progression I-outcome
were O
similar O
between O
groups O
. O
The O
reason O
for O
the O
difference O
in O
mortality O
between O
groups O
could O
not O
be O
determined O
from O
additional O
subsequent O
analyses O
involving O
both O
study O
data O
and O
chart O
review O
. O
In O
this O
trial O
, O
the O
use O
of O
epoetin O
alfa O
to O
maintain O
high O
Hb O
targets O
in O
women O
with O
MBC O
, O
most O
of O
whom O
did O
not O
have O
anemia O
at O
the O
start O
of O
treatment O
, O
was O
associated O
with O
decreased O
survival O
. O
Additional O
research O
is O
required O
to O
clarify O
the O
potential O
impact O
of O
erythropoietic O
agents O
on O
survival O
when O
the O
Hb O
target O
range O
is O
10 O
to O
12 O
g O
/ O
dL O
. O

[ O
Comparison O
between O
intratumoral B-intervention
and O
peritumoral B-control
injection I-control
of I-control
radiotracer I-control
for O
locating O
and O
biopsying O
the O
sentinel O
lymph O
node O
in O
nonpalpable O
breast O
cancer O
] O
. O
To O
determine O
whether O
there O
are O
differences O
in O
the O
technical O
efficacy O
in O
detecting O
and O
biopsying O
the O
sentinel O
node O
after O
intratumoral O
or O
peritumoral O
administration O
of O
the O
radiotracer O
in O
patients O
with O
nonpalpable O
early O
- O
stage O
breast O
cancer O
. O
This O
prospective O
, O
randomized O
study O
included O
80 B-total-participants
patients B-eligibility
with I-eligibility
nonpalpable I-eligibility
breast I-eligibility
cancer I-eligibility
without I-eligibility
axillary I-eligibility
adenopathies I-eligibility
who I-eligibility
were I-eligibility
scheduled I-eligibility
for I-eligibility
primary I-eligibility
surgical I-eligibility
treatment I-eligibility
. O
Patients O
were O
randomized O
to O
one O
of O
two O
groups O
: O
the O
INTRA O
group O
( O
intratumoral O
radiotracer O
administration O
, O
n= O
35 B-intervention-participants
) O
or O
the O
PERI O
group O
( O
peritumoral O
radiotracer O
administration O
, O
n= O
45 B-control-participants
) O
. O
Patients O
with O
suspicious O
axillary O
lymph O
nodes O
at O
clinical O
or O
ultrasonographic O
examination O
that O
had O
positive O
results O
after O
fine O
- O
needle O
aspiration O
cytology O
were O
excluded O
. O
The O
rates B-outcome
of I-outcome
sentinel I-outcome
node I-outcome
detection I-outcome
were O
97.1 B-iv-bin-percent
% I-iv-bin-percent
( O
34 B-iv-bin-abs
/ O
35 B-intervention-participants
) O
for O
intratumoral O
injection O
and O
84.4 B-cv-bin-percent
% I-cv-bin-percent
( O
38 B-cv-bin-abs
/ O
45 B-control-participants
) O
for O
peritumoral O
injection O
. O
Radiotracer B-outcome
migration I-outcome
failure I-outcome
occurred O
in O
8 O
cases O
( O
one B-iv-bin-abs
in O
the O
INTRA O
group O
and O
7 B-cv-bin-abs
in O
the O
PERI O
group O
) O
. O
The O
sentinel B-outcome
node I-outcome
was I-outcome
detected I-outcome
in I-outcome
an I-outcome
extra I-outcome
- I-outcome
axillary I-outcome
location I-outcome
in O
21.9 O
% O
of O
cases O
( O
11 B-iv-bin-abs
/ O
59 B-intervention-participants
in O
the O
INTRA O
group O
and O
16 B-cv-bin-abs
/ O
64 B-control-participants
in O
the O
PERI O
group O
) O
. O
Our O
study O
found O
no O
statistically O
significant O
differences O
in O
the O
detection O
rates O
of O
axillary O
or O
extra O
- O
axillary O
sentinel O
lymph O
nodes O
between O
the O
two O
groups O
; O
however O
, O
we O
observed O
greater O
technical O
efficacy O
with O
intratumoral O
radiotracer O
administration O
. O

Differences O
between O
palpable B-intervention
and O
nonpalpable B-control
tumors I-control
in O
early B-eligibility
- I-eligibility
stage I-eligibility
, I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
. O
We O
compared O
characteristics O
and O
outcomes O
of O
palpable O
versus O
nonpalpable O
, O
hormone O
- O
sensitive O
, O
early O
- O
stage O
breast O
cancers O
. O
Patients O
from O
the O
North B-location
American I-location
Fareston O
vs. O
Tamoxifen O
Adjuvant O
( O
NAFTA O
) O
trial O
were O
divided O
into O
palpable O
( O
n O
  O
= O
  O
513 B-intervention-participants
) O
and O
nonpalpable O
( O
n O
  O
= O
  O
1063 B-control-participants
) O
tumor O
groups O
. O
Differences O
in O
pathological O
features O
, O
loco O
- O
regional O
therapy O
, O
disease O
- O
free O
survival O
( O
DFS O
) O
and O
overall O
survival O
( O
OS O
) O
were O
analyzed O
. O
Patients O
with O
palpable O
tumors O
were O
older O
, O
had O
larger O
tumors O
, O
and O
higher O
rates O
of O
lymph O
- O
node O
involvement O
. O
The O
tumors O
were O
more O
likely O
to O
be O
poorly O
differentiated O
, O
of O
high O
nuclear O
grade O
, O
and O
display O
lymphovascular O
invasion O
. O
After O
mean O
followup O
of O
59 O
months O
, O
DFS B-outcome
and O
OS B-outcome
were O
significantly O
lower O
for O
palpable O
than O
nonpalpable O
tumors O
( O
DFS B-outcome
93.5 B-iv-bin-percent
% I-iv-bin-percent
vs. O
98.4 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
  O
< O
  O
0.001 O
, O
OS B-outcome
88.5 B-iv-bin-percent
% I-iv-bin-percent
vs. O
95.6 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
  O
< O
  O
0.001 O
) O
. O
Controlling O
for O
age O
, O
size O
and O
nodal O
status O
, O
palpability O
was O
an O
independent O
factor O
for O
DFS O
( O
OR O
  O
= O
  O
2.56 O
; O
95 O
% O
CI O
, O
1.37 O
- O
4.79 O
, O
p O
  O
= O
  O
0.003 O
) O
and O
OS O
( O
OR O
  O
= O
  O
2.12 O
; O
95 O
% O
CI O
, O
1.38 O
- O
3.28 O
, O
p O
  O
< O
  O
0.001 O
) O
. O
In O
a O
group O
of O
hormone O
- O
sensitive O
, O
mostly O
postmenopausal O
early O
- O
stage O
breast O
cancer O
patients O
, O
palpable O
tumors O
were O
more O
likely O
to O
have O
more O
aggressive O
features O
and O
metastatic O
potential O
, O
which O
translated O
in O
to O
a O
higher O
incidence O
of O
breast O
cancer O
- O
related O
events O
and O
worse O
overall O
survival O
. O

Selecting O
the O
optimal O
position O
of O
CDK B-intervention
4 I-intervention
/ I-intervention
6 I-intervention
inhibitors I-intervention
in O
hormone O
receptor O
- O
positive O
advanced O
breast O
cancer O
- O
the O
SONIA O
study O
: O
study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O
Combining O
cyclin O
- O
dependent O
kinases O
4 O
and O
6 O
( O
CDK O
4 O
/ O
6 O
) O
inhibitors O
with O
endocrine O
therapy O
is O
an O
effective O
strategy O
to O
improve O
progression O
- O
free O
survival O
in O
hormone O
receptor O
- O
positive O
( O
HR+ O
) O
, O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER O
2 O
) O
-negative O
advanced O
breast O
cancer O
. O
There O
is O
a O
lack O
of O
comparative O
data O
to O
help O
clinicians O
decide O
if O
CDK O
4 O
/ O
6 O
inhibitors O
can O
best O
be O
added O
to O
first- O
or O
second O
- O
line O
endocrine O
therapy O
. O
Improvement O
in O
median O
progression O
- O
free O
survival O
in O
first O
- O
line O
studies O
is O
larger O
than O
in O
second O
- O
line O
studies O
, O
but O
CDK O
4 O
/ O
6 O
inhibitors O
have O
not O
consistently O
shown O
to O
improve O
overall O
survival O
or O
quality O
of O
life O
. O
They O
do O
come O
with O
added O
toxicity O
and O
costs O
, O
and O
many O
patients O
have O
lasting O
disease O
remission O
on O
endocrine O
therapy O
alone O
. O
No O
subgroup O
has O
been O
identified O
to O
select O
patients O
who O
are O
most O
likely O
to O
benefit O
from O
the O
addition O
of O
CDK O
4 O
/ O
6 O
inhibition O
in O
any O
line O
of O
treatment O
. O
Altogether O
, O
these O
factors O
make O
that O
the O
optimal O
strategy O
for O
using O
CDK O
4 O
/ O
6 O
inhibitors O
in O
clinical O
practice O
is O
unknown O
. O
The O
SONIA O
study O
is O
an O
investigator O
- O
initiated O
, O
multicenter O
, O
randomized O
phase O
III O
study O
in O
patients B-eligibility
with I-eligibility
HR+ I-eligibility
/ I-eligibility
HER I-eligibility
2 I-eligibility
- I-eligibility
negative I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Patients O
are O
randomly O
assigned O
to O
receive O
either O
strategy O
A O
( O
first O
- O
line O
treatment O
with O
a O
non O
- O
steroidal O
aromatase O
inhibitor O
combined O
with O
CDK O
4 O
/ O
6 O
inhibition O
, O
followed O
on O
progression O
by O
fulvestrant O
) O
or O
strategy B-control
B I-control
( O
first O
- O
line O
treatment O
with O
a O
non O
- O
steroidal O
aromatase O
inhibitor O
, O
followed O
on O
progression O
by O
fulvestrant O
combined O
with O
CDK O
4 O
/ O
6 O
inhibition O
) O
. O
The O
primary O
objective O
is O
to O
test O
whether O
strategy O
A O
is O
more O
effective O
than O
strategy O
B O
. O
The O
primary O
endpoint O
is O
time B-outcome-measure
from I-outcome-measure
randomization I-outcome-measure
to I-outcome-measure
second I-outcome-measure
objective I-outcome-measure
progression I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
2 I-outcome-measure
) I-outcome-measure
. O
Secondary O
endpoints O
include O
overall B-outcome-measure
survival I-outcome-measure
, O
safety B-outcome-measure
, O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
, O
and O
cost B-outcome-measure
- I-outcome-measure
effectiveness I-outcome-measure
. O
Five O
- O
hundred O
seventy O
- O
four O
events O
yield O
89 O
% O
power O
to O
show O
that O
strategy O
A O
has O
statistically O
significant O
, O
clinically O
meaningful O
superior O
PFS B-outcome
2 I-outcome
( O
according O
to O
ESMO O
- O
MCBS O
) O
in O
a O
log O
- O
rank O
test O
at O
the O
two O
- O
sided O
95 O
% O
confidence O
level O
. O
Given O
an O
accrual O
period O
of O
42 O
  O
months O
and O
an O
additional O
18 O
  O
months O
follow O
- O
up O
, O
inclusion O
of O
1050 O
evaluable O
patients O
is O
required O
. O
This O
study O
design O
represents O
daily O
clinical O
practice O
, O
and O
the O
results O
will O
aid O
clinicians O
in O
deciding O
when O
adding O
CDK O
4 O
/ O
6 O
inhibitors O
to O
endocrine O
therapy O
will O
benefit O
their O
patients O
most O
. O
Additional O
biomarker O
analyses O
may O
help O
to O
optimize O
patient O
selection O
. O
http: O
/ O
/ O
clinicaltrials O
. O
gov O
: O
NCT O
03425838 O
( O
8 O
February O
2018 O
) O
. O
EudraCT O
- O
number O
: O
2017 O
- O
002334 O
- O
23 O
( O
29 O
September O
2017 O
) O
. O

Rivaroxaban B-intervention
compared O
to O
no B-control
treatment I-control
in O
ER O
- O
negative O
stage O
I O
- O
III O
early O
breast O
cancer O
patients O
( O
the O
TIP O
Trial O
) O
: O
study O
protocol O
for O
a O
phase O
II O
preoperative O
window O
- O
of O
- O
opportunity O
study O
design O
randomised O
controlled O
trial O
. O
Breast O
cancer O
patients O
are O
at O
a O
four O
- O
fold O
increased O
risk O
of O
developing O
a O
venous O
thromboembolism O
( O
VTE O
) O
, O
a O
major O
cause O
of O
death O
in O
this O
group O
. O
Conversely O
, O
coagulation O
factors O
promote O
tumour O
growth O
and O
metastasis O
. O
This O
has O
been O
evidenced O
in O
preclinical O
models O
, O
with O
an O
inhibitory O
effect O
of O
anticoagulants O
on O
cancer O
growth O
through O
proliferative O
, O
angiogenic O
, O
apoptotic O
, O
cancer O
stem O
cell O
and O
metastatic O
processes O
. O
The O
extrinsic O
clotting O
pathway O
is O
also O
more O
upregulated O
in O
patients O
in O
the O
relatively O
poorer O
prognosis O
oestrogen O
receptor O
( O
ER O
) O
-negative O
breast O
cancer O
subgroup O
, O
with O
increased O
tumour O
stromal O
expression O
of O
the O
coagulation O
factors O
Tissue O
Factor O
and O
thrombin O
. O
Rivaroxaban O
( O
Xarelto O
® O
, O
Bayer O
AG O
, O
Leverkusen O
, O
Germany O
) O
is O
a O
direct O
oral O
anticoagulant O
( O
DOAC O
) O
. O
It O
is O
a O
Factor O
Xa O
inhibitor O
that O
is O
routinely O
prescribed O
for O
the O
prevention O
of O
stroke O
in O
non O
- O
valvular O
atrial O
fibrillation O
and O
for O
both O
VTE O
prophylaxis O
and O
treatment O
. O
This O
trial O
will O
assess O
the O
anti O
- O
proliferative O
and O
other O
anti O
- O
cancer O
progression O
mechanisms O
of O
Rivaroxaban O
in O
ER O
- O
negative O
early O
breast O
cancer O
patients O
. O
This O
UK B-location
- O
based O
preoperative O
window O
- O
of O
- O
opportunity O
phase O
II O
randomised O
control O
trial O
will O
randomise O
88 B-total-participants
treatment B-eligibility
- I-eligibility
naïve I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
to O
receive O
20 O
  O
mg O
OD O
Rivaroxaban O
treatment O
for O
11 O
to O
17 O
  O
days O
or O
no O
treatment O
. O
Treatment O
will O
be O
stopped O
24 O
  O
h O
( O
range O
18 O
- O
36 O
  O
h O
) O
prior O
to O
surgery O
or O
repeat O
core O
biopsy O
. O
All O
patients O
will O
be O
followed O
up O
for O
2 O
  O
weeks O
following O
surgery O
or O
repeat O
core O
biopsy O
. O
The O
primary O
endpoint O
is O
change B-outcome-measure
in I-outcome-measure
tumour I-outcome-measure
Ki I-outcome-measure
67 I-outcome-measure
. O
Secondary O
outcome O
measures O
include O
tumour B-outcome-measure
markers I-outcome-measure
of I-outcome-measure
apoptosis I-outcome-measure
and I-outcome-measure
angiogenesis I-outcome-measure
, I-outcome-measure
extrinsic I-outcome-measure
clotting I-outcome-measure
pathway I-outcome-measure
activation I-outcome-measure
and I-outcome-measure
systemic I-outcome-measure
markers I-outcome-measure
of I-outcome-measure
metastasis I-outcome-measure
, I-outcome-measure
tumour I-outcome-measure
load I-outcome-measure
and I-outcome-measure
coagulation I-outcome-measure
. O
Laboratory O
evidence O
supports O
an O
anti O
- O
cancer O
role O
for O
anticoagulants O
; O
however O
, O
this O
has O
failed O
to O
translate O
into O
survival B-outcome
benefit I-outcome
when O
trialled O
in O
patients O
with O
metastatic O
disease O
or O
poor O
prognosis O
cancers O
, O
such O
as O
lung O
cancer O
. O
Subgroup O
analysis O
supported O
a O
potential B-outcome
survival I-outcome
benefit I-outcome
in O
better O
prognosis O
advanced O
disease O
patients O
. O
This O
is O
the O
first O
study O
to O
investigate O
the O
anti O
- O
cancer O
effects O
of O
anticoagulants O
in O
early O
breast O
cancer O
. O
UK O
National O
Research O
Ethics O
Service O
( O
NRES O
) O
approval O
15 O
/NW O
/ O
0406 O
, O
MHRA O
Clinical O
Trials O
Authorisation O
48380 O
/ O
0003 O
/ O
001 O
- O
0001 O
. O
The O
sponsor O
is O
Manchester O
University O
NHS O
Foundation O
Trust O
, O
and O
the O
trial O
is O
co O
- O
ordinated O
by O
Cancer O
Research O
UK O
Liverpool O
Cancer O
Trials O
Unit O
( O
LCTU O
) O
. O
EudraCT O
2014 O
- O
004909 O
- O
33 O
, O
registered O
27 O
July O
2015 O
. O
ISRCTN O
14785273 O
. O

An O
open O
- O
label O
, O
randomized O
, O
multicenter O
dose O
- O
finding O
study O
of O
once O
- O
per O
- O
cycle O
pegfilgrastim B-intervention
versus O
daily O
filgrastim B-control
in O
Chinese B-ethinicity
breast B-eligibility
cancer I-eligibility
patients I-eligibility
receiving I-eligibility
TAC I-eligibility
chemotherapy I-eligibility
. O
A O
chemotherapy O
regimen O
of O
docetaxel O
, O
doxorubicin O
and O
cyclophosphamide O
( O
TAC O
) O
has O
been O
accepted O
as O
a O
standard O
care O
because O
of O
their O
superior O
clinical O
benefit O
in O
early O
- O
stage O
breast O
cancer O
patients O
, O
but O
with O
a O
higher O
risk O
of O
neutropenia O
. O
Pegfilgrastim O
is O
a O
once O
- O
per O
- O
cycle O
therapy O
for O
prophylactic O
neutrophil O
support O
and O
neutropenia O
prevention O
. O
There O
was O
still O
a O
lack O
of O
direct O
evidences O
for O
finding O
an O
optimal O
fixed O
dose O
of O
pegfilgrastim O
in O
Chinese O
breast O
cancer O
patients O
receiving O
TAC O
regimen O
. O
An O
open O
- O
label O
, O
randomized O
, O
phase O
II O
study O
was O
designed O
to O
compare O
the O
effects O
of O
pegfilgrastim O
with O
filgrastim O
. O
Eighteen O
centers O
in O
China B-location
enrolled O
171 B-total-participants
eligible O
female O
breast O
cancer O
patients O
with O
cycles O
of O
TAC O
chemotherapy O
treatment O
, O
randomized O
into O
four O
arms O
, O
received O
a O
single O
subcutaneous O
injection O
of O
pegfilgrastim O
( O
60 O
, O
100 O
or O
120 O
µg O
/ O
kg O
) O
per O
chemotherapy O
cycle O
or O
daily O
subcutaneous O
injections O
of O
filgrastim O
5 O
µg O
/ O
kg O
24 O
h O
after O
chemotherapy O
. O
Efficacy O
and O
safety O
were O
analyzed O
. O
In O
ITT O
population O
, O
the O
mean B-outcome
duration I-outcome
of I-outcome
grade I-outcome
3 I-outcome
+ I-outcome
neutropenia I-outcome
( O
neutrophil O
count O
< O
1.0 O
× O
10 O
( O
9 O
) O
/l O
) O
was O
2.09 B-iv-cont-mean
, O
1.53 B-iv-cont-mean
and O
1.73 B-iv-cont-mean
days I-iv-cont-mean
in O
patients O
who O
received O
pegfilgrastim O
60 O
, O
100 O
and O
120 O
µg O
/ O
kg O
/ O
cycle O
, O
respectively O
, O
and O
1.69 B-cv-cont-mean
days I-cv-cont-mean
in O
patients O
who O
received O
5 O
µg O
/ O
kg O
/ O
day O
filgrastim O
( O
P O
= O
0.043 O
) O
. O
The O
incidence B-outcome
of I-outcome
grade I-outcome
3 I-outcome
+ I-outcome
neutropenia I-outcome
was O
76 B-iv-bin-percent
, O
83 B-iv-bin-percent
and O
74 B-iv-bin-percent
% I-iv-bin-percent
for O
doses O
of O
pegfilgrastim O
and O
90 B-iv-bin-percent
% I-iv-bin-percent
for O
filgrastim O
( O
P O
= O
0.409 O
) O
. O
The O
results O
for O
febrile B-outcome
neutropenia I-outcome
, O
time B-outcome
to I-outcome
neutrophil I-outcome
recovery I-outcome
and O
neutrophil B-outcome
profile I-outcome
were O
also O
not O
significantly O
different O
between O
arms O
. O
The O
safety B-outcome
profiles I-outcome
of O
pegfilgrastim O
and O
filgrastim O
were O
similar O
. O
A O
single O
dose O
of O
100 O
µg O
/ O
kg O
once O
- O
per O
- O
cycle O
administration O
of O
pegfilgrastim O
provided O
neutrophil O
support O
and O
a O
safety O
profile O
comparable O
to O
daily O
subcutaneous O
injections O
of O
filgrastim O
in O
Chinese O
breast O
cancer O
patients O
receiving O
TAC O
chemotherapy O
. O

Randomized O
sham O
- O
controlled O
pilot O
trial O
of O
weekly O
electro B-intervention
- I-intervention
acupuncture I-intervention
for O
the O
prevention O
of O
taxane B-condition
- I-condition
induced I-condition
peripheral I-condition
neuropathy I-condition
in O
women O
with O
early O
stage O
breast O
cancer O
. O
To O
investigate O
the O
effect O
of O
electro O
- O
acupuncture O
( O
EA O
) O
as O
a O
non O
- O
pharmacological O
intervention O
to O
prevent O
or O
reduce O
chemotherapy O
- O
induced O
peripheral O
neuropathy O
( O
CIPN O
) O
in O
breast O
cancer O
patients O
undergoing O
chemotherapy O
of O
taxane O
. O
Women B-eligibility
with I-eligibility
stage I-eligibility
I I-eligibility
- I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
scheduled I-eligibility
to I-eligibility
receive I-eligibility
taxane I-eligibility
therapy I-eligibility
were O
randomized O
to O
receive O
a O
standardized B-control
protocol I-control
of I-control
12 I-control
true I-control
or O
sham O
EA O
( O
SEA O
) O
weekly O
treatments O
concurrent O
with O
taxane O
treatment O
. O
Subjects O
completed O
the O
Brief O
Pain O
Inventory O
- O
Short O
Form O
( O
BPI O
- O
SF O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Taxane O
neurotoxicity O
subscale O
( O
FACT O
- O
NTX O
) O
, O
and O
other O
assessments O
at O
baseline O
and O
weeks O
6 O
, O
12 O
, O
and O
16 O
. O
A O
total O
of O
180 B-total-participants
subjects O
were O
screened O
, O
63 B-total-participants
enrolled O
and O
48 B-total-participants
completed O
week O
16 O
assessments O
. O
Mean B-age
age I-age
was I-age
50 I-age
with O
25 O
% O
white B-ethinicity
, O
25 O
% O
black B-ethinicity
, O
and O
43 O
% O
Hispanic B-ethinicity
; O
52 O
% O
had O
no O
prior O
chemotherapy O
. O
At B-outcome
week I-outcome
12 I-outcome
, O
both O
groups O
reported O
an O
increase O
in O
mean B-outcome
BPI I-outcome
- I-outcome
SF I-outcome
worst I-outcome
pain I-outcome
score I-outcome
, O
but O
no O
mean O
differences O
were O
found O
between O
groups O
( O
SEA O
2.8 B-iv-cont-mean
vs. O
EA O
2.6 B-cv-cont-mean
, O
P O
= O
. O
86 O
) O
. O
By O
week B-outcome
16 I-outcome
, O
the O
SEA O
group O
returned O
to O
baseline O
, O
while O
the O
EA O
group O
continued O
to O
worsen O
( O
SEA O
1.7 B-iv-cont-mean
vs. O
EA O
3.4 B-cv-cont-mean
, O
P O
= O
. O
03 O
) O
. O
The O
increase O
in O
BPI B-outcome
- I-outcome
SF I-outcome
worst I-outcome
pain I-outcome
score I-outcome
was O
1.62 O
points O
higher O
in O
the O
EA O
group O
than O
in O
the O
SEA O
group O
at O
week O
16 O
( O
P O
= O
. O
04 O
) O
. O
In O
a O
randomized O
, O
sham O
- O
controlled O
trial O
of O
EA O
for O
prevention O
of O
taxane O
- O
induced O
CIPN O
, O
there O
were O
no O
differences O
in O
pain B-outcome
or I-outcome
neuropathy I-outcome
between O
groups O
at O
week O
12 O
. O
Of O
concern O
, O
subjects O
on O
EA O
had O
a O
slower O
recovery O
than O
SEA O
subjects O
. O
Future O
studies O
should O
focus O
on O
EA O
for O
treatment O
as O
opposed O
to O
prevention O
of O
CIPN O
. O

Prescribing O
tamoxifen O
in O
primary O
care O
for O
the O
prevention O
of O
breast O
cancer O
: O
a O
national O
online O
survey O
of O
GPs B-intervention
' I-intervention
attitudes I-intervention
. O
The O
cancer O
strategy O
for O
England O
( O
2015 O
- O
2020 O
) O
recommends O
GPs O
prescribe O
tamoxifen O
for O
breast O
cancer O
primary O
prevention O
among O
women B-eligibility
at I-eligibility
increased I-eligibility
risk I-eligibility
. O
To O
investigate O
GPs O
' O
attitudes O
towards O
prescribing O
tamoxifen O
. O
In O
an O
online O
survey O
, O
GPs O
in O
England B-location
, O
Northern B-location
Ireland I-location
, O
and O
Wales B-location
( O
n O
= O
928 B-total-participants
) O
were O
randomised O
using O
a O
2 O
× O
2 O
between O
- O
subjects O
design O
to O
read O
one O
of O
four O
vignettes O
describing O
a O
healthy O
patient O
seeking O
a O
tamoxifen O
prescription O
. O
In O
the O
vignette O
, O
the O
hypothetical O
patient O
's O
breast O
cancer O
risk O
( O
moderate O
versus O
high O
) O
and O
the O
clinician O
initiating O
the O
prescription O
( O
GP O
prescriber O
versus O
secondary B-control
care I-control
clinician I-control
[ I-control
SCC I-control
] I-control
prescriber I-control
) O
were O
manipulated O
in O
a O
1 O
:1 O
:1 O
:1 O
ratio O
. O
Outcomes O
were O
willingness O
to O
prescribe O
, O
comfort O
discussing O
harms O
and O
benefits O
, O
comfort O
managing O
the O
patient O
, O
factors O
affecting O
the O
prescribing O
decision O
, O
and O
awareness O
of O
tamoxifen O
and O
the O
National O
Institute O
for O
Health O
and O
Care O
Excellence O
( O
NICE O
) O
guideline O
CG O
164 O
. O
Half O
( O
51.7 B-iv-bin-percent
% I-iv-bin-percent
) O
of O
the O
GPs O
knew B-outcome
tamoxifen I-outcome
can I-outcome
reduce I-outcome
breast I-outcome
cancer I-outcome
risk I-outcome
, O
and O
one O
- O
quarter O
( O
24.1 B-cv-bin-percent
% I-cv-bin-percent
) O
were O
aware B-outcome
of I-outcome
NICE I-outcome
guideline I-outcome
CG I-outcome
164 I-outcome
. O
Responders O
asked O
to O
initiate O
prescribing O
( O
GP O
prescriber O
) O
were O
less O
willing B-outcome
to I-outcome
prescribe I-outcome
tamoxifen I-outcome
than O
those O
continuing O
a O
prescription O
initiated O
in O
secondary O
care O
( O
SCC O
prescriber O
) O
( O
68.9 B-iv-bin-percent
% I-iv-bin-percent
versus O
84.6 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
< O
0.001 O
) O
. O
The O
GP O
prescribers O
reported O
less B-outcome
comfort I-outcome
discussing I-outcome
tamoxifen I-outcome
( O
53.4 B-iv-bin-percent
% I-iv-bin-percent
versus O
62.5 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
0.01 O
) O
. O
GPs O
willing O
to O
prescribe O
were O
more O
likely O
to O
be O
aware O
of O
the O
NICE O
guideline O
( O
P O
= O
0.039 O
) O
and O
to O
have O
acknowledged O
the O
benefits O
of O
tamoxifen O
( O
P O
< O
0.001 O
) O
, O
and O
were O
less O
likely O
to O
have O
considered O
its O
off O
- O
licence O
status O
( O
P O
< O
0.001 O
) O
. O
Initiating O
tamoxifen O
prescriptions O
for O
preventive O
therapy O
in O
secondary O
care O
before O
asking O
GPs O
to O
continue O
the O
patient O
's O
care O
may O
overcome O
some O
prescribing O
barriers O
. O

Chemotherapy B-intervention
( I-intervention
CT I-intervention
) I-intervention
and O
hormonotherapy B-control
( I-control
HT I-control
) I-control
as O
neoadjuvant O
treatment O
in O
luminal B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
: O
results O
from O
the O
GEICAM O
/ O
2006 O
- O
03 O
, O
a O
multicenter O
, O
randomized O
, O
phase O
- O
II O
study O
. O
Luminal O
breast O
cancer O
is O
a O
highly O
endocrine O
responsive O
disease O
. O
However O
, O
the O
therapeutic O
benefit O
of O
chemotherapy O
( O
CT O
) O
in O
this O
population O
is O
not O
fully O
characterized O
. O
This O
study O
investigates O
the O
value O
of O
CT O
and O
hormone O
therapy O
( O
HT O
) O
in O
luminal O
breast O
cancer O
patients O
in O
the O
neoadjuvant O
setting O
. O
Patients O
with O
operable O
breast O
cancer O
and O
immunophenotypically O
defined O
luminal O
disease O
( O
ER+ O
/ O
PR+ O
/ O
HER O
2 O
- O
/ O
cytokeratin O
8 O
/ O
18 O
+ O
) O
were O
recruited O
. O
Patients O
were O
randomized O
to O
CT O
( O
epirubicin O
90 O
mg O
/ O
m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg O
/ O
m O
( O
2 O
) O
4 O
cycles O
followed O
by O
docetaxel O
100 O
mg O
/ O
m O
( O
2 O
) O
4 O
cycles O
[ O
EC O
- O
T O
] O
) O
or O
HT O
( O
exemestane O
25 O
mg O
daily O
24 O
weeks O
[ O
combined O
with O
goserelin O
in O
premenopausal O
patients O
] O
) O
. O
The O
primary O
end O
point O
was O
the O
clinical B-outcome-measure
response I-outcome-measure
measured O
by O
magnetic O
resonance O
imaging O
. O
Ninety B-total-participants
- I-total-participants
five I-total-participants
patients O
were O
randomized O
( O
47 B-intervention-participants
CT O
, O
48 B-control-participants
HT O
) O
. O
The O
clinical B-outcome
response I-outcome
rate I-outcome
was O
66 B-iv-bin-percent
% I-iv-bin-percent
for O
CT O
and O
48 B-cv-bin-percent
% I-cv-bin-percent
for O
HT O
( O
P O
= O
0.075 O
) O
. O
We O
performed O
an O
unplanned O
analysis O
based O
on O
Ki O
67 O
levels O
( O
cut O
- O
off O
of O
10 O
% O
) O
. O
Similar O
clinical B-outcome
response I-outcome
was O
seen O
between O
arms O
in O
patients B-outcome
with I-outcome
low I-outcome
Ki I-outcome
67 I-outcome
( O
CT O
: O
63 B-iv-bin-percent
% I-iv-bin-percent
, O
HT O
: O
58 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.74 O
) O
; O
patients B-outcome
with I-outcome
high I-outcome
Ki I-outcome
67 I-outcome
had O
a O
better O
response O
with O
CT O
( O
67 B-iv-bin-percent
versus O
42 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.075 O
) O
. O
Grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
toxicity I-outcome
was O
more O
frequent O
with O
CT O
. O
Luminal O
immunophenotype O
is O
not O
enough O
to O
identify O
patients O
who O
do O
not O
benefit O
from O
neoadjuvant O
CT O
. O
Luminal O
patients O
with O
low O
proliferation O
index O
could O
potentially O
avoid O
CT O
. O

Anthracycline B-intervention
could O
be O
essential O
for O
triple O
- O
negative O
breast O
cancer O
: O
A O
randomised O
phase O
II O
study O
by O
the O
Kanagawa B-location
Breast O
Oncology O
Group O
( O
KBOG O
) O
1101 O
. O
It O
is O
important O
to O
determine O
whether O
anthracycline O
- O
containing O
regimens O
or O
taxane O
- O
containing O
regimens O
are O
more O
effective O
in O
individual O
patients O
. O
The O
present O
study O
compared O
the O
efficacy O
of O
six O
cycles O
of O
docetaxel O
and O
cyclophosphamide O
( O
TC O
6 O
) O
with O
that O
of O
three O
cycles O
of O
5 O
-fluorouracil O
, O
epirubicin O
and O
cyclophosphamide O
followed O
by O
docetaxel O
( O
FEC O
- O
D O
) O
in O
Japanese B-ethinicity
patients O
with O
hormone O
receptor O
( O
HR O
) O
-negative O
breast O
cancer O
( O
BC O
) O
to O
identify O
subtypes O
requiring O
anthracycline O
treatment O
. O
The O
study O
included O
103 B-total-participants
patients O
with O
operable O
HR O
- O
negative O
BC O
. O
Of O
these O
patients O
53 B-intervention-participants
received O
FEC O
- O
D O
and O
50 B-control-participants
received O
TC B-control
6 I-control
. I-control
The O
primary O
endpoint O
was O
pathological B-outcome-measure
complete I-outcome-measure
response I-outcome-measure
( I-outcome-measure
pCR I-outcome-measure
) I-outcome-measure
. O
The O
secondary O
endpoints O
were O
safety B-outcome-measure
, O
breast B-outcome-measure
- I-outcome-measure
conserving I-outcome-measure
surgery I-outcome-measure
, O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
DFS I-outcome-measure
) I-outcome-measure
and O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
. O
The O
predictive O
factors O
for O
each O
regimen O
were O
evaluated O
. O
Of O
the O
103 B-total-participants
patients O
, O
97 B-total-participants
completed O
the O
study O
( O
FEC O
- O
D O
, O
50 B-intervention-participants
patients O
; O
TC O
6 O
, O
47 B-control-participants
patients O
) O
. O
The O
pCR B-outcome
rate I-outcome
was O
higher O
with O
FEC O
- O
D O
( O
36 B-iv-bin-percent
% I-iv-bin-percent
) O
than O
with O
TC O
6 O
( O
25.5 B-cv-bin-percent
% I-cv-bin-percent
) O
; O
however O
, O
the O
difference O
was O
not O
significant O
( O
P O
  O
= O
  O
0.265 O
) O
. O
TC O
6 O
was O
safer B-outcome
than O
FEC O
- O
D O
, O
as O
the O
adverse O
events O
with O
docetaxel O
in O
the O
FEC O
- O
D O
regimen O
were O
similar O
to O
those O
with O
the O
TC O
6 O
regimen O
. O
Among B-outcome
patients I-outcome
with I-outcome
basal I-outcome
BC I-outcome
, O
the O
pCR B-outcome
rate I-outcome
was O
significantly O
higher O
with O
FEC O
- O
D O
( O
42.9 B-iv-bin-percent
% I-iv-bin-percent
) O
than O
with O
TC O
6 O
( O
13.6 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
  O
= O
  O
0.033 O
) O
. O
Among B-outcome
patients I-outcome
with I-outcome
triple I-outcome
- I-outcome
negative I-outcome
breast I-outcome
cancer I-outcome
( I-outcome
TNBC I-outcome
) I-outcome
, O
the O
DFS B-outcome
and O
OS B-outcome
were O
significantly O
better O
with O
FEC O
- O
D O
than O
with O
TC O
6 O
( O
P O
  O
= O
  O
0.016 O
and O
P O
  O
= O
  O
0.034 O
, O
respectively O
) O
. O
TC O
6 O
was O
not O
as O
effective O
as O
FEC O
- O
D O
for O
treating O
HR O
- O
negative O
BC O
, O
as O
TC O
6 O
was O
not O
sufficient O
to O
treat O
TNBC O
, O
particularly O
the O
basal O
subtype O
. O
Our O
findings O
suggest O
that O
anthracyclines O
are O
better O
treatment O
options O
than O
taxanes O
for O
basal O
BC O
. O

Randomised O
controlled O
trial O
comparing O
hypnotherapy B-intervention
versus O
gabapentin B-control
for O
the O
treatment O
of O
hot B-condition
flashes I-condition
in O
breast O
cancer O
survivors O
: O
a O
pilot O
study O
. O
To O
compare O
the O
efficacy O
of O
hypnotherapy O
versus O
gabapentin O
for O
the O
treatment O
of O
hot O
flashes O
in O
breast O
cancer O
survivors O
, O
and O
to O
evaluate O
the O
feasibility O
of O
conducting O
a O
clinical O
trial O
comparing O
a O
drug O
with O
a O
complementary O
or O
alternative O
method O
( O
CAM O
) O
. O
Prospective O
randomised O
trial O
. O
Breast O
health O
centre O
of O
a O
tertiary O
care O
centre O
. O
15 B-total-participants
women B-eligibility
with I-eligibility
a I-eligibility
personal I-eligibility
history I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
or I-eligibility
an I-eligibility
increased I-eligibility
risk I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
reported I-eligibility
at I-eligibility
least I-eligibility
one I-eligibility
daily I-eligibility
hot I-eligibility
flash I-eligibility
. O
Gabapentin O
900 O
mg O
daily O
in O
three O
divided O
doses O
( O
control O
) O
compared O
with O
standardised O
hypnotherapy O
. O
Participation O
lasted O
8 O
weeks O
. O
The O
primary O
endpoints O
were O
the O
number B-outcome-measure
of I-outcome-measure
daily I-outcome-measure
hot I-outcome-measure
flashes I-outcome-measure
and O
hot B-outcome-measure
flash I-outcome-measure
severity I-outcome-measure
score I-outcome-measure
( I-outcome-measure
HFSS I-outcome-measure
) I-outcome-measure
. O
The O
secondary O
endpoint O
was O
the O
Hot B-outcome-measure
Flash I-outcome-measure
Related I-outcome-measure
Daily I-outcome-measure
Interference I-outcome-measure
Scale I-outcome-measure
( I-outcome-measure
HFRDIS I-outcome-measure
) I-outcome-measure
. O
27 B-total-participants
women O
were O
randomised O
and O
15 B-total-participants
( O
56 O
% O
) O
were O
considered O
evaluable O
for O
the O
primary O
endpoint O
( O
n= O
8 B-control-participants
gabapentin O
, O
n= O
7 B-intervention-participants
hypnotherapy O
) O
. O
The O
median B-outcome
number I-outcome
of I-outcome
daily I-outcome
hot I-outcome
flashes I-outcome
at I-outcome
enrolment I-outcome
was O
4.5 B-cv-cont-median
in O
the O
gabapentin O
arm O
and O
5 B-iv-cont-median
in O
the O
hypnotherapy O
arm O
. O
HFSS B-outcome
scores I-outcome
were O
7.5 B-cv-cont-median
in O
the O
gabapentin O
arm O
and O
10 B-iv-cont-median
in O
the O
hypnotherapy O
arm O
. O
After B-outcome
8 I-outcome
weeks I-outcome
, O
the O
median B-outcome
number I-outcome
of I-outcome
daily I-outcome
hot I-outcome
flashes I-outcome
was O
reduced O
by O
33.3 B-cv-cont-median
% I-cv-cont-median
in O
the O
gabapentin O
arm O
and O
by O
80 B-iv-cont-median
% I-iv-cont-median
in O
the O
hypnotherapy O
arm O
. O
The O
median B-outcome
HFSS I-outcome
was O
reduced O
by O
33.3 B-cv-cont-median
% I-cv-cont-median
in O
the O
gabapentin O
arm O
and O
by O
85 B-iv-cont-median
% I-iv-cont-median
in O
the O
hypnotherapy O
arm O
. O
HFRDIS B-outcome
scores I-outcome
improved I-outcome
by O
51.6 B-cv-cont-mean
% I-cv-cont-mean
in O
the O
gabapentin O
group O
and O
by O
55.2 B-iv-cont-median
% I-iv-cont-median
in O
the O
hypnotherapy O
group O
. O
There O
were O
no O
statistically O
significant O
differences O
between O
groups O
. O
Hypnotherapy O
and O
gabapentin O
demonstrate O
efficacy O
in O
improving O
hot O
flashes O
. O
A O
definitive O
trial O
evaluating O
traditional O
interventions O
against O
CAM O
methods O
is O
feasible O
, O
but O
not O
without O
challenges O
. O
Further O
studies O
aimed O
at O
defining O
evidence O
- O
based O
recommendations O
for O
CAM O
are O
necessary O
. O
clinicaltrials O
. O
gov O
( O
NCT O
00711529 O
) O
. O

EduCan O
trial O
: O
study O
protocol O
for O
a O
randomised O
controlled O
trial O
on O
the O
effectiveness O
of O
pain B-intervention
neuroscience I-intervention
education I-intervention
after O
breast O
cancer O
surgery O
on O
pain B-condition
, I-condition
physical I-condition
, I-condition
emotional I-condition
and I-condition
work I-condition
- I-condition
related I-condition
functioning I-condition
. O
Over O
the O
past O
decades O
, O
awareness O
on O
the O
importance O
of O
educational O
interventions O
in O
cancer O
pain O
management O
has O
increased O
. O
However O
, O
education O
is O
often O
restricted O
to O
biomedical O
pain O
management O
instructions O
. O
A O
more O
modern O
educational O
approach O
, O
also O
known O
as O
pain O
neuroscience O
education O
( O
PNE O
) O
, O
explains O
pain O
from O
a O
biopsychosocial O
perspective O
. O
We O
hypothesise O
that O
this O
more O
comprehensive O
educational O
approach O
in O
the O
early O
treatment O
phase O
of O
breast O
cancer O
will O
lead O
to O
more O
beneficial O
effects O
for O
cancer O
pain O
management O
. O
Therefore O
, O
the O
aim O
of O
the O
present O
study O
is O
to O
investigate O
the O
effectiveness O
of O
this O
PNE O
intervention O
, O
in O
addition O
to O
best O
evidence O
physical O
therapy O
modalities O
for O
treatment O
and O
prevention O
of O
pain O
, O
physical O
, O
emotional O
and O
work O
- O
related O
functioning O
after O
breast O
cancer O
surgery O
, O
compared O
with O
a O
traditional B-control
biomedical I-control
educational I-control
intervention I-control
. O
A O
double O
- O
blinded O
randomised O
controlled O
trial O
has O
been O
started O
in O
November O
2017 O
at O
the O
University O
Hospitals O
of O
Leuven B-location
. O
Immediately O
after O
breast O
cancer O
surgery O
, O
all O
participants O
( O
n= O
184 B-total-participants
) O
receive O
a O
12 O
-week O
intensive O
standard O
physical O
therapy O
programme O
. O
They O
receive O
three O
additional O
refresher O
sessions O
at O
6 O
, O
8 O
and O
12 O
months O
postsurgery O
. O
In O
addition O
, O
participants O
receive O
three O
educational O
sessions O
during O
the O
first O
- O
month O
postsurgery O
and O
three O
' O
booster O
sessions O
' O
at O
6 O
, O
8 O
and O
12 O
months O
postsurgery O
. O
In O
the O
intervention O
group O
, O
the O
content O
of O
the O
education O
sessions O
is O
based O
on O
the O
modern O
PNE O
approach O
. O
Whereas O
in O
the O
control O
group O
, O
the O
education O
is O
based O
on O
the O
traditional O
biomedical O
approach O
. O
The O
primary O
outcome O
parameter O
is O
pain B-outcome-measure
- I-outcome-measure
related I-outcome-measure
disability I-outcome-measure
1 I-outcome-measure
  I-outcome-measure
year I-outcome-measure
after I-outcome-measure
surgery I-outcome-measure
. O
Secondary O
outcomes O
related O
to O
other B-outcome-measure
dimensions I-outcome-measure
of I-outcome-measure
pain I-outcome-measure
, O
physical B-outcome-measure
, I-outcome-measure
emotional I-outcome-measure
and I-outcome-measure
work I-outcome-measure
- I-outcome-measure
related I-outcome-measure
functioning I-outcome-measure
at O
1 O
-week O
, O
4 O
, O
6 O
, O
8 O
, O
12 O
and O
18 O
months O
postsurgery O
. O
The O
study O
will O
be O
conducted O
in O
accordance O
with O
the O
Declaration O
of O
Helsinki O
. O
This O
protocol O
has O
been O
approved O
by O
the O
ethical O
committee O
of O
the O
University O
Hospitals O
of O
Leuven O
. O
Results O
will O
be O
disseminated O
via O
peer O
- O
reviewed O
scientific O
journals O
and O
presentations O
at O
congresses O
. O
NCT O
03351075 O
. O

Prospective O
randomized O
trial O
of O
paravertebral B-intervention
block I-intervention
for O
patients O
undergoing O
breast O
cancer O
surgery O
. O
The O
goal O
of O
the O
current O
study O
was O
to O
evaluate O
the O
effect O
of O
regional O
anesthesia O
using O
paravertebral O
block O
( O
PVB O
) O
on O
postoperative O
pain O
after O
breast O
surgery O
. O
Patients B-eligibility
undergoing I-eligibility
unilateral I-eligibility
breast I-eligibility
surgery I-eligibility
without I-eligibility
reconstruction I-eligibility
were O
randomized O
to O
general B-control
anesthesia I-control
( I-control
GA I-control
) I-control
only I-control
or O
PVB O
with O
GA O
and O
pain O
scores O
assessed O
. O
Eighty B-total-participants
patients O
were O
randomized O
( O
41 B-intervention-participants
to O
GA O
and O
39 B-control-participants
to O
PVB O
with O
GA O
) O
. O
Operative O
times O
were O
not O
significantly O
different O
between O
groups O
. O
Pain B-outcome
scores I-outcome
were O
lower O
after O
PVB O
compared O
to O
GA O
at B-outcome
1 I-outcome
hour I-outcome
( O
1 B-iv-cont-mean
vs O
3 B-cv-cont-mean
, O
P O
= O
. O
006 O
) O
and O
3 B-outcome
hours I-outcome
( O
0 B-iv-cont-mean
vs O
2 B-cv-cont-mean
, O
P O
= O
. O
001 O
) O
but O
not O
at O
later O
time O
points O
. O
The O
overall B-outcome
worst I-outcome
pain I-outcome
experienced I-outcome
was O
lower O
with O
PVB O
( O
3 B-iv-cont-mean
vs O
5 B-cv-cont-mean
, O
P O
= O
. O
02 O
) O
. O
More O
patients O
were O
pain B-outcome
- I-outcome
free I-outcome
in O
the O
PVB O
group O
at B-outcome
1 I-outcome
hour I-outcome
( O
44 B-iv-bin-percent
% I-iv-bin-percent
vs O
17 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
. O
014 O
) O
and O
3 B-outcome
hours I-outcome
( O
54 B-iv-bin-percent
% I-iv-bin-percent
vs O
17 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
. O
005 O
) O
postoperatively O
. O
PVB O
significantly O
decreases O
postoperative O
pain O
up O
to O
3 O
hours O
after O
breast O
cancer O
surgery O
. O

